<SEC-DOCUMENT>0001171843-17-006746.txt : 20171108
<SEC-HEADER>0001171843-17-006746.hdr.sgml : 20171108
<ACCEPTANCE-DATETIME>20171108151411
ACCESSION NUMBER:		0001171843-17-006746
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		47
CONFORMED PERIOD OF REPORT:	20170930
FILED AS OF DATE:		20171108
DATE AS OF CHANGE:		20171108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		171186324

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q_110817p.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<html><head>
     <title></title>
</head><body style="font: 10pt Times New Roman, Times, Serif">





<p style="margin: 0">&nbsp;</p>

<!-- Field: Rule-Page --><div align="left" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 18pt; text-align: center; margin: 0pt 0 0pt 9pt"><b>UNITED STATES</b></p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Washington, D.C. 20549</b></p>

<!-- Field: Rule-Page --><div align="center" style="margin-top: 9pt; margin-bottom: 9pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>FORM 10-Q</b></p>

<!-- Field: Rule-Page --><div align="center" style="margin-top: 9pt; margin-bottom: 9pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</div></div><!-- Field: /Rule-Page -->



<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Quarterly Report Pursuant to Section&nbsp;13 or 15(d)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>For the quarterly period ended September&nbsp;30, 2017</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Commission File Number 000-23186</b></p>

<!-- Field: Rule-Page --><div align="center" style="margin-top: 9pt; margin-bottom: 9pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</div></div><!-- Field: /Rule-Page -->



<p style="font-size: 24pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Exact name of registrant as specified in its charter)</b></p>

<!-- Field: Rule-Page --><div align="center" style="margin-top: 9pt; margin-bottom: 9pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</div></div><!-- Field: /Rule-Page -->



<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 50%; text-align: center"><font style="font-size: 10pt">&nbsp;<b>DELAWARE</b></font></td>
    <td style="width: 50%; text-align: center"><font style="font-size: 10pt"><b>62-1413174</b></font></td></tr>
<tr>
    <td style="text-align: center"><font style="font-size: 10pt"><b>(State of other jurisdiction of</b></font></td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>(I.R.S. Employer</b></font></td></tr>
<tr>
    <td style="text-align: center"><font style="font-size: 10pt"><b>incorporation or organization)</b></font></td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Identification No.)</b></font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr>
    <td style="text-align: center"><font style="font-size: 10pt"><b>4505 Emperor Blvd., Suite&nbsp;200</b></font></td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Durham, North Carolina</b></font></td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>27703</b></font></td></tr>
<tr>
    <td style="text-align: center"><font style="font-size: 10pt"><b>(Address of principal executive offices)</b></font></td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>(Zip Code)</b></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(919) 859-1302</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Registrant&#8217;s telephone number, including area code)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<!-- Field: Rule-Page --><div align="center" style="margin-top: 9pt; margin-bottom: 9pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required
to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such
shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements
for the past 90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp; <font style="font-family: Wingdings">x</font> &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<font style="font-family: Wingdings">&#168;</font></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant has submitted electronically and posted
on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of
Regulation&nbsp;S-T during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit
and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp; <font style="font-family: Wingdings">x</font> &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<font style="font-family: Wingdings">&#168;</font></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, or a non- accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth
company&#8221; in Rule&nbsp;12b-2 of the Exchange Act.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="width: 23%"><font style="font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</font></td>
    <td style="width: 43%"><font style="font-family: Wingdings; font-size: 10pt">&#168;</font></td>
    <td style="width: 28%"><font style="font-size: 10pt">Accelerated&nbsp;filer</font></td>
    <td style="width: 6%"><font style="font-family: Wingdings; font-size: 10pt">x</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 10pt">Non-accelerated filer</font></td>
    <td><font style="font-family: Wingdings; font-size: 10pt">&#168;</font> <font style="font-size: 10pt">&nbsp;&nbsp;(Do not check if a smaller reporting company)</font></td>
    <td><font style="font-size: 10pt">Smaller&nbsp;reporting&nbsp;company</font></td>
    <td><font style="font-family: Wingdings; font-size: 10pt">&#168;</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="width: 23%"><font style="font-size: 10pt">Emerging growth company</font></td>
    <td style="width: 43%"><font style="font-family: Wingdings; font-size: 10pt">&#168;</font></td>
    <td style="width: 27%">&nbsp;</td>
    <td style="width: 7%">&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant has elected not
to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. <font style="font-family: Wingdings">&#168;</font></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2
of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp; <font style="font-family: Wingdings">&#168;</font> &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<font style="font-family: Wingdings">x</font></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">The number of shares of Common Stock, par value $0.01, of the Registrant outstanding
as of October 31, 2017 was 98,404,761.&nbsp;&nbsp;</p>



<p style="font-size: 10pt; margin: 0pt 0"></p>



<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div align="center" style="margin-top: 9pt; margin-bottom: 9pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>INDEX</b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 90%; padding-left: 0.75pt">&nbsp;</td>
    <td style="width: 10%; border-bottom: black 1pt solid; padding-left: 0.75pt; text-align: center"><font style="font-size: 10pt"><b>Page&nbsp;No.</b></font></td></tr>
<tr>
    <td colspan="2" style="padding-left: 0.75pt; text-align: center"><font style="font-size: 10pt">Part I. Financial Information</font></td></tr>
<tr>
    <td style="padding-left: 0.75pt"><a href="#a_002"><font style="font-size: 10pt"><u>Item&nbsp;1. Financial Statements:</u></font></a></td>
    <td style="padding-left: 0.75pt; text-align: center"><a href="#a_002"><font style="font-size: 10pt"><u>3</u></font></a></td></tr>
<tr>
    <td style="padding-left: 20pt"><a href="#a_003"><font style="font-size: 10pt"><u>Consolidated Balance Sheets &#8212; September&nbsp;30, 2017 and December&nbsp;31, 2016</u></font></a></td>
    <td style="padding-left: 0.75pt; text-align: center"><a href="#a_003"><font style="font-size: 10pt"><u>3</u></font></a></td></tr>
<tr>
    <td style="padding-left: 20pt"><a href="#a_004"><font style="font-size: 10pt"><u>Consolidated Statements of Comprehensive Loss &#8212; Three and Nine Months Ended September&nbsp;30, 2017 and 2016</u></font></a></td>
    <td style="padding-left: 0.75pt; text-align: center"><a href="#a_004"><font style="font-size: 10pt"><u>4</u></font></a></td></tr>
<tr>
    <td style="padding-left: 20pt"><a href="#a_005"><font style="font-size: 10pt"><u>Consolidated Statements of Cash Flows &#8212; Nine Months Ended September&nbsp;30, 2017 and 2016</u></font></a></td>
    <td style="padding-left: 0.75pt; text-align: center"><a href="#a_005"><font style="font-size: 10pt"><u>5</u></font></a></td></tr>
<tr>
    <td style="padding-left: 20pt"><a href="#a_006"><font style="font-size: 10pt"><u>Notes to Consolidated Financial Statements</u></font></a></td>
    <td style="padding-left: 0.75pt; text-align: center"><a href="#a_006"><font style="font-size: 10pt"><u>6</u></font></a></td></tr>
<tr>
    <td style="padding-left: 0.75pt"><a href="#a_001"><font style="font-size: 10pt"><u>Item&nbsp;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</u></font></a></td>
    <td style="padding-left: 0.75pt; text-align: center"><a href="#a_001"><font style="font-size: 10pt"><u>19</u></font></a></td></tr>
<tr>
    <td style="padding-left: 0.75pt"><a href="#a_008"><font style="font-size: 10pt"><u>Item&nbsp;3. Quantitative and Qualitative Disclosures About
    Market Risk</u></font></a></td>
    <td style="padding-left: 0.75pt; text-align: center"><a href="#a_008"><font style="font-size: 10pt"><u>29</u></font></a></td></tr>
<tr>
    <td style="padding-left: 0.75pt"><a href="#a_009"><font style="font-size: 10pt"><u>Item&nbsp;4. Controls and Procedures</u></font></a></td>
    <td style="padding-left: 0.75pt; text-align: center"><a href="#a_009"><font style="font-size: 10pt"><u>30</u></font></a></td></tr>
<tr>
    <td colspan="2" style="padding-left: 0.75pt; text-align: center"><font style="font-size: 10pt">Part II. Other Information</font></td></tr>
<tr>
    <td style="padding-left: 0.75pt"><a href="#a_010"><font style="font-size: 10pt"><u>Item&nbsp;1A. Risk Factors</u></font></a></td>
    <td style="padding-left: 0.75pt; text-align: center"><a href="#a_010"><font style="font-size: 10pt"><u>30</u></font></a></td></tr>
<tr>
    <td style="padding-left: 0.75pt"><a href="#a_011"><font style="font-size: 10pt"><u>Item&nbsp;6. Exhibits</u></font></a></td>
    <td style="padding-left: 0.75pt; text-align: center"><a href="#a_011"><font style="font-size: 10pt"><u>48</u></font></a></td></tr>
<tr>
    <td style="padding-left: 0.75pt"><a href="#a_012"><font style="font-size: 10pt"><u>Signatures</u></font></a></td>
    <td style="padding-left: 0.75pt; text-align: center"><a href="#a_012"><font style="font-size: 10pt"><u>49</u></font></a></td></tr>
<tr>
    <td style="padding-left: 0.75pt">&nbsp;</td>
    <td style="padding-left: 0.75pt; text-align: center">&nbsp;</td></tr>
<tr>
    <td><a href="exh_101.htm">
<u>EX-10.1</u></a></td>
    <td style="padding-left: 0.75pt; text-align: center">&nbsp;</td></tr>
<tr>
    <td><a href="exh_311.htm">EX-31.1</a></td>
    <td style="padding-left: 0.75pt; text-align: center">&nbsp;</td></tr>
<tr>
    <td style="padding-left: 0.75pt"><a href="exh_312.htm"><font style="font-size: 10pt"><u>EX-31.2</u></font></a></td>
    <td style="padding-left: 0.75pt; text-align: center">&nbsp;</td></tr>
<tr>
    <td style="padding-left: 0.75pt"><a href="exh_321.htm"><font style="font-size: 10pt"><u>EX-32.1</u></font></a></td>
    <td style="padding-left: 0.75pt; text-align: center">&nbsp;</td></tr>
<tr>
    <td style="padding-left: 0.75pt"><a href="exh_322.htm"><font style="font-size: 10pt"><u>EX-32.2</u></font></a></td>
    <td style="padding-left: 0.75pt; text-align: center">&nbsp;</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>



<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>PART I. FINANCIAL INFORMATION</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_002"></a>Item&nbsp;1. &nbsp;&nbsp;&nbsp;Financial Statements</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="a_003"></a><b>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>September&nbsp;30, 2017 and December&nbsp;31, 2016</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share data)</b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="balance-sheet"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017<br> (Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016<br> (Note 1)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; font-size: 10pt; text-align: left">Cash and cash equivalents</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">117,776</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">22,104</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Restricted cash</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,122</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,546</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">43,848</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">32,546</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Receivables from collaborations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,985</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,768</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">500</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Prepaid expenses and other current assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,421</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,438</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Deferred collaboration expense</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">218</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">85</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Total current assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">175,370</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">66,987</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,539</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,926</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Property and equipment, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,613</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,922</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">199</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Other assets</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,955</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">3,813</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total assets</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">191,492</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">89,847</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities and Stockholders&#8217; Equity</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accounts payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">4,603</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">4,269</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accrued expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,871</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,836</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,705</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,990</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,686</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,022</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Lease financing obligation</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">73</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Senior credit facility</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,727</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Non-recourse notes payable</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">28,572</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">28,243</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Total current liabilities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">69,237</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">54,360</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">296</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,184</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred rent</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">178</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">244</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Lease financing obligation</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,770</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,704</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Senior credit facility</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">18,379</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,777</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stockholders&#8217; equity:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares issued and outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Common stock, $0.01 par value: shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 98,389 in 2017 and 73,782 in 2016</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">984</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">738</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Additional paid-in capital</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">711,965</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">566,913</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accumulated other comprehensive loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(17</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(12</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Accumulated deficit</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(612,300</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(566,061</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Total stockholders&#8217; equity</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">100,632</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,578</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total liabilities and stockholders&#8217; equity</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">191,492</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">89,847</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">See accompanying notes to consolidated financial statements.&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="a_004"></a>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Three and Nine Months Ended September&nbsp;30, 2017 and 2016</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share data-Unaudited)</b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="comprehensive-income"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td nowrap colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Three Months</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td nowrap colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Nine Months</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Revenues</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; font-size: 10pt; text-align: left">Product sales</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">1,501</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">1,501</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Royalty revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">442</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,501</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,252</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,020</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Collaborative and other research and development</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">6,817</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">4,262</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">12,543</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">11,350</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 30pt">Total revenues</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,760</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,763</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,296</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17,370</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cost of products sold</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,142</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,142</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Research and development</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17,509</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,105</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">50,038</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">48,850</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">General and administrative</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,343</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,756</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,235</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,692</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.1pt">Royalty</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">115</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">143</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">431</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">247</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 30pt">Total operating expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,109</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17,004</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">60,846</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">57,789</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Loss from operations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(13,349</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(9,241</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(39,550</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(40,419</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest and other income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">225</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">109</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">537</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">695</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,140</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,465</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(6,334</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(4,356</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Gain (loss) on foreign currency derivative</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">130</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(931</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(892</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(6,561</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(15,134</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(11,528</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(46,239</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(50,641</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common share</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.18</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.16</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.58</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.69</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Weighted average shares outstanding</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">83,570</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">73,734</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">79,749</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">73,677</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Unrealized loss on available for sale investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(24</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">228</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Comprehensive loss</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(15,136</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(11,552</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(46,244</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(50,413</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="a_005"></a><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Nine Months Ended September&nbsp;30, 2017 and 2016</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands-Unaudited)</b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="cash-flows"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Operating activities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; font-size: 10pt; text-align: left">Net loss</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(46,239</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(50,641</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Depreciation and amortization</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">522</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">311</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Loss on disposal of property and equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock-based compensation expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,307</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,478</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Amortization of debt issuance costs</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">658</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">335</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Amortization of premium/discount on investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">125</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">499</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Change in fair value of foreign currency derivative</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,858</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,372</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Receivables</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(217</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">275</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">500</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(620</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Prepaid expenses and other assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">667</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Deferred collaboration expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">51</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">43</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,303</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(12,066</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Interest payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,715</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">817</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Deferred revenue</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(1,224</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(1,075</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Net cash used in operating activities</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(30,624</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(47,584</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Investing activities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Acquisitions of property and equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(213</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5,278</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Change in restricted cash</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,576</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">106</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Purchases of investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(39,572</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Sales and maturities of investments</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">32,527</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">38,272</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Net cash (used in) provided by investing activities</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(8,834</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">33,100</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Financing activities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Sale of common stock, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">133,500</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net proceeds from common stock issued under stock-based compensation plans</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,491</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">204</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Proceeds from senior credit facility</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,658</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Payment of foreign currency derivative collateral</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,190</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Increase in lease financing obligation</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">139</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">300</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Net cash provided by financing activities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">135,130</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">20,972</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Increase in cash and cash equivalents</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">95,672</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">6,488</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Cash and cash equivalents at beginning of period</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">22,104</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">28,899</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">117,776</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">35,387</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b> &nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="a_006"></a>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 1 &#8212; Significant Accounting Policies</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>The Company</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a biotechnology
company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of
diseases. The Company focuses on oral treatments for rare diseases in which significant unmet medical needs exist and that align
with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham,
North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to
discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred
losses and negative cash flows from operations since inception.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">With the funds available at September 30, 2017, the Company believes
these resources will be sufficient to fund its operations at least through the third quarter of 2019. The Company has sustained
operating losses for the majority of its corporate history and expects that its 2017 expenses will exceed its 2017 revenues. The
Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support
ongoing operations. The Company&rsquo;s liquidity needs will be largely determined by the success of operations in regards to the
progression of its product candidates in the future. The Company also may consider other plans to fund operations beyond the third
quarter of 2019 including: (1)&nbsp;securing or increasing U.S. Government funding of its programs, including obtaining procurement
contracts; (2)&nbsp;out-licensing rights to certain of its products or product candidates, pursuant to which the Company would
receive cash milestones; (3)&nbsp;raising additional capital through equity or debt financings or from other sources; (4)&nbsp;obtaining
additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (5)&nbsp;reducing spending
on one or more research and development programs, including by discontinuing development; and/or (6)&nbsp;restructuring operations
to change its overhead structure. The Company may issue securities, including common stock, preferred stock, depositary shares,
stock purchase contracts, warrants and units, through private placement transactions or registered public offerings in the future.
The Company&rsquo;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its
product candidates and key development and regulatory events and its decisions in the future.&nbsp;&nbsp;</p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Basis of Presentation</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiaries, JPR Royalty Sub LLC (&#8220;Royalty Sub&#8221;) and MDCP, LLC (&#8220;MDCP&#8221;).
Both subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a
$30,000&nbsp;financing transaction the Company completed on March&nbsp;9, 2011. See Note 4, Royalty Monetization, for a further
description of this transaction. MDCP was formed in connection with a $23,000 Senior Credit Facility that the Company closed on
September 23, 2016. See Note 5, Senior Credit Facility, for a further description of this transaction. All intercompany transactions
and balances have been eliminated.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial
reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete
financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present
fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There
were no adjustments other than normal recurring adjustments.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These financial statements should be read in conjunction with the
financial statements for the year ended December&nbsp;31, 2016 and the notes thereto included in the Company&#8217;s 2016 Annual
Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance
sheet as of December&nbsp;31, 2016 has been derived from the audited consolidated financial statements included in the Company&#8217;s
most recent Annual Report on Form 10-K.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held
in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities
of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to
the short-term nature of these items.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Restricted Cash</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Restricted cash as of September&nbsp;30, 2017 reflects $1,713 in royalty
revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;) designated for interest on the PhaRMA Notes (defined in
Note 4) and $1,409 the Company is required to maintain as collateral for a letter of credit associated with the lease execution
and build-out of its Birmingham research facilities.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Investments</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance
with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment
policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow
requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government
agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable
debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments,
municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#8217;s
investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years
and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market
risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize
this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the
need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to
interest rate risk arising from its investments. Generally, the Company&#8217;s investments are not collateralized. The Company
has not realized any significant losses from its investments.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale.
Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be
other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments
for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary
declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in
the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions
recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature
at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from
the balance sheet date are classified as long-term. At September 30, 2017, the Company believes that the cost of its investments
is recoverable in all material respects.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#8217;s
investments by type. The estimated fair values of the Company&#8217;s fixed income investments are classified as Level 2 in the
fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted
prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets
that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">September&nbsp;30, 2017</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized<br> Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued<br> Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br> Unrealized<br> Gains</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br> Unrealized<br> Losses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated<br> Fair&nbsp;Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of the U.S. Government and its agencies</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 7%; font-size: 10pt; text-align: right">27,897</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 7%; font-size: 10pt; text-align: right">96</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 7%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 7%; font-size: 10pt; text-align: right">(7</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 7%; font-size: 10pt; text-align: right">27,986</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Corporate debt securities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,230</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">39</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(8</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,261</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt">Certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">12,108</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">34</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">4</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(6</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">12,140</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">48,235</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">169</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(21</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">48,387</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2016</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized<br> Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued<br> Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br> Unrealized<br> Gains</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br> Unrealized<br> Losses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated<br> Fair&nbsp;Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of the U.S. Government and its agencies</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 7%; font-size: 10pt; text-align: right">20,266</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 7%; font-size: 10pt; text-align: right">34</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 7%; font-size: 10pt; text-align: right">2</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 7%; font-size: 10pt; text-align: right">(4</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 7%; font-size: 10pt; text-align: right">20,298</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Corporate debt securities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,179</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">26</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(8</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,199</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt">Certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">14,962</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">17</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">7</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(11</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">14,975</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">41,407</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">77</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">11</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(23</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">41,472</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company&#8217;s
investments at September&nbsp;30, 2017 and December&nbsp;31, 2016.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 85%">
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-size: 10pt; text-align: left">Maturing in one year or less</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">43,848</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">32,546</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Maturing after one year through two years</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">4,539</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">8,926</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">48,387</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">41,472</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Receivables from Collaborations</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development
costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&ldquo;Green
Cross&rdquo;), Mundipharma International Holdings Limited (&ldquo;Mundipharma&rdquo;) and Seqirus UK Limited (&ldquo;SUL&rdquo;),
and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each
reporting date. At September 30, 2017 and December&nbsp;31, 2016, the Company had the following receivables.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">September&nbsp;30, 2017</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">63</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">1,906</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">1,969</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">653</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">653</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">48</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">48</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Mundipharma International Holdings Limited</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">46</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">46</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Seqirus UK Limited</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">5,794</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">475</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">6,269</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total receivables</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,604</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,381</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,985</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2016</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">3,495</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">3,495</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,451</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,451</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">686</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">686</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Seqirus UK Limited</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">957</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">179</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,136</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total receivables</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,094</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,674</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,768</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and
Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of
indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates
are subject to audit by the U.S. Government.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Receivables from Product Sales</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the
Company related to sales of RAPIVAB<b><sup>&#174;</sup></b>. These receivables are evaluated to determine if any reserve or allowance
should be established at each reporting date.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Inventory</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s inventory consisted primarily of peramivir work
in process and is being manufactured for the Company&#8217;s partners. Inventory is stated at the lower of cost and net realizable
value, determined under the first-in, first-out (&#8220;FIFO&#8221;) method, or market. The Company expenses costs related to the
production of inventories as research and development expenses in the period incurred until such time it is believed that future
economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory
approval, the Company will capitalize subsequent costs related to the production of inventories.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Property and Equipment</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Property and equipment are recorded at cost. Depreciation is computed
using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of
three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures
are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the expected
lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded
at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related
lease.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In accordance with U.S. GAAP, the Company periodically reviews its
property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets
may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from
the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover
the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed
of are reported at the lower of carrying amount or fair value less cost to sell.</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Patents and Licenses</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes
and products. All patent related costs are expensed to general and administrative expenses when incurred as recoverability of such
expenditures is uncertain.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Accrued Expenses</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally enters into contractual agreements with third-party
vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these
contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records
liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of
the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel
to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost
incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service
providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of
each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the
accuracy of its estimates with its service providers and makes adjustments if necessary. Examples of estimated accrued expenses
include:</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">fees paid to Contract Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to contract manufacturers in connection with the production of the Company&#8217;s raw materials, drug substance and drug products;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">professional fees.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates
of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and
manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary
from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such
as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company
estimates the time period over which services will be performed and the level of effort expended in each period. If the actual
timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.
As of September 30, 2017 and December 31, 2016, the carrying value of accrued expenses approximates their fair value due to their
short-term settlement.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Income Taxes</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The liability method is used in the Company&#8217;s accounting for
income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting
and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect
when the differences are expected to reverse.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Accumulated Other Comprehensive Loss</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Accumulated other comprehensive loss is comprised of unrealized gains
and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Amounts reclassified
from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive
Loss. No reclassifications out of accumulated other comprehensive loss were recorded during the nine months ended September 30,
2017. Realized gains of $11 were reclassified out of accumulated other comprehensive loss during the nine months ended September
30, 2016.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Revenue Recognition</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research
and development arrangements and royalties when realized or realizable and earned. Revenue is realized or realizable and earned
when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery has occurred
or services have been rendered; (iii)&nbsp;the seller&#8217;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability
is reasonably assured.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 9; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and
research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing
performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received
under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined
by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result
of changes in the estimated revenue period are recognized prospectively.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of the Company&#8217;s license agreements, the Company
receives royalty payments based upon its licensees&#8217; net sales of covered products. The Company recognizes royalty revenues
when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element,
each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting.
This determination is based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer. The consideration that
is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable.
The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective
evidence of fair value, (ii) third-party evidence of selling price (&#8220;TPE&#8221;) and (iii) best estimate of selling price
(&#8220;BESP&#8221;). The BESP reflects the Company&#8217;s best estimate of what the selling price would be if the deliverable
was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration
to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are
delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify
deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to
use an asset, or another performance obligation.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, the Company entered into a License Agreement (the &#8220;SUL
Agreement&#8221;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture
and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone
payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory
and (iii) regulatory support to obtain Canadian and European Union (&#8220;EU&#8221;) marketing approvals. The Company received
an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be
deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue
in 2015. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized in 2015,
when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the
expected period of involvement in these regulatory support activities.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement
of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured
at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these
revenue recognition criteria are recorded as deferred revenue.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During the first nine months of 2017, the Company received a $2,000
milestone payment related to the approval of RAPIVAB by Health Canada and a $5,000 milestone payment associated with the U.S. Food
and Drug Administration (&ldquo;FDA&rdquo;) approval of a supplemental new drug application (&ldquo;sNDA&rdquo;) for RAPIVAB extending
its availability for the treatment of acute uncomplicated influenza to pediatric patients two years and older. The Company evaluated
each event based payment under the provisions of ASU 2010-17, <i>Milestone Method of Revenue Recognition</i>, and determined that
each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of
accounting. Under the terms of the SUL Agreement, the Company may receive an additional $5,000 payment related to the successful
marketing approval by the European Medicines Agency (&ldquo;EMA&rdquo;) for an adult indication in the EU. No event-based payments
were achieved during the first nine months of 2016.&nbsp;</p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related
to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a
reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within
the United States Department of Health and Human Services (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious
Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the three and nine
months ended September&nbsp;30, 2017 and 2016:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three Months</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Nine Months</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: left">Product sales</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">1,501</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">1,501</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Royalty revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">442</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,501</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,252</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,020</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">U.S. Department of Health and Human Services</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,490</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,813</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,305</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,846</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Shionogi&nbsp;&amp; Co. Ltd.</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">296</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">296</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">888</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">888</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; text-indent: 20pt">Seqirus UK Limited</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">5,031</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">153</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">7,350</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">616</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Total collaborative and other research and development revenues</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">6,817</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">4,262</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">12,543</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">11,350</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,760</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,763</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">21,296</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">17,370</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s research and development costs are charged to
expense when incurred. Research and development expenses include all direct and indirect development costs related to the development
of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for
future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related
goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel
costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials
and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s
manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued
by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#8217;s
on-going review of the level of services actually performed.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with third parties,
such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;),
and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance
fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which
case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments
as incurred.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid
to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration
paid to the Company&#8217;s academic partners for modification to existing license agreements. These deferred expenses would not
have been incurred without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being
expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately
matches expenses with the associated revenue.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Stock-Based Compensation</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards
and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on
their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value
of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is
recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding
performance-based stock options for which no compensation expense is recognized until &#8220;performance&#8221; is deemed to have
occurred.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Interest Expense and Deferred Financing Costs</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense for the three months ended September&nbsp;30, 2017 and 2016 was $2,140 and $1,465, respectively,
and for the nine months ended September 30, 2017 and 2016 was $6,334 and $4,356, respectively, and primarily relates to the issuance
of the PhaRMA Notes (defined in Note 4) and the Senior Credit Facility (defined in Note 5). Costs directly associated with the
issuance of the PhaRMA Notes and the Senior Credit Facility have been capitalized and are netted against the PhaRMA Notes and Senior
Credit Facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA
Notes and the Senior Credit Facility using the effective interest rate method. Amortization of deferred financing costs and original
issue discount included in interest expense was $219 and $116 for each of the three months ended September&nbsp;30, 2017 and 2016,
respectively, and $658 and $335 for each of the nine months ended September&nbsp;30, 2017 and 2016, respectively.</p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Lease Financing Obligation</i></b></p>

<p style="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on the terms of the lease agreement for the research facility
in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the
owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset
of $1,589 at December 31, 2015, representing the Company&#8217;s leased portion of the building and recorded a corresponding liability.
Upon completion of leasehold improvement construction, which ended in 2016, the Company did not meet the sale-leaseback criteria
for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset
will be depreciated over the expected duration of the lease of 20.5 years, and rental payments will be treated as principal and
interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on
cash flows associated with the underlying lease or construction in process. Interest expense for the three months ended September&nbsp;30,
2017 and 2016 includes $82 and $86, respectively, and for the nine months ended September 30, 2017 and 2016 includes $217 and $300,
respectively, related to the lease financing obligation.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 11; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At each of September 30, 2017 and December 31, 2016, the lease financing
obligation balance was $2,704 and was recorded as a long term liability on the consolidated balance sheets. At September 30, 2017
the remaining future minimum payments under the lease financing obligation are $4,444.</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Currency Hedge Agreement</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese
yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore mark to
market adjustments are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market
adjustments for the nine months ended September&nbsp;30, 2017 and 2016 resulted in losses of $1,858 and $7,372, respectively. Mark
to market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded
and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined
by U.S. GAAP. In addition, the Company realized currency exchange gains of $966 and $811 during the first nine months of 2017 and
2016, respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement.
The Company is also required to post collateral in connection with the mark to market adjustments based on thresholds defined in
the Currency Hedge Agreement. As of September&nbsp;30, 2017 and December 31, 2016, no hedge collateral was posted under the agreement.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Net Loss Per Share</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Net loss per share is based upon the weighted average number of common
shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented
herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&#8217;s
employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended September&nbsp;30,
2017 and 2016 does not include 1,996 and 1,291, respectively, of such potential common shares, as their impact would be anti-dilutive.
The calculation of diluted earnings per share for the nine months ended September&nbsp;30, 2017 and 2016 does not include 2,519
and 1,190, respectively, of such potential common shares, as their impact would be anti-dilutive.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Use of Estimates</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP
requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results
could differ from those estimates.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Significant Customers and Other Risks</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Significant Customers</i></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">All peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) are
made by the Company&#8217;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy
receivables.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Other than royalty revenues, the Company&#8217;s primary source
of revenue that has an underlying cash flow stream is the reimbursement of galidesivir (formerly BCX4430) development expenses
earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS. The Company relies on BARDA/HHS and NIAID/HHS to reimburse
predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents
a significant portion of the Company&#8217;s collaborative and other research and development revenues. The completion (as with
the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts
could negatively impact the Company&#8217;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes
royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except
for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#8217;s non-recourse
notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future
royalty payments derived from net sales of RAPIACTA. Further, the Company&#8217;s drug development activities are performed by
a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly
impact the Company&#8217;s ability to complete its drug development activities.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 12; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Credit Risk</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially
subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess
cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits.
The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities
that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio
of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables
discussed above, the majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which
there is no assumed credit risk.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Recent Accounting Pronouncements</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In November 2016, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards
Update 2016-18: <i>Statement of Cash Flows (Topic 230): Restricted Cash</i> (&ldquo;ASU 2016-18&rdquo;). The new standard requires
that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally
described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted
cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total
amounts shown on the statement of cash flows. The standard is effective for annual periods beginning after December&nbsp;15, 2017,
and interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the
impact of this update on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In August 2016, the FASB issued Accounting Standards Update No. 2016-15:
<i>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</i> (&#8220;ASU 2016-15&#8221;).
The amendments in this update clarify how entities should classify certain cash receipts and cash payments on the Consolidated
Statements of Cash Flows. The new guidance also clarifies how the predominance principle should be applied when cash receipts and
cash payments have aspects of more than one class of cash flows. ASU 2016-15 will be effective for annual periods beginning after
December 15, 2017, including interim periods within those annual reporting periods, but early adoption is permitted. The Company
is currently evaluating the impact of this update on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2016, the FASB issued Accounting Standards Update No. 2016-09:
<i>Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</i> (&ldquo;ASU 2016-09&rdquo;).
The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including
the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement
of cash flows. ASU 2016-09 eliminates the requirement that excess tax benefits be realized as a reduction
in current taxes payable before the associated tax benefit can be recognized as an increase in paid in capital. Under ASU 2016-09,
these previously unrecognized deferred tax assets were recognized on a modified retrospective basis as of January 1, 2017, the
start of the year in which the Company adopted ASU 2016-09. The U.S. federal and state net operating losses and credits recognized
as of January 1, 2017 have been offset by a full valuation allowance. As a result, there is no cumulative-effect adjustment to
retained earnings as of September 30, 2017. The Company elected not to change its policy on accounting for forfeitures and
continues to estimate the total number of awards for which the requisite service period will not be rendered. The Company adopted
ASU 2016-09 as of January 1, 2017. Adoption of ASU 2016-09 did not have a material impact on the Company&rsquo;s consolidated financial
statements.</p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In February 2016, the FASB issued Accounting Standards Update No.
2016-02: <i>Leases (Topic 842)</i> (&#8220;ASU 2016-02&#8221;). The amendments in this update require lessees, among other things,
to recognize lease assets and lease liabilities on the balance sheet for all leases with terms greater than 12 months. This update
also introduces new disclosure requirements for leasing arrangements. ASU 2016-02 will be effective for the Company in fiscal year
2019, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial
statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In January 2016, the FASB issued Accounting Standards Update No. 2016-01:
<i>Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>
(&#8220;ASU 2016-01&#8221;). The amendments in this update address certain aspects of recognition, measurement, presentation and
disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the
requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required
to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU 2016-01 will be effective for the
Company in fiscal year 2018, but early adoption is permitted. The Company does not expect this standard to have a material impact
on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In July 2015, the FASB issued Accounting Standards Update No. 2015-11:
<i>Inventory (Topic 330): Simplifying the Measurement of Inventory</i> (&#8220;ASU 2015-11&#8221;), which changes the measurement
principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU 2015-11 defines net
realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion,
disposal, and transportation. The update does not apply to inventory that is measured using last-in, first-out or the retail inventory
method. The update applies to all other inventory, which includes inventory that is measured using first-in, first-out or average
cost methods. The amendments in ASU 2015-11 are effective for the Company for fiscal years, and the interim periods within those
years, beginning after December 15, 2016. The Company adopted ASU 2015-11 as of January 1, 2017. Adoption did not have a material
impact on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2014, the FASB issued Standards Update No. 2014-09: <i>Revenue
from Contracts with Customers (Topic 606)</i> (&#8220;ASU 2014-09&#8221;), which provides a single, comprehensive revenue recognition
model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers
promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled
in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty
of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets
recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective
date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original
effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified
retrospective method. The Company will adopt the standard effective January 1, 2018 and expects to utilize the modified retrospective
methodology. The Company is continuing to evaluate the effect that the standard will have on its consolidated financial statements
and related disclosures.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 2 &#8212; Stock-Based Compensation</b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of September&nbsp;30, 2017, the Company had two stock-based employee
compensation plans, the Stock Incentive Plan (&#8220;Incentive Plan&#8221;) and the Employee Stock Purchase Plan (&#8220;ESPP&#8221;).
The Incentive Plan was amended and restated in April 2017 and approved by the Company&#8217;s stockholders in May 2017. The ESPP
was amended and restated in March 2014 and approved by the Company&#8217;s stockholders in May 2014. Stock-based compensation expense
of $10,307 ($10,107 of expense related to the Incentive Plan and $200 of expense related to the ESPP) was recognized during the
first nine months of 2017, while $6,478 ($6,331 of expense related to the Incentive Plan and $147 of expense related to the ESPP)
was recognized during the first nine months of 2016.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There was approximately $16,282 of total unrecognized compensation cost related to non-vested stock option awards
and restricted stock unit awards granted by the Company as of September&nbsp;30, 2017. That cost is expected to be recognized as
follows: $2,264 during the remainder of 2017, $6,745 in 2018, $4,527 in 2019, $2,395 in 2020 and $351 in 2021. In addition, the
Company has outstanding performance-based stock options for which no compensation expense is recognized until &ldquo;performance&rdquo;
has occurred and the award vests. At the time of vesting, compensation expense will be recognized. During the third quarter of
2017, the Company achieved a performance metric under a performance-based option award resulting in 404 options vesting and $3,193
compensation expense recorded as a result of this achievement.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Stock Incentive Plan</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company grants stock option awards and restricted stock unit awards
to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted
with an exercise price equal to the market price of the Company&rsquo;s stock at the date of grant. Stock option awards granted
to employees generally vest 25% each year until fully vested after four years. In August 2013 and December 2014, the Company issued
1,032 and 1,250 performance-based stock options, respectively. These awards vest upon successful completion of specific development
milestones. As of September 30, 2017, 75% of the August 2013 grants have vested based upon achievement of three milestones: (1)
successful completion of the OPuS-1 clinical trial, for which vesting occurred in the second quarter of 2014, (2) FDA approval
of RAPIVAB, for which vesting occurred in the fourth quarter of 2014, and (3) initiation of a Phase 1 clinical trial to evaluate
the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers, for which vesting occurred
in the second quarter of 2015. As of September 30, 2017, 30% of the December 2014 grants have vested based upon achievement of
successful completion of an HAE patient trial with a 2<sup>nd</sup> generation compound, for which vesting occurred in August 2017.
Thus, as of September 30, 2017, 25% of the August 2013 performance-based grants and 70% of the December 2014 performance-based
grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based
grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over one year. All stock option
awards have contractual terms of 5 to 10&nbsp;years. The vesting exercise provisions of all awards granted under the Incentive
Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change
in control as defined in the Incentive Plan.&nbsp;</p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Related activity under the Incentive Plan is as follows:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Awards<br> Available</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Options<br> Outstanding</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Weighted<br> Average<br> Exercise<br> Price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; font-size: 10pt">Balance December&nbsp;31, 2016</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 11%; font-size: 10pt; text-align: right">2,273</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 11%; font-size: 10pt; text-align: right">12,095</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">6.55</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Plan amendment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,000</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock unit awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(16</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock unit awards cancelled</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,591</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,591</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5.49</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(422</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3.49</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Stock option awards cancelled</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">912</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(912</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10.22</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Balance September&nbsp;30, 2017</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,581</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">13,352</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">6.19</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For stock option awards granted under the Incentive Plan during the
first nine months of 2017 and 2016, the fair value was estimated on the date of grant using a Black-Scholes option pricing model
and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during
the first nine months of 2017 and 2016 was $3.74 and $2.17, respectively. The fair value of the stock option awards is amortized
to expense over the vesting periods using a straight-line expense attribution method. The following table summarizes the key assumptions
used by the Company to value the stock option awards granted during the first nine months of 2017 and 2016. The expected life is
based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption
that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting
(if not yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#8217;s
publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or
option holders and will not be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield
currently available on zero-coupon government issues with a remaining term equal to the expected term.</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Weighted Average Assumptions for Stock Option Awards Granted to</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Employees and Directors under the Incentive Plan</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 65%; font-size: 10pt; text-align: left">Expected Life in Years</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 14%; font-size: 10pt; text-align: right">5.5</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 14%; font-size: 10pt; text-align: right">5.5</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected Volatility</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">82.0</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">82.0</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Expected Dividend Yield</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.0</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.0</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Risk-Free Interest Rate</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1.9</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1.4</td><td style="font-size: 10pt; text-align: left">%</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has reserved a total of 1,475&nbsp;shares of common stock
to be purchased under the ESPP, of which 330&nbsp;shares remain available for purchase at September&nbsp;30, 2017. Eligible employees
may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price
during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates
and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year.
The Company issued 91 shares during the first nine months of 2017 under the ESPP. Compensation expense for shares purchased under
the ESPP related to the purchase discount and the &#8220;look-back&#8221; option were determined using a Black-Scholes option pricing
model.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 3 &#8212; Collaborative and Other Research and Development Contracts</b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>U.S.&nbsp;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;).</i>
On March 31, 2015, the Company announced that BARDA/HHS had awarded the Company a contract for the continued development of galidesivir
as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&nbsp;This BARDA/HHS contract includes a base
contract of $16,265 to support galidesivir drug manufacturing, as well as $22,855 in additional development options that can be
exercised by the government, bringing the potential value of the contract to $39,120. As of September 30, 2017, a total of $20,574
has been awarded under exercised options within this contract.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>National Institute of Allergy and Infectious Diseases (&ldquo;NIAID/HHS&rdquo;).</i>
In September 2013, NIAID/HHS contracted with the Company for the development of galidesivir as a treatment
for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company.
The goals of this contract, including the amendments thereto, are to file IND applications for intravenous (&ldquo;i.v.&rdquo;)
and intramuscular (&ldquo;i.m.&rdquo;) galidesivir for the treatment of Marburg virus disease and other hemorrhagic fever virus
diseases, including Ebola virus disease, and to conduct an initial Phase 1 human clinical trial. As of September 30, 2017, the
total NIAID/HHS contract amount to advance the program through the completion of the Phase 1 clinical program is $39,477. As of
September 30, 2017, all options have been exercised under this contract.</p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 15; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee
contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions
that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments
of progress and the continuation of the contract is based on the Company&#8217;s performance, the timeliness and quality of deliverables,
and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable
by the government at any time for breach or without cause.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"><i>Seqirus UK Limited (&#8220;SUL&#8221;).</i> On June 16, 2015,
the Company and Seqirus UK Limited (&#8220;SUL&#8221;), a limited company organized under the laws of the United Kingdom and a
subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &#8220;SUL Agreement&#8221;)
granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the
treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies
together constituting the &#8220;Territory&#8221;). Peramivir is an intravenous treatment for acute uncomplicated influenza and
is currently approved for use in the United States, Canada, Japan, Taiwan and Korea. Peramivir is the first and only intravenous
influenza treatment in the world and was approved by the FDA in December 2014 for the treatment of acute uncomplicated influenza
in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and associated
economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government
stockpiling outside the U.S.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Pursuant to the SUL Agreement, RAPIVAB is commercialized by CSL's
subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets.
SUL manufactures, commercializes and exercises decision-making authority with respect to the commercialization of RAPIVAB within
the Territory and is responsible for all related costs, including sales and promotion.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company is responsible for
fulfilling all post-marketing commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer
ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in the EU, the Company
is also responsible for regulatory filings and interactions with the European Medicines Agency ("EMA") until marketing
approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint
steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct
and progress of the commercialization of RAPIVAB in the Territory and any additional development.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company received an upfront
payment of $33,740, has received $7,000 of milestone payments and may receive an additional $5,000 milestone payment related to
the successful marketing approval by the EMA for an adult indication in the EU. The Company is also entitled under the SUL Agreement
to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales,
as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically,
the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract
Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the
Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events
impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire,
on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from
the date of the SUL Agreement. The Company developed peramivir under a license from UAB and will owe sublicense payments to them
on any future milestone payments and/or royalties received by the Company from SUL.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;).</i> In
February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in
Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi
obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and
will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In
October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include
Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Green Cross Corporation (&#8220;Green Cross&#8221;).</i> In June
2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of
the agreement, Green Cross is responsible for all development, regulatory, and commercialization costs in Korea. The Company received
a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir
in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay
the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Mundipharma International Holdings Limited (&ldquo;Mundipharma&rdquo;).</i>
In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development
and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&ldquo;PNP&rdquo;) inhibitor, for use in oncology. Under
the terms of the license agreement, as amended, Mundipharma obtained rights to forodesine in markets across Europe, Asia, and Australasia
in exchange for a $10,000 up-front payment. In April 2017, Mundipharma obtained regulatory approval of Mundesine<b><sup>&reg;</sup></b>
(forodesine hydrochloride) for the treatment of relapsed/refractory PTCL (Peripheral T-Cell Lymphoma) by the Ministry of Health,
Labor and Welfare in Japan and is responsible for all commercialization costs in Japan.</p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Albert Einstein College of Medicine of Yeshiva University and Industrial
Research, Ltd. (&#8220;AECOM&#8221; and &#8220;IRL&#8221; respectively).</i> In June 2000, the Company licensed a series of potent
inhibitors of PNP from AECOM and IRL, (collectively, the &#8220;Licensors&#8221;). The lead product candidates from this collaboration
are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or
any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement
to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially
reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed
product (which range in the aggregate from $1,400 to almost $4,000&nbsp;per indication) for future development of these inhibitors,
single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future
payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which
can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement
may be terminated by the Company at any time by giving 60&nbsp;days advance notice or in the event of material uncured breach by
the Licensors.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2010, the Company amended the licensee agreement through which
the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from
research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed
to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed
PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments the Company
may receive in the future under its license agreement dated February&nbsp;1, 2006 with Mundipharma and (ii)&nbsp;royalties received
from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect.
The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On June&nbsp;19, 2012, the Company further amended its agreements
with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to
exclusive worldwide license of galidesivir to BioCryst for any antiviral use.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>The University of Alabama at Birmingham (&#8220;UAB&#8221;).</i>
The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements,
UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain
rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company
has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other
third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year
terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company
upon three months&#8217; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other
parties&#8217; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall
resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements,
but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes
products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 4 &#8212; Royalty Monetization</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Overview</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, the Company completed a $30,000&nbsp;financing
transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi
licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of $22,691&nbsp;from
the transaction after transaction costs of $4,309&nbsp;and the establishment of a $3,000&nbsp;interest reserve account by Royalty
Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with
the September 2012 interest payment.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As part of the transaction, the Company entered into a purchase and
sale agreement dated as of March&nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things,
(i)&nbsp;its rights to receive all non-governmental royalty and milestone payments from Shionogi arising under the Shionogi Agreement,
and (ii)&nbsp;the right to receive payments under a Japanese yen/US dollar foreign currency hedge agreement (as further described
below, the &#8220;Currency Hedge Agreement&#8221;) put into place by the Company in connection with the transaction. Royalty payments
will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&#8217;s collaboration with
Shionogi was not impacted as a result of this transaction.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Non-Recourse Notes Payable</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, Royalty Sub completed a private placement to
institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#8220;PhaRMA
Notes&#8221;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&nbsp;9, 2011 (the &#8220;Indenture&#8221;),
by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are
payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the
Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest
at 14%&nbsp;per annum, payable annually in arrears on September&nbsp;1st of each year. The Company remains entitled to receive
any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes. &nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 17; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub&#8217;s obligations to pay principal and interest on the
PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except
to the extent of the Company&#8217;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company
may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion
pay any interest shortfall on, the PhaRMA Notes.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On September 1, 2014, Royalty Sub was unable to pay the full amount
of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified
as current liabilities on the balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA
Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest
in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event,
the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the
PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of
any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from
Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating
the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease
to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the default of the PhaRMA
Notes is not expected to have a significant impact on the Company&#8217;s future results of operations or cash flows. As of September
30, 2017, the PhaRMA Notes remain in default.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Indenture does not contain any financial covenants. The Indenture
includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of
Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters
typical for indentures used in structured financings of this type.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of September 30, 2017, the aggregate fair value of the PhaRMA Notes
was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified
as Level 2 in the fair value hierarchy as defined in U.S. GAAP.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The PhaRMA Notes are redeemable at the option of Royalty Sub at any
time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid
interest through the redemption date on the PhaRMA Notes being redeemed.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Currency Hedge Agreement</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese
yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen
at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2018 through 2020, provided
the Currency Hedge Agreement remains in effect. A payment of $1,950&nbsp;will be required if, on May&nbsp;18 of the relevant year,
the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting
treatment; therefore, mark to market adjustments are recognized in the Company&#8217;s Consolidated Statement of Comprehensive
Loss. Cumulative mark to market adjustments for the nine months ended September&nbsp;30, 2017 and 2016 resulted in losses of $1,858
and $7,372, respectively. The Company is also required to post collateral in connection with the mark to market adjustments based
on defined thresholds. As of September 30, 2017 and December&nbsp;31, 2016, no collateral was posted under the Currency Hedge Agreement.
The Company will not be required to post collateral exceeding the maximum premium payments remaining payable under the Currency
Hedge Agreement. As of September 30, 2017, the maximum amount of hedge collateral the Company may be required to post is $5,850.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 5 &#8212; Senior Credit Facility</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">On September 23, 2016, the Company closed a $23,000 Senior Credit
Facility with an affiliate of MidCap Financial Services, LLC (&#8220;MidCap&#8221;), as administrative agent (the &#8220;Senior
Credit Facility&#8221;). The Senior Credit Facility was fully funded at closing and bears a variable interest rate of LIBOR (which
shall not be less than 0.5%) plus 8%. The Senior Credit Facility includes an interest-only payment period through fiscal 2017 and
scheduled monthly principal and interest payments for the subsequent 40 months. The Company has the option to repay the Senior
Credit Facility at any time prior to the scheduled principal repayment date subject to prepayment fees. Final payment of the Senior
Credit Facility is subject to a final payment fee equal to 5% of the principal funded under the Senior Credit Facility.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 18; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">As of September 30, 2017, the Company had borrowings of $23,000
under the Senior Credit Facility bearing an interest rate of 9.2%. The carrying amount of the debt approximates its fair value
based on prevailing interest rates as of the balance sheet date. Scheduled principal repayments of the Senior Credit Facility are
as follows:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%">
<tr style="vertical-align: bottom">
    <td nowrap colspan="5" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Principal Payments</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt">2017</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 82%; font-size: 10pt; text-align: justify; text-indent: 3.2pt">2018</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 20%; font-size: 10pt; text-align: right">6,900</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt">2019</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,900</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt">2020</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,900</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.1pt; text-indent: 3.2pt">2021</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">2,300</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; text-indent: 3.2pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">23,000</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The debt agreement contains two provisions that if deemed probable
would create the recognition of an embedded feature; however, we do not believe either provision is probable.</p></div><p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 6 &#8212; Stockholders&#8217; Equity</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 3, 2015, the Company filed a $150,000 shelf registration
statement on Form S-3 with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). This shelf registration statement became
effective upon filing and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock
purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. On February
26, 2016, the Company filed a post-effective amendment to this registration statement, which allowed for its use by the Company
when declared effective by the SEC&rsquo;s staff on April 18, 2016.</p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2017, the Company completed a public offering of 6,061 shares
of its common stock at a price of $8.50 per share, which included the underwriters&#8217; overallotment option to purchase additional
shares. Net proceeds were approximately $47,750 after deducting underwriting discounts and offering expenses.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In September 2017, the Company completed a public offering of 17,864
shares of its common stock at a price of $5.15 per share, which included the underwriters&#8217; overallotment option to purchase
additional shares. Net proceeds were approximately $85,750 after deducting underwriting discounts and offering expenses.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_001"></a>Item&nbsp;2. &nbsp;&nbsp;&nbsp;&nbsp;Management&#8217;s Discussion and Analysis of
Financial Condition and Results of Operations</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>This Quarterly Report on Form 10-Q contains statements of a forward-looking
nature relating to future events or the future financial performance of BioCryst. Such statements are only predictions and the
actual events or results may differ materially from the results discussed in the forward-looking statements. Factors that could
cause or contribute to such differences include those discussed below and elsewhere in this report, as well as those discussed
in other filings made by the Company with the Securities and Exchange Commission, including the Company&#8217;s Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. See &#8220;Information Regarding Forward-Looking Statements.&#8221;</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Cautionary Statement</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The discussion herein contains forward-looking statements within the
meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221;
created in Section&nbsp;21E. Forward looking statements regarding our financial condition and our results of operations that are
based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted
within the United States (&#8220;U.S. GAAP&#8221;), as well as projections for the future. The preparation of these financial statements
requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses,
and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. Our estimates are based
on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The results
of our estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We operate in a highly competitive environment that involves a number
of risks, some of which are beyond our control. We are subject to risks common to biotechnology and biopharmaceutical companies,
including risks inherent in our drug discovery, drug development and commercialization efforts, clinical trials, uncertainty of
regulatory actions and marketing approvals, reliance on collaborative partners, enforcement of patent and proprietary rights, the
need for future capital, competition associated with products, potential competition associated with our product candidates and
retention of key employees. In order for any of our product candidates to be commercialized, it will be necessary for us, or our
collaborative partners, to conduct clinical trials, demonstrate efficacy and safety of the product candidate to the satisfaction
of regulatory authorities, obtain marketing approval, enter into manufacturing, distribution and marketing arrangements, and obtain
market acceptance and adequate reimbursement from government and private insurers. We cannot provide assurance that we will generate
significant revenues or achieve and sustain profitability in the future. In addition, we can provide no assurance that we will
have sufficient funding to meet our future capital requirements. Statements contained in Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations and elsewhere in this report which are not historical facts are, or may constitute,
forward-looking statements. Forward-looking statements involve known and unknown risks that could cause our actual results to differ
materially from expected results. The most significant known risks are discussed in the section entitled &#8220;Risk Factors.&#8221;
Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.&nbsp;We caution you not to place undue reliance on any forward-looking statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our revenues are difficult to predict and depend on numerous factors,
including the prevalence and severity of influenza in regions for which peramivir has received regulatory approval, seasonality
of influenza, effort and resources dedicated to peramivir&#8217;s commercialization, ongoing discussions with government agencies
regarding future peramivir and/or galidesivir development and stockpiling procurement, as well as entering into, or modifying,
licensing agreements for our product candidates. Furthermore, revenues related to our collaborative development activities are
dependent upon the progress toward and the achievement of developmental milestones by us or our collaborative partners.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our operating expenses are also difficult to predict and depend on
several factors, including research and development expenses (and whether these expenses are reimbursable under government contracts),
drug manufacturing, and clinical research activities, the ongoing requirements of our development programs, and the availability
of capital and direction from regulatory agencies, which are difficult to predict. Management may be able to control the timing
and level of research and development and general and administrative expenses, but many of these expenditures will occur irrespective
of our actions due to contractually committed activities and/or payments.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As a result of these factors, we believe that period to period comparisons
are not necessarily meaningful and you should not rely on them as an indication of future performance. Due to all of the foregoing
factors, it is possible that our operating results will be below the expectations of market analysts and investors. In such event,
the prevailing market price of our common stock could be materially adversely affected.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><u>Overview</u></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are a biotechnology company that designs, optimizes and develops
novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. We focus on oral treatments for rare
diseases in which significant unmet medical needs exist and that align with our capabilities and expertise. We integrate the disciplines
of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through
the process known as structure-guided drug design.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Critical Accounting Policies and Estimates</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The accompanying discussion and analysis of our financial condition
and results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared
in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments
that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities.
We evaluate our estimates, judgments and the policies underlying these estimates on a periodic basis, as situations change, and
regularly discuss financial events, policies, and issues with members of our audit committee and our independent registered public
accounting firm. We routinely evaluate our estimates and policies regarding revenue recognition, administration, inventory and
manufacturing, taxes, stock-based compensation, research and development, consulting and other expenses and any associated liabilities.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Recent Corporate Highlights</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>RAPIVAB/RAPIACTA/PERAMIFLU (peramivir injection)</i></b></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Peramivir (i.e., product sold or marketed under the RAPIVAB, RAPIACTA,
and PERAMIFLU trade names) is approved for commercial sale in the United States, Canada, Japan, Taiwan and Korea and has a pending
Marketing Authorization Application (MAA) under review for treatment of symptoms typical of influenza in adults 18 years and older
in all 28 states of the European Union, Norway and Iceland. In September 2017, the FDA approved a sNDA for RAPIVAB extending its
availability for the treatment of acute uncomplicated influenza to pediatric patients two years and older.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In 2016, our Japanese partner, Shionogi, fulfilled a relatively large
stockpiling order to the Japanese Government in advance of the 2016/2017 influenza season for which we recorded $5.7 million of
net royalties. In the first quarter of 2017, we received $4.1 million of net royalties from the continued stockpiling of RAPIACTA
by the Japanese Government. Unlike the royalties for commercial sales by Shionogi, the proceeds from these stockpiling sales to
the Japanese Government are available to us for general corporate use and are not dedicated to satisfying non-recourse obligations
under the PhaRMA Notes.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 20; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0"><b><i>BCX7353</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">In August 2016, we announced that we had dosed the first subject
in the APeX-1 clinical trial of BCX7353 for the prevention of attacks in patients with HAE. APeX-1 was a 3-part dose ranging trial
designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (&ldquo;PK&rdquo;) and pharmacodynamics of orally administered
once-daily (&ldquo;QD&rdquo;) BCX7353 for 28 days, as a preventative treatment to reduce the frequency of attacks in HAE patients.
APEX-1 was conducted in several European countries, Australia and Canada.</p>



<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">On September 5, 2017, we reported final results from our APeX-1
clinical trial in HAE patients. This final interim analysis evaluated data from all patients in Parts 1, 2 and 3 and evaluated
doses of BCX7353 62.5 mg (n=7), 125 mg (n=14), 250 mg (n=14) and 350 mg (n=18) QD versus placebo (n=22) for 28 days. The pre-specified
per-protocol interim analysis included data on a total of 67 subjects with confirmed Type 1 or Type 2 HAE completing 28 days of
treatment. The percentage reductions by treatment group in the mean rate of independently-adjudicated angioedema attacks for the
pre-defined effective dosing period (weeks 2 through 4) in BCX7353 treated subjects were: 62.5mg QD, 7% (p=.715); 125 mg QD, 73%
(p&lt;0.001); 250 mg QD, 46% (p=0.006) and 350 mg QD, 58% (p&lt;0.001) compared to placebo. In the intent-to-treat (ITT) population,
corresponding reductions by treatment group were: 62.5mg QD, 9% (p=0.687); 125 mg QD, 73% (p&lt;0.001); 250 mg QD, 44% (p=0.014)
and 350 mg QD, 45% (p=0.007) compared to placebo.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Oral BCX7353 once-daily for 28 days was generally safe and well tolerated in subjects with HAE. No new clinically
significant safety findings were seen in Part 3 of the trial. Overall, there was one serious adverse event (&ldquo;AE&rdquo;) of
moderate gastrointestinal infection that was determined by the investigator not to be drug-related. As previously reported, study
drug was discontinued before day 28 in three subjects in the BCX7353 350 mg treatment arm (due to an unrelated pre-existing liver
disorder; drug-related gastroenteritis with liver disorder; and drug-related vomiting/abdominal cramps). The most common treatment-emergent
AEs in descending order of frequency were the common cold, headache, diarrhea, nausea and abdominal pain. Gastrointestinal AEs
were infrequent at the 125 mg and 62.5 mg dose levels, and there were no clinically significant laboratory abnormalities at these
dose levels.&nbsp;The observed efficacy, dose response, PK, safety and tolerability profile of BCX7353 strongly support its advancement
into Phase 3 development. Going forward, we have changed our nomenclature to a standardized &ldquo;base&rdquo; content reference
rather than the total &ldquo;salt&rdquo; weight of the compound. This change in referencing nomenclature results in the previously
described dose of 125 mg (&ldquo;salt&rdquo; reference) to be referred to as a 110 mg dose (&ldquo;base&rdquo; reference) in the
future. This change reflects only the referencing terminology rather than a change in the dose of the compound.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">In the fourth quarter of 2017, we completed regulatory interactions
with the FDA and EMA and reached agreement on the Phase 3 program requirements to support NDA and MAA submissions for prophylactic
treatment of HAE with BCX7353. Based upon this agreement, we expect to begin the remaining significant aspects of the program in
the first quarter of 2018. Accordingly, we will initiate a 24-week randomized, double-blind, placebo-controlled Phase 3 clinical
trial studying two doses of BCX7353 (&ldquo;APeX-2&rdquo;). Patients will roll-over into a 24 week safety extension. Separately,
we will initiate a long-term safety trial (&ldquo;APeX-S&rdquo;), which will enroll at least 160 patients who will be randomized
to the two doses of BCX7353 included in APeX-2. Subjects will remain on study-drug for 48 weeks. In the fourth quarter of 2017,
we received orphan drug status for BCX7353.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">On August 2, 2017, we announced the dosing of the first subject
into ZENITH-1, a clinical trial studying up to three dosage strengths of a liquid formulation of BCX7353 given as a single oral
dose for the acute treatment of angioedema attacks in patients with HAE. ZENITH-1 is a randomized, double-blind, placebo-controlled,
adaptive dose-ranging trial of the efficacy, safety and tolerability of BCX7353 for treatment of acute angioedema attacks, and
will enroll up to 60 subjects with HAE. Blinded study drug will be dosed as an oral liquid after onset of symptoms, for up to 3
attacks in each subject, with each subject receiving both BCX7353 (for 2 attacks) and placebo (for one attack) in a randomized
sequence. The trial is structured with up to 3 consecutive cohorts testing single doses of 750 mg (from 12 to 36 subjects), 500
mg (up to 12 subjects) and 250 mg (up to 12 subjects), starting with 750 mg. Efficacy assessments include patient-reported composite
visual analogue scale (&ldquo;VAS&rdquo;) scores, patient global assessment, change in symptoms, and use of rescue medication.
Treatment effect will be assessed on accumulating results, beginning after 12 subjects have completed study in the first cohort
(750 mg), by comparing the proportion of BCX7353-treated and placebo-treated attacks which have a stable or improved composite
VAS at 4 hours post dose. Once a treatment effect is demonstrated, enrollment at the 500 mg dose level will commence. If treatment
effect at the 500 mg dose level is similar to 750 mg dose level, the 250 mg dose cohort will be enrolled.</p>



<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0; background-color: white"><b><i>Forodesine</i></b></p>

<p style="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0; background-color: white"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In April 2017, Mundipharma obtained regulatory approval of Mundesine
(forodesine hydrochloride) for the treatment of relapsed/refractory PTCL (Peripheral T-Cell Lymphoma) by the Ministry of Health,
Labor and Welfare in Japan. Forodesine is a Purine Nucleoside Phosphorylase (&#8220;PNP&#8221;) inhibitor in development by Mundipharma,
licensed from us under a world-wide license agreement, as a treatment for cancer. PNP is a purine salvage pathway enzyme. High
doses of PNP inhibitors could be useful in the treatment of hematological malignancies. Mundipharma has received orphan drug status
for forodesine.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0"><b><i>Galidesivir</i></b></p>

<p style="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">After discussions with the FDA, NIAID and BARDA, we have delayed
the initiation of the galidesivir i.v. Phase 1 clinical trial. Based upon ongoing conversations, we expect the next step in galidesivir&rsquo;s
development will be to obtain agreement from the FDA on the nonclinical efficacy program before finalizing the Phase 1 clinical
trial protocol design. Until these additional non-clinical studies are initiated or until additional funding is authorized, development
activity under our existing U.S. Government contracts will continue to be restrained.</p>



<p style="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 21; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Results of Operations (three months ended September 30, 2017 compared to the three
months ended September 30, 2016)</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For the three months ended September 30, 2017, total revenues were
$8.8 million as compared to $7.8 million for the three months ended September 30, 2016. The increase in revenue in the third quarter
of 2017, as compared to 2016, resulted primarily from a $5.0 million milestone payment associated with the FDA approval of a sNDA
for RAPIVAB extending its availability for the treatment of acute uncomplicated influenza to pediatric patients two years and older
and the recognition of $1.5 million of peramivir product sales to Green Cross. These increases were partially offset by a $3.1
million decrease in RAPIACTA royalties primarily due to lower government stockpiling sales by Shionogi.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Revenues in the third quarter of 2017 included $1.5 million of peramivir
product sales to Green Cross, $0.4 million of royalty revenue from SUL, Shionogi and Green Cross associated with sales of peramivir
in the United States, Japan and Korea, $1.5 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS under
U.S. Government development contracts and $5.3 million associated with milestone revenue and collaborative revenue amortization
from other corporate partnerships. Revenues in the third quarter of 2016 included $3.5 million of royalty revenue from Shionogi
and Green Cross associated with sales of peramivir in the Japan, Korea and Taiwan, $3.8 million of reimbursement of collaborative
expenses from NIAID/HHS and BARDA/HHS related to the development of galidesivir, and $0.4 million associated with collaborative
revenue amortization from other corporate partnerships.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Research and development (&ldquo;R&amp;D&rdquo;) expenses increased
to $17.5 million for the third quarter of 2017 from $14.1 million in 2016. The increase in 2017 R&amp;D expenses, as compared to
2016, was due primarily to increased spending on the Company&rsquo;s HAE portfolio, including the achievement of a performance-based
stock option grant related to the successful completion of the APeX-1 clinical trial. These increases were partially offset by
a decrease in the Company&rsquo;s galidesivir expense under U.S. Government development contracts.&nbsp;</p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">General and administrative (&#8220;G&amp;A&#8221;) expenses for the
third quarter of 2017 increased to $3.3 million compared to $2.8&nbsp;million in the third quarter of 2016. The increase was primarily
due to the achievement of a performance-based stock option grant related to the successful completion of the APeX-1 clinical trial.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense increased to $2.1 million in the third quarter of
2017 as compared to $1.5 million in 2016 primarily due to our execution of a $23.0 million Senior Credit Facility in September
2016.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">A mark-to-market gain of $0.1 million was also recognized in the third
quarter of 2017 related to our foreign currency hedge, compared to a mark-to-market loss of $0.9 million in the same quarter in
the prior year, both resulting from changes in the U.S. dollar/Japanese yen exchange rate in the related time periods.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Results of Operations (nine months ended September 30, 2017 compared to the nine months
ended September 30, 2016)</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For the nine months ended September 30, 2017, total revenues were
$21.3 million as compared to $17.4 million for the nine months ended September 30, 2016. The increase in 2017 revenue was primarily
due to $7.0 million of milestone payments from Seqirus associated with the Canadian regulatory approval and the pediatric sNDA
approval of RAPIVAB<b><sup>&reg;</sup></b>, and a $1.2 million increase in royalty revenue from Shionogi &amp; Co. Ltd., Green
Cross Corporation and Seqirus. The increase in royalty revenue was largely the result of continued Japanese Government stockpiling
of RAPIACTA<b><sup>&reg;</sup></b>. Future government stockpiling orders are difficult to predict, as they are subject to the relevant
appropriation and stockpiling processes. These revenue increases were partially offset by a decrease in collaboration revenue under
U.S. Government development contracts.</p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Revenues in the first nine months of 2017 included $1.5 million of
peramivir product sales to Green Cross, $7.3 million of royalty revenue from SUL, Shionogi and Green Cross associated with sales
of peramivir in the United States, Japan and Korea, $4.3 million of reimbursement of collaborative expenses from NIAID/HHS and
BARDA/HHS under U.S. Government development contracts and $8.2 million associated with milestone revenue and collaborative revenue
amortization from other corporate partnerships. Revenues in the first nine months of 2016 included $6.0 million of royalty revenue
from SUL, Shionogi and Green Cross associated with sales of peramivir in the United States, Japan, Korea and Taiwan, $6.9 million
of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS related to the development of galidesivir, $2.9 million
of reimbursement of collaborative expenses from BARDA/HHS related to the development of RAPIVAB and $1.5 million associated with
collaborative revenue amortization from other corporate partnerships.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;	</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">R&amp;D expenses increased to $50.0 million for the first nine months
of 2017 from $48.9 million in 2016. The increase in 2017 R&amp;D expenses, as compared to 2016, was primarily due increased spending
on the Company&rsquo;s HAE portfolio, including the achievement of a performance-based stock option grant related to the successful
completion of the APeX-1 clinical trial, as well as increased spending on the Company&rsquo;s discovery programs. These increases
were partially offset by a decrease in galidesivir expenses under U.S. Government development contracts.&nbsp;</p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 22; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes our R&amp;D expenses for the periods
indicated (amounts are in thousands).</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp; &nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td nowrap colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended<br> September 30,</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td nowrap colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended<br> September&nbsp;30,</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td nowrap colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">R&amp;D expenses by program:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; font-size: 10pt; text-indent: 10pt">Avoralstat</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">1,377</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">320</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">13,011</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: 10pt">BCX7353</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,173</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,671</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">29,913</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,168</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">2nd generation kallikrein inhibitors</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">121</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">141</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">996</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,139</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: 10pt">Galidesivir</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,173</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,462</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,466</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,213</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: 10pt">Peramivir</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,005</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,017</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,911</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,679</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; text-indent: 10pt">Other research, preclinical and development costs</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">5,037</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">2,437</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">11,432</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">7,640</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total R&amp;D expenses</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">17,509</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">14,105</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">50,038</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">48,850</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">G&amp;A expenses for the first nine months of 2017 increased to $9.2
million compared to $8.7&nbsp;million of in the first nine months of 2016. The increase was primarily due to the achievement of
a performance-based stock option grant related to the successful completion of the APeX-1 clinical trial.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense, which is primarily related to the non-recourse notes
issued in conjunction with the non-dilutive RAPIACTA royalty monetization transaction in March 2011 and borrowings under the Senior
Credit Facility, was $6.3 million in the first nine months of 2017, compared to $4.4 million in the first nine months of 2016.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">A mark-to-market loss of $1.9 million was recognized in the first
nine months of 2017 related to our foreign currency hedge, compared to a mark-to-market loss of $7.4 million in the same period
in the prior year, both resulting from changes in the U.S. dollar/Japanese yen exchange rate in the related time periods. In addition,
we realized a currency exchange gain of $1.0 million and $0.8 million, respectively, in the first nine months of 2017 and 2016
related to the exercise of a U.S. dollar/Japanese yen currency option under our foreign currency hedge.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Cash expenditures have exceeded revenues since our inception and we
expect our 2017 operating expenses to exceed our 2017 revenues. Our operations have principally been funded through public offerings
and private placements of equity securities; cash from collaborative and other research and development agreements, including U.S.
Government contracts for RAPIVAB and galidesivir; and to a lesser extent, the PhaRMA Notes and the Senior Credit Facility financings.
To date, we have been awarded a BARDA/HHS RAPIVAB development contract totaling $234.8 million, which expired on June 30, 2014,
a NIAID/HHS galidesivir development contract totaling $39.5 million, which is ongoing, and a BARDA/HHS galidesivir development
contract totaling $39.1 million, which is also ongoing. The total amount of NIAID/HHS and BARDA/HHS galidesivir funding obligated
under awarded options is $39.5&nbsp;million and $20.6 million, respectively. We may issue securities through private placement
transactions or registered public offerings pursuant to a registration statement filed with the SEC. In addition to the above,
we have received funding from other sources, including other collaborative and other research and development agreements; government
grants; equipment lease financing; facility leases; research grants; and interest income on our investments.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of September 30, 2017, we had net working capital of $106.1 million,
an increase of approximately $93.5 million from $12.6 million at December&nbsp;31, 2016. The increase in working capital was principally
due to $133.5 million of proceeds from our March 2017 and September 2017 public offerings of common stock, partially offset by
our normal operating expenses associated with the development of our product candidates. Our principal sources of liquidity at
September 30, 2017 were approximately $117.8 million in cash and cash equivalents, approximately $48.4 million in investments considered
available-for-sale, and approximately $2.0 million in U.S. Government receivables. We anticipate our cash and investments will
fund our operations at least through the third quarter of 2019.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We intend to contain costs and cash flow requirements by closely managing
our third party costs and headcount, leasing scientific equipment and facilities, contracting with other parties to conduct certain
research and development projects and using consultants. We expect to incur additional expenses, potentially resulting in significant
losses, as we continue to pursue our research and development activities and begin to build a commercial infrastructure. We may
incur additional expenses related to the filing, prosecution, maintenance, defense and enforcement of patent and other intellectual
property claims and additional regulatory costs as our clinical programs advance through later stages of development. The objective
of our investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient
to meet cash flow requirements. We place our excess cash with high credit quality financial institutions, commercial companies,
and government agencies in order to limit the amount of our credit exposure. We have not realized any significant losses on our
investments.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 23; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We plan to finance our needs principally from the following:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">lease or loan financing and future public or private equity financing;</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">our existing capital resources and interest earned on that capital;</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">payments under existing and executing new contracts with the U.S. Government; and</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">payments under collaborative and licensing agreements with corporate partners.</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As our programs continue to advance, our costs will increase. Our
current and planned clinical trials, plus the related development, manufacturing, regulatory approval process requirements and
additional personnel resources and testing required for the continuing development of our product candidates will consume significant
capital resources and will increase our expenses. Our expenses, revenues and cash utilization rate could vary significantly depending
on many factors, including our ability to raise additional capital, the development progress of our collaborative agreements for
our product candidates, the amount and timing of funding we receive from existing U.S. Government contracts for galidesivir, the
amount of funding or assistance, if any, we receive from new U.S. Government contracts or other new partnerships with third parties
for the development and or commercialization of our product candidates, the progress and results of our current and proposed clinical
trials for our most advanced product candidates, the progress made in the manufacturing of our lead product candidates and the
progression of our other programs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">With the funds available at September 30, 2017, we believe these resources
will be sufficient to fund our operations at least through the third quarter of 2019. We have sustained operating losses for the
majority of our corporate history and expect that our 2017 expenses will exceed our 2017 revenues. We expect to continue to incur
operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. Our liquidity needs
will be largely determined by the success of operations in regards to the progression of our product candidates in the future.
We also may consider other plans to fund operations beyond the third quarter of 2019 including: (1)&nbsp;securing or increasing
U.S. Government funding of our programs, including obtaining procurement contracts; (2)&nbsp;out-licensing rights to certain of
our products or product candidates, pursuant to which the we would receive cash milestones; (3)&nbsp;raising additional capital
through equity or debt financings or from other sources; (4)&nbsp;obtaining additional product candidate regulatory approvals,
which would generate revenue, milestones and cash flow; (5)&nbsp;reducing spending on one or more research and development programs,
including by discontinuing development; and/or (6)&nbsp;restructuring operations to change our overhead structure. We may issue
securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private
placement transactions or registered public offerings. Our future liquidity needs, and ability to address those needs, will largely
be determined by the success of our product candidates and key development and regulatory events and our decisions in the future.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our long-term capital requirements and the adequacy of our available
funds will depend upon many factors, including:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="width: 92%"><font style="font-size: 10pt">our ability to perform under our government contracts and receive reimbursement, and receive stockpiling procurement contracts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td><font style="font-size: 10pt">the magnitude of work under our government contracts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td><font style="font-size: 10pt">the progress and magnitude of our research, drug discovery and development programs;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td><font style="font-size: 10pt">changes in existing or securing additional collaborative relationships or government contracts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td><font style="font-size: 10pt">our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies and governmental agencies or other third parties;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td><font style="font-size: 10pt">the extent to which our partners, including governmental agencies, will share in the costs associated with the development of our programs or run the development programs themselves;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td><font style="font-size: 10pt">our ability to negotiate favorable development and marketing strategic alliances for certain product candidates or a decision to build or expand internal development and commercial capabilities;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td><font style="font-size: 10pt">successful commercialization of marketed products by either us or a partner;</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="width: 92%"><font style="font-size: 10pt">the scope and results of preclinical studies and clinical trials to identify and develop product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td><font style="font-size: 10pt">our ability to engage sites and enroll subjects in our clinical trials;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td><font style="font-size: 10pt">the scope of manufacturing of our product candidates to support our preclinical research and clinical trials;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td><font style="font-size: 10pt">increases in personnel and related costs to support the development and commercialization of our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td><font style="font-size: 10pt">the scope of manufacturing of our drug substance and product candidates required for future NDA filings;</font></td></tr>
</table>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 24; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="width: 92%"><font style="font-size: 10pt">competitive and technological advances;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td><font style="font-size: 10pt">the time and costs involved in obtaining regulatory approvals;&nbsp;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td><font style="font-size: 10pt">post-approval commitments for RAPIVAB and other products that receive regulatory approval; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td><font style="font-size: 10pt">the costs involved in all aspects of intellectual property strategy and protection including the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We expect that we will be required to raise additional capital to
complete the development and commercialization of our current product candidates and we may seek to raise capital in the future.
Additional funding, whether through additional sales of equity or debt securities, collaborative or other arrangements with corporate
partners or from other sources, including governmental agencies in general and existing government contracts specifically, may
not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities,
with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect
of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative arrangements
may require us to transfer certain material rights to such corporate partners. Insufficient funds may require us to delay, scale
back or eliminate certain of our research and development programs. Our future working capital requirements, including the need
for additional working capital, will be largely determined by the advancement of our portfolio of product candidates as well as
rate of reimbursement by U.S. Government agencies of our galidesivir expenses and any future decisions regarding the future of
the RAPIVAB and galidesivir programs, including those relating to stockpiling procurement. More specifically, our working capital
requirements will be dependent on the number, magnitude, scope and timing of our development programs; regulatory approval of our
product candidates; obtaining funding from collaborative partners; the cost, timing and outcome of regulatory reviews, regulatory
investigations, and changes in regulatory requirements; the costs of obtaining patent protection for our product candidates; the
timing and terms of business development activities; the rate of technological advances relevant to our operations; the efficiency
of manufacturing processes developed on our behalf by third parties; and the level of required administrative support for our daily
operations.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The restrictive covenants contained in the Senior Credit Facility
could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial without the lender&#8217;s
permission or without repaying all Senior Credit Facility obligations. These covenants limit our ability to, among other things,
convey, sell, lease, license, transfer or otherwise dispose of certain parts of our business or property; change the nature of
our business; liquidate or dissolve; enter into certain change in control or acquisition transactions; incur or assume certain
debt; grant certain types of liens on our assets; modify, liquidate or transfer assets in certain collateral accounts; pay dividends
or make certain distributions to our stockholders; make certain investments; enter into material transactions with affiliates;
and modify existing debt or collaboration arrangements. A breach of any of these covenants could result in an event of default
under the Senior Credit Facility.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Financial Outlook for 2017</b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based upon our development plans, expected operations and our awarded
government contracts, we expect 2017 operating cash usage to be in the upper half of our previously disclosed range of $30 to $50
million, and expect our total 2017 operating expenses to be in the upper half of our previously disclosed range of $53 to $73 million.
Our operating expense range excludes equity-based compensation expense due to the difficulty in accurately projecting this expense
as it is significantly impacted by the volatility and price of the Company&#8217;s stock, as well as vesting of the Company&#8217;s
outstanding performance-based stock options. Our operating cash forecast excludes any impact of our royalty monetization, hedge
collateral posted or returned, and any other non-routine cash outflows or inflows. Our ability to remain within our operating expense
and operating cash target ranges is subject to multiple factors, including unanticipated or additional general development and
administrative costs and other factors described under the Risk Factors located elsewhere in this report.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of September 30, 2017, we do not have any unconsolidated entities
or off&#8211;balance sheet arrangements.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Critical Accounting Policies</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have established various accounting policies that govern the application
of U.S. GAAP, which were utilized in the preparation of our consolidated financial statements. Certain accounting policies involve
significant judgments and assumptions by management that have a material impact on the carrying value of certain assets and liabilities.
Management considers such accounting policies to be critical accounting policies. The judgments and assumptions used by management
are based on historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the
nature of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which
could have a material impact on the carrying values of assets and liabilities and the results of operations.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">While our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements included in our 2016 Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2016, we believe that the following accounting policies are the most critical to aid you in fully understanding
and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation
of our financial statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 25; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Inventory</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our inventories consist of peramivir work in process, which is valued
at the lower of cost and net realizable value using the first-in, first-out (i.e., FIFO) method. Cost includes materials, labor,
overhead, shipping and handling costs. Our inventories are subject to expiration dating. We regularly evaluate the carrying value
of our inventories and provide valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition,
we may experience spoilage of our raw materials and supplies. Our determination that a valuation reserve might be required, in
addition to the quantification of such reserve, requires us to utilize significant judgment.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Accrued Expenses</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We enter into contractual agreements with third-party vendors who
provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts
are subject to milestone-based invoicing and services are completed over an extended period of time. We record liabilities under
these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and
purchase orders, communicating with our applicable personnel to identify services that have been performed and estimating the level
of service performed and the associated cost when we have not yet been invoiced or otherwise notified of actual cost. The majority
of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued expenses as of
each balance sheet date based on the facts and circumstances known to us. We periodically confirm the accuracy of our estimates
with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 90%"><font style="font-size: 10pt">fees paid to Contract Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</font></td>
    <td style="width: 2%">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and product candidates;&nbsp;and</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">professional fees.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We base our expenses related to clinical trials on our estimates of
the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and
manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to
contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful
enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over
which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services
or the level of effort varies from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have
begun to incur or if we underestimate or overestimate the level of these costs, our actual expenses could differ from our estimates.</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Revenue Recognition</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We recognize revenues from collaborative and other research and development
arrangements and product sales. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive
evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#8217;s
price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 23pt"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 23pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and
research and development fees are recognized as revenue when the earnings process is complete and we have no further continuing
performance obligations or we have completed the performance obligations under the terms of the agreement. Fees received under
licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by
management based on the terms of the agreement and the products licensed. In the event a license agreement contains multiple deliverables,
we evaluate whether the deliverables are separate or combined units of accounting. Revisions to revenue or profit estimates as
a result of changes in the estimated revenue period are recognized prospectively.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of our license agreements, we receive royalty payments
based upon our licensees&#8217; net sales of covered products. We recognize royalty revenues when we can reliably estimate such
amounts and collectability is reasonably assured. Royalty revenue paid by Shionogi on their product sales is subject to returns.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element,
each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting.
This determination is based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer. The consideration that
is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable.
The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective
evidence of fair value, (ii) third-party evidence of selling price (&#8220;TPE&#8221;) and (iii) best estimate of selling price
(&#8220;BESP&#8221;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold
by us on a stand-alone basis. In most cases we expect to use TPE or BESP for allocating consideration to each deliverable. The
consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the
consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the
use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another
performance obligation.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 26; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, we entered into a License Agreement (the "SUL Agreement")
granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize
RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments,
and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii)
regulatory support to obtain Canadian and EU marketing approvals. We received an upfront payment of $33.7 million from SUL of which
$7.0 million was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21.8
million of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately
$3.7 million of the upfront payment was allocated to the sale of inventory and was recognized in the third quarter when the inventory
transfer was completed. Approximately $1.2 million of the revenue from the SUL Agreement will be recognized ratably over the expected
period of involvement in these regulatory support activities.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement
of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured
at the inception of the SUL Agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying
these revenue recognition criteria are recorded as deferred revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During the first nine months of 2017, we received a $2.0 million milestone
payment related to the approval of RAPIVAB by Health Canada and a $5.0 million milestone payment associated with the FDA approval
of a sNDA for RAPIVAB extending its availability for the treatment of acute uncomplicated influenza to pediatric patients two years
and older. We evaluated each event based payment under the provisions of ASU 2010-17, <i>Milestone Method of Revenue Recognition</i>,
and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the
milestone method of accounting. Under the terms of the SUL Agreement, we may receive an additional $5.0 million payment related
to the successful marketing approval by the EMA for an adult indication in the EU. No event-based payments were achieved during
the first nine months of 2016.&nbsp;</p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related
to research and development costs are recorded as revenue in the income statement rather than as a reduction in expenses. Under
our contracts with BARDA/HHS and NIAID/HHS, revenue is recognized as reimbursable direct and indirect costs are incurred.</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our research and development costs are charged to expense when incurred.
Advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed.
Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs,
clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of
various administrative and facilities related costs. Most of our manufacturing and clinical and preclinical studies are performed
by third-party CROs. Costs for studies performed by CROs are accrued by us over the service periods specified in the contracts
and estimates are adjusted, if required, based upon our on-going review of the level of services actually performed.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, we have license agreements with third parties, such
as AECOM, IRL, and UAB, which require fees related to sublicense agreements or maintenance fees. We expense sublicense payments
as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized
over the related revenue recognition period. We expense maintenance payments as incurred.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments paid
to our academic partners upon receipt of consideration from various commercial partners, and other consideration to our academic
partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt
of such payments or modifications from our commercial partners and are being expensed in proportion to the related revenue being
recognized. We believe that this accounting treatment appropriately matches expenses with the associated revenue.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We group our R&amp;D expenses into two major categories: direct external
expenses and indirect expenses. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct
laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials,
as well as other costs related to our clinical and preclinical studies. These costs are accumulated and tracked by active program.
Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead
of our research and development efforts. These costs apply to work on non-active product candidates and our discovery research
efforts. &nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Stock-Based Compensation</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards
and restricted stock unit awards, are recognized in our Consolidated Statements of Comprehensive Loss based on their fair values.
Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense
on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related
assumptions for the model requires judgment, including estimating the life of an award, the stock price volatility, and the expected
term. We utilize the Black-Scholes option-pricing model to value our awards and recognize compensation expense on a straight-line
basis over the vesting periods. The estimation of share-based payment awards that will ultimately vest requires judgment, and to
the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative
adjustment in the period estimates are revised. In addition, we have outstanding performance-based stock options for which no compensation
expense is recognized until &#8220;performance&#8221; has occurred. Significant management judgment is also required in determining
estimates of future stock price volatility and forfeitures to be used in the valuation of the options. Actual results, and future
changes in estimates, may differ substantially from our current estimates.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Currency Hedge Agreement</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with our issuance of the PhaRMA Notes, we entered into
a foreign Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to
the U.S.&nbsp;dollar. Under the Currency Hedge Agreement, we have the right to purchase dollars and sell yen at a rate of 100 yen
per dollar for which we may be required to pay a premium in each year from 2018 through 2020, provided the Currency Hedge Agreement
remains in effect. A payment of $2.0&nbsp;million will be required if, on May&nbsp;18 of the relevant year, the U.S. dollar is
worth 100 yen or less as determined in accordance with the Currency Hedge Agreement. In conjunction with establishing the Currency
Hedge Agreement, we will be required to post collateral to the counterparty, which may cause us to experience additional quarterly
volatility in our financial results. We will not be required at any time to post collateral exceeding the maximum premium payments
remaining payable under the Currency Hedge Agreement. As of September 30, 2017, the maximum amount of hedge collateral we may be
required to post is $5.9 million.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting
treatment and therefore mark to market adjustments will be recognized in our Consolidated Statements of Comprehensive Loss. Mark
to market adjustments are determined by quoted prices in markets that are not actively traded and for which significant inputs
are observable directly or indirectly, representing the Level 2 in the fair value hierarchy as defined by generally accepted accounting
principles (&#8220;U.S. GAAP&#8221;). We are also required to post collateral in connection with the mark to market adjustments
based on defined thresholds. As of September 30, 2017, no collateral was posted under the agreement.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Tax</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We account for uncertain tax positions in accordance with U.S. GAAP.
Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities
and any valuation allowance recorded against net deferred tax assets. We have recorded a valuation allowance against all potential
tax assets, due to uncertainties in our ability to utilize deferred tax assets, primarily consisting of certain net operating losses
carried forward, before they expire. The valuation allowance is based on estimates of taxable income in each of the jurisdictions
in which we operate and the period over which our deferred tax assets will be recoverable.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Information Regarding Forward-Looking Statements</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">This filing contains forward-looking statements within the meaning
of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221; created
in Section&nbsp;21E. All statements other than statements of historical facts contained in this filing are forward-looking statements.
These forward-looking statements can generally be identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221;
&#8220;predicts,&#8221; &#8220;potential,&#8221; the negative of these words or similar expressions. Statements that describe our
future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions
containing these forward-looking statements are principally contained in &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as any amendments
we make to those sections in filings with the SEC. These forward-looking statements include, but are not limited to, statements
about:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="width: 2%; text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="vertical-align: middle; width: 92%">the preclinical development, clinical development, commercialization, or post-marketing studies of our product candidates and products, including our HAE program, peramivir, galidesivir, and early stage discovery programs;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">the potential funding from our contracts with NIAID/HHS and BARDA/HHS for the development of galidesivir;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top"></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">the potential for government stockpiling orders of peramivir, additional regulatory approvals of peramivir or milestones, royalties or profit from sales of peramivir by us or our partners;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top"></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">the potential use of peramivir as a treatment for H1N1, H5N1, and H7N9 or other strains of influenza;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top"></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">the implementation of our business model, strategic plans for our business, products, product candidates and technology;</td></tr>
</table>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 28; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="text-align: left; vertical-align: top; width: 2%">&#8226;</td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="vertical-align: middle; width: 92%">our ability to establish and maintain collaborations or out-license rights to our product candidates;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top"></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">plans, programs, progress and potential success of our collaborations, including SUL for peramivir, Mundipharma for forodesine and Shionogi and Green Cross for peramivir in their territories;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top"></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle"><p style="margin: 0pt 0">Royalty Sub&rsquo;s ability to service its payment obligations in respect of the PhaRMA Notes;</p>


</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top"></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">the Currency Hedge Agreement entered into by us in connection with the issuance by Royalty Sub of the PhaRMA Notes;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top"></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top"></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">our ability to operate our business without infringing the intellectual property rights of others;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top"></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">estimates of our expenses, revenues, capital requirements, annual cash utilization, and our needs for additional financing;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top"></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">our ability to continue as a going concern;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top"></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">the timing or likelihood of regulatory filings or regulatory agreements, deferrals, and approvals;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top"></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">our ability to raise additional capital to fund our operations or repay our recourse debt obligations;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top"></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">our ability to comply with the covenants as set forth in the agreements governing our debt obligations;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">our financial performance;&nbsp;and</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top"></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">&#8226;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: middle">competitive companies, technologies and our industry.</td></tr>
</table>


<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These statements relate to future events or to our future financial
performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking
statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those
listed under &#8220;Risk Factors.&#8221; Any forward-looking statement reflects our current views with respect to future events
and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry
and future growth. Except as required by law, we assume no obligation to update or revise these forward-looking statements for
any reason, even if new information becomes available in the future.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_008"></a>Item&nbsp;3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Quantitative and Qualitative Disclosures
about Market Risk</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 9pt"><i>Interest Rate Risk</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are subject to interest rate risk on our investment portfolio and
borrowings under our fixed-interest rate PhaRMA Notes and our variable-interest rate Senior Credit Facility. The interest rate
applicable to our borrowings under the PhaRMA Notes is fixed at 14% and the Senior Credit Facility bears a floating interest rate
based on LIBOR. Increases in interest rates could therefore increase the associated interest payments that we are required to make
on the Senior Credit Facility. As of September 30, 2017, our Senior Credit Facility had an interest rate of 9.2%.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We invest in marketable securities in accordance with our investment
policy. The primary objectives of our investment policy are to preserve capital, maintain proper liquidity to meet operating needs
and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit
exposure to any single issue, issuer or type of investment. We place our excess cash with high credit quality financial institutions,
commercial companies, and government agencies in order to limit the amount of credit exposure. Some of the securities we invest
in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment
to fluctuate.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our investment exposure to market risk for changes in interest rates
relates to the increase or decrease in the amount of interest income we can earn on our portfolio, changes in the market value
due to changes in interest rates and other market factors as well as the increase or decrease in any realized gains and losses.
Our investment portfolio includes only marketable securities and instruments with active secondary or resale markets to help ensure
portfolio liquidity. A hypothetical 100 basis point increase or decrease in interest rates along the entire interest rate yield
curve would not significantly affect the fair value of our interest sensitive financial instruments, including our borrowings,
but may affect our future earnings and cash flows. We generally have the ability to hold our fixed-income investments to maturity
and therefore do not expect that our operating results, financial position or cash flows will be materially impacted due to a sudden
change in interest rates. However, our future investment income may fall short of expectations due to changes in interest rates,
or we may suffer losses in principal if forced to sell securities which have declined in market value due to changes in interest
rates or other factors, such as changes in credit risk related to the securities&#8217; issuers. To minimize this risk, we schedule
our investments to have maturities that coincide with our expected cash flow needs, thus avoiding the need to redeem an investment
prior to its maturity date. Accordingly, we do not believe that we have material exposure to interest rate risk arising from our
investments. Generally, our investments are not collateralized. We have not realized any significant losses from our investments.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 29; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We do not use interest rate derivative instruments to manage exposure
to interest rate changes. We ensure the safety and preservation of invested principal funds by limiting default risk, market risk
and reinvestment risk. We reduce default risk by investing in investment grade securities.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Foreign Currency Risk</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The majority of our transactions occur in U.S. dollars and we do not
have significant operating subsidiaries or significant investments in foreign countries. Therefore, we are not subject to significant
foreign currency exchange risk in our normal operations.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
we entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative
to the U.S. dollar. Under the Currency Hedge Agreement, we are required to post collateral based on our potential obligations under
the Currency Hedge Agreement as determined by periodic mark to market adjustments. Provided the Currency Hedge Agreement remains
in effect, we may be required to pay an annual premium in the amount of $2.0&nbsp;million from May&nbsp;2018 through May&nbsp;2020.
Such payment will be required if, in May of the relevant year, the spot rate of exchange for Japanese yen-U.S. dollars (determined
in accordance with the Currency Hedge Agreement) is such that the U.S. dollar is worth 100 yen or less.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_009"></a>Item&nbsp;4. &nbsp;&nbsp;&nbsp;&nbsp;Controls and Procedures</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We maintain a set of disclosure controls and procedures that are designed
to ensure that information relating to BioCryst Pharmaceuticals, Inc. required to be disclosed in our periodic filings under the
Exchange Act is recorded, processed, summarized and reported in a timely manner under the Exchange Act. We carried out an evaluation,
under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer,
of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, the Chief
Executive Officer and Chief Financial Officer concluded that, as of September 30, 2017, the Company&#8217;s disclosure controls
and procedures are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted
by it under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s
rules and forms, and include controls and procedures designed to ensure that information required to be disclosed by the Company
in such reports is accumulated and communicated to the Company&#8217;s management, including the Chief Executive Officer and Chief
Financial Officer of the Company, as appropriate to allow timely decisions regarding required disclosure.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There have been no changes in our internal control over financial
reporting that occurred during the quarter ended September 30, 2017 that have materially affected, or are reasonably likely to
materially affect, the Company&#8217;s internal control over financial reporting. &nbsp;</p>

<p style="font-size: 10pt; text-align: right; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: right; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>PART II. OTHER INFORMATION</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_010"></a>ITEM&nbsp;1A. <i>&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i></i></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>An investment in our stock involves risks. You should carefully read this entire report and consider the
following uncertainties and risks, which may adversely affect our business, financial condition, liquidity, prospects or results
of operations, along with all of the other information included in our other filings with the Securities and Exchange Commission,
before deciding to buy our common stock.</i></p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i></i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Risks Relating to Our Business</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We have incurred losses since our inception, expect to continue to incur
such losses, and may never be profitable.</i></b> &nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Since our inception, we have not achieved sustained profitability.
We expect to incur additional losses for the foreseeable future, and our losses could increase as our research and development
efforts progress. We expect that such losses will fluctuate from quarter to quarter and losses and fluctuations may be substantial.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">To become profitable, we, or our collaborative partners, must successfully
manufacture and develop product candidates, receive regulatory approval, and successfully commercialize and/or enter into profitable
agreements with other parties. It could be several years, if ever, before we receive significant revenue from any current or future
license agreements or revenues directly from product sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Because of the numerous risks and uncertainties associated with developing
our product candidates and their potential for commercialization, we are unable to predict the extent of any future losses. Even
if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are
unable to achieve and sustain profitability, the market value of our common stock will likely decline.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 30; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our success depends upon our ability to advance our products through
the various stages of development, especially through the clinical trial process.</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">To receive the regulatory approvals necessary for the sale of our
product candidates, we or our partners must demonstrate through preclinical studies and clinical trials that each product candidate
is safe and effective. The development process and related regulatory process are complex and uncertain. Because of the cost and
duration of clinical trials, we may decide to discontinue development of product candidates that are unlikely to show good results
in the clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have reasonable
commercial potential. We may suffer significant setbacks in pivotal pre-clinical studies and clinical trials (e.g. galidesivir,
BCX7353, other kallikrein inhibitors and our other rare disease product candidates), even after earlier clinical trials show promising
results. The development of our product candidates, including our clinical trials, may not be adequately designed or executed,
which could affect the potential outcome and analysis of study results. Any of our product candidates may produce undesirable side
effects in humans. The pre-clinical and clinical data from our product candidates could cause us or regulatory authorities to interrupt,
delay, modify or halt preclinical or clinical trials of a product candidate. Undesirable or inconclusive data or side effects in
humans could also result in the FDA or foreign regulatory authorities refusing to approve the product candidate for any targeted
indications. In addition, the FDA or other regulatory agencies may determine that study data from our product candidates necessitates
additional studies or study designs which differ from our planned development strategy, and regulatory agencies may also require
patient monitoring and testing or may implement restrictions or other conditions on our development activities, any of which could
materially impact the cost and timing of our planned development strategy. We, our partners, the FDA or foreign regulatory authorities
may suspend or terminate clinical trials at any time if we or they believe the trial participants face unacceptable health risks.
Clinical trials may fail to demonstrate that our product candidates are safe or effective and have acceptable commercial viability.
Regulatory authorities may interrupt, delay or halt clinical trials for a product candidate for any number of reasons.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our ability to successfully complete clinical trials is dependent
upon many factors, including but not limited to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; width: 95%"><font style="font-size: 10pt">our ability to find suitable clinical sites and investigators to enroll patients;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">the ability to maintain contact with patients to provide complete data after treatment;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">our product candidates may not prove to be either safe or effective;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">clinical protocols or study procedures may not be adequately designed or followed by the investigators;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">formulation improvements may not work as expected, which could negatively impact commercial demand for our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">manufacturing or quality control problems could affect the supply of product candidates for our trials; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">delays or changes in our planned development strategy, the regulations or guidelines, or other unexpected conditions or requirements of government agencies.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Clinical trials are lengthy and expensive. We or our partners incur substantial expense for, and devote significant
time to, preclinical testing and clinical trials, yet we cannot be certain that the tests and trials will ever result in the commercial
sale of a product. For example, clinical trials require adequate supplies of drug and sufficient patient enrollment. Lack of adequate
drug supply or delays in patient enrollment, including for APeX-2, APeX-S and ZENITH-1, can result in increased costs and longer
development times. Even if we or our partners successfully complete clinical trials for our product candidates, we or our partners
might not file the required regulatory submissions in a timely manner and may not receive regulatory approval for the product candidates.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We focus on rare diseases, which may create additional risks and challenges.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Because we focus on developing drugs as treatments for rare diseases,
we may seek orphan drug, breakthrough therapy or fast track designations for our product candidates in the United States or the
equivalent designations elsewhere in the world. Often, regulatory agencies have broad discretion in determining whether or not
to grant such designations. We cannot guarantee that we will be able to receive orphan drug status from the FDA or equivalent regulatory
designations elsewhere. We also cannot guarantee that we will obtain breakthrough therapy or fast track designation, which may
provide certain potential benefits such as more frequent meetings with the FDA to discuss the development plan, intensive guidance
on an efficient drug development program, and potential eligibility for rolling review or priority review. Even if we are successful
in obtaining any such designation by the FDA or other regulatory agency for our product candidates, such designations may not lead
to faster development or regulatory review or approval, and it does not increase the likelihood that our product candidates will
receive marketing approval. We may not be able to obtain or maintain such designations for our product candidates, and our competitors
may obtain these designations for their product candidates, which could impact our ability to develop and commercialize our product
candidates or compete with such competitors, which may adversely impact our business, financial condition or results of operations.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 31; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Although we have received Sakigake designation for BCX7353 in Japan,
we may not experience a faster development, review or approval process compared to the conventional process.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our clinical trials may not adequately show that our product candidates
are safe or effective.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">Progression of our product candidates through
the clinical development process is dependent upon our trials indicating our product candidates have adequate safety and efficacy
in the patients being treated by achieving pre-determined safety and efficacy endpoints according to the clinical trial protocols.
Failure to achieve any of these endpoints in any of our programs, including BCX7353, galidesivir and our other rare disease product
candidates, could result in delays in our trials or require the performance of additional unplanned trials. This could result in
delays in the development of our product candidates and could result in significant unexpected costs or the termination of programs.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>If our development collaborations with third parties, such as our development
partners and contract research organizations, fail, the development of our product candidates will be delayed or stopped.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 20pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We rely heavily upon third parties for many important stages of our
product candidate development, including but not limited to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">discovery of compounds that cause or enable biological reactions necessary for the progression of the disease or disorder, called enzyme targets;</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="3">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">licensing or designing of enzyme inhibitors for development as product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">execution of certain preclinical studies and late-stage development for our compounds and product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">management of our clinical trials, including medical monitoring and data management;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">execution of additional toxicology studies that may be required to obtain approval for our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">formulation improvement strategies and methods; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">manufacturing the starting materials and drug substance required to formulate our products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our failure to engage in successful collaborations at any one of these
stages would greatly impact our business. If we do not license enzyme targets or inhibitors from academic institutions or from
other biotechnology companies on acceptable terms, our drug development efforts would suffer. Similarly, if the contract research
organizations that conduct our initial or late-stage clinical trials, conduct our toxicology studies, manufacture our starting
materials, drug substance and product candidates or manage our regulatory function breached their obligations to us or perform
their services inconsistent with industry standards and not in accordance with the required regulations, this would delay or prevent
both the development of our product candidates and the availability of any potential commercial product.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we lose our relationship with any one or more of these parties,
we could experience a significant delay in both identifying another comparable provider and then contracting for its services.
We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it
is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service
as the original provider. In addition, any provider that we retain will be subject to applicable FDA current Good Laboratory Practices
(&#8220;cGLP&#8221;), current Good Manufacturing Practices (&#8220;cGMP&#8221;) and current Good Clinical Practices (&#8220;cGCP&#8221;),
and comparable foreign standards. We do not have control over compliance with these regulations by these providers. Consequently,
if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates
could be delayed. If any of the foregoing risks are realized, our business, financial condition and results of operations could
be materially adversely affected.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Because we have limited manufacturing experience, we depend on third-party
manufacturers to manufacture our product, product candidates and the materials for our product candidates. Often, especially early
in the development and commercialization process, we have only one source for manufacturing. If we cannot rely on existing third-party
manufacturers, we will be required to incur significant costs and potential delays in finding new third-party manufacturers.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have limited manufacturing experience and only a small scale manufacturing
facility. We currently rely upon a very limited number of third-party manufacturers to manufacture the materials required for our
product, product candidates and most of the preclinical and clinical quantities of our product candidates. We depend on these third-party
manufacturers to perform their obligations in a timely manner and in accordance with applicable governmental regulations. Our third-party
manufacturers, which may be the only manufacturer we have engaged for a particular product, may encounter difficulties with meeting
our requirements, including but not limited to problems involving:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">inconsistent production yields;</font></td></tr>
</table>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 32; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">product liability claims or recalls of commercial product;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">difficulties in scaling production to commercial and validation sizes;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">interruption of the delivery of materials required for the manufacturing process;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">scheduling of plant time with other vendors or unexpected equipment failure;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">potential catastrophes that could strike their facilities or have an effect on infrastructure;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">poor quality control and assurance or inadequate process controls; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA or other foreign regulatory agencies, particularly associated with peramivir, BCX7353, galidesivir and our early stage compounds.</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These contract manufacturers may not be able to manufacture the materials
required for our product candidates at a cost or in quantities necessary to make them commercially viable. We also have no control
over whether third-party manufacturers breach their agreements with us or whether they may terminate or decline to renew agreements
with us. To date, our third-party manufacturers have met our manufacturing requirements, but they may not continue to do so. Furthermore,
changes in the manufacturing process or procedure, including a change in the location where the drug is manufactured or a change
of a third-party manufacturer, may require prior review and approval in accordance with the FDA&#8217;s cGMP and comparable foreign
requirements. This review may be costly and time-consuming and could delay or prevent the launch of a product. The FDA or similar
foreign regulatory agencies may at any time implement new standards, or change their interpretation and enforcement of existing
standards for manufacture, packaging or testing of products. If we or our contract manufacturers are unable to comply, we or they
may be subject to regulatory action, civil actions or penalties any of which could be costly to the Company and could result in
a delay or shortage of product.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we are unable to maintain current manufacturing or other contract
relationships, or enter into new agreements with additional manufacturers on commercially reasonable terms, or if there is poor
manufacturing performance or failure to comply with any regulatory agency on the part of any of our third-party manufacturers,
we may not be able to complete development of, seek timely approval of, or market, our product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our raw materials, drug substances, and product candidates are manufactured
by a limited group of suppliers, including some at a single facility. If any of these suppliers were unable to produce these items,
this could significantly impact our supply of product candidate material for further preclinical testing and clinical trials.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We face intense competition, and if we are unable to compete effectively,
the demand for our products, if any, may be reduced.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The biotechnology and pharmaceutical industries are highly competitive
and subject to rapid and substantial technological change. There are many companies seeking to develop products for the same indications
that we currently target. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational
pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors have greater resources than
we do, including greater financial resources, larger research and development staffs and more experienced marketing and manufacturing
organizations. In addition, most of our competitors have greater experience than we do in conducting clinical trials and obtaining
FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals of
product candidates more rapidly than we do. Companies that complete clinical trials, obtain required regulatory approvals, and
commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including patent and FDA
exclusivity rights that would delay our ability to market products. We face, and will continue to face, competition in the licensing
of potential product candidates for desirable disease targets, licensing of desirable product candidates, and development and marketing
of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical
companies. Competition may also arise from, among other things:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">other drug development technologies;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">methods of preventing or reducing the incidence of disease, including vaccines;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">new small molecule or other classes of therapeutic agents.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 33; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Developments by others may render our product candidates or technologies
obsolete or noncompetitive.</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We are performing research on or developing products for the treatment
of several rare disorders, including HAE, as well as developing broad spectrum antivirals for use as medical countermeasures. We
expect to encounter significant competition for any of the pharmaceutical products we are developing and plan to develop. Companies
that complete clinical trials, obtain required funding or government support, obtain required regulatory approvals and commence
commercial sales or stockpiling orders of their products before their competitors may achieve a significant competitive advantage.
Such is the case with the current neuraminidase inhibitors marketed by GSK and Roche for influenza; CINRYZE<sup>&reg;</sup> , KALBITOR<sup>&reg;</sup>
and FIRAZYR<sup>&reg;</sup>, marketed by Shire Pharmaceuticals, Inc. (&ldquo;Shire&rdquo;) for HAE; BERINERT<sup>&reg;</sup> and
HAEGARDA<sup>&reg;</sup> marketed by CSL for HAE; and RUCONEST<sup>&reg;</sup> marketed by Pharming Healthcare, Inc. (&ldquo;Pharming&rdquo;)
for HAE.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Further, several pharmaceutical and biotechnology firms have announced efforts in HAE and in other therapeutic
areas where we have discovery and development efforts ongoing. Notably, prophylactic treatment for HAE is becoming increasingly
competitive with the recent approval of CSL&rsquo;s HAEGARDA, Shire&rsquo;s positive Phase 3 data for the monoclonal antibody,
lanadelumab, and Pharming&rsquo;s completion of a Phase 2 HAE prophylaxis trial for RUCONEST. Additionally, Kalvista Pharmaceuticals,
Inc. (KVD818) and Attune Pharmaceuticals, Inc. (ATN-249) have oral candidates for HAE prophylaxis in Phase 1 development. Therapeutic
products with potentially promising data to treat Ebola include Mapp Biopharmaceutical, Inc.&rsquo;s ZMapp (antibody-based) and
Gilead Sciences, Inc.&rsquo;s product currently under development (small molecule), both of which have been used in Ebola infected
patients. Shionogi also recently announced positive Phase 3 data for S033188, an oral treatment for influenza. If one or more of
our competitors&rsquo; products or programs are successful, the market for our products may be reduced or eliminated.</p>



<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Compared to us, many of our competitors and potential competitors
have substantially greater:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">capital resources;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">research and development resources, including personnel and technology;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">regulatory experience;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">preclinical study and clinical testing experience;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">manufacturing and marketing experience;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">production facilities.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Any of these competitive factors could impede our funding efforts,
render technology and product candidates noncompetitive or eliminate or reduce demand for our product candidates.</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We face risks related to our government-funded programs; if BARDA/HHS
or NIAID/HHS were to eliminate, reduce or delay funding from our contracts, this would have a significant negative impact on the
programs associated with such funding and could have a significant negative impact on our revenues and cash flows.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our projections of revenues and incoming cash flows are substantially
dependent upon BARDA/HHS and NIAID/HHS reimbursement for the costs related to our galidesivir program. If BARDA/HHS or NIAID/HHS
were to eliminate, reduce or delay the funding for these programs or disallow some of our incurred costs, we would have to obtain
additional funding for continued development or regulatory registration for these product candidates or significantly reduce or
stop the development effort.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In contracting with BARDA/HHS and NIAID/HHS, we are subject to various
U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which
may limit our reimbursement or if we are found to be in violation could result in contract termination. If the U.S. Government
terminates any of its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract
schedule and terms, significant negative impact on our cash flows and operations could result.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Our government contracts with BARDA/HHS and NIAID/HHS have special contracting
requirements, which create additional risks of reduction or loss of funding.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 20pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have completed work under a contract with BARDA/HHS for the development
of our neuraminidase inhibitor, RAPIVAB. We also have entered into contracts with BARDA/HHS and NIAID/HHS for the development of
galidesivir as a treatment for diseases caused by RNA pathogens, including Marburg virus disease and Ebola virus disease. In contracting
with these government agencies, we are subject to various U.S. Government contract requirements, including general clauses for
a cost-reimbursement research and development contract, which may limit our reimbursement or, if we are found to be in violation,
could result in contract termination.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 34; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">U.S. Government contracts typically contain a number of extraordinary
provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to
us as compared to competitors that do not rely on U.S. Government contracts. These risks include the ability of the U.S. Government
to unilaterally:</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">terminate or reduce the scope of our contract with or without cause;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">interpret relevant regulations (federal acquisition regulation clauses);</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">require performance under circumstances which may not be favorable to us;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">require an in process review where the U.S. Government will review the project and its options under the contract;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">control the timing and amount of funding, which impacts the development progress of our programs; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">audit and object to our contract-related costs and fees, including allocated indirect costs.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Our government contracts with BARDA/HHS and NIAID/HHS have termination
and audit provisions which create additional risks to us.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The U.S. Government may terminate its contracts with us either for
its convenience or if we default by failing to perform in accordance with the contract schedule and terms. Termination for convenience
provisions generally enable us to recover only our costs incurred or committed, and settlement expenses and profit on the work
completed prior to termination. Termination does not permit these recoveries under default provisions. In the event of termination
or upon expiration of a contract, the U.S. Government may dispute wind-down and termination costs and may question prior expenses
under the contract and deny payment of those expenses. Should we choose to challenge the U.S. Government for denying certain payments
under a contract, such a challenge could subject us to substantial additional expenses which we may or may not recover. Further,
if the U.S. Government terminates its contracts with us for its convenience, or if we default by failing to perform in accordance
with the contract schedule and terms, significant negative impact on our cash flows and operations could result.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As a U.S. Government contractor, we are required to comply with applicable
laws, regulations and standards relating to our accounting practices and are subject to periodic audits and reviews. As part of
any such audit or review, the U.S. Government may review the adequacy of, and our compliance with, our internal control systems
and policies, including those relating to our purchasing, property, estimating, compensation and management information systems.
Audits conducted by the U.S. Government for the completed BARDA/HHS peramivir contract have been performed and concluded through
fiscal 2009; all subsequent fiscal years are still open and auditable. Audits under the active BARDA/HHS and NIAID/HHS galidesivir
contracts may occur at the election of the U.S. Government and have been concluded through fiscal 2013. Based on the results of
its audits, the U.S. Government may adjust our contract-related costs and fees, including allocated indirect costs. This adjustment
could impact the amount of revenues reported on a historic basis and could impact our cash flows under the contracts prospectively.
In addition, in the event BARDA/HHS or NIAID/HHS determines that certain costs and fees were unallowable or determines that the
allocated indirect cost rate was higher than the actual indirect cost rate, BARDA/HHS or NIAID/HHS would be entitled to recoup
any overpayment from us as a result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject
to civil and criminal penalties and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension
of payments, fines and suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm
to our reputation if allegations of impropriety were made against us. In addition, under U.S. Government purchasing regulations,
some of our costs may not be reimbursable or allowed under our contracts. Further, as a U.S. Government contractor, we are subject
to an increased risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities
as compared to private sector commercial companies.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to reach milestones or to make annual minimum payments or
otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional
remedies.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we are unable or fail to meet payment obligations, performance
milestones relating to the timing of regulatory filings, product supply obligations, post approval commitments for RAPIVAB, or
development and commercial diligence obligations; are unable or fail to make milestone payments or material data use payments in
accordance with applicable provisions; or fail to pay the minimum annual payments under our respective licenses, our licensors
may terminate the applicable license or seek other available remedies. As a result, our development of the respective product candidate
or commercialization of the product would cease.&nbsp;&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to obtain additional financing or acceptable partnership
arrangements, we may be unable to complete the development and commercialization of our product candidates or continue operations.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As our programs advance, our costs are likely to increase. Our current
and planned discovery activities, pre-clinical and clinical trials, the related development, manufacturing, regulatory approval
process requirements, and the additional personnel resources and testing required for supporting the development of our product
candidates will consume significant capital resources. Our expenses, revenues and cash utilization rate could vary significantly
depending on many factors, including: our ability to raise additional capital; the development progress of our collaborative agreements
for our product candidates; the amount of funding we receive from NIAID/HHS and BARDA/HHS for galidesivir or from other new partnerships
with third parties for the development of our product candidates, including BCX7353 and our other rare disease product candidates;
the commercial success of peramivir achieved by our partners; the amount or profitability of any orders for peramivir or galidesivir
by any government agency or other party; the progress and results of our current and proposed clinical trials for our most advanced
product candidates, including BCX7353 and our other rare disease product candidates; the progress made in the manufacture of our
lead products and the progression of our other programs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 35; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We expect that we will be required to raise additional capital to
complete the development and commercialization of our current product candidates and we may seek to raise capital at any time.
Additional funding, whether through additional sales of securities, additional borrowings, or collaborative arrangements with partners,
including governmental agencies in general and from any BARDA/HHS or NIAID/HHS contract specifically, may not be available when
needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices
significantly more favorable than those of the currently outstanding common stock, could have the effect of diluting or adversely
affecting the holdings or rights of our existing stockholders. Additional borrowings may subject us to more restrictive covenants
than are currently applicable to us under our September 23, 2016 Senior Credit Facility with an affiliate of MidCap Financial Services,
LLC, as administrative agent (the &ldquo;Senior Credit Facility&rdquo;). In addition, collaborative arrangements may require us
to transfer certain material rights to such corporate partners. Insufficient funds or lack of an acceptable partnership may require
us to delay, scale-back or eliminate certain of our research and development programs.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">In order to continue future operations and continue our drug development programs, we will be required to
raise additional capital. In addition to seeking strategic partnerships, transactions and government funding, we may decide to
access the equity or debt markets, incur additional borrowings, or seek other sources to meet liquidity needs. Our ability to raise
additional capital may be limited and may greatly depend upon the success of ongoing development related to our current drug development
programs, including post approval studies for RAPIVAB,&nbsp;the progress, timeline and ultimate outcome of&nbsp;our kallikrein
inhibitors, including the BCX7353 program (including, but not limited to, formulation progress, Phase 3 trials, long-term human
safety studies, and the timing of carcinogenicity or other required studies), the progress of our other rare disease product candidates,
funding for and continued successful development of galidesivir, and the progress of our early discovery programs. In addition,
constriction and volatility in the equity and debt markets may restrict our future flexibility to raise capital when such needs
arise. Furthermore, we have exposure to many different industries, financing partners and counterparties, including commercial
banks, investment banks and partners (which include investors, licensing partners, and the U.S. Government) which may be unstable
or may become unstable in the current economic and political environment. Any such instability may impact these parties&rsquo;
ability to fulfill contractual obligations to us or they might limit or place burdensome conditions upon future transactions with
us. Also, it is possible that suppliers may be negatively impacted. Any such unfavorable outcomes in our current programs or unfavorable
economic conditions could place severe downward pressure on the price of our common stock and may decrease opportunities to raise
capital in the capital or credit markets, and further could reduce the return available on invested corporate cash, which, if severe
and sustained, could have a material and adverse impact on our results of operations and cash flows and limit our ability to continue
development of our product candidates.</p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We may not be able to continue as a going concern if we do not obtain
additional capital.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We have sustained operating losses for the majority of our corporate
history and expect that our 2017 expenses will exceed our 2017 revenues. We expect to continue to incur operating losses and negative
cash flows until revenues reach a level sufficient to support ongoing operations.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Our liquidity needs will be largely determined by the success of operations in regards to the progression
of our product candidates in the future. Our plans to alleviate the doubt regarding our ability to continue as a going concern
primarily include our ability to control the timing and spending on our research and development programs and raising additional
funds through equity financings.&nbsp; We also may consider other plans to fund operations including: (1) securing or increasing
U.S. Government funding of our programs, including obtaining procurement contracts; (2) out-licensing rights to certain of our
products or product candidates, pursuant to which the we would receive cash milestones; (3) raising additional capital through
equity or debt financings or from other sources; (4) obtaining additional product candidate regulatory approvals, which would generate
revenue, milestones and cash flow; (5) reducing spending on one or more research and development programs, including by discontinuing
development; and/or (6) restructuring operations to change our overhead structure.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">There can be no assurance that any of our plans will be successful
or that additional capital will be available to us on reasonable terms, or at all, when needed. If we are unable to obtain sufficient
additional capital, we may be forced to curtail operations, delay or stop ongoing clinical trials, cease operations altogether
or file for bankruptcy.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to successfully commercialize or establish collaborative
relationships to commercialize certain of our product candidates, or if any partner terminates or fails to perform its obligations
under agreements with us, potential revenues from commercialization of our product candidates could be reduced, delayed or eliminated.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our business strategy is to increase the asset value of our product
candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative arrangements with
third parties as appropriate. As needed, potential third-party relationships could include preclinical development, clinical development,
regulatory approval, marketing, sales and distribution of our product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 36; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Currently, we have established collaborative relationships with Mundipharma
for the development and commercialization of forodesine and with each of Shionogi and Green Cross for the development and commercialization
of peramivir in Japan, Taiwan and South Korea. Most recently we have established a collaborative relationship with Seqirus UK Limited
for RAPIVAB on a worldwide basis other than Israel, Japan, Korea and Taiwan. The process of establishing and implementing collaborative
relationships is difficult, time-consuming and involves significant uncertainty, including:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 92%"><font style="font-size: 10pt">our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory commercial, regulatory or clinical results, including post approval clinical commitments, a change in business strategy, a change of control or other reasons;</font></td>
    <td style="width: 3%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our contracts for collaborative arrangements may expire;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our partners may choose to pursue alternative technologies, including those of our competitors;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we may have disputes with a partner that could lead to litigation or arbitration;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we do not have day to day control over the activities of our partners and have limited control over their decisions;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">we or our partners may not devote sufficient capital or resources towards our product candidates; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td colspan="2"><font style="font-size: 10pt">we or our partners may not comply with applicable government regulatory requirements.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we or our partners fail to fulfill our responsibilities in a timely
manner, or at all, our commercialization efforts related to that collaboration could be reduced, delayed or terminated, or it may
be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our partner. If
we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue further
development of one or more of our product candidates, undertake commercialization activities at our own expense or find alternative
sources of funding. Any delay in the development or commercialization of our product candidates would severely affect our business,
because if our product candidates do not progress through the development process or reach the market in a timely manner, or at
all, we may not receive additional future event payments and may never receive milestone, product sales or royalty payments.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We do not have a great deal of experience in commercializing our products
or technologies, and our future revenue generation is uncertain.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We do not have a great deal of experience in commercializing our product
candidates or technologies. We currently have limited marketing and commercial capability, no direct or third-party sales force
and limited distribution capabilities. We may be unable to establish or sufficiently increase these capabilities for products we
currently, or plan to, commercialize. In addition, our revenue from collaborative agreements may be dependent upon the status of
our preclinical and clinical programs.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our ability to receive revenue from products we commercialize presents
several risks, including:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">we or our collaborators may fail to successfully complete clinical trials, or satisfy post-marketing commitments, sufficient to obtain and keep FDA marketing approval;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">many competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company and our products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">reimbursement is constantly changing, which could greatly affect usage of our products; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">future revenue from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market and commercialize our approved drugs.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 37; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Commercialization of peramivir by our partners is subject to the potential
commercialization risks described herein and numerous additional risks. Any potential revenue benefits to us in the form of milestone
payments, royalties or other consideration are highly speculative.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Commercialization success of peramivir is uncertain and is subject
to all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization. In addition,
commercialization of peramivir products is subject to further risks and may be negatively impacted by a number of factors, including,
but not limited to, the following:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">peramivir may not prove to be adequately safe and effective for market approval in markets other than the United States, Canada, Japan, Korea and Taiwan;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">necessary funding for post-marketing commitments and further development of peramivir may not be available timely, at all, or in sufficient amounts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">flu prevention or pandemic treatment concerns may not materialize at all, or in the near future;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">advances in flu vaccines or other antivirals, including competitive i.v. antivirals, could substantially replace potential demand for peramivir;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">a limited number of governmental entities are expected to be the primary potential stockpiling customers for peramivir and if we are not successful at marketing peramivir to these entities for any reason, we will not receive substantial revenues from stockpiling orders;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">government and third party payors may not provide sufficient coverage or reimbursement which would negatively impact the demand for peramivir;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we may not be able to supply commercial material to our partners and our partners may not be able to maintain or establish sufficient and acceptable commercial manufacturing, either directly or through third-party manufacturers;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">the commercial demand and acceptance for peramivir by healthcare providers and by patients may not be sufficient to result in substantial revenues of peramivir to our partners and may result in little to no milestones or royalties to us;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">effectiveness of marketing and commercialization efforts for peramivir by our partners;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">market satisfaction with existing alternative therapies;</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">perceived efficacy relative to other available therapies;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">disease prevalence;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">cost of treatment;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">pricing and availability of alternative products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">marketing and sales activities of competitors;</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">shifts in the medical community to new treatment paradigms or standards of care; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">relative convenience and ease of administration.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We are subject to various federal and state laws related to RAPIVAB and
other products under development and, if we or our partners do not comply with these regulations, we could face substantial penalties.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our or our partners&#8217; activities related to RAPIVAB, or any of
our other products under development and following their regulatory approval, are subject to regulatory and law enforcement authorities
in addition to the FDA, including the Federal Trade Commission, the Department of Justice, and state and local governments. In
the case of our collaboration with SUL, although SUL is responsible for RAPIVAB marketing and commercialization efforts, we continue
to carry certain risks associated with RAPIVAB because we hold the RAPIVAB NDA. For example, we are responsible for reporting adverse
drug experiences, we have responsibility for certain post-approval studies, we may have responsibilities and costs related to a
recall or withdrawal of RAPIVAB from sale, we may incur liability associated with RAPIVAB manufacturing contracted by us or in
support of any of our partners, we are required to maintain records and provide data and reports to regulatory agencies related
to RAPIVAB (e.g. risk evaluation and mitigation strategies, track and trace requirements, adverse events), and we may incur certain
promotional regulatory and government pricing risks, all of which could have a material adverse impact on our operations and financial
condition.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 38; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, we are subject to the federal physician sunshine act
and certain similar physician payment and drug pricing transparency legislation in various states. We are also subject to various
federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including both federal and state anti-kickback
and false claims laws. These laws regulate our or our partners&#8217; operations, sales and marketing practices, price reporting,
and relationships with physicians and other customers and third-party payors. Anti-kickback laws generally prohibit a manufacturer
from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase or prescription of
a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may be no regulations,
guidance or court decisions that clarify how the laws apply to particular industry practices. False claims laws prohibit anyone
from knowingly and willingly presenting, or causing to be presented for payment to third party payors (including Medicare and Medicaid)
claims for reimbursement or services that are false or fraudulent, claims for items or services not provided as claimed, or claims
for medically unnecessary items or services. The sunshine provisions apply to manufacturers with products reimbursed under certain
government programs and require those manufacturers to disclose annually to the federal government certain payments made to physicians
(defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as, ownership
and investment interests held by physicians (as defined above) and their immediate family members. State laws may also require
disclosure of pharmaceutical pricing information and marketing expenditures. Although we seek to comply with these statutes, it
is possible that our practices, or those of our partners, might be challenged under health care fraud and abuse, anti-kickback,
false claims or similar laws. Violations of the physician sunshine act and similar state legislation or the fraud and abuse laws
may be punishable by civil or criminal sanctions, including fines and civil monetary penalties, and future exclusion from participation
in government healthcare programs.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have a number of outstanding post-marketing commitments to the
FDA that we retain, despite our partnership with SUL, which we may not complete successfully or on time for any number of reasons,
including but not limited to lack of funds to complete the studies and insufficient interest by appropriate sites, investigators
or study subjects. For example, as a condition of the approval of RAPIVAB, we are required to complete a pediatric patient study
of RAPIVAB and to submit the final results of this clinical trial to the FDA. Depending on the FDA&#8217;s evaluation of the data
from this clinical trial, we may be unable to expand the indication for RAPIVAB or we may be required to include specific warnings
or limitations on dosing this product, which could negatively impact sales of RAPIVAB and negatively impact our relationship with
our partner. We may be subject to penalties if we fail to comply with post-approval legal and regulatory requirements and our products
could be subject to continual recordkeeping and reporting requirements, review and periodic inspections by the FDA and other regulatory
bodies. Regulatory approval of a product may be subject to limitations on the indicated uses for which the product may be marketed
or to the other restrictive conditions of approval that limit our ability to promote, sell or distribute a product. Furthermore,
the approval of RAPIVAB and any other future product candidates may be subject to requirements for costly post-marketing testing
and surveillance to monitor its safety or efficacy.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Advertising and promotion are subject to stringent FDA rules and oversight
and as the holder of the NDA we may be held responsible for any advertising and promotion conducted by our partner that is not
in compliance with the rules and regulations. In particular, the claims in all promotional materials and activities must be consistent
with the FDA approvals for approved products, and must be appropriately substantiated and fairly balanced with information on the
safety risks and limitations of the products. Adverse event information concerning approved products must be reviewed and as the
NDA holder of RAPIVAB we are required to make expedited and periodic adverse event reports to the FDA and other regulatory authorities.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, the research, manufacturing, distribution, sale and promotion
of products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including
the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department
of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments. Until we can
successfully transfer the pricing responsibilities to our partner, we remain responsible for pricing and rebate programs. Pricing
and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990, as amended,
and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of the Federal Supply
Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially
subject to federal and state healthcare false claims and fraud and abuse laws, as well as consumer protection and unfair competition
laws.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">If our operations with respect to RAPIVAB or our other products
that are subject to healthcare laws and regulations are found to be in violation of any of the healthcare fraud and abuse laws
described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal
penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or
restructuring of our operations could adversely affect our ability to operate our business and our financial results. Although
compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely
eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur
significant legal expenses and divert our management's attention from the operation of our business. Moreover, achieving and sustaining
compliance with all applicable federal and state fraud and abuse laws may be costly.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i></i></b></p>

<!-- Field: Page; Sequence: 39; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20.15pt"><b><i>We and our partners may be subject to new legislation, regulatory proposals
and healthcare payor initiatives that may increase our costs of compliance and adversely affect our or our partners&#8217; ability
to market our products, including RAPIVAB, obtain collaborators and raise capital.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Patient Protection and Affordable Care Act, or PPACA, made extensive
changes to the delivery of health care in the U.S. The PPACA included numerous provisions that affect pharmaceutical companies,
some of which became effective immediately and others of which have taken effect over the past several years. For example, the
PPACA expanded health care coverage to the uninsured through private health insurance reforms and an expansion of Medicaid. The
PPACA also imposed substantial costs on pharmaceutical manufacturers, such as an increase in liability for rebates paid to Medicaid,
new drug discounts that must be offered to certain enrollees in the Medicare prescription drug benefit, an annual fee imposed on
all manufacturers of brand prescription drugs in the U.S., and an expansion of an existing program requiring pharmaceutical discounts
to certain types of hospitals and federally subsidized clinics. The PPACA also contains cost containment measures that could reduce
reimbursement levels for health care items and services generally, including pharmaceuticals. It also required reporting and public
disclosure of payments and other transfers of value provided by pharmaceutical companies to physicians and teaching hospitals.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We expect that the current presidential administration and U.S. Congress
will likely continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the PPACA. There is still
significant uncertainty with respect to the impact that the current presidential administration and the U.S. Congress may have
on the PPACA, if any, and any changes will likely take time to unfold. As such, we cannot predict what effect the PPACA or other
healthcare reform initiatives that may be adopted in the future will have on our business.</p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We cannot predict what effect the PPACA or other healthcare reform
initiatives that may be adopted in the future will have on our business. The continuing efforts of the government, insurance companies,
managed care organizations and other payors of health care services to contain or reduce costs of health care could result in decreased
net revenues from our pharmaceutical products and decrease potential returns from our development efforts. In addition, pharmaceutical
and device manufacturers are also required to report and disclose certain payments and transfers of value to, and investment interests
held by, physicians and their immediate family members during the preceding calendar year. Failure to submit required information
may result in civil monetary penalties for payments, transfers of value or ownership or investment interests not reported in an
annual submission. Compliance with the PPACA and state laws with similar provisions is difficult and time consuming, and companies
that do not comply with these state laws face civil penalties. Because of the breadth of these laws and the narrowness of the safe
harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such
a challenge could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, there have been a number of other legislative and regulatory
proposals aimed at changing the pharmaceutical industry. In particular, legislation has been enacted in certain states and at a
federal level that requires development of an electronic pedigree to track and trace each prescription drug at the saleable unit
level through the distribution system. Compliance with these electronic pedigree requirements may increase our operational expenses
and impose significant administrative burdens. In addition, our compliance may be deemed insufficient and we could face a material
adverse effect on our business, financial condition, results of operations and growth prospects.&nbsp;As a result of these and
other new proposals, we may determine to change our current manner of operation, provide additional benefits or change our contract
arrangements, any of which could have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Adequate coverage and reimbursement in the U.S. and other markets
is critical to the commercial success of RAPIVAB or any other product that we might bring to market. Recently in the U.S. there
has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which
has resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement
methodologies. Third-party payors are increasingly challenging the prices charged for medical products and services and, in some
cases, imposing restrictions on the coverage of particular drugs. Many third-party payors negotiate the price of medical services
and products and develop formularies which establish pricing and reimbursement levels. Exclusion of a product from a formulary
can lead to its sharply reduced usage in the third-party payor&#8217;s patient population. The process for obtaining coverage can
be lengthy and costly, and we expect that it could take several months before a particular payor initially reviews our product
and makes a decision with respect to coverage. For example, third-party payors may require cost-benefit analysis data from us in
order to demonstrate the cost-effectiveness of RAPIVAB or any other product we might bring to market. For any individual third-party
payor, we may not be able to provide data sufficient to gain reimbursement on a similar or preferred basis to competitive products,
or at all which may have a material adverse effect on our business, financial condition and results of operations.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>There are risks related to the potential government use or sale of peramivir
(RAPIVAB).</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">United States Government use or sale of RAPIVAB in emergency situations,
or otherwise, may result in the use of RAPIVAB outside of its approved use. To the extent that RAPIVAB is used as a treatment for
influenza by the U.S. Government or peramivir by any other government entity, there can be no assurance that it will prove to be
generally safe, well-tolerated and effective. Such government use of RAPIVAB/peramivir may create certain liabilities for us or
our partners in the case of government use outside of the U.S. There is no assurance that we or our manufacturers will be able
to fully meet the demand for peramivir in the event of additional orders. Further, we may not achieve a favorable price for additional
orders of RAPIVAB in the U.S. or peramivir in any other country. Our competitors may develop products that could compete with or
replace peramivir. We may face competition in markets where we have no existing intellectual property protection or are unable
to successfully enforce our intellectual property rights.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 40; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There is no assurance that the non-U.S. partnerships that we have
entered into for peramivir will result in any order for peramivir in those countries. There is no assurance that peramivir will
be approved for any use or will achieve market approval in additional countries. In the event that any emergency use or market
approval is granted, there is no assurance that any government order or commercialization of peramivir in any countries will be
substantial or will be profitable to us. In addition, the sale of peramivir, emergency use or other use of peramivir in any country
may create certain liabilities for us and our partners.</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20.15pt"><b><i>If we or our partners do not obtain and maintain governmental approvals
for our product candidates under development, we or our partners will not be able to sell these potential products, which would
significantly harm our business because we will receive no revenue.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We or our partners must obtain regulatory approval before marketing
or selling our future product candidates. If we or our partners are unable to receive regulatory approval and do not market or
sell our future product candidates, we will never receive any revenue from such product sales. In the United States, we or our
partners must obtain FDA approval for product candidates that we intend to commercialize. The process of preparing for and obtaining
FDA approval may be lengthy and expensive, and approval is never certain. Products distributed abroad are also subject to foreign
government regulation and export laws of the United States. Because of the risks and uncertainties in biopharmaceutical development,
our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval.
If the FDA delays regulatory approval of our product candidates, our management&#8217;s credibility, our value and our operating
results may suffer. Even if the FDA or foreign regulatory agencies approve a product candidate, the approval may limit the indicated
uses for a product candidate and/or may require post-approval studies.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The FDA regulates, among other things, the record keeping and storage
of data pertaining to potential pharmaceutical products. We currently store most of our preclinical research data, our clinical
data and our manufacturing data at our facility. While we do store duplicate copies of most of our clinical data offsite and a
significant portion of our data is included in regular backups of our systems, we could lose important data if our facility incurs
damage, or if our vendor data systems fail, suffer damage or are destroyed. If we receive approval to market our potential products,
whether in the United States or internationally, we will continue to be subject to extensive regulatory requirements. These requirements
are wide ranging and govern, among other things:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">adverse drug experience reporting regulations;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">product promotion;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">product manufacturing, including good manufacturing practice requirements;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">product changes or modifications.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our failure to comply with existing or future regulatory requirements,
or our loss of, or changes to, previously obtained approvals, could have a material adverse effect on our business because we will
not receive product or royalty revenues if we or our partners do not receive approval of our products for marketing. &nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Royalties and milestone payments from Shionogi under our license agreement
with Shionogi (the &#8220;Shionogi Agreement&#8221;) will be required to be used by Royalty Sub to service its obligations under
its PhaRMA Notes, and generally will not be available to us for other purposes until Royalty Sub has repaid in full its obligations
under the PhaRMA Notes.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2011, our wholly-owned subsidiary Royalty Sub issued $30.0
million in aggregate principal amount of PhaRMA Notes. The PhaRMA Notes are secured principally by (i) certain royalty and milestone
payments under the Shionogi Agreement, pursuant to which Shionogi licensed from us the rights to market peramivir in Japan and
Taiwan, (ii) rights to certain payments under a Japanese yen/U.S. dollar Currency Hedge Agreement put into place by us in connection
with the issuance of the PhaRMA Notes and (iii) the pledge by us of our equity interest in Royalty Sub. Payments from Shionogi
to us on non-governmental sales under the Shionogi Agreement will generally not be available to us for other purposes until Royalty
Sub has repaid in full its obligations under the PhaRMA Notes. Accordingly, these funds will be required to be dedicated to Royalty
Sub&#8217;s debt service and not available to us for product development or other purposes. As of September 1, 2014, the payments
from Shionogi were insufficient for Royalty Sub to service its obligations under the PhaRMA Notes, resulting in an event of default
with respect to the PhaRMA Notes. As a result of this event of default, the holders of the PhaRMA Notes may be able to pursue acceleration
of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may&nbsp;exercise
other remedies available to them under the indenture or other documents related to&nbsp;the PhaRMA Notes. In such event, we may
not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes, we
may incur legal costs&nbsp;and we might otherwise be adversely affected.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Because an event of default has occurred under the PhaRMA Notes, the
holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the
PhaRMA Notes and our equity interest in Royalty Sub, in which case we may not realize the benefit of future royalty payments that
might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely affected.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub&#8217;s ability to service its payment obligations in
respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub, is subject to numerous risks.
Royalty Sub&#8217;s ability to service the PhaRMA Notes may be adversely affected by, among other things, changes in or any termination
of our relationship with Shionogi, reimbursement, regulatory, manufacturing and/or intellectual property issues, product returns,
product recalls, product liability claims and allegations of safety issues, as well as other factors. As Royalty Sub has been unable
to service its obligations under the PhaRMA Notes and an event of default has occurred under the PhaRMA Notes, the holders of the
PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and
our equity interest in Royalty Sub and may&nbsp;exercise other remedies available to them under the indenture&nbsp;or other documents
related to&nbsp;the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise
accrue to us following repayment of the PhaRMA Notes, we may incur legal costs&nbsp;and we might otherwise be adversely affected.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 41; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We may be required to pay significant premiums under the Currency Hedge
Agreement entered into by us in connection with the issuance of the PhaRMA Notes. In addition, because our potential obligations
under the foreign currency hedge are marked to market, we may experience additional quarterly volatility in our operating results
and cash flows attributable to the Currency Hedge Agreement.&nbsp;</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
we entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative
to the U.S. dollar. Under the foreign currency hedge agreement, we may be required to pay an annual premium in the amount of $2.0
million in each May continuing through May 2020. Such payment will be required if, in May of the relevant year, the spot rate of
exchange for Japanese yen-U.S. dollars (determined in accordance with the Currency Hedge Agreement) is such that the U.S. dollar
is worth 100 yen or less. We will be required to mark to market our potential obligations under the currency hedge and post cash
collateral, which may cause us to experience additional quarterly volatility in our operating results and cash flows as a result.
Additionally, we may be required to pay significant premiums or a termination fee under the foreign currency hedge agreement entered
into by us in connection with the issuance of the PhaRMA Notes. We are required to maintain a foreign currency hedge at 100 yen
per dollar under the agreements governing the PhaRMA Notes.</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in; background-color: white"><b><i>Our Senior Credit Facility
contains restrictions that limit our flexibility in operating our business. We may be required to make a prepayment or repay the
outstanding indebtedness earlier than we expect if a prepayment event or an event of default occurs, including a material adverse
change with respect to us, which could have a material adverse effect on our business.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; background-color: white">The Senior Credit Facility contains various
covenants that limit our ability to engage in specified types of transactions. These covenants limit our ability to, among other
things:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 95%; text-align: justify"><font style="font-size: 10pt">convey, sell, lease, license, transfer or otherwise dispose of certain parts of our business or property;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">change the nature of our business;</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">liquidate or dissolve;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">enter into certain change in control or acquisition transactions;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">incur or assume certain debt;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">grant certain types of liens on our assets;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">modify, liquidate or transfer assets in certain collateral accounts;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">pay dividends or make certain distributions to our stockholders;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">make certain investments;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">enter into material transactions with affiliates; and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">modify existing debt or collaboration arrangements.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; background-color: white">The restrictive covenants contained in the
Senior Credit Facility could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial
without the lender&#8217;s permission or without repaying all Senior Credit Facility obligations.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">A breach of any of these covenants could result in an event of default
under the Senior Credit Facility. An event of default will also occur if, among other things, a material adverse change in our
business, operations or condition occurs, which could potentially include negative results in clinical trials, or a material impairment
of the prospect of our repayment of any portion of the amounts we owe under the Senior Credit Facility occurs. In the case of a
continuing event of default under the agreement, the lender could elect to declare all amounts outstanding to be immediately due
and payable, proceed against the collateral in which we granted to the lender a security interest under the Senior Credit Facility,
or otherwise exercise the rights of a secured creditor. Amounts outstanding under the Senior Credit Facility are secured by substantially
all of our assets and those of our subsidiaries, excluding certain specified assets but including proceeds from those assets.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 42; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to adequately protect or enforce our intellectual property
rights or secure rights to patents of others, the value of those rights would diminish.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our success will depend in part on our ability and the abilities of
our partners to obtain, protect and enforce viable intellectual property rights including but not limited to trade name, trademark
and patent protection for our Company and its products, methods, processes and other technologies we may license or develop, to
preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both domestically and abroad.
The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves complex legal and factual
questions and has recently been the subject of much litigation. Neither the United States Patent and Trademark Office (&#8220;USPTO&#8221;),
the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions have consistent policies nor
predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology and pharmaceutical
patents. Further, we may not have worldwide patent protection for all of our product candidates and our intellectual property rights
may not be legally protected or enforceable in all countries throughout the world. In some jurisdictions, some of our product candidates
in certain programs, including our HAE program, may have short or no composition of matter patent life and we may therefore rely
on orphan drug exclusivity or data exclusivity. There can be no assurance that we will obtain orphan drug exclusivity or data exclusivity
in every jurisdiction. Further, in some jurisdictions, we may rely on formulation patents or method of use patents. Both the ability
to achieve issuance and the enforcement of formulation and method of use patents can be highly uncertain and can vary from jurisdiction
to jurisdiction, and such patents may therefore not adequately prevent competitors and potential infringers in some jurisdictions.
The validity, scope, enforceability and commercial value of the rights protected by such patents, therefore, is highly uncertain.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We also rely on trade secrets to protect technology in cases when
we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. If we cannot maintain
the confidentiality of our technology and other confidential information in connection with our collaborators and advisors, our
ability to receive patent protection or protect our proprietary information may be imperiled.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We may be involved in lawsuits to protect or enforce our patents, the
patents of our partners or our other intellectual property rights, which could be expensive, time consuming and unsuccessful</i></b>
..</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Competitors may infringe or otherwise violate our patents, the patents
of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to
file legal claims, which can be expensive and time-consuming and unsuccessful. An adverse result in any litigation or defense proceeding
could put one or more of our patents at risk. Our success depends in part on avoiding the infringement of other parties&#8217;
patents and other intellectual property rights as well as avoiding the breach of any licenses relating to our technologies and
products. In the United States, patent applications filed in recent years are confidential for 18 months, while older applications
are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently
infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors
that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally
cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, our partners or our licensors,
we or they could be forced to stop or delay research, development, manufacturing or sales of any infringing product in the country
or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. Such a license may not be
available on acceptable terms, or at all, particularly if the third party is developing or marketing a product competitive with
the infringing product. Even if we, our partners or our licensors were able to obtain a license, the rights may be nonexclusive,
which would give our competitors access to the same intellectual property.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we or our partners are unable or fail to adequately initiate, protect,
defend or enforce our intellectual property rights in any area of commercial interest or in any part of the world where we wish
to seek regulatory approval for our products, methods, processes and other technologies, the value of the product candidates to
produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies or our commercial use
of such products, processes, and other technologies, including but not limited to any trade name, trademark or commercial strategy
infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent offices of other jurisdictions
have issued to us a number of patents for our various inventions and we have in-licensed several patents from various institutions.
We have filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding
foreign patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We have also filed
certain trademark and trade name applications worldwide. We cannot assure you as to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">the degree and range of protection any patents will afford against competitors with similar products;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">if and when patents will issue;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">if patents do issue we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents;&nbsp;or</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 43; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">If the USPTO or other foreign patent office upholds patents issued
to others or if the USPTO grants patent applications filed by others, we may have to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">obtain licenses or redesign our products or processes to avoid infringement;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">stop using the subject matter claimed in those patents;&nbsp;or</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">pay damages.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We may initiate, or others may bring against us, litigation or
administrative proceedings related to intellectual property rights, including proceedings before the USPTO or other foreign patent
office. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent application
could materially and adversely affect our business, financial condition and results of operations. In addition, the costs of any
such proceeding may be substantial whether or not we are successful.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our success is also dependent upon the skills, knowledge and experience,
none of which is patentable, of our scientific and technical personnel. To help protect our rights, we require all employees, consultants,
advisors and partners to enter into confidentiality agreements that prohibit the disclosure of confidential information to anyone
outside of our company and require disclosure and assignment to us of their ideas, developments, discoveries and inventions. These
agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of
any unauthorized use or disclosure or the lawful development by others of such information, and if any of our proprietary information
is disclosed, our business will suffer because our revenues depend upon our ability to license or commercialize our product candidates
and any such events would significantly impair the value of such product candidates.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; background-color: white"><b><i>Our failure to comply with data protection
laws and regulations could lead to government enforcement actions and significant penalties against us and adversely impact our
operating results.</i></b></p>

<p style="font-size: 10pt; text-indent: 10.35pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0; background-color: white">European Union (&#8220;EU&#8221;) Member
States, Switzerland and other countries have adopted data protection laws and regulation, which impose significant compliance obligations.&nbsp;For
example, the EU Data Protection Directive, as implemented into national laws by the EU Member States, imposes strict obligations
and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and
adverse event reporting.&nbsp;Data protection authorities from the different EU Member States may interpret the EU Data Protection
Directive and national laws differently, which adds to the complexity of processing personal data in the European Union, and guidance
on implementation and compliance practices is often updated or otherwise revised.&nbsp;Our failure to comply with these laws and
regulations could lead to government enforcement actions and significant penalties against us and adversely impact our operating
results.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 10.35pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; background-color: white"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; background-color: white"><b><i>We are subject to litigation, which could
result in losses or unexpected expenditure of time and resources.&nbsp;</i></b></p>

<p style="font-size: 10pt; text-indent: 10.35pt; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">From time to time, we may be called upon to defend ourselves against
lawsuits relating to our business.&nbsp;Due to the inherent uncertainties in litigation, we cannot accurately predict the ultimate
outcome of any such proceedings.&nbsp;An unfavorable outcome in any such proceedings could have an adverse impact on our business,
financial condition and results of operations.&nbsp;If our stock price is volatile, we may become involved in securities class
action lawsuits in the future.&nbsp;Any litigation in the future, regardless of its merits, could result in substantial costs and
a diversion of management&#8217;s attention and resources that are needed to successfully run our business.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We face an inherent risk of liability in the event that the use or misuse
of our products results in personal injury or death and our product liability insurance coverage may be insufficient.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If the use or misuse of peramivir, forodesine or any other regulatory body-approved products we or a partner
may sell in the future harms people, we may be subject to costly and damaging product liability claims brought against us by consumers,
healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product candidates in clinical trials,
including post marketing clinical studies, could also expose us to product liability claims. We cannot predict all of the possible
harms or side effects that may result from the use of our products or the testing of product candidates and, therefore, the amount
of insurance coverage we currently have may not be adequate to cover all liabilities or defense costs we might incur. A product
liability claim or series of claims brought against us could give rise to a substantial liability that could exceed our resources.
Even if claims are not successful, the costs of defending such claims and potential adverse publicity could be harmful to our business.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We face an inherent risk of product liability exposure related to
the testing of our product candidates in human clinical trials and will face even greater risks upon any commercialization by us
of our product candidates. We have product liability insurance covering our clinical trials. Clinical trial and product liability
insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance or increase our existing
coverage at a reasonable cost to protect us against losses that could have a material adverse effect on our business. An individual
may bring a product liability claim against us if one of our products or product candidates causes, or is claimed to have caused,
an injury or is found to be unsuitable for consumer use. Any product liability claim brought against us, with or without merit,
could result in:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;</font></td></tr>
</table>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 44; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">withdrawal of clinical trial volunteers or patients;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">damage to our reputation and the reputation of our products, resulting in lower sales;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">regulatory investigations that could require costly recalls or product modifications;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">litigation costs;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">the diversion of management&#8217;s attention from managing our business.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Insurance coverage is increasingly more costly and difficult to obtain
or maintain.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">While we currently have insurance for our business, property, directors
and officers, and our products, insurance is increasingly more costly and narrower in scope, and we may be required to assume more
risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage, we will be required
to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage that is outside of our
insurance coverage, we may incur significant uninsured costs associated with loss or damage that could have an adverse effect on
our operations and financial position. Furthermore, any claims made on our insurance policies may impact our ability to obtain
or maintain insurance coverage at reasonable costs or at all.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If our facility incurs damage or power is lost for a significant length
of time, our business will suffer.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We store clinical and stability samples at our facility that could
be damaged if our facility incurs physical damage or in the event of an extended power failure. We have backup power systems in
addition to backup generators to maintain power to all critical functions, but any loss of these samples could result in significant
delays in our drug development process.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27.35pt; margin: 0pt 0">In addition, we store most of our preclinical
and clinical data at our facilities. Duplicate copies of most critical data are secured off-site. Any significant degradation or
failure of our computer systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant
delays in our drug development process and any system failure could harm our business and operations.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>A significant disruption in our information technology systems or a
cyber-security breach could adversely affect our business.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are increasingly dependent on information technology systems to
operate our business. Like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks
or intrusions, including by computer hackers, foreign governments, foreign companies or competitors, or may be breached by employee
error, malfeasance or other disruption. A breakdown, invasion, corruption, destruction or interruption of critical information
technology systems could negatively impact operations.&nbsp;If our systems are damaged, fail to function properly or otherwise
become unavailable, we may incur substantial costs to repair or replace them, and we may experience loss of critical data and interruptions
or delays in our ability to perform critical functions, which could adversely affect our business, financial condition or results
of operations. Any compromise of our data security could also result in a violation of applicable privacy and other laws, significant
legal and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our data
security measures, which could harm our business. There can be no assurance that our efforts to protect our data and information
technology systems will prevent breakdowns or breaches in our systems, or those of third parties with which we do business, and
any such events could adversely affect our business.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to retain our existing key personnel or fail to attract and
retain additional key personnel, the development of our product candidates and commercialization of our products and the related
expansion of our business will be delayed or stopped.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are highly dependent upon our senior management and scientific
team, the unexpected loss of whose services might impede the achievement of our development and commercial objectives. Competition
for key personnel with the experience that we require is intense and is expected to continue to increase. Our inability to attract
and retain the required number of skilled and experienced management, commercial, operational and scientific personnel will harm
our business because we rely upon these personnel for many critical functions of our business.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If because of our use of hazardous materials, we violate any environmental
controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our research and development involves the controlled use of hazardous
materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing
the use, storage, handling and disposal of these materials and some waste products. Accidental contamination or injury from these
materials could occur. In the event of an accident, we could be liable for any damages that result and any liabilities could exceed
our resources. Compliance with environmental laws and regulations or a violation of such environmental laws and regulations could
require us to incur substantial unexpected costs, which would materially and adversely affect our results of operations.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 45; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Risks relating to investing in our common stock</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our existing principal stockholders hold a substantial amount of our
common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Several of our stockholders own greater than 5% of our outstanding
common stock. Our top ten stockholders own more than 50% of BioCryst and can individually, and as a group, influence our operations
based upon their concentrated ownership. These stockholders, if they act together, may be able to influence the outcome of matters
requiring approval of the stockholders, including the election of our directors and other corporate actions.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our stock price has been, and is likely to continue to be, highly volatile,
which could cause the value of an investment in our common stock to decline significantly.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The market prices for securities of biotechnology companies in general
have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price has fluctuated frequently,
and these fluctuations are often not related to our financial results. For the twelve months ended September 30, 2017, the 52-week
range of the market price of our stock was from $2.82 to $9.25 per share. The following factors, in addition to other risk factors
described in this section, may have a significant impact on the market price of our common stock:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">announcements of technological innovations or new products by us or our competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">developments or disputes concerning patents or proprietary rights;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">additional dilution through sales of our common stock or other derivative securities;</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">status of new or existing licensing or collaborative agreements and government contracts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">announcements relating to the status of our programs;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">developments and announcements regarding new and virulent strains of influenza;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we or our partners achieving or failing to achieve development milestones;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">publicity regarding actual or potential medical results relating to products under development by us or our competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">publicity regarding certain public health concerns for which we are or may be developing treatments;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">regulatory developments in both the United States and foreign countries;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">public concern as to the safety of pharmaceutical products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">actual or anticipated fluctuations in our operating results;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">changes in financial estimates or recommendations by securities analysts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">changes in the structure of healthcare payment systems, including developments in price control legislation;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">additions or departures of key personnel or members of our board of directors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">economic and other external factors or other disasters or crises; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">period-to-period fluctuations in our financial results.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 46; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Future sales and issuances of securities may dilute the ownership interests
of our current stockholders and cause our stock price to decline.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Future sales of our common stock by current stockholders into the
public market could cause the market price of our stock to fall. As of October 31, 2017, there were 98,404,761 shares of our common
stock outstanding. We may from time to time issue securities in relation to a license arrangement, collaboration, merger or acquisition.
We may also sell, for our own account, shares of common stock or other equity securities, from time to time at prices and on terms
to be determined at the time of sale.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of October 31, 2017, there were 13,530,572 stock options and restricted
stock units outstanding, 1,606,959 shares available for issuance under our Amended and Restated Stock Incentive Plan, and 330,270
shares available for issuance under our Employee Stock Purchase Plan. In addition, we could also make equity compensation grants
outside of our Stock Incentive Plan. The shares underlying existing stock options, restricted stock units and possible future stock
options, stock appreciation rights and stock awards have been registered pursuant to registration statements on Form S-8.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If some or all of such shares are sold or otherwise issued into the
public market over a short period of time, our current stockholders&#8217; ownership interests may be diluted and the value of
all publicly traded shares is likely to decline, as the market may not be able to absorb those shares at then-current market prices.
Additionally, such sales and issuances may make it more difficult for us to sell equity securities or equity-related securities
in the future at a time and price that our management deems acceptable, or at all.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In March 2017, we entered into a Registration
Rights Agreement with entities affiliated with Baker Bros. Advisors LP (the &ldquo;Baker Entities&rdquo;) to provide that, if requested,
we will register the shares of our common stock beneficially owned by the Baker Entities for resale under the Securities Act. Our
registration obligations pursuant to the Registration Rights Agreement cover all shares then held or thereafter acquired by the
Baker Entities, for up to ten years, and include our obligation to facilitate certain underwritten public offerings of our common
stock by the Baker Entities in the future. On May 10, 2017, we filed a registration statement on Form S-3 with respect to 11,710,951
shares of common stock held by the Baker Entities. If the Baker Entities, by exercising their underwriting rights or otherwise,
sell a large number of our shares, or the market perceives that the Baker Entities intend to sell a large number of our shares,
this could adversely affect the market price of our common stock.</p>



<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We have anti-takeover provisions in our corporate charter documents
that may result in outcomes with which you do not agree.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our board of directors has the authority to issue up to 4,800,000
shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without
further vote or action by our stockholders. The rights of the holders of any preferred stock that may be issued in the future may
adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third
parties to acquire a majority of our outstanding voting stock.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">In addition, our certificate of incorporation provides for staggered
terms for the members of the board of directors and supermajority approval of the removal of any member of the board of directors
and prevents our stockholders from acting by written consent or from calling special meetings of stockholders. Our certificate
also requires supermajority approval of any amendment of these provisions. These provisions and other provisions of our by-laws
and of Delaware law applicable to us could delay or make more difficult a merger, tender offer or proxy contest involving us.&nbsp;</p>



<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We have never paid dividends on our common stock and do not anticipate
doing so in the foreseeable future.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have never paid cash dividends on our stock. We currently intend
to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do not anticipate paying cash
dividends on our common stock in the foreseeable future.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<!-- Field: Page; Sequence: 47; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><a name="a_011"></a><b>Item&nbsp;6. &nbsp;&nbsp;&nbsp;&nbsp;Exhibits</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>INDEX TO EXHIBITS</b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 7%; text-align: center">&nbsp;</td>
    <td style="width: 93%">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><font style="font-size: 10pt"><b>Number</b></font></td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Description</b></font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><a href="http://www.sec.gov/Archives/edgar/data/882796/000103570406000836/d42297exv3w1.htm" style="-sec-extract: exhibit"><font style="font-size: 10pt">3.1</font></a></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000103570406000836/d42297exv3w1.htm" style="-sec-extract: exhibit"><font style="font-size: 10pt">Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed December&nbsp;22, 2006.</font></a></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231007001386/c70813exv3w1.htm" style="-sec-extract: exhibit"><font style="font-size: 10pt">3.2</font></a></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231007001386/c70813exv3w1.htm" style="-sec-extract: exhibit"><font style="font-size: 10pt">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed July&nbsp;24, 2007.</font></a></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w1.htm" style="-sec-extract: exhibit"><font style="font-size: 10pt">3.3</font></a></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w1.htm" style="-sec-extract: exhibit"><font style="font-size: 10pt">Certificate of Increase of Authorized Number of Shares of Series&nbsp;B Junior Participating Preferred Stock. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed November&nbsp;4, 2008.</font></a></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex31.htm" style="-sec-extract: exhibit"><font style="font-size: 10pt">3.4</font></a></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex31.htm" style="-sec-extract: exhibit"><font style="font-size: 10pt">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed May&nbsp;8, 2014.</font></a></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex32.htm" style="-sec-extract: exhibit"><font style="font-size: 10pt">3.5</font></a></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex32.htm" style="-sec-extract: exhibit"><font style="font-size: 10pt">Certificate of Increase of Authorized Number of Shares of Series&nbsp;B Junior Participating Preferred Stock. Incorporated by reference to Exhibit&nbsp;3.2 to the Company&#8217;s Form&nbsp;8-K filed May&nbsp;8, 2014.</font></a></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w2.htm" style="-sec-extract: exhibit"><font style="font-size: 10pt">3.6</font></a></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w2.htm" style="-sec-extract: exhibit"><font style="font-size: 10pt">Amended and Restated Bylaws of Registrant effective October&nbsp;29, 2008. Incorporated by reference to Exhibit&nbsp;3.2 to the Company&#8217;s Form&nbsp;8-K filed November&nbsp;4, 2008.</font></a></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><a href="exh_101.htm"><font style="font-size: 10pt">(10.1)</font></a></td>
    <td><a href="exh_101.htm"><font style="font-size: 10pt">Amendment #8 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated September 20, 2017.</font></a></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt"><a href="exh_311.htm">(31.1)</a></font></td>
    <td><a href="exh_311.htm"><font style="font-size: 10pt">Certification of the Chief Executive Officer Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</font></a></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt"><a href="exh_312.htm">(31.2)</a></font></td>
    <td><a href="exh_312.htm"><font style="font-size: 10pt">Certification of the Chief Financial Officer Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</font></a></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt"><a href="exh_321.htm">(32.1)</a></font></td>
    <td><a href="exh_321.htm"><font style="font-size: 10pt">Certification pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</font></a></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt"><a href="exh_322.htm">(32.2)</a></font></td>
    <td><a href="exh_322.htm"><font style="font-size: 10pt">Certification pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</font></a></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">(101)</font></td>
    <td><font style="font-size: 10pt">Financial statements from the Quarterly Report on Form 10-Q of BioCryst Pharmaceuticals, Inc. for the three months ended September 30, 2017, formatted in XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">_______________________</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: top; width: 4%"><font style="font-size: 10pt">(&nbsp;&nbsp;)</font></td>
    <td style="width: 96%"><font style="font-size: 10pt">Filed or furnished herewith.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 48; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="a_012"></a>SIGNATURES</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 8th day of November, 2017.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 54%">&nbsp;</td>
    <td style="width: 32%">&nbsp;</td>
    <td style="width: 14%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">BIOCRYST PHARMACEUTICALS, INC.</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/ Jon P. Stonehouse</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Jon P. Stonehouse</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2">
        <p style="font-size: 10pt; margin: 0pt 7pt 0pt 0"><i>President and Chief Executive Officer</i></p>
        <p style="font-size: 10pt; margin: 0pt 7pt 0pt 0"><i>(Principal Executive Officer)</i></p></td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/ Thomas R. Staab, II</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Thomas R. Staab, II</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt"><i>Senior Vice President, Chief Financial Officer and Treasurer</i></font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt"><i>(Principal Financial and Principal Accounting Officer)</i></font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: right; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: right; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>




<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">49</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div align="center" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exh_101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><img src="exh101_01.jpg"></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; padding-top: 12pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><img src="exh101_02.jpg"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exh_311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 31.1</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATIONS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Jon P. Stonehouse, certify that:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; font-size: 10pt"><FONT STYLE="font-size: 10pt">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 19%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Date: November 8, 2017</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Jon P. Stonehouse</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Jon P. Stonehouse</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exh_312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 31.2</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATIONS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Thomas R. Staab, II, certify that:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; font-size: 10pt"><FONT STYLE="font-size: 10pt">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 51%"><FONT STYLE="font-size: 10pt">Date: November 8, 2017</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Thomas R. Staab, II</FONT></TD>
    <TD STYLE="width: 19%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Thomas R. Staab, II</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Senior Vice President, Chief Financial Officer and Treasurer</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exh_321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
on Form 10-Q for the period ending September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the
&ldquo;Report&rdquo;), I, Jon P. Stonehouse, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350,
as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3">
        <P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 9.2pt 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 9.2pt 0pt 0">&nbsp;</P></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Jon P. Stonehouse</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">Jon P. Stonehouse</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="5">
        <P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 17pt 0pt 0.25in">President and Chief Executive Officer</P>
        <P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 17pt 0pt 0.25in">Date: November 8, 2017</P></TD></TR>
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 21%">&nbsp;</TD>
    <TD STYLE="width: 67%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exh_322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;32.2</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
on Form 10-Q for the period ending September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the
&ldquo;Report&rdquo;), I, Thomas R. Staab, II, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350,
as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; font-size: 10pt"><FONT STYLE="font-size: 10pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 70%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Thomas R. Staab, II</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Thomas R. Staab, II</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font-size: 10pt; margin: 0pt 8pt 0pt 0">Senior Vice President, Chief Financial Officer and Treasurer</P>
        <P STYLE="font-size: 10pt; margin: 0pt 8pt 0pt 0">Date: November 8, 2017</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>bcrx-20170930.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 04:53PM UTC 2017-11-08--><xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.xbrl.org/2003/instance" xmlns:bcrx="http://www.biocryst.com/20170930" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="bcrx-20170930.xsd" xlink:type="simple"/>
  <bcrx:AccruedExpensesPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198098">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accrued Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally enters into contractual agreements with &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with its service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; min-width: 700px;"&gt; &lt;tr&gt; &lt;td style="width: 5%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to Contract Research Organizations (&amp;#x201c;CROs&amp;#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to contract manufacturers in connection with the production of the Company&amp;#x2019;s raw materials, drug substance and drug products;&amp;nbsp;and&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;professional fees.&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016, &lt;/div&gt;the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:AccruedExpensesPolicyTextBlock>
  <bcrx:AdvanceNoticePeriodForTerminationOfAgreement contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" id="c23198698">P60D</bcrx:AdvanceNoticePeriodForTerminationOfAgreement>
  <bcrx:AmortizationOfDiscountAndPremiumOnInvestments contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198024" unitRef="iso4217-usd">125000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
  <bcrx:AmortizationOfDiscountAndPremiumOnInvestments contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198025" unitRef="iso4217-usd">499000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
  <bcrx:AnnualLicenseFeeMaximum contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c23198697" unitRef="iso4217-usd">500000</bcrx:AnnualLicenseFeeMaximum>
  <bcrx:AnnualLicenseFeeMinimum contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c23198696" unitRef="iso4217-usd">150000</bcrx:AnnualLicenseFeeMinimum>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2017-09-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c23198431" unitRef="iso4217-usd">96000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2017-09-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c23198436" unitRef="iso4217-usd">39000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2017-09-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c23198441" unitRef="iso4217-usd">34000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2017-09-30" decimals="-3" id="c23198446" unitRef="iso4217-usd">169000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c23198451" unitRef="iso4217-usd">34000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c23198456" unitRef="iso4217-usd">26000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c23198461" unitRef="iso4217-usd">17000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-12-31" decimals="-3" id="c23198466" unitRef="iso4217-usd">77000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue contextRef="i_2017-09-30" decimals="-3" id="c23198472" unitRef="iso4217-usd">4539000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue contextRef="i_2016-12-31" decimals="-3" id="c23198473" unitRef="iso4217-usd">8926000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock contextRef="d_2017-01-01_2017-09-30" id="c-17">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;43,848&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,546&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Maturing after one year through two years&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,539&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,926&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48,387&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,472&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock>
  <bcrx:AveragematurityForPortfolioInvestments contextRef="d_2017-01-01_2017-09-30_RangeAxis-MaximumMember" id="c23198335">P1Y180D</bcrx:AveragematurityForPortfolioInvestments>
  <bcrx:AveragematurityPeriodOfHighQualityMarketableSecurities contextRef="d_2017-01-01_2017-09-30_RangeAxis-MaximumMember" id="c23198156">P1Y180D</bcrx:AveragematurityPeriodOfHighQualityMarketableSecurities>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23197947" unitRef="iso4217-usd">6817000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23197948" unitRef="iso4217-usd">4262000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23197949" unitRef="iso4217-usd">12543000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23197950" unitRef="iso4217-usd">11350000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2017-07-01_2017-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c23198518" unitRef="iso4217-usd">1490000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-07-01_2016-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c23198519" unitRef="iso4217-usd">3813000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2017-01-01_2017-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c23198520" unitRef="iso4217-usd">4305000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c23198521" unitRef="iso4217-usd">9846000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2017-07-01_2017-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c23198522" unitRef="iso4217-usd">296000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-07-01_2016-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c23198523" unitRef="iso4217-usd">296000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2017-01-01_2017-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c23198524" unitRef="iso4217-usd">888000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c23198525" unitRef="iso4217-usd">888000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2017-07-01_2017-09-30_CounterpartyNameAxis-SeqirusUKLimitedMember" decimals="-3" id="c23198526" unitRef="iso4217-usd">5031000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-07-01_2016-09-30_CounterpartyNameAxis-SeqirusUKLimitedMember" decimals="-3" id="c23198527" unitRef="iso4217-usd">153000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2017-01-01_2017-09-30_CounterpartyNameAxis-SeqirusUKLimitedMember" decimals="-3" id="c23198528" unitRef="iso4217-usd">7350000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-09-30_CounterpartyNameAxis-SeqirusUKLimitedMember" decimals="-3" id="c23198529" unitRef="iso4217-usd">616000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23198530" unitRef="iso4217-usd">6817000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23198531" unitRef="iso4217-usd">4262000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198532" unitRef="iso4217-usd">12543000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198533" unitRef="iso4217-usd">11350000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:ConcentrationOfMarketRiskPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198126">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers and Other Risks&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;All peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) are made by the Company&amp;#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Other than royalty revenues, the Company&amp;#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of galidesivir (formerly &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;BCX4430&lt;/div&gt;) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&amp;#x2019;s collaborative and other research and development revenues. The completion (as with the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 30, 2014 &lt;/div&gt;BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&amp;#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&amp;#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&amp;#x2019;s drug development activities are performed by a limited group of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&amp;#x2019;s ability to complete its drug development activities.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 12; Value: 3 --&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Credit Risk&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt; months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&amp;#x2019;s receivables from collaborations are due from the U.S. Government, for which there is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; assumed credit risk.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:ConcentrationOfMarketRiskPolicyTextBlock>
  <bcrx:CurrencyHedgeAgreementPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198119">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Currency Hedge Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; resulted in losses of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,858&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7,372,&lt;/div&gt; respectively. Mark to market adjustments are determined by a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; party pricing model that uses quoted prices in markets that are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; actively traded and for which significant inputs are observable directly or indirectly, representing Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized currency exchange gains of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$966&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$811&lt;/div&gt; during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement. The Company is also required to post collateral in connection with the mark to market adjustments based on thresholds defined in the Currency Hedge Agreement. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; hedge collateral was posted under the agreement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:CurrencyHedgeAgreementPolicyTextBlock>
  <bcrx:DebtInstrumentFinalPaymentFeePercentage contextRef="d_2016-09-23_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" decimals="3" id="c23198775" unitRef="xbrli-pure">0.05</bcrx:DebtInstrumentFinalPaymentFeePercentage>
  <bcrx:DebtInstrumentMinimumLibor contextRef="d_2016-09-23_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" decimals="3" id="c23198771" unitRef="xbrli-pure">0.005</bcrx:DebtInstrumentMinimumLibor>
  <bcrx:DeferredCollaborationExpenseAssets contextRef="i_2017-09-30" decimals="-3" id="c23197872" unitRef="iso4217-usd">15000</bcrx:DeferredCollaborationExpenseAssets>
  <bcrx:DeferredCollaborationExpenseAssets contextRef="i_2016-12-31" decimals="-3" id="c23197873" unitRef="iso4217-usd">199000</bcrx:DeferredCollaborationExpenseAssets>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198035" unitRef="iso4217-usd">-51000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198036" unitRef="iso4217-usd">-43000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <bcrx:DescriptionOfCompanyPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198076">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;BioCryst Pharmaceuticals, Inc. (the &amp;#x201c;Company&amp;#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on oral treatments for rare diseases in which significant unmet medical needs exist and that align with its capabilities and expertise. The Company was incorporated in Delaware in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1986&lt;/div&gt; and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;With the funds available at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017, &lt;/div&gt;the Company believes these resources will be sufficient to fund its operations at least through the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019.&lt;/div&gt; The Company has sustained operating losses for the majority of its corporate history and expects that its &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; expenses will exceed its &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&amp;#x2019;s liquidity needs will be largely determined by the success of operations in regards to the progression of its product candidates in the future. The Company also &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;consider other plans to fund operations beyond the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019&lt;/div&gt; including: (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;)&amp;nbsp;securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;)&amp;nbsp;out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;)&amp;nbsp;raising additional capital through equity or debt financings or from other sources; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;)&amp;nbsp;obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;)&amp;nbsp;reducing spending on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; or more research and development programs, including by discontinuing development; and/or (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;)&amp;nbsp;restructuring operations to change its overhead structure. The Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings in the future. The Company&amp;#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:DescriptionOfCompanyPolicyTextBlock>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear contextRef="i_2017-09-30" decimals="-3" id="c23198557" unitRef="iso4217-usd">2264000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive contextRef="i_2017-09-30" decimals="-3" id="c23198565" unitRef="iso4217-usd">351000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour contextRef="i_2017-09-30" decimals="-3" id="c23198563" unitRef="iso4217-usd">2395000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree contextRef="i_2017-09-30" decimals="-3" id="c23198561" unitRef="iso4217-usd">4527000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo contextRef="i_2017-09-30" decimals="-3" id="c23198559" unitRef="iso4217-usd">6745000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo>
  <bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts contextRef="d_2013-09-01_2017-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-3" id="c23198678" unitRef="iso4217-usd">39477000</bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:IncreaseDecreaseInFinancingLeaseObligations contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198065" unitRef="iso4217-usd">139000</bcrx:IncreaseDecreaseInFinancingLeaseObligations>
  <bcrx:IncreaseDecreaseInFinancingLeaseObligations contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198066" unitRef="iso4217-usd">300000</bcrx:IncreaseDecreaseInFinancingLeaseObligations>
  <bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198113">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Interest Expense and Deferred Financing Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Interest expense for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,140&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,465,&lt;/div&gt; respectively, and for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6,334&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,356,&lt;/div&gt; respectively, and primarily relates to the issuance of the PhaRMA Notes (defined in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;) and the Senior Credit Facility (defined in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;). Costs directly associated with the issuance of the PhaRMA Notes and the Senior Credit Facility have been capitalized and are netted against the PhaRMA Notes and Senior Credit Facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Senior Credit Facility using the effective interest rate method. Amortization of deferred financing costs and original issue discount included in interest expense was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$219&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$116&lt;/div&gt; for each of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively, and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$658&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$335&lt;/div&gt; for each of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock>
  <bcrx:Interestreserve contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="-3" id="c23198719" unitRef="iso4217-usd">3000000</bcrx:Interestreserve>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2017-09-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c23198297" unitRef="iso4217-usd">2704000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2016-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c23198424" unitRef="iso4217-usd">2704000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2017-09-30" decimals="-3" id="c23197899" unitRef="iso4217-usd">2770000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2016-12-31" decimals="-3" id="c23197900" unitRef="iso4217-usd">2704000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LongtermInvestmentMaturityMinimum contextRef="d_2017-01-01_2017-09-30_RangeAxis-MinimumMember" id="c23198166">P1Y</bcrx:LongtermInvestmentMaturityMinimum>
  <bcrx:MaturityPeriodOfHighQualityMarketablesecurities contextRef="d_2017-01-01_2017-09-30_RangeAxis-MaximumMember" id="c23198154">P3Y</bcrx:MaturityPeriodOfHighQualityMarketablesecurities>
  <bcrx:MaturityperiodOfShortTermInvestment contextRef="d_2017-01-01_2017-09-30_RangeAxis-MaximumMember" id="c23198165">P1Y</bcrx:MaturityperiodOfShortTermInvestment>
  <bcrx:MaximumAggregateOfferingPrice contextRef="i_2015-03-03" decimals="-4" id="c23198788" unitRef="iso4217-usd">150000000</bcrx:MaximumAggregateOfferingPrice>
  <bcrx:MaximumAmountOfCollateralRequiredToPost contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="-3" id="c23198759" unitRef="iso4217-usd">5850000</bcrx:MaximumAmountOfCollateralRequiredToPost>
  <bcrx:MilestonePaymentMaximum contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="-3" id="c23198232" unitRef="iso4217-usd">5000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMaximum contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" decimals="-3" id="c23198686" unitRef="iso4217-usd">5000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMaximum contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c23198693" unitRef="iso4217-usd">4000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMinimum contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c23198692" unitRef="iso4217-usd">1400000</bcrx:MilestonePaymentMinimum>
  <bcrx:MilestonePaymentReceived contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" decimals="-3" id="c23198685" unitRef="iso4217-usd">7000000</bcrx:MilestonePaymentReceived>
  <bcrx:NumberOfStockbasedCompensationPlans contextRef="d_2017-01-01_2017-09-30" decimals="INF" id="c23198541" unitRef="xbrli-pure">2</bcrx:NumberOfStockbasedCompensationPlans>
  <bcrx:PercentageOfCarryingAmountInExcessOfFairValue1 contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="INF" id="c23198739" unitRef="xbrli-pure">0.5</bcrx:PercentageOfCarryingAmountInExcessOfFairValue1>
  <bcrx:PercentageOfCommonStockSharesBeginning contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c23198622" unitRef="xbrli-pure">0.85</bcrx:PercentageOfCommonStockSharesBeginning>
  <bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c23198621" unitRef="xbrli-pure">0.15</bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum>
  <bcrx:PeriodOfAgreement contextRef="d_2017-01-01_2017-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" id="c23198708">P25Y</bcrx:PeriodOfAgreement>
  <bcrx:PrivatePlacementOfSeniorSecuredNotes contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="-3" id="c23198725" unitRef="iso4217-usd">30000000</bcrx:PrivatePlacementOfSeniorSecuredNotes>
  <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts contextRef="d_2015-04-01_2017-09-30_TypeOfArrangementAxis-ASPRBARDAContractMember" decimals="-3" id="c23198674" unitRef="iso4217-usd">20574000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts contextRef="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-3" id="c23198675" unitRef="iso4217-usd">5000000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:RenewablePeriodOfAgreement contextRef="d_2017-01-01_2017-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" id="c23198709">P5Y</bcrx:RenewablePeriodOfAgreement>
  <bcrx:RequiredForeignCurrencyHedgePerDollar contextRef="i_2016-05-18_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="INF" id="c23198747" unitRef="iso4217-jpy">100</bcrx:RequiredForeignCurrencyHedgePerDollar>
  <bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="-3" id="c23198717" unitRef="iso4217-usd">22691000</bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet>
  <bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized contextRef="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember" decimals="-3" id="c23198112" unitRef="iso4217-usd">30000000</bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized>
  <bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized contextRef="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="-3" id="c23198716" unitRef="iso4217-usd">30000000</bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized>
  <bcrx:RoyaltyMonetizationTextBlock contextRef="d_2017-01-01_2017-09-30" id="s693053">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt; &amp;#x2014; Royalty Monetization&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Overview&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011,&lt;/div&gt; the Company completed a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$30,000&lt;/div&gt;&amp;nbsp;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$22,691&lt;/div&gt;&amp;nbsp;from the transaction after transaction costs of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,309&lt;/div&gt;&amp;nbsp;and the establishment of a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3,000&lt;/div&gt;&amp;nbsp;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 2012 &lt;/div&gt;interest payment.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As part of the transaction, the Company entered into a purchase and sale agreement dated as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011&lt;/div&gt; with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i)&amp;nbsp;its rights to receive all non-governmental royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&amp;nbsp;the right to receive payments under a Japanese yen/US dollar foreign currency hedge agreement (as further described below, the &amp;#x201c;Currency Hedge Agreement&amp;#x201d;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&amp;#x2019;s collaboration with Shionogi was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; impacted as a result of this transaction.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Non-Recourse Notes Payable&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011,&lt;/div&gt; Royalty Sub completed a private placement to institutional investors of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$30,000&lt;/div&gt; in aggregate principal amount of its PhaRMA Senior Secured &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14.0%&lt;/div&gt; Notes due &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2020&lt;/div&gt; (the &amp;#x201c;PhaRMA Notes&amp;#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011&lt;/div&gt; (the &amp;#x201c;Indenture&amp;#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14%&lt;/div&gt;&amp;nbsp;per annum, payable annually in arrears on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1st&lt;/div&gt; of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes. &amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Royalty Sub&amp;#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&amp;#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may, &lt;/div&gt;but is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; obligated to, make capital contributions to a capital account that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be used to redeem, or on up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; occasion pay any interest shortfall on, the PhaRMA Notes.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 1, 2014, &lt;/div&gt;Royalty Sub was unable to pay the full amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;pursue acceleration of the PhaRMA Notes, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;incur costs associated with liquidating the related Currency Hedge Agreement, which would &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the default of the PhaRMA Notes is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expected to have a significant impact on the Company&amp;#x2019;s future results of operations or cash flows. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017, &lt;/div&gt;the PhaRMA Notes remain in default.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Indenture does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017, &lt;/div&gt;the aggregate fair value of the PhaRMA Notes was estimated to be approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt; of its carrying value of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$30,000.&lt;/div&gt; The estimated fair value of the PhaRMA Notes is classified as Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; in the fair value hierarchy as defined in U.S. GAAP.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Currency Hedge Agreement&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;100&lt;/div&gt; yen per dollar for which the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be required to pay a premium in each year from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2020,&lt;/div&gt; provided the Currency Hedge Agreement remains in effect. A payment of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,950&lt;/div&gt;&amp;nbsp;will be required if, on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt; of the relevant year, the U.S. dollar is worth &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;100&lt;/div&gt; yen or less as determined in accordance with the Currency Hedge Agreement.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Currency Hedge Agreement does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; qualify for hedge accounting treatment; therefore, mark to market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statement of Comprehensive Loss. Cumulative mark to market adjustments for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; resulted in losses of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,858&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7,372,&lt;/div&gt; respectively. The Company is also required to post collateral in connection with the mark to market adjustments based on defined thresholds. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt;&lt;/div&gt; collateral was posted under the Currency Hedge Agreement. The Company will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be required to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017, &lt;/div&gt;the maximum amount of hedge collateral the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be required to post is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,850.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:RoyaltyMonetizationTextBlock>
  <bcrx:RoyaltyTerm contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" id="c23198687">P10Y</bcrx:RoyaltyTerm>
  <bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock contextRef="d_2017-01-01_2017-09-30" id="c-18">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;September&amp;nbsp;30, 2017&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 58%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;63&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,906&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,969&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;653&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;653&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Mundipharma International Holdings Limited&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;46&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;46&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,794&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;475&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,269&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,604&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,381&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,985&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;December&amp;nbsp;31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 58%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,495&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,495&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,451&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,451&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;686&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;686&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;957&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;179&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,136&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,094&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,674&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,768&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock>
  <bcrx:ScheduleOfRevenuesFromCollaborationsTableTextBlock contextRef="d_2017-01-01_2017-09-30" id="c-19">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Three Months&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Nine Months&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;Product sales&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,501&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,501&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;442&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,501&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,252&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,020&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,490&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,813&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,305&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,846&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;296&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;296&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;888&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;888&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; text-indent: 20pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,031&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;153&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,350&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;616&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Total collaborative and other research and development revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,817&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,262&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,543&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,350&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,760&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,763&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,296&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,370&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:ScheduleOfRevenuesFromCollaborationsTableTextBlock>
  <bcrx:ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount contextRef="i_2017-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c23198630" unitRef="iso4217-usd">25000</bcrx:ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate contextRef="d_2017-01-01_2017-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember" id="c23198595">P1Y</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c23198650" unitRef="xbrli-shares">2591000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
  <bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage contextRef="d_2017-01-01_2017-09-30_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c23198592" unitRef="xbrli-pure">0.25</bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage>
  <bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage contextRef="d_2017-01-01_2017-09-30_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c23198593" unitRef="xbrli-pure">0.7</bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage>
  <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c23198656" unitRef="xbrli-shares">912000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
  <bcrx:TransactionCosts contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="-3" id="c23198718" unitRef="iso4217-usd">4309000</bcrx:TransactionCosts>
  <bcrx:UpfrontPaymentsReceivableAmount contextRef="d_2006-02-01_2006-02-28_TypeOfArrangementAxis-MundipharmaMember" decimals="-3" id="c23198690" unitRef="iso4217-usd">10000000</bcrx:UpfrontPaymentsReceivableAmount>
  <dei:AmendmentFlag contextRef="d_2017-01-01_2017-09-30" id="c-14">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2017-01-01_2017-09-30" id="c-4">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2017-01-01_2017-09-30" id="c-13">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2017-01-01_2017-09-30" id="c-12">2017</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2017-01-01_2017-09-30" id="c-11">2017-09-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2017-01-01_2017-09-30" id="c-10">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2017-01-01_2017-09-30" id="c-2">0000882796</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2017-10-31" decimals="INF" id="c-9" unitRef="xbrli-shares">98404761</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2017-01-01_2017-09-30" id="c-6">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="d_2017-01-01_2017-09-30" id="c-5">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="d_2017-01-01_2017-09-30" id="c-1">BIOCRYST PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="d_2017-01-01_2017-09-30" id="c-7">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2017-01-01_2017-09-30" id="c-8">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="d_2017-01-01_2017-09-30" id="c-3">bcrx</dei:TradingSymbol>
  <us-gaap:AccountsPayableCurrent contextRef="i_2017-09-30" decimals="-3" id="c23197879" unitRef="iso4217-usd">4603000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="i_2016-12-31" decimals="-3" id="c23197880" unitRef="iso4217-usd">4269000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2017-09-30" decimals="-3" id="c23197858" unitRef="iso4217-usd">8985000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2016-12-31" decimals="-3" id="c23197859" unitRef="iso4217-usd">8768000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2017-09-30" decimals="-3" id="c23197881" unitRef="iso4217-usd">11871000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2016-12-31" decimals="-3" id="c23197882" unitRef="iso4217-usd">10836000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2017-09-30" decimals="-3" id="c23197926" unitRef="iso4217-usd">-17000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2016-12-31" decimals="-3" id="c23197927" unitRef="iso4217-usd">-12000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2017-09-30" decimals="-3" id="c23197924" unitRef="iso4217-usd">711965000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2016-12-31" decimals="-3" id="c23197925" unitRef="iso4217-usd">566913000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198542" unitRef="iso4217-usd">10307000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c23198543" unitRef="iso4217-usd">10107000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c23198544" unitRef="iso4217-usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198548" unitRef="iso4217-usd">6478000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-09-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c23198549" unitRef="iso4217-usd">6331000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c23198550" unitRef="iso4217-usd">147000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-07-01_2017-09-30_AwardTypeAxis-PerformanceBasedOptionMember" decimals="-3" id="c23198571" unitRef="iso4217-usd">3193000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-01-01_2017-09-30_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c23198594" unitRef="iso4217-usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23198266" unitRef="iso4217-usd">219000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23198267" unitRef="iso4217-usd">116000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198273" unitRef="iso4217-usd">658000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198274" unitRef="iso4217-usd">335000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23198323" unitRef="xbrli-shares">1996000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23198324" unitRef="xbrli-shares">1291000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198330" unitRef="xbrli-shares">2519000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198331" unitRef="xbrli-shares">1190000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="i_2017-09-30" decimals="-3" id="c23197876" unitRef="iso4217-usd">191492000</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2016-12-31" decimals="-3" id="c23197877" unitRef="iso4217-usd">89847000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2017-09-30" decimals="-3" id="c23197866" unitRef="iso4217-usd">175370000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2016-12-31" decimals="-3" id="c23197867" unitRef="iso4217-usd">66987000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2017-09-30" decimals="-3" id="c23198474" unitRef="iso4217-usd">48387000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-12-31" decimals="-3" id="c23198475" unitRef="iso4217-usd">41472000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2017-09-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c23198434" unitRef="iso4217-usd">27986000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2017-09-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c23198439" unitRef="iso4217-usd">8261000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2017-09-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c23198444" unitRef="iso4217-usd">12140000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c23198454" unitRef="iso4217-usd">20298000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c23198459" unitRef="iso4217-usd">6199000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c23198464" unitRef="iso4217-usd">14975000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2017-09-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" id="c23198432" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2017-09-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember" id="c23198437" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2017-09-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c23198442" unitRef="iso4217-usd">4000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2017-09-30" decimals="-3" id="c23198447" unitRef="iso4217-usd">4000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c23198452" unitRef="iso4217-usd">2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c23198457" unitRef="iso4217-usd">2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c23198462" unitRef="iso4217-usd">7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-12-31" decimals="-3" id="c23198467" unitRef="iso4217-usd">11000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2017-09-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c23198433" unitRef="iso4217-usd">7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2017-09-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c23198438" unitRef="iso4217-usd">8000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2017-09-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c23198443" unitRef="iso4217-usd">6000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2017-09-30" decimals="-3" id="c23198448" unitRef="iso4217-usd">21000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c23198453" unitRef="iso4217-usd">4000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c23198458" unitRef="iso4217-usd">8000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c23198463" unitRef="iso4217-usd">11000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-12-31" decimals="-3" id="c23198468" unitRef="iso4217-usd">23000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2017-09-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c23198430" unitRef="iso4217-usd">27897000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2017-09-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c23198435" unitRef="iso4217-usd">8230000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2017-09-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c23198440" unitRef="iso4217-usd">12108000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2017-09-30" decimals="-3" id="c23198445" unitRef="iso4217-usd">48235000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c23198450" unitRef="iso4217-usd">20266000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c23198455" unitRef="iso4217-usd">6179000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c23198460" unitRef="iso4217-usd">14962000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-12-31" decimals="-3" id="c23198465" unitRef="iso4217-usd">41407000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="i_2017-09-30" decimals="-3" id="c23198470" unitRef="iso4217-usd">43848000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="i_2016-12-31" decimals="-3" id="c23198471" unitRef="iso4217-usd">32546000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="i_2017-09-30" decimals="-3" id="c23197856" unitRef="iso4217-usd">43848000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="i_2016-12-31" decimals="-3" id="c23197857" unitRef="iso4217-usd">32546000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="i_2017-09-30" decimals="-3" id="c23197868" unitRef="iso4217-usd">4539000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="i_2016-12-31" decimals="-3" id="c23197869" unitRef="iso4217-usd">8926000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="d_2017-01-01_2017-09-30" id="c-16">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;September&amp;nbsp;30, 2017&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 50%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27,897&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;96&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(7&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27,986&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,230&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,261&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,108&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(6&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,140&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48,235&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;169&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(21&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48,387&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;December&amp;nbsp;31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 50%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,266&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,298&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,179&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,199&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,962&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,975&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,407&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;77&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(23&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,472&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198079">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, JPR Royalty Sub LLC (&amp;#x201c;Royalty Sub&amp;#x201d;) and MDCP, LLC (&amp;#x201c;MDCP&amp;#x201d;). Both subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$30,000&lt;/div&gt;&amp;nbsp;financing transaction the Company completed on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011.&lt;/div&gt; See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,&lt;/div&gt; Royalty Monetization, for a further description of this transaction. MDCP was formed in connection with a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$23,000&lt;/div&gt; Senior Credit Facility that the Company closed on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 23, 2016. &lt;/div&gt;See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,&lt;/div&gt; Senior Credit Facility, for a further description of this transaction. All intercompany transactions and balances have been eliminated.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201c;U.S. GAAP&amp;#x201d;) for interim financial reporting and the instructions to Form &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-Q and do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&amp;#x2019;s opinion, necessary to present fairly, in all material respects, the Company&amp;#x2019;s consolidated financial position, results of operations, and cash flows. There were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; adjustments other than normal recurring adjustments.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;These financial statements should be read in conjunction with the financial statements for the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and the notes thereto included in the Company&amp;#x2019;s &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; Annual Report on Form &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-K. Interim operating results are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; necessarily indicative of operating results for the full year. The balance sheet as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; has been derived from the audited consolidated financial statements included in the Company&amp;#x2019;s most recent Annual Report on Form &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-K.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="i_2017-09-30" decimals="-3" id="c23197887" unitRef="iso4217-usd">73000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="i_2016-12-31" id="c23197888" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="i_2017-09-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c23198298" unitRef="iso4217-usd">4444000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2017-09-30" decimals="-3" id="c23197852" unitRef="iso4217-usd">117776000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2016-12-31" decimals="-3" id="c23197853" unitRef="iso4217-usd">22104000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-12-31" decimals="-3" id="c23198072" unitRef="iso4217-usd">28899000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2016-09-30" decimals="-3" id="c23198074" unitRef="iso4217-usd">35387000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198069" unitRef="iso4217-usd">95672000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198070" unitRef="iso4217-usd">6488000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198081">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="d_2017-01-01_2017-09-30" id="c23198084">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Restricted Cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Restricted cash as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; reflects &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,713&lt;/div&gt; in royalty revenue paid by Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;) designated for interest on the PhaRMA Notes (defined in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;) and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,409&lt;/div&gt; the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its Birmingham research facilities.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2017-01-01_2017-09-30" id="s693052">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; &amp;#x2014; Collaborative and Other Research and Development Contracts&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;U.S.&amp;nbsp;Department of Health and Human Services (&amp;#x201c;BARDA/HHS&amp;#x201d;).&lt;/div&gt; On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2015, &lt;/div&gt;the Company announced that BARDA/HHS had awarded the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&amp;nbsp;This BARDA/HHS contract includes a base contract of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$16,265&lt;/div&gt; to support galidesivir drug manufacturing, as well as &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$22,855&lt;/div&gt; in additional development options that can be exercised by the government, bringing the potential value of the contract to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$39,120.&lt;/div&gt; As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017, &lt;/div&gt;a total of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$20,574&lt;/div&gt; has been awarded under exercised options within this contract.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;).&lt;/div&gt; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 2013, &lt;/div&gt;NIAID/HHS contracted with the Company for the development of galidesivir as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,000&lt;/div&gt; to the Company. The goals of this contract, including the amendments thereto, are to file IND applications for intravenous (&amp;#x201c;i.v.&amp;#x201d;) and intramuscular (&amp;#x201c;i.m.&amp;#x201d;) galidesivir for the treatment of Marburg virus disease and other hemorrhagic fever virus diseases, including Ebola virus disease, and to conduct an initial Phase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; human clinical trial. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017, &lt;/div&gt;the total NIAID/HHS contract amount to advance the program through the completion of the Phase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; clinical program is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$39,477.&lt;/div&gt; As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017, &lt;/div&gt;all options have been exercised under this contract.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&amp;#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;).&lt;/div&gt; On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 16, 2015, &lt;/div&gt;the Company and Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &amp;#x201c;SUL Agreement&amp;#x201d;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &amp;#x201c;Territory&amp;#x201d;). Peramivir is an intravenous treatment for acute uncomplicated influenza and is currently approved for use in the United States, Canada, Japan, Taiwan and Korea. Peramivir is the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; and only intravenous influenza treatment in the world and was approved by the FDA in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2014 &lt;/div&gt;for the treatment of acute uncomplicated influenza in patients &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt; years and older who have been symptomatic for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; days. The Company retains all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Pursuant to the SUL Agreement, RAPIVAB is commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL manufactures, commercializes and exercises decision-making authority with respect to the commercialization of RAPIVAB within the Territory and is responsible for all related costs, including sales and promotion.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in the EU, the Company is also responsible for regulatory filings and interactions with the European Medicines Agency (&amp;quot;EMA&amp;quot;) until marketing approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company received an upfront payment of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$33,740,&lt;/div&gt; has received &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7,000&lt;/div&gt; of milestone payments and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;receive an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,000&lt;/div&gt; milestone payment related to the successful marketing approval by the EMA for an adult indication in the EU. The Company is also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 1 - &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 30) &lt;/div&gt;and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt; years from the date of the SUL Agreement. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;).&lt;/div&gt; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2007, &lt;/div&gt;the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 2008, &lt;/div&gt;the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Green Cross Corporation (&amp;#x201c;Green Cross&amp;#x201d;).&lt;/div&gt; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2006, &lt;/div&gt;the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross is responsible for all development, regulatory, and commercialization costs in Korea. The Company received a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-time license fee of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$250.&lt;/div&gt; The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Mundipharma International Holdings Limited (&amp;#x201c;Mundipharma&amp;#x201d;).&lt;/div&gt; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2006, &lt;/div&gt;the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&amp;#x201c;PNP&amp;#x201d;) inhibitor, for use in oncology. Under the terms of the license agreement, as amended, Mundipharma obtained rights to forodesine in markets across Europe, Asia, and Australasia in exchange for a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10,000&lt;/div&gt; up-front payment. In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 2017, &lt;/div&gt;Mundipharma obtained regulatory approval of Mundesine&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;&amp;reg;&lt;/div&gt;&lt;/div&gt; (forodesine hydrochloride) for the treatment of relapsed/refractory PTCL (Peripheral T-Cell Lymphoma) by the Ministry of Health, Labor and Welfare in Japan and is responsible for all commercialization costs in Japan.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&amp;#x201c;AECOM&amp;#x201d; and &amp;#x201c;IRL&amp;#x201d; respectively).&lt;/div&gt; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2000, &lt;/div&gt;the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &amp;#x201c;Licensors&amp;#x201d;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,400&lt;/div&gt; to almost &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,000&lt;/div&gt;&amp;nbsp;per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; quarter of future payments received from other &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$150&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$500,&lt;/div&gt; that are creditable against actual royalties and other payments due to the Licensors. This agreement &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be terminated by the Company at any time by giving &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;60&lt;/div&gt;&amp;nbsp;days advance notice or in the event of material uncured breach by the Licensors.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2010, &lt;/div&gt;the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-half in the percentage of future payments received from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; apply to (i)&amp;nbsp;any milestone payments the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;receive in the future under its license agreement dated &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2006&lt;/div&gt; with Mundipharma and (ii)&amp;nbsp;royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2012,&lt;/div&gt; the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of galidesivir to BioCryst for any antiviral use.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;).&lt;/div&gt; The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party partners. The Company has completed the research under the UAB agreements. These &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; agreements have initial &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25&lt;/div&gt;-year terms, are automatically renewable for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt;-year terms throughout the life of the last patent and are terminable by the Company upon &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months&amp;#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&amp;#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2017-09-30_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="-3" id="c23198317" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2016-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="-3" id="c23198425" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="-3" id="c23198757" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="-3" id="c23198761" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2017-09-30" decimals="INF" id="c23197916" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2016-12-31" decimals="INF" id="c23197917" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2017-09-30" decimals="-3" id="c23197918" unitRef="xbrli-shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2016-12-31" decimals="-3" id="c23197919" unitRef="xbrli-shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="i_2017-09-30" decimals="-3" id="c23197920" unitRef="xbrli-shares">98389000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2016-12-31" decimals="-3" id="c23197921" unitRef="xbrli-shares">73782000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2017-09-30" decimals="-3" id="c23197922" unitRef="xbrli-shares">98389000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2016-12-31" decimals="-3" id="c23197923" unitRef="xbrli-shares">73782000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="i_2017-09-30" decimals="-3" id="c23197914" unitRef="iso4217-usd">984000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2016-12-31" decimals="-3" id="c23197915" unitRef="iso4217-usd">738000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23198008" unitRef="iso4217-usd">-15136000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23198009" unitRef="iso4217-usd">-11552000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198010" unitRef="iso4217-usd">-46244000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198011" unitRef="iso4217-usd">-50413000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198103">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accumulated Other Comprehensive Loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&amp;#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No&lt;/div&gt; reclassifications out of accumulated other comprehensive loss were recorded during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017. &lt;/div&gt;Realized gains of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$11&lt;/div&gt; were reclassified out of accumulated other comprehensive loss during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2016.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:CostOfGoodsSold contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23197956" unitRef="iso4217-usd">1142000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="d_2016-07-01_2016-09-30" id="c23197957" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CostOfGoodsSold contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23197958" unitRef="iso4217-usd">1142000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="d_2016-01-01_2016-09-30" id="c23197959" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CostsAndExpenses contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23197972" unitRef="iso4217-usd">22109000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23197973" unitRef="iso4217-usd">17004000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23197974" unitRef="iso4217-usd">60846000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23197975" unitRef="iso4217-usd">57789000</us-gaap:CostsAndExpenses>
  <us-gaap:DebtDisclosureTextBlock contextRef="d_2017-01-01_2017-09-30" id="s693054">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt; &amp;#x2014; Senior Credit Facility&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 23, 2016, &lt;/div&gt;the Company closed a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$23,000&lt;/div&gt; Senior Credit Facility with an affiliate of MidCap Financial Services, LLC (&amp;#x201c;MidCap&amp;#x201d;), as administrative agent (the &amp;#x201c;Senior Credit Facility&amp;#x201d;). The Senior Credit Facility was fully funded at closing and bears a variable interest rate of LIBOR (which shall &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be less than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.5%&lt;/div&gt;) plus &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8%.&lt;/div&gt; The Senior Credit Facility includes an interest-only payment period through fiscal &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and scheduled monthly principal and interest payments for the subsequent &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt; months. The Company has the option to repay the Senior Credit Facility at any time prior to the scheduled principal repayment date subject to prepayment fees. Final payment of the Senior Credit Facility is subject to a final payment fee equal to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5%&lt;/div&gt; of the principal funded under the Senior Credit Facility.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017, &lt;/div&gt;the Company had borrowings of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$23,000&lt;/div&gt; under the Senior Credit Facility bearing an interest rate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.2%.&lt;/div&gt; The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date. Scheduled principal repayments of the Senior Credit Facility are as follows:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" colspan="5" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Principal Payments&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 82%; font-size: 10pt; text-align: justify; text-indent: 3.2pt"&gt;2018&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 20%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,900&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt"&gt;2019&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,900&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt"&gt;2020&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,900&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1.1pt; text-indent: 3.2pt"&gt;2021&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,300&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; text-indent: 3.2pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,000&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The debt agreement contains &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; provisions that if deemed probable would create the recognition of an embedded feature; however, we do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; believe either provision is probable.&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="d_2016-09-23_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember" decimals="3" id="c23198772" unitRef="xbrli-pure">0.08</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="INF" id="c23198726" unitRef="xbrli-pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentTerm contextRef="d_2016-09-23_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" id="c23198774">P3Y120D</us-gaap:DebtInstrumentTerm>
  <us-gaap:DeferredCostsCurrent contextRef="i_2017-09-30" decimals="-3" id="c23197864" unitRef="iso4217-usd">218000</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredCostsCurrent contextRef="i_2016-12-31" decimals="-3" id="c23197865" unitRef="iso4217-usd">85000</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="i_2017-09-30" decimals="-3" id="c23197897" unitRef="iso4217-usd">178000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="i_2016-12-31" decimals="-3" id="c23197898" unitRef="iso4217-usd">244000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRevenueAdditions contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="-3" id="c23198217" unitRef="iso4217-usd">3740000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueAdditions contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="-3" id="c23198219" unitRef="iso4217-usd">1223000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2017-09-30" decimals="-3" id="c23197885" unitRef="iso4217-usd">8686000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2016-12-31" decimals="-3" id="c23197886" unitRef="iso4217-usd">2022000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2017-09-30" decimals="-3" id="c23197895" unitRef="iso4217-usd">296000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2016-12-31" decimals="-3" id="c23197896" unitRef="iso4217-usd">8184000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198016" unitRef="iso4217-usd">522000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198017" unitRef="iso4217-usd">311000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DerivativeForwardExchangeRate1 contextRef="i_2017-09-30_CurrencyAxis-JPY_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="INF" id="c23198742" unitRef="xbrli-pure">100</us-gaap:DerivativeForwardExchangeRate1>
  <us-gaap:DerivativeGainOnDerivative contextRef="d_2017-01-01_2017-09-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="-3" id="c23198309" unitRef="iso4217-usd">966000</us-gaap:DerivativeGainOnDerivative>
  <us-gaap:DerivativeGainOnDerivative contextRef="d_2016-01-01_2016-09-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="-3" id="c23198310" unitRef="iso4217-usd">811000</us-gaap:DerivativeGainOnDerivative>
  <us-gaap:DerivativeLossOnDerivative contextRef="d_2017-01-01_2017-09-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="-3" id="c23198304" unitRef="iso4217-usd">1858000</us-gaap:DerivativeLossOnDerivative>
  <us-gaap:DerivativeLossOnDerivative contextRef="d_2016-01-01_2016-09-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="-3" id="c23198305" unitRef="iso4217-usd">7372000</us-gaap:DerivativeLossOnDerivative>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2017-01-01_2017-09-30" id="s693049">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; &amp;#x2014; Stock-Based Compensation&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; the Company had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; stock-based employee compensation plans, the Stock Incentive Plan (&amp;#x201c;Incentive Plan&amp;#x201d;) and the Employee Stock Purchase Plan (&amp;#x201c;ESPP&amp;#x201d;). The Incentive Plan was amended and restated in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 2017 &lt;/div&gt;and approved by the Company&amp;#x2019;s stockholders in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2017. &lt;/div&gt;The ESPP was amended and restated in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2014 &lt;/div&gt;and approved by the Company&amp;#x2019;s stockholders in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2014. &lt;/div&gt;Stock-based compensation expense of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10,307&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10,107&lt;/div&gt; of expense related to the Incentive Plan and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$200&lt;/div&gt; of expense related to the ESPP) was recognized during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; while &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6,478&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6,331&lt;/div&gt; of expense related to the Incentive Plan and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$147&lt;/div&gt; of expense related to the ESPP) was recognized during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;There was approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$16,282&lt;/div&gt; of total unrecognized compensation cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt; That cost is expected to be recognized as follows: &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,264&lt;/div&gt; during the remainder of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6,745&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,527&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,395&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2020&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$351&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2021.&lt;/div&gt; In addition, the Company has outstanding performance-based stock options for which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; has occurred and the award vests. At the time of vesting, compensation expense will be recognized. During the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; the Company achieved a performance metric under a performance-based option award resulting in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;404&lt;/div&gt; options vesting and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3,193&lt;/div&gt; compensation expense recorded as a result of this achievement.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock Incentive Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&amp;#x2019;s stock at the date of grant. Stock option awards granted to employees generally vest &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25%&lt;/div&gt; each year until fully vested after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;four&lt;/div&gt; years. In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 2013 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2014, &lt;/div&gt;the Company issued &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,032&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,250&lt;/div&gt; performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;75%&lt;/div&gt; of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 2013 &lt;/div&gt;grants have vested based upon achievement of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; milestones: (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;) successful completion of the OPuS-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; clinical trial, for which vesting occurred in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;second&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;) FDA approval of RAPIVAB, for which vesting occurred in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;fourth&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; and (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;) initiation of a Phase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;BCX7353&lt;/div&gt; in healthy volunteers, for which vesting occurred in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;second&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015.&lt;/div&gt; As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30%&lt;/div&gt; of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2014 &lt;/div&gt;grants have vested based upon achievement of successful completion of an HAE patient trial with a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;nd&lt;/div&gt; generation compound, for which vesting occurred in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 2017. &lt;/div&gt;Thus, as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25%&lt;/div&gt; of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 2013 &lt;/div&gt;performance-based grants and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;70%&lt;/div&gt; of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2014 &lt;/div&gt;performance-based grants remain unvested and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; year. All stock option awards have contractual terms of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;&amp;nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Related activity under the Incentive Plan is as follows:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Awards&lt;br /&gt; Available&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Options&lt;br /&gt; Outstanding&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Weighted&lt;br /&gt; Average&lt;br /&gt; Exercise&lt;br /&gt; Price&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 58%; font-size: 10pt"&gt;Balance December&amp;nbsp;31, 2016&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,273&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,095&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.55&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Plan amendment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,000&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock unit awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(16&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock unit awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,591&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,591&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.49&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards exercised&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(422&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.49&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt"&gt;Stock option awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;912&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(912&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10.22&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Balance September&amp;nbsp;30, 2017&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,581&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,352&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.19&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;For stock option awards granted under the Incentive Plan during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.74&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.17,&lt;/div&gt; respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. The following table summarizes the key assumptions used by the Company to value the stock option awards granted during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt; The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&amp;#x2019;s publicly traded common stock. The Company has assumed &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; expected dividend yield, as dividends have never been paid to stock or option holders and will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;zero&lt;/div&gt;-coupon government issues with a remaining term equal to the expected term.&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted Average Assumptions for Stock Option Awards Granted to&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Employees and Directors under the Incentive Plan&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 65%; font-size: 10pt; text-align: left"&gt;Expected Life in Years&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.5&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.5&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Volatility&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;82.0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;82.0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Dividend Yield&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-Free Interest Rate&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.9&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.4&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Employee Stock Purchase Plan (&amp;#x201c;ESPP&amp;#x201d;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has reserved a total of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,475&lt;/div&gt;&amp;nbsp;shares of common stock to be purchased under the ESPP, of which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;330&lt;/div&gt;&amp;nbsp;shares remain available for purchase at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt; Eligible employees &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;authorize up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15%&lt;/div&gt; of their salary to purchase common stock at the lower of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;85%&lt;/div&gt; of the beginning or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;85%&lt;/div&gt; of the ending price during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;six&lt;/div&gt;-month purchase intervals. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No&lt;/div&gt; more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; shares &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be purchased by any &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; employee at the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;six&lt;/div&gt;-month purchase dates and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; employee &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;purchase stock having a fair market value at the commencement date of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$25&lt;/div&gt; or more in any &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; calendar year. The Company issued &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;91&lt;/div&gt; shares during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &amp;#x201c;look-back&amp;#x201d; option were determined using a Black-Scholes option pricing model.&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2017-07-01_2017-09-30" decimals="INF" id="c23197996" unitRef="iso4217-usd-per-xbrli-shares">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2016-07-01_2016-09-30" decimals="INF" id="c23197997" unitRef="iso4217-usd-per-xbrli-shares">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2017-01-01_2017-09-30" decimals="INF" id="c23197998" unitRef="iso4217-usd-per-xbrli-shares">-0.58</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2016-01-01_2016-09-30" decimals="INF" id="c23197999" unitRef="iso4217-usd-per-xbrli-shares">-0.69</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198122">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&amp;#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; include &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,996&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,291,&lt;/div&gt; respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; include &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,519&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,190,&lt;/div&gt; respectively, of such potential common shares, as their impact would be anti-dilutive.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="i_2017-09-30" decimals="-3" id="c23198554" unitRef="iso4217-usd">16282000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:GainLossOnDispositionOfAssets1 contextRef="d_2017-01-01_2017-09-30" id="c23198018" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:GainLossOnDispositionOfAssets1 contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198019" unitRef="iso4217-usd">-21000</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23197988" unitRef="iso4217-usd">130000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23197989" unitRef="iso4217-usd">-931000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23197990" unitRef="iso4217-usd">-892000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23197991" unitRef="iso4217-usd">-6561000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember" decimals="-3" id="c23198671" unitRef="iso4217-usd">16265000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember" decimals="-3" id="c23198672" unitRef="iso4217-usd">22855000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember" decimals="-3" id="c23198673" unitRef="iso4217-usd">39120000</us-gaap:GovernmentContractReceivable>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198100">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The liability method is used in the Company&amp;#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198037" unitRef="iso4217-usd">1303000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198038" unitRef="iso4217-usd">-12066000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198041" unitRef="iso4217-usd">-1224000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198042" unitRef="iso4217-usd">-1075000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDerivativeAssets contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198026" unitRef="iso4217-usd">-1858000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInDerivativeAssets contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198027" unitRef="iso4217-usd">-7372000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198039" unitRef="iso4217-usd">1715000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198040" unitRef="iso4217-usd">817000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198031" unitRef="iso4217-usd">-500000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198032" unitRef="iso4217-usd">620000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198033" unitRef="iso4217-usd">-17000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198034" unitRef="iso4217-usd">-667000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198029" unitRef="iso4217-usd">217000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198030" unitRef="iso4217-usd">-275000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198048" unitRef="iso4217-usd">1576000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198049" unitRef="iso4217-usd">-106000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2017-01-01_2017-09-30" id="c23198096">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patents and Licenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:InterestAndOtherIncome contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23197980" unitRef="iso4217-usd">225000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23197981" unitRef="iso4217-usd">109000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23197982" unitRef="iso4217-usd">537000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23197983" unitRef="iso4217-usd">695000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestExpense contextRef="d_2017-07-01_2017-09-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c23198290" unitRef="iso4217-usd">82000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2016-07-01_2016-09-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c23198291" unitRef="iso4217-usd">86000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2017-01-01_2017-09-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c23198294" unitRef="iso4217-usd">217000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2016-01-01_2016-09-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="-3" id="c23198295" unitRef="iso4217-usd">300000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23197984" unitRef="iso4217-usd">2140000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23197985" unitRef="iso4217-usd">1465000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23197986" unitRef="iso4217-usd">6334000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23197987" unitRef="iso4217-usd">4356000</us-gaap:InterestExpense>
  <us-gaap:InterestExpenseDebt contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23198256" unitRef="iso4217-usd">2140000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23198257" unitRef="iso4217-usd">1465000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198261" unitRef="iso4217-usd">6334000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198262" unitRef="iso4217-usd">4356000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestPayableCurrent contextRef="i_2017-09-30" decimals="-3" id="c23197883" unitRef="iso4217-usd">10705000</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestPayableCurrent contextRef="i_2016-12-31" decimals="-3" id="c23197884" unitRef="iso4217-usd">8990000</us-gaap:InterestPayableCurrent>
  <us-gaap:InventoryNet contextRef="i_2017-09-30" id="c23197860" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:InventoryNet contextRef="i_2016-12-31" decimals="-3" id="c23197861" unitRef="iso4217-usd">500000</us-gaap:InventoryNet>
  <us-gaap:InventoryPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198091">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s inventory consisted primarily of peramivir work in process and is being manufactured for the Company&amp;#x2019;s partners. Inventory is stated at the lower of cost and net realizable value, determined under the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-in, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-out (&amp;#x201c;FIFO&amp;#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:InvestmentPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198086">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&amp;#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&amp;#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; years and requires an average portfolio maturity of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt; months. Some of the securities the Company invests in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;have market risk. This means that a change in prevailing interest rates &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&amp;#x2019;s investments are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; collateralized. The Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; realized any significant losses from its investments.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months and which mature at or less than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; months from the balance sheet date are classified as current. Investments with a maturity beyond &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; months from the balance sheet date are classified as long-term. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017, &lt;/div&gt;the Company believes that the cost of its investments is recoverable in all material respects.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following tables summarize the fair value of the Company&amp;#x2019;s investments by type. The estimated fair values of the Company&amp;#x2019;s fixed income investments are classified as Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; active. These fair values are obtained from independent pricing services which utilize Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; inputs.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;September&amp;nbsp;30, 2017&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 50%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27,897&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;96&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(7&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27,986&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,230&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,261&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,108&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(6&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,140&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48,235&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;169&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(21&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48,387&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;December&amp;nbsp;31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 50%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,266&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,298&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,179&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,199&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,962&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,975&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,407&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;77&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(23&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,472&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 7; Value: 3 --&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following table summarizes the scheduled maturity for the Company&amp;#x2019;s investments at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;43,848&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,546&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Maturing after one year through two years&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,539&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,926&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48,387&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,472&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:LesseeLeasesPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198116">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Lease Financing Obligation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 12pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Based on the terms of the lease agreement for the research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,589&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2015, &lt;/div&gt;representing the Company&amp;#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, which ended in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20.5&lt;/div&gt; years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; impact on cash flows associated with the underlying lease or construction in process. Interest expense for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; includes &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$82&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$86,&lt;/div&gt; respectively, and for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; includes &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$217&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$300,&lt;/div&gt; respectively, related to the lease financing obligation.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 11; Value: 3 --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At each of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016, &lt;/div&gt;the lease financing obligation balance was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,704&lt;/div&gt; and was recorded as a long term liability on the consolidated balance sheets. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017 &lt;/div&gt;the remaining future minimum payments under the lease financing obligation are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,444.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2017-09-30" decimals="-3" id="c23197932" unitRef="iso4217-usd">191492000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2016-12-31" decimals="-3" id="c23197933" unitRef="iso4217-usd">89847000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2017-09-30" decimals="-3" id="c23197893" unitRef="iso4217-usd">69237000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2016-12-31" decimals="-3" id="c23197894" unitRef="iso4217-usd">54360000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LineOfCredit contextRef="i_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" decimals="-3" id="c23198123" unitRef="iso4217-usd">23000000</us-gaap:LineOfCredit>
  <us-gaap:LineOfCredit contextRef="i_2017-09-30_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" decimals="-6" id="c23198777" unitRef="iso4217-usd">23000000</us-gaap:LineOfCredit>
  <us-gaap:LineOfCredit contextRef="i_2017-09-30" decimals="-3" id="c23197901" unitRef="iso4217-usd">18379000</us-gaap:LineOfCredit>
  <us-gaap:LineOfCredit contextRef="i_2016-12-31" decimals="-3" id="c23197902" unitRef="iso4217-usd">22777000</us-gaap:LineOfCredit>
  <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="i_2017-09-30_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" decimals="3" id="c23198778" unitRef="xbrli-pure">0.092</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
  <us-gaap:LinesOfCreditCurrent contextRef="i_2017-09-30" decimals="-3" id="c23197889" unitRef="iso4217-usd">4727000</us-gaap:LinesOfCreditCurrent>
  <us-gaap:LinesOfCreditCurrent contextRef="i_2016-12-31" id="c23197890" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:LongTermDebt contextRef="i_2017-09-30" decimals="-5" id="c23198786" unitRef="iso4217-usd">23000000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="i_2017-09-30" decimals="-5" id="c23198785" unitRef="iso4217-usd">2300000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="i_2017-09-30" decimals="-5" id="c23198784" unitRef="iso4217-usd">6900000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="i_2017-09-30" decimals="-5" id="c23198783" unitRef="iso4217-usd">6900000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="i_2017-09-30" decimals="-5" id="c23198782" unitRef="iso4217-usd">6900000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="i_2017-09-30" id="c23198781" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:LossOnSaleOfInvestments contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198161" unitRef="iso4217-usd">0</us-gaap:LossOnSaleOfInvestments>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198067" unitRef="iso4217-usd">135130000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198068" unitRef="iso4217-usd">20972000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198054" unitRef="iso4217-usd">-8834000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198055" unitRef="iso4217-usd">33100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198043" unitRef="iso4217-usd">-30624000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198044" unitRef="iso4217-usd">-47584000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198013" unitRef="iso4217-usd">-46239000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198014" unitRef="iso4217-usd">-50641000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23197992" unitRef="iso4217-usd">-15134000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23197993" unitRef="iso4217-usd">-11528000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198129">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 2016, &lt;/div&gt;the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Statement of Cash Flows (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;230&lt;/div&gt;): Restricted Cash&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&amp;#x201d;&lt;/div&gt;). The new standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for annual periods beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; and interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 2016, &lt;/div&gt;the FASB issued Accounting Standards Update &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Statement of Cash Flows (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;230&lt;/div&gt;): Classification of Certain Cash Receipts and Cash Payments&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15&amp;#x201d;&lt;/div&gt;). The amendments in this update clarify how entities should classify certain cash receipts and cash payments on the Consolidated Statements of Cash Flows. The new guidance also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; class of cash flows. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15&lt;/div&gt; will be effective for annual periods beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2017, &lt;/div&gt;including interim periods within those annual reporting periods, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2016, &lt;/div&gt;the FASB issued Accounting Standards Update &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Compensation - Stock Compensation (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt;): Improvements to Employee Share-Based Payment Accounting&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&amp;#x201d;&lt;/div&gt;). The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&lt;/div&gt; eliminates the requirement that excess tax benefits be realized as a reduction in current taxes payable before the associated tax benefit can be recognized as an increase in paid in capital. Under ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09,&lt;/div&gt; these previously unrecognized deferred tax assets were recognized on a modified retrospective basis as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2017, &lt;/div&gt;the start of the year in which the Company adopted ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09.&lt;/div&gt; The U.S. federal and state net operating losses and credits recognized as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2017 &lt;/div&gt;have been offset by a full valuation allowance. As a result, there is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; cumulative-effect adjustment to retained earnings as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017. &lt;/div&gt;The Company elected &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to change its policy on accounting for forfeitures and continues to estimate the total number of awards for which the requisite service period will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be rendered. The Company adopted ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2017. &lt;/div&gt;Adoption of ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&lt;/div&gt; did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have a material impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2016, &lt;/div&gt;the FASB issued Accounting Standards Update &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Leases (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt;)&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02&amp;#x201d;&lt;/div&gt;). The amendments in this update require lessees, among other things, to recognize lease assets and lease liabilities on the balance sheet for all leases with terms greater than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; months. This update also introduces new disclosure requirements for leasing arrangements. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02&lt;/div&gt; will be effective for the Company in fiscal year &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019,&lt;/div&gt; but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2016, &lt;/div&gt;the FASB issued Accounting Standards Update &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;01:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Financial Instruments - Overall (Subtopic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;825&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;): Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;01&amp;#x201d;&lt;/div&gt;). The amendments in this update address certain aspects of recognition, measurement, presentation and disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;01&lt;/div&gt; will be effective for the Company in fiscal year &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; but early adoption is permitted. The Company does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expect this standard to have a material impact on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2015, &lt;/div&gt;the FASB issued Accounting Standards Update &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Inventory (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;330&lt;/div&gt;): Simplifying the Measurement of Inventory&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&amp;#x201d;&lt;/div&gt;), which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt; defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; apply to inventory that is measured using last-in, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-out or the retail inventory method. The update applies to all other inventory, which includes inventory that is measured using &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-in, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-out or average cost methods. The amendments in ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt; are effective for the Company for fiscal years, and the interim periods within those years, beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2016. &lt;/div&gt;The Company adopted ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2017. &lt;/div&gt;Adoption did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have a material impact on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 13; Value: 3 --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2014, &lt;/div&gt;the FASB issued Standards Update &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Revenue from Contracts with Customers (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;606&lt;/div&gt;)&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&amp;#x201d;&lt;/div&gt;), which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&lt;/div&gt; also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2015, &lt;/div&gt;the FASB finalized a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; year delay in the effective date of this standard, which will now be effective &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2018; &lt;/div&gt;however, early adoption is permitted any time after the original effective date, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2017. &lt;/div&gt;Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company will adopt the standard effective &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2018 &lt;/div&gt;and expects to utilize the modified retrospective methodology. The Company is continuing to evaluate the effect that the standard will have on its consolidated financial statements and related disclosures.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NotesPayableCurrent contextRef="i_2017-09-30" decimals="-3" id="c23197891" unitRef="iso4217-usd">28572000</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableCurrent contextRef="i_2016-12-31" decimals="-3" id="c23197892" unitRef="iso4217-usd">28243000</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableFairValueDisclosure contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" decimals="-3" id="c23198740" unitRef="iso4217-usd">30000000</us-gaap:NotesPayableFairValueDisclosure>
  <us-gaap:OperatingIncomeLoss contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23197976" unitRef="iso4217-usd">-13349000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23197977" unitRef="iso4217-usd">-9241000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23197978" unitRef="iso4217-usd">-39550000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23197979" unitRef="iso4217-usd">-40419000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2017-09-30" decimals="-3" id="c23197874" unitRef="iso4217-usd">1955000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2016-12-31" decimals="-3" id="c23197875" unitRef="iso4217-usd">3813000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23198004" unitRef="iso4217-usd">-2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23198005" unitRef="iso4217-usd">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198006" unitRef="iso4217-usd">-5000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198007" unitRef="iso4217-usd">228000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:PaymentsForHedgeFinancingActivities contextRef="d_2017-01-01_2017-09-30" id="c23198063" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PaymentsForHedgeFinancingActivities contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198064" unitRef="iso4217-usd">2190000</us-gaap:PaymentsForHedgeFinancingActivities>
  <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities contextRef="d_2016-05-18_2016-05-18_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="-3" id="c23198745" unitRef="iso4217-usd">1950000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198050" unitRef="iso4217-usd">39572000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="d_2016-01-01_2016-09-30" id="c23198051" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198046" unitRef="iso4217-usd">213000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198047" unitRef="iso4217-usd">5278000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2017-09-30" decimals="INF" id="c23197906" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2016-12-31" decimals="INF" id="c23197907" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2017-09-30" decimals="-3" id="c23197908" unitRef="xbrli-shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2016-12-31" decimals="-3" id="c23197909" unitRef="xbrli-shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2017-09-30" decimals="-3" id="c23197910" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2016-12-31" decimals="-3" id="c23197911" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2017-09-30" decimals="-3" id="c23197912" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2016-12-31" decimals="-3" id="c23197913" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="i_2017-09-30" decimals="-3" id="c23197904" unitRef="iso4217-usd">0</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue contextRef="i_2016-12-31" decimals="-3" id="c23197905" unitRef="iso4217-usd">0</us-gaap:PreferredStockValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2017-09-30" decimals="-3" id="c23197862" unitRef="iso4217-usd">1421000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2016-12-31" decimals="-3" id="c23197863" unitRef="iso4217-usd">1438000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2017-03-01_2017-03-31" decimals="-4" id="c23198792" unitRef="iso4217-usd">47750000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2017-09-01_2017-09-30" decimals="-4" id="c23198795" unitRef="iso4217-usd">85750000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198057" unitRef="iso4217-usd">133500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2016-01-01_2016-09-30" id="c23198058" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="-3" id="c23198212" unitRef="iso4217-usd">33740000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_StatementScenarioAxis-ContingentUponEuMarketingApprovalMember_TypeOfArrangementAxis-AgreementMember" decimals="-3" id="c23198213" unitRef="iso4217-usd">7000000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" decimals="-3" id="c23198684" unitRef="iso4217-usd">33740000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember" decimals="-3" id="c23198689" unitRef="iso4217-usd">250000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLinesOfCredit contextRef="d_2017-01-01_2017-09-30" id="c23198061" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromLinesOfCredit contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198062" unitRef="iso4217-usd">22658000</us-gaap:ProceedsFromLinesOfCredit>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198052" unitRef="iso4217-usd">32527000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198053" unitRef="iso4217-usd">38272000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198059" unitRef="iso4217-usd">1491000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198060" unitRef="iso4217-usd">204000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="-3" id="c23198281" unitRef="iso4217-usd">1589000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2017-09-30" decimals="-3" id="c23197870" unitRef="iso4217-usd">9613000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2016-12-31" decimals="-3" id="c23197871" unitRef="iso4217-usd">9922000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198093">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; years. Laboratory equipment, office equipment, and software are depreciated over a life of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years. Furniture and fixtures are depreciated over a life of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;seven&lt;/div&gt; years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Property consists of a leased building which did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 8; Value: 3 --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2017-01-01_2017-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" id="c23198187">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2017-01-01_2017-09-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" id="c23198188">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2017-01-01_2017-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" id="c23198189">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2017-01-01_2017-09-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" id="c23198284">P20Y182D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c23198476" unitRef="iso4217-usd">63000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c23198477" unitRef="iso4217-usd">1906000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c23198478" unitRef="iso4217-usd">1969000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c23198479" unitRef="iso4217-usd">653000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" id="c23198480" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c23198481" unitRef="iso4217-usd">653000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" decimals="-3" id="c23198482" unitRef="iso4217-usd">48000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" id="c23198483" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" decimals="-3" id="c23198484" unitRef="iso4217-usd">48000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember" decimals="-3" id="c23198485" unitRef="iso4217-usd">46000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember" id="c23198486" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember" decimals="-3" id="c23198487" unitRef="iso4217-usd">46000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c23198488" unitRef="iso4217-usd">5794000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c23198489" unitRef="iso4217-usd">475000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c23198490" unitRef="iso4217-usd">6269000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" decimals="-3" id="c23198491" unitRef="iso4217-usd">6604000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" decimals="-3" id="c23198492" unitRef="iso4217-usd">2381000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2017-09-30" decimals="-3" id="c23198493" unitRef="iso4217-usd">8985000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" id="c23198494" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c23198495" unitRef="iso4217-usd">3495000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c23198496" unitRef="iso4217-usd">3495000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c23198497" unitRef="iso4217-usd">3451000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" id="c23198498" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c23198499" unitRef="iso4217-usd">3451000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" decimals="-3" id="c23198500" unitRef="iso4217-usd">686000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" id="c23198501" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" decimals="-3" id="c23198502" unitRef="iso4217-usd">686000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c23198503" unitRef="iso4217-usd">957000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c23198504" unitRef="iso4217-usd">179000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c23198505" unitRef="iso4217-usd">1136000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" decimals="-3" id="c23198506" unitRef="iso4217-usd">5094000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" decimals="-3" id="c23198507" unitRef="iso4217-usd">3674000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-12-31" decimals="-3" id="c23198508" unitRef="iso4217-usd">8768000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198089">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Collaborations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&amp;#x201c;Green Cross&amp;#x201d;), Mundipharma International Holdings Limited (&amp;#x201c;Mundipharma&amp;#x201d;) and Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company had the following receivables.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;September&amp;nbsp;30, 2017&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 58%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;63&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,906&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,969&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;653&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;653&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Mundipharma International Holdings Limited&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;46&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;46&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,794&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;475&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,269&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,604&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,381&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,985&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;December&amp;nbsp;31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 58%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,495&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,495&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,451&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,451&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;686&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;686&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;957&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;179&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,136&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,094&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,674&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,768&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&amp;#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Product Sales&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;&amp;reg;&lt;/div&gt;&lt;/div&gt;. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
  <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198199" unitRef="iso4217-usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
  <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198202" unitRef="iso4217-usd">11000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23197960" unitRef="iso4217-usd">17509000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23197961" unitRef="iso4217-usd">14105000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23197962" unitRef="iso4217-usd">50038000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23197963" unitRef="iso4217-usd">48850000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2017-01-01_2017-09-30" id="c23198108">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&amp;#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&amp;#x2019;s manufacturing and clinical and preclinical studies are performed by &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&amp;#x2019;s on-going review of the level of services actually performed.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Additionally, the Company has license agreements with &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties, such as Albert Einstein College of Medicine of Yeshiva University (&amp;#x201c;AECOM&amp;#x201d;), Industrial Research, Ltd. (&amp;#x201c;IRL&amp;#x201d;), and the University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&amp;#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&amp;#x2019;s academic partners for modification to existing license agreements. These deferred expenses would &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have been incurred without receipt of such payments or modifications from the Company&amp;#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2017-09-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember" decimals="-3" id="c23198150" unitRef="iso4217-usd">1713000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2017-09-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember" decimals="-3" id="c23198152" unitRef="iso4217-usd">1409000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2017-09-30" decimals="-3" id="c23197854" unitRef="iso4217-usd">3122000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2016-12-31" decimals="-3" id="c23197855" unitRef="iso4217-usd">1546000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2017-09-30" decimals="-3" id="c23197928" unitRef="iso4217-usd">-612300000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2016-12-31" decimals="-3" id="c23197929" unitRef="iso4217-usd">-566061000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="d_2017-01-01_2017-09-30_ProductOrServiceAxis-RAPIVABMember" decimals="-3" id="c23198226" unitRef="iso4217-usd">2000000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="d_2017-01-01_2017-09-30_ProductOrServiceAxis-SupplementalNDAForRaAPIVABMember" decimals="-3" id="c23198227" unitRef="iso4217-usd">5000000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2017-01-01_2017-09-30" id="c23198105">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenues from collaborative and other research and development arrangements and royalties when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&amp;nbsp;persuasive evidence of an arrangement exists; (ii)&amp;nbsp;delivery has occurred or services have been rendered; (iii)&amp;nbsp;the seller&amp;#x2019;s price to the buyer is fixed or determinable; and (iv)&amp;nbsp;collectability is reasonably assured.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 9; Value: 3 --&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Under certain of the Company&amp;#x2019;s license agreements, the Company receives royalty payments based upon its licensees&amp;#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;For arrangements that involve the delivery of more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &amp;#x201c;stand-alone value&amp;#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party evidence of selling price (&amp;#x201c;TPE&amp;#x201d;) and (iii) best estimate of selling price (&amp;#x201c;BESP&amp;#x201d;). The BESP reflects the Company&amp;#x2019;s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2015, &lt;/div&gt;the Company entered into a License Agreement (the &amp;#x201c;SUL Agreement&amp;#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&amp;#x201c;EU&amp;#x201d;) marketing approvals. The Company received an upfront payment of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$33,740&lt;/div&gt; from SUL, of which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7,000&lt;/div&gt; was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$21,777&lt;/div&gt; of the upfront payment was allocated to the license rights and recognized as revenue in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015.&lt;/div&gt; Approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3,740&lt;/div&gt; of the upfront payment was allocated to the pending sale of inventory and was recognized in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; when the inventory transfer was completed. Approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,223&lt;/div&gt; of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;During the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; the Company received a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,000&lt;/div&gt; milestone payment related to the approval of RAPIVAB by Health Canada and a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,000&lt;/div&gt; milestone payment associated with the U.S. Food and Drug Administration (&amp;#x201c;FDA&amp;#x201d;) approval of a supplemental new drug application (&amp;#x201c;sNDA&amp;#x201d;) for RAPIVAB extending its availability for the treatment of acute uncomplicated influenza to pediatric patients &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; years and older. The Company evaluated each event based payment under the provisions of ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Milestone Method of Revenue Recognition&lt;/div&gt;, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. Under the terms of the SUL Agreement, the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;receive an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,000&lt;/div&gt; payment related to the successful marketing approval by the European Medicines Agency (&amp;#x201c;EMA&amp;#x201d;) for an adult indication in the EU. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No&lt;/div&gt; event-based payments were achieved during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&amp;#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&amp;#x201d;BARDA/HHS&amp;#x201d;) and the National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 10; Value: 3 --&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recorded the following revenues for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Three Months&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Nine Months&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;Product sales&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,501&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,501&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;442&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,501&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,252&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,020&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,490&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,813&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,305&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,846&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;296&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;296&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;888&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;888&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; text-indent: 20pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,031&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;153&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,350&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;616&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Total collaborative and other research and development revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,817&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,262&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,543&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,350&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,760&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,763&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,296&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,370&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:Revenues contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="-3" id="c23198214" unitRef="iso4217-usd">21777000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23198534" unitRef="iso4217-usd">8760000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23198535" unitRef="iso4217-usd">7763000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198536" unitRef="iso4217-usd">21296000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198537" unitRef="iso4217-usd">17370000</us-gaap:Revenues>
  <us-gaap:RoyaltyExpense contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23197968" unitRef="iso4217-usd">115000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23197969" unitRef="iso4217-usd">143000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23197970" unitRef="iso4217-usd">431000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23197971" unitRef="iso4217-usd">247000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyRevenue contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23197942" unitRef="iso4217-usd">442000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23197944" unitRef="iso4217-usd">3501000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23197945" unitRef="iso4217-usd">7252000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23197946" unitRef="iso4217-usd">6020000</us-gaap:RoyaltyRevenue>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23197936" unitRef="iso4217-usd">1501000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-07-01_2016-09-30" id="c23197938" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23197939" unitRef="iso4217-usd">1501000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-09-30" id="c23197941" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:SalesRevenueNet contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23197951" unitRef="iso4217-usd">8760000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23197952" unitRef="iso4217-usd">7763000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23197953" unitRef="iso4217-usd">21296000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23197954" unitRef="iso4217-usd">17370000</us-gaap:SalesRevenueNet>
  <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="d_2017-01-01_2017-09-30" id="c-22">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" colspan="5" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Principal Payments&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 82%; font-size: 10pt; text-align: justify; text-indent: 3.2pt"&gt;2018&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 20%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,900&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt"&gt;2019&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,900&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt"&gt;2020&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,900&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1.1pt; text-indent: 3.2pt"&gt;2021&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,300&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; text-indent: 3.2pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,000&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="d_2017-01-01_2017-09-30" id="c-20">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Awards&lt;br /&gt; Available&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Options&lt;br /&gt; Outstanding&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Weighted&lt;br /&gt; Average&lt;br /&gt; Exercise&lt;br /&gt; Price&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 58%; font-size: 10pt"&gt;Balance December&amp;nbsp;31, 2016&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,273&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,095&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.55&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Plan amendment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,000&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock unit awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(16&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Restricted stock unit awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,591&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,591&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.49&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock option awards exercised&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(422&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.49&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt"&gt;Stock option awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;912&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(912&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10.22&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Balance September&amp;nbsp;30, 2017&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,581&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,352&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.19&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2017-01-01_2017-09-30" id="c-21">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 65%; font-size: 10pt; text-align: left"&gt;Expected Life in Years&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.5&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.5&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Volatility&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;82.0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;82.0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Dividend Yield&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.0&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-Free Interest Rate&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.9&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.4&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23197964" unitRef="iso4217-usd">3343000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23197965" unitRef="iso4217-usd">2756000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23197966" unitRef="iso4217-usd">9235000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23197967" unitRef="iso4217-usd">8692000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198020" unitRef="iso4217-usd">10307000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198021" unitRef="iso4217-usd">6478000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2017-01-01_2017-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" id="c23198573">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="d_2017-01-01_2017-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c23198647" unitRef="xbrli-shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2017-01-01_2017-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c23198644" unitRef="xbrli-shares">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2017-01-01_2017-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c23198614" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="3" id="c23198666" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2016-01-01_2016-09-30_PlanNameAxis-IncentivePlanMember" decimals="3" id="c23198667" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="3" id="c23198664" unitRef="xbrli-pure">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2016-01-01_2016-09-30_PlanNameAxis-IncentivePlanMember" decimals="3" id="c23198665" unitRef="xbrli-pure">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="3" id="c23198668" unitRef="xbrli-pure">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2016-01-01_2016-09-30_PlanNameAxis-IncentivePlanMember" decimals="3" id="c23198669" unitRef="xbrli-pure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c23198626" unitRef="xbrli-shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c23198641" unitRef="xbrli-shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="i_2017-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c23198617" unitRef="xbrli-shares">1475000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2017-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c23198618" unitRef="xbrli-shares">330000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2016-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c23198638" unitRef="xbrli-shares">2273000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c23198659" unitRef="xbrli-shares">1581000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c23198661" unitRef="iso4217-usd-per-xbrli-shares">6.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c23198657" unitRef="xbrli-shares">912000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c23198658" unitRef="iso4217-usd-per-xbrli-shares">10.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c23198651" unitRef="xbrli-shares">2591000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="-3" id="c23198574" unitRef="xbrli-shares">1032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2014-01-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="-3" id="c23198575" unitRef="xbrli-shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c23198607" unitRef="iso4217-usd-per-xbrli-shares">3.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2016-01-01_2016-09-30_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c23198608" unitRef="iso4217-usd-per-xbrli-shares">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2016-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c23198639" unitRef="xbrli-shares">12095000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c23198660" unitRef="xbrli-shares">13352000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2016-12-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c23198640" unitRef="iso4217-usd-per-xbrli-shares">6.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c23198655" unitRef="iso4217-usd-per-xbrli-shares">3.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c23198652" unitRef="iso4217-usd-per-xbrli-shares">5.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2017-01-01_2017-09-30" id="c23198110">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; is deemed to have occurred.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2017-01-01_2017-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" decimals="INF" id="c23198572" unitRef="xbrli-pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2017-01-01_2017-09-30_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c23198576" unitRef="xbrli-pure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2017-01-01_2017-09-30_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c23198590" unitRef="xbrli-pure">0.3</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember" id="c23198662">P5Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2016-01-01_2016-09-30_PlanNameAxis-IncentivePlanMember" id="c23198663">P5Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2017-01-01_2017-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MinimumMember" id="c23198596">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2017-01-01_2017-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember" id="c23198597">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="d_2017-07-01_2017-09-30_AwardTypeAxis-PerformanceBasedOptionMember" decimals="-3" id="c23198570" unitRef="xbrli-shares">404000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2017-03-31" decimals="INF" id="c23198791" unitRef="iso4217-usd-per-xbrli-shares">8.50</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2017-09-30" decimals="INF" id="c23198794" unitRef="iso4217-usd-per-xbrli-shares">5.15</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2017-01-01_2017-09-30" id="s693042">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; &amp;#x2014; Significant Accounting Policies&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;BioCryst Pharmaceuticals, Inc. (the &amp;#x201c;Company&amp;#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on oral treatments for rare diseases in which significant unmet medical needs exist and that align with its capabilities and expertise. The Company was incorporated in Delaware in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1986&lt;/div&gt; and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;With the funds available at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017, &lt;/div&gt;the Company believes these resources will be sufficient to fund its operations at least through the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019.&lt;/div&gt; The Company has sustained operating losses for the majority of its corporate history and expects that its &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; expenses will exceed its &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&amp;#x2019;s liquidity needs will be largely determined by the success of operations in regards to the progression of its product candidates in the future. The Company also &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;consider other plans to fund operations beyond the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019&lt;/div&gt; including: (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;)&amp;nbsp;securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;)&amp;nbsp;out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;)&amp;nbsp;raising additional capital through equity or debt financings or from other sources; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;)&amp;nbsp;obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;)&amp;nbsp;reducing spending on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; or more research and development programs, including by discontinuing development; and/or (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;)&amp;nbsp;restructuring operations to change its overhead structure. The Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings in the future. The Company&amp;#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, JPR Royalty Sub LLC (&amp;#x201c;Royalty Sub&amp;#x201d;) and MDCP, LLC (&amp;#x201c;MDCP&amp;#x201d;). Both subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$30,000&lt;/div&gt;&amp;nbsp;financing transaction the Company completed on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011.&lt;/div&gt; See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,&lt;/div&gt; Royalty Monetization, for a further description of this transaction. MDCP was formed in connection with a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$23,000&lt;/div&gt; Senior Credit Facility that the Company closed on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 23, 2016. &lt;/div&gt;See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,&lt;/div&gt; Senior Credit Facility, for a further description of this transaction. All intercompany transactions and balances have been eliminated.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201c;U.S. GAAP&amp;#x201d;) for interim financial reporting and the instructions to Form &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-Q and do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&amp;#x2019;s opinion, necessary to present fairly, in all material respects, the Company&amp;#x2019;s consolidated financial position, results of operations, and cash flows. There were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; adjustments other than normal recurring adjustments.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;These financial statements should be read in conjunction with the financial statements for the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and the notes thereto included in the Company&amp;#x2019;s &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; Annual Report on Form &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-K. Interim operating results are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; necessarily indicative of operating results for the full year. The balance sheet as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; has been derived from the audited consolidated financial statements included in the Company&amp;#x2019;s most recent Annual Report on Form &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-K.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Restricted Cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Restricted cash as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; reflects &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,713&lt;/div&gt; in royalty revenue paid by Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;) designated for interest on the PhaRMA Notes (defined in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;) and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,409&lt;/div&gt; the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its Birmingham research facilities.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&amp;#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&amp;#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; years and requires an average portfolio maturity of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt; months. Some of the securities the Company invests in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;have market risk. This means that a change in prevailing interest rates &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&amp;#x2019;s investments are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; collateralized. The Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; realized any significant losses from its investments.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months and which mature at or less than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; months from the balance sheet date are classified as current. Investments with a maturity beyond &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; months from the balance sheet date are classified as long-term. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017, &lt;/div&gt;the Company believes that the cost of its investments is recoverable in all material respects.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following tables summarize the fair value of the Company&amp;#x2019;s investments by type. The estimated fair values of the Company&amp;#x2019;s fixed income investments are classified as Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; active. These fair values are obtained from independent pricing services which utilize Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; inputs.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;September&amp;nbsp;30, 2017&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 50%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27,897&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;96&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(7&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27,986&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,230&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,261&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,108&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(6&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,140&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48,235&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;169&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(21&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48,387&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;December&amp;nbsp;31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 50%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,266&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 7%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,298&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,179&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,199&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,962&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,975&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,407&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;77&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(23&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,472&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following table summarizes the scheduled maturity for the Company&amp;#x2019;s investments at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;43,848&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,546&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Maturing after one year through two years&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,539&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,926&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48,387&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,472&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Collaborations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&amp;#x201c;Green Cross&amp;#x201d;), Mundipharma International Holdings Limited (&amp;#x201c;Mundipharma&amp;#x201d;) and Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company had the following receivables.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;September&amp;nbsp;30, 2017&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 58%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;63&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,906&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,969&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;653&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;653&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Mundipharma International Holdings Limited&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;46&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;46&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,794&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;475&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,269&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,604&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,381&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,985&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;December&amp;nbsp;31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 58%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,495&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,495&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,451&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,451&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Green Cross Corporation&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;686&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;686&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;957&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;179&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,136&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,094&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,674&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,768&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&amp;#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Product Sales&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;&amp;reg;&lt;/div&gt;&lt;/div&gt;. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s inventory consisted primarily of peramivir work in process and is being manufactured for the Company&amp;#x2019;s partners. Inventory is stated at the lower of cost and net realizable value, determined under the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-in, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-out (&amp;#x201c;FIFO&amp;#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; years. Laboratory equipment, office equipment, and software are depreciated over a life of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years. Furniture and fixtures are depreciated over a life of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;seven&lt;/div&gt; years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Property consists of a leased building which did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patents and Licenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accrued Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally enters into contractual agreements with &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with its service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr&gt; &lt;td style="width: 5%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to Contract Research Organizations (&amp;#x201c;CROs&amp;#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to contract manufacturers in connection with the production of the Company&amp;#x2019;s raw materials, drug substance and drug products;&amp;nbsp;and&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;professional fees.&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016, &lt;/div&gt;the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The liability method is used in the Company&amp;#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accumulated Other Comprehensive Loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&amp;#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No&lt;/div&gt; reclassifications out of accumulated other comprehensive loss were recorded during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017. &lt;/div&gt;Realized gains of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$11&lt;/div&gt; were reclassified out of accumulated other comprehensive loss during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2016.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenues from collaborative and other research and development arrangements and royalties when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&amp;nbsp;persuasive evidence of an arrangement exists; (ii)&amp;nbsp;delivery has occurred or services have been rendered; (iii)&amp;nbsp;the seller&amp;#x2019;s price to the buyer is fixed or determinable; and (iv)&amp;nbsp;collectability is reasonably assured.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Under certain of the Company&amp;#x2019;s license agreements, the Company receives royalty payments based upon its licensees&amp;#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;For arrangements that involve the delivery of more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &amp;#x201c;stand-alone value&amp;#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party evidence of selling price (&amp;#x201c;TPE&amp;#x201d;) and (iii) best estimate of selling price (&amp;#x201c;BESP&amp;#x201d;). The BESP reflects the Company&amp;#x2019;s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2015, &lt;/div&gt;the Company entered into a License Agreement (the &amp;#x201c;SUL Agreement&amp;#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&amp;#x201c;EU&amp;#x201d;) marketing approvals. The Company received an upfront payment of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$33,740&lt;/div&gt; from SUL, of which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7,000&lt;/div&gt; was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$21,777&lt;/div&gt; of the upfront payment was allocated to the license rights and recognized as revenue in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015.&lt;/div&gt; Approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3,740&lt;/div&gt; of the upfront payment was allocated to the pending sale of inventory and was recognized in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; when the inventory transfer was completed. Approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,223&lt;/div&gt; of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;During the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; the Company received a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,000&lt;/div&gt; milestone payment related to the approval of RAPIVAB by Health Canada and a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,000&lt;/div&gt; milestone payment associated with the U.S. Food and Drug Administration (&amp;#x201c;FDA&amp;#x201d;) approval of a supplemental new drug application (&amp;#x201c;sNDA&amp;#x201d;) for RAPIVAB extending its availability for the treatment of acute uncomplicated influenza to pediatric patients &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; years and older. The Company evaluated each event based payment under the provisions of ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Milestone Method of Revenue Recognition&lt;/div&gt;, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. Under the terms of the SUL Agreement, the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;receive an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,000&lt;/div&gt; payment related to the successful marketing approval by the European Medicines Agency (&amp;#x201c;EMA&amp;#x201d;) for an adult indication in the EU. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No&lt;/div&gt; event-based payments were achieved during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&amp;#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&amp;#x201d;BARDA/HHS&amp;#x201d;) and the National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recorded the following revenues for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Three Months&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Nine Months&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2017&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;Product sales&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,501&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,501&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;442&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,501&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,252&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,020&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,490&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,813&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,305&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,846&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;296&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;296&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;888&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;888&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; text-indent: 20pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,031&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;153&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,350&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;616&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Total collaborative and other research and development revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,817&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,262&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,543&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,350&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,760&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,763&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,296&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,370&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&amp;#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&amp;#x2019;s manufacturing and clinical and preclinical studies are performed by &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&amp;#x2019;s on-going review of the level of services actually performed.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Additionally, the Company has license agreements with &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties, such as Albert Einstein College of Medicine of Yeshiva University (&amp;#x201c;AECOM&amp;#x201d;), Industrial Research, Ltd. (&amp;#x201c;IRL&amp;#x201d;), and the University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&amp;#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&amp;#x2019;s academic partners for modification to existing license agreements. These deferred expenses would &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have been incurred without receipt of such payments or modifications from the Company&amp;#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; is deemed to have occurred.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Interest Expense and Deferred Financing Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Interest expense for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,140&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,465,&lt;/div&gt; respectively, and for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6,334&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,356,&lt;/div&gt; respectively, and primarily relates to the issuance of the PhaRMA Notes (defined in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;) and the Senior Credit Facility (defined in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;). Costs directly associated with the issuance of the PhaRMA Notes and the Senior Credit Facility have been capitalized and are netted against the PhaRMA Notes and Senior Credit Facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Senior Credit Facility using the effective interest rate method. Amortization of deferred financing costs and original issue discount included in interest expense was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$219&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$116&lt;/div&gt; for each of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively, and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$658&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$335&lt;/div&gt; for each of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Lease Financing Obligation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 12pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Based on the terms of the lease agreement for the research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,589&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2015, &lt;/div&gt;representing the Company&amp;#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, which ended in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20.5&lt;/div&gt; years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; impact on cash flows associated with the underlying lease or construction in process. Interest expense for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; includes &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$82&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$86,&lt;/div&gt; respectively, and for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; includes &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$217&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$300,&lt;/div&gt; respectively, related to the lease financing obligation.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At each of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016, &lt;/div&gt;the lease financing obligation balance was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,704&lt;/div&gt;&lt;/div&gt; and was recorded as a long term liability on the consolidated balance sheets. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017 &lt;/div&gt;the remaining future minimum payments under the lease financing obligation are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,444.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0 0pt 12pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Currency Hedge Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; resulted in losses of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,858&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7,372,&lt;/div&gt; respectively. Mark to market adjustments are determined by a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; party pricing model that uses quoted prices in markets that are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; actively traded and for which significant inputs are observable directly or indirectly, representing Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized currency exchange gains of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$966&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$811&lt;/div&gt; during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement. The Company is also required to post collateral in connection with the mark to market adjustments based on thresholds defined in the Currency Hedge Agreement. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt;&lt;/div&gt; hedge collateral was posted under the agreement.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&amp;#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; include &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,996&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,291,&lt;/div&gt; respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; include &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,519&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,190,&lt;/div&gt; respectively, of such potential common shares, as their impact would be anti-dilutive.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers and Other Risks&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;All peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) are made by the Company&amp;#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Other than royalty revenues, the Company&amp;#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of galidesivir (formerly &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;BCX4430&lt;/div&gt;) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&amp;#x2019;s collaborative and other research and development revenues. The completion (as with the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 30, 2014 &lt;/div&gt;BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&amp;#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&amp;#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&amp;#x2019;s drug development activities are performed by a limited group of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&amp;#x2019;s ability to complete its drug development activities.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Credit Risk&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt; months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&amp;#x2019;s receivables from collaborations are due from the U.S. Government, for which there is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; assumed credit risk.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 2016, &lt;/div&gt;the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Statement of Cash Flows (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;230&lt;/div&gt;): Restricted Cash&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&amp;#x201d;&lt;/div&gt;). The new standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for annual periods beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; and interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 2016, &lt;/div&gt;the FASB issued Accounting Standards Update &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Statement of Cash Flows (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;230&lt;/div&gt;): Classification of Certain Cash Receipts and Cash Payments&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15&amp;#x201d;&lt;/div&gt;). The amendments in this update clarify how entities should classify certain cash receipts and cash payments on the Consolidated Statements of Cash Flows. The new guidance also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; class of cash flows. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15&lt;/div&gt; will be effective for annual periods beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2017, &lt;/div&gt;including interim periods within those annual reporting periods, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2016, &lt;/div&gt;the FASB issued Accounting Standards Update &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Compensation - Stock Compensation (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt;): Improvements to Employee Share-Based Payment Accounting&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&amp;#x201d;&lt;/div&gt;). The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&lt;/div&gt; eliminates the requirement that excess tax benefits be realized as a reduction in current taxes payable before the associated tax benefit can be recognized as an increase in paid in capital. Under ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09,&lt;/div&gt; these previously unrecognized deferred tax assets were recognized on a modified retrospective basis as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2017, &lt;/div&gt;the start of the year in which the Company adopted ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09.&lt;/div&gt; The U.S. federal and state net operating losses and credits recognized as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2017 &lt;/div&gt;have been offset by a full valuation allowance. As a result, there is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; cumulative-effect adjustment to retained earnings as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017. &lt;/div&gt;The Company elected &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to change its policy on accounting for forfeitures and continues to estimate the total number of awards for which the requisite service period will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be rendered. The Company adopted ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2017. &lt;/div&gt;Adoption of ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&lt;/div&gt; did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have a material impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2016, &lt;/div&gt;the FASB issued Accounting Standards Update &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Leases (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt;)&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02&amp;#x201d;&lt;/div&gt;). The amendments in this update require lessees, among other things, to recognize lease assets and lease liabilities on the balance sheet for all leases with terms greater than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; months. This update also introduces new disclosure requirements for leasing arrangements. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02&lt;/div&gt; will be effective for the Company in fiscal year &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019,&lt;/div&gt; but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2016, &lt;/div&gt;the FASB issued Accounting Standards Update &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;01:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Financial Instruments - Overall (Subtopic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;825&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;): Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;01&amp;#x201d;&lt;/div&gt;). The amendments in this update address certain aspects of recognition, measurement, presentation and disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;01&lt;/div&gt; will be effective for the Company in fiscal year &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; but early adoption is permitted. The Company does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expect this standard to have a material impact on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2015, &lt;/div&gt;the FASB issued Accounting Standards Update &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Inventory (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;330&lt;/div&gt;): Simplifying the Measurement of Inventory&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&amp;#x201d;&lt;/div&gt;), which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt; defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; apply to inventory that is measured using last-in, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-out or the retail inventory method. The update applies to all other inventory, which includes inventory that is measured using &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-in, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-out or average cost methods. The amendments in ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt; are effective for the Company for fiscal years, and the interim periods within those years, beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2016. &lt;/div&gt;The Company adopted ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2017. &lt;/div&gt;Adoption did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have a material impact on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2014, &lt;/div&gt;the FASB issued Standards Update &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09:&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Revenue from Contracts with Customers (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;606&lt;/div&gt;)&lt;/div&gt; (&amp;#x201c;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&amp;#x201d;&lt;/div&gt;), which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09&lt;/div&gt; also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2015, &lt;/div&gt;the FASB finalized a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; year delay in the effective date of this standard, which will now be effective &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2018; &lt;/div&gt;however, early adoption is permitted any time after the original effective date, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2017. &lt;/div&gt;Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company will adopt the standard effective &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2018 &lt;/div&gt;and expects to utilize the modified retrospective methodology. The Company is continuing to evaluate the effect that the standard will have on its consolidated financial statements and related disclosures.&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c23198632" unitRef="xbrli-shares">91000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c23198790" unitRef="xbrli-shares">6061000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-09-01_2017-09-30" decimals="-3" id="c23198793" unitRef="xbrli-shares">17864000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c23198654" unitRef="xbrli-shares">422000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockholdersEquity contextRef="i_2017-09-30" decimals="-3" id="c23197930" unitRef="iso4217-usd">100632000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31" decimals="-3" id="c23197931" unitRef="iso4217-usd">1578000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2017-01-01_2017-09-30" id="s693056">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt; &amp;#x2014; Stockholders&amp;#x2019; Equity&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 3, 2015, &lt;/div&gt;the Company filed a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$150,000&lt;/div&gt; shelf registration statement on Form S-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; with the Securities and Exchange Commission (the &amp;#x201c;SEC&amp;#x201d;). This shelf registration statement became effective upon filing and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 26, 2016, &lt;/div&gt;the Company filed a post-effective amendment to this registration statement, which allowed for its use by the Company when declared effective by the SEC&amp;#x2019;s staff on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 18, 2016.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2017, &lt;/div&gt;the Company completed a public offering of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,061&lt;/div&gt; shares of its common stock at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$8.50&lt;/div&gt; per share, which included the underwriters&amp;#x2019; overallotment option to purchase additional shares. Net proceeds were approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$47,750&lt;/div&gt; after deducting underwriting discounts and offering expenses.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 2017, &lt;/div&gt;the Company completed a public offering of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,864&lt;/div&gt; shares of its common stock at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.15&lt;/div&gt; per share, which included the underwriters&amp;#x2019; overallotment option to purchase additional shares. Net proceeds were approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$85,750&lt;/div&gt; after deducting underwriting discounts and offering expenses.&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:UseOfEstimates contextRef="d_2017-01-01_2017-09-30" id="c23198124">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2017-07-01_2017-09-30" decimals="-3" id="c23198000" unitRef="xbrli-shares">83570000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2016-07-01_2016-09-30" decimals="-3" id="c23198001" unitRef="xbrli-shares">73734000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2017-01-01_2017-09-30" decimals="-3" id="c23198002" unitRef="xbrli-shares">79749000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2016-01-01_2016-09-30" decimals="-3" id="c23198003" unitRef="xbrli-shares">73677000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"/>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="iso4217-jpy">
    <xbrli:measure>iso4217:JPY</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2000-06-01</xbrli:startDate>
      <xbrli:endDate>2000-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2006-02-01_2006-02-28_TypeOfArrangementAxis-MundipharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-02-01</xbrli:startDate>
      <xbrli:endDate>2006-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-06-01</xbrli:startDate>
      <xbrli:endDate>2006-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>
      <xbrli:endDate>2011-03-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>
      <xbrli:endDate>2011-03-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-08-01</xbrli:startDate>
      <xbrli:endDate>2013-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-09-01_2017-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2017-09-30_TypeOfArrangementAxis-ASPRBARDAContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_StatementScenarioAxis-ContingentUponEuMarketingApprovalMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">bcrx:ContingentUponEuMarketingApprovalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-16</xbrli:startDate>
      <xbrli:endDate>2015-06-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-09-30_CounterpartyNameAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-09-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-09-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-09-30_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-05-18_2016-05-18_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-05-18</xbrli:startDate>
      <xbrli:endDate>2016-05-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-07-01_2016-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-07-01_2016-09-30_CounterpartyNameAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-07-01_2016-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-07-01_2016-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-07-01_2016-09-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-09-23_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-09-23</xbrli:startDate>
      <xbrli:endDate>2016-09-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-09-23_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-09-23</xbrli:startDate>
      <xbrli:endDate>2016-09-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:August2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcrx:NonEmployeeDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_CounterpartyNameAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_ProductOrServiceAxis-RAPIVABMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_ProductOrServiceAxis-SupplementalNDAForRaAPIVABMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:SupplementalNDAForRaAPIVABMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:UABMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-01_2017-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-01_2017-09-30_AwardTypeAxis-PerformanceBasedOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformanceBasedOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-01_2017-09-30_CounterpartyNameAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-01_2017-09-30_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-01_2017-09-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-01_2017-09-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-09-01_2017-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-09-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2000-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-03">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AdditionalDevelopmentOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:BaseContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-05-18_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-05-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-09-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_InvestmentTypeAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_CurrencyAxis-JPY_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_InvestmentTypeAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-10-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>bcrx-20170930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 04:53PM UTC 2017-11-08--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:bcrx="http://www.biocryst.com/20170930" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biocryst.com/20170930">
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20170930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20170930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20170930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20170930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.biocryst.com/20170930/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-current-period-unaudited" roleURI="http://www.biocryst.com/20170930/role/statement-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.biocryst.com/20170930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-comprehensive-loss-unaudited" roleURI="http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-comprehensive-loss-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows-unaudited" roleURI="http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies" roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Disclosure - Note 1 - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation" roleURI="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 2 - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-collaborative-and-other-research-and-development-contracts" roleURI="http://www.biocryst.com/20170930/role/statement-note-3-collaborative-and-other-research-and-development-contracts">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-royalty-monetization" roleURI="http://www.biocryst.com/20170930/role/statement-note-4-royalty-monetization">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 4 - Royalty Monetization</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-senior-credit-facility" roleURI="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 5 - Senior Credit Facility</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockholders-equity" roleURI="http://www.biocryst.com/20170930/role/statement-note-6-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 6 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.biocryst.com/20170930/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-tables" roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 1 - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation-tables" roleURI="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 2 - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-senior-credit-facility-tables" roleURI="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 5 - Senior Credit Facility (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-details-textual" roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 1 - Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 1 - Significant Accounting Policies - Fair Value of the Company's Investments by Type (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 1 - Significant Accounting Policies - Scheduled Maturity for the Company's Investments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-summary-of-receivables-details" roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 1 - Significant Accounting Policies - Summary of Receivables (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-summary-of-revenues-details" roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 1 - Significant Accounting Policies - Summary of Revenues (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation-details-textual" roleURI="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 2 - Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details" roleURI="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 2 - Stock-based Compensation - Stock Incentive Plan Activities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" roleURI="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 2 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Incentive Plan (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" roleURI="http://www.biocryst.com/20170930/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-royalty-monetization-details-textual" roleURI="http://www.biocryst.com/20170930/role/statement-note-4-royalty-monetization-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 4 - Royalty Monetization (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-senior-credit-facility-details-textual" roleURI="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 5 - Senior Credit Facility (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" roleURI="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 5 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockholders-equity-details-textual" roleURI="http://www.biocryst.com/20170930/role/statement-note-6-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 6 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="bcrx_AECOMAndIRLMember" name="AECOMAndIRLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ASPRBARDAContractMember" name="ASPRBARDAContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AccruedExpensesPolicyTextBlock" name="AccruedExpensesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AdditionalDevelopmentOptionsMember" name="AdditionalDevelopmentOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" name="AdvanceNoticePeriodForTerminationOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AgreementMember" name="AgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" name="AmortizationOfDiscountAndPremiumOnInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMaximum" name="AnnualLicenseFeeMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMinimum" name="AnnualLicenseFeeMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_August2013Member" name="August2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesAccruedInterest" name="AvailableForSaleSecuritiesAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" name="AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AveragematurityForPortfolioInvestments" name="AveragematurityForPortfolioInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" name="AveragematurityPeriodOfHighQualityMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BaseContractMember" name="BaseContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BirminghamResearchFacilityMember" name="BirminghamResearchFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CSLLimitedMember" name="CSLLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CSLMember" name="CSLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAndOtherResearchAndDevelopment" name="CollaborativeAndOtherResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" name="CollaborativeAndOtherResearchAndDevelopmentRevenues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CollateralForCreditMember" name="CollateralForCreditMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" name="ConcentrationOfMarketRiskPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ContingentUponEuMarketingApprovalMember" name="ContingentUponEuMarketingApprovalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CurrencyHedgeAgreementMember" name="CurrencyHedgeAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CurrencyHedgeAgreementPolicyTextBlock" name="CurrencyHedgeAgreementPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DebtInstrumentFinalPaymentFeePercentage" name="DebtInstrumentFinalPaymentFeePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DebtInstrumentMinimumLibor" name="DebtInstrumentMinimumLibor" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_December2014Member" name="December2014Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DeferredCollaborationExpenseAssets" name="DeferredCollaborationExpenseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" name="DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DescriptionOfCompanyPolicyTextBlock" name="DescriptionOfCompanyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" name="ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_GreenCrossCorporationMember" name="GreenCrossCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_IncentivePlanMember" name="IncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_IncreaseDecreaseInFinancingLeaseObligations" name="IncreaseDecreaseInFinancingLeaseObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" name="InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_Interestreserve" name="Interestreserve" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_JPRRoyaltySubLLCMember" name="JPRRoyaltySubLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" name="LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_LeaseFinancingObligationNetOfCurrent" name="LeaseFinancingObligationNetOfCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_LongtermInvestmentMaturityMinimum" name="LongtermInvestmentMaturityMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" name="MaturityPeriodOfHighQualityMarketablesecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityperiodOfShortTermInvestment" name="MaturityperiodOfShortTermInvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaximumAggregateOfferingPrice" name="MaximumAggregateOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_MaximumAmountOfCollateralRequiredToPost" name="MaximumAmountOfCollateralRequiredToPost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_MidCapFinancialServicesLLCMember" name="MidCapFinancialServicesLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentMaximum" name="MilestonePaymentMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentMinimum" name="MilestonePaymentMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentReceived" name="MilestonePaymentReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_MundipharmaInternationalHoldingsLimitedMember" name="MundipharmaInternationalHoldingsLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_MundipharmaMember" name="MundipharmaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_NumberOfStockbasedCompensationPlans" name="NumberOfStockbasedCompensationPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" name="PercentageOfCarryingAmountInExcessOfFairValue1" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesBeginning" name="PercentageOfCommonStockSharesBeginning" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" name="PercentageOfSalaryToPurchaseCommonStockMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_PerformanceBasedOptionMember" name="PerformanceBasedOptionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PeriodOfAgreement" name="PeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_PhaRMANotesMember" name="PhaRMANotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PrivatePlacementOfSeniorSecuredNotes" name="PrivatePlacementOfSeniorSecuredNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" name="ProceedsFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RAPIVABMember" name="RAPIVABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" name="RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RenewablePeriodOfAgreement" name="RenewablePeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RequiredForeignCurrencyHedgePerDollar" name="RequiredForeignCurrencyHedgePerDollar" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" name="RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" name="RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" name="RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyMonetizationMember" name="RoyaltyMonetizationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyMonetizationTextBlock" name="RoyaltyMonetizationTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyReceivableMember" name="RoyaltyReceivableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyTerm" name="RoyaltyTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" name="ScheduleOfReceivablesFromCollaborationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" name="ScheduleOfRevenuesFromCollaborationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SeniorCreditFacilityMember" name="SeniorCreditFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SeqirusUKLimitedMember" name="SeqirusUKLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" name="ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" name="SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ShionogiAndCoLtdMember" name="ShionogiAndCoLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SupplementalNDAForRaAPIVABMember" name="SupplementalNDAForRaAPIVABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_TransactionCosts" name="TransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_UABMember" name="UABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_USDepartmentOfHealthAndHumanServicesMember" name="USDepartmentOfHealthAndHumanServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_UpfrontPaymentsReceivableAmount" name="UpfrontPaymentsReceivableAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Vest25PercentEachYearUntilFullyVestedMember" name="Vest25PercentEachYearUntilFullyVestedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" name="VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" name="statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" name="statement-statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" name="statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" name="statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-tables" name="statement-statement-note-1-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details" name="statement-statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-stockbased-compensation-tables" name="statement-statement-note-2-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" name="statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" name="statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-5-senior-credit-facility-tables" name="statement-statement-note-5-senior-credit-facility-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>bcrx-20170930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 04:54PM UTC 2017-11-08--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20170930.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20170930/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="bcrx_DeferredCollaborationExpenseAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LinesOfCreditCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20170930.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForHedgeFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20170930.xsd#statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:href="bcrx-20170930.xsd#statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:href="bcrx-20170930.xsd#statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>bcrx-20170930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 04:54PM UTC 2017-11-08--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-document-and-entity-information" xlink:href="bcrx-20170930.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="bcrx-20170930.xsd#statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies" xlink:href="bcrx-20170930.xsd#statement-note-1-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SupplementalNDAForRaAPIVABMember" xlink:label="bcrx_SupplementalNDAForRaAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="bcrx_SupplementalNDAForRaAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation" xlink:href="bcrx-20170930.xsd#statement-note-2-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PerformanceBasedOptionMember" xlink:label="bcrx_PerformanceBasedOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_PerformanceBasedOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20170930.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-4-royalty-monetization" xlink:href="bcrx-20170930.xsd#statement-note-4-royalty-monetization" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-4-royalty-monetization" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_JPY" xlink:label="currency_JPY" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_JPY" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility" xlink:href="bcrx-20170930.xsd#statement-note-5-senior-credit-facility" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-6-stockholders-equity" xlink:href="bcrx-20170930.xsd#statement-note-6-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-6-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20170930.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-tables" xlink:href="bcrx-20170930.xsd#statement-note-1-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-tables" xlink:href="bcrx-20170930.xsd#statement-note-2-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-tables" xlink:href="bcrx-20170930.xsd#statement-note-5-senior-credit-facility-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-details-textual" xlink:href="bcrx-20170930.xsd#statement-note-1-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SupplementalNDAForRaAPIVABMember" xlink:label="bcrx_SupplementalNDAForRaAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossOnSaleOfInvestments" xlink:label="us-gaap_LossOnSaleOfInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="bcrx_SupplementalNDAForRaAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossOnSaleOfInvestments" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueAdditions" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityForPortfolioInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-details-textual" xlink:href="bcrx-20170930.xsd#statement-note-2-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NumberOfStockbasedCompensationPlans" xlink:label="bcrx_NumberOfStockbasedCompensationPlans" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PerformanceBasedOptionMember" xlink:label="bcrx_PerformanceBasedOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_PerformanceBasedOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfStockbasedCompensationPlans" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:href="bcrx-20170930.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MilestonePaymentReceived" xlink:label="bcrx_MilestonePaymentReceived" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyTerm" xlink:label="bcrx_RoyaltyTerm" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentReceived" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyTerm" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-4-royalty-monetization-details-textual" xlink:href="bcrx-20170930.xsd#statement-note-4-royalty-monetization-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-4-royalty-monetization-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_JPY" xlink:label="currency_JPY" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_JPY" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_Interestreserve" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-details-textual" xlink:href="bcrx-20170930.xsd#statement-note-5-senior-credit-facility-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DebtInstrumentFinalPaymentFeePercentage" xlink:label="bcrx_DebtInstrumentFinalPaymentFeePercentage" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DebtInstrumentMinimumLibor" xlink:label="bcrx_DebtInstrumentMinimumLibor" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentMinimumLibor" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentFinalPaymentFeePercentage" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-6-stockholders-equity-details-textual" xlink:href="bcrx-20170930.xsd#statement-note-6-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-6-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20170930.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="bcrx_DeferredCollaborationExpenseAssets" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20170930.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForHedgeFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20170930.xsd#statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details" xlink:href="bcrx-20170930.xsd#statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:href="bcrx-20170930.xsd#statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:href="bcrx-20170930.xsd#statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:href="bcrx-20170930.xsd#statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20170930.xsd#statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:href="bcrx-20170930.xsd#statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:label="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:href="bcrx-20170930.xsd#statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>bcrx-20170930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 04:53PM UTC 2017-11-08--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DocumentAndEntityInformation" xlink:label="bcrx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DocumentAndEntityInformation" xlink:to="bcrx_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DebtInstrumentMinimumLibor" xlink:label="bcrx_DebtInstrumentMinimumLibor" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentMinimumLibor-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentMinimumLibor</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentMinimumLibor-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Minimum LIBOR</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentMinimumLibor-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum LIBOR interest that will be added to the basis spread.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentMinimumLibor" xlink:to="bcrx_DebtInstrumentMinimumLibor-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementsignificantaccountingpoliciespolicies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciestables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2stockbasedcompensationtables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:to="bcrx_statement-statement-note-2-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-5-senior-credit-facility-tables" xlink:label="bcrx_statement-statement-note-5-senior-credit-facility-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-5-senior-credit-facility-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote5seniorcreditfacilitytables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-5-senior-credit-facility-tables" xlink:to="bcrx_statement-statement-note-5-senior-credit-facility-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciesfairvalueofthecompanysinvestmentsbytypedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciesscheduledmaturityforthecompanysinvestmentsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciessummaryofreceivablesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciessummaryofrevenuesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2stockbasedcompensationstockincentiveplanactivitiesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details" xlink:to="bcrx_statement-statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2stockbasedcompensationweightedaverageassumptionsforstockoptionawardsgrantedtoemployeesanddirectorsundertheincentiveplandetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:to="bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:label="bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote5seniorcreditfacilityscheduledprincipalrepaymentsofthecreditfacilitydetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:to="bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NotesToFinancialStatements" xlink:label="bcrx_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatements" xlink:to="bcrx_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="bcrx_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) on foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDeferredRevenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</link:label>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInterestPayableNet</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MilestonePaymentReceived" xlink:label="bcrx_MilestonePaymentReceived" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentReceived</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Received</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentReceived-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of milestone payment received.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentReceived" xlink:to="bcrx_MilestonePaymentReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SalesRevenueNet</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase in lease financing obligation</link:label>
    <link:label xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the period for financing lease obligations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:to="bcrx_IncreaseDecreaseInFinancingLeaseObligations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NotesPayableFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SeqirusUKLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seqirus UK Limited [Member]</link:label>
    <link:label xlink:label="bcrx_SeqirusUKLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Seqirus UK Limited.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SeqirusUKLimitedMember" xlink:to="bcrx_SeqirusUKLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDerivativeAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInReceivables</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, stock option awards exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of premium/discount on investments</link:label>
    <link:label xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of amortization expense attributable to the discount and premium on investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options outstanding, stock option awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product sales</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_JPY" xlink:label="currency_JPY" xlink:type="locator"/>
    <link:label xlink:label="currency_JPY-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_JPY" xlink:to="currency_JPY-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DeferredCollaborationExpenseAssets</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred collaboration expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseAssets" xlink:to="bcrx_DeferredCollaborationExpenseAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xlink:type="locator"/>
    <link:label xlink:label="currency_AllCurrenciesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueAdditions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenueAdditions</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueAdditions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Additions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAdditions" xlink:to="us-gaap_DeferredRevenueAdditions-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value: shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 98,389 in 2017 and 73,782 in 2016</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</link:label>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition Royalty and Milestone Revenue Recognized</link:label>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue recognition royalty and milestone revenue recognized.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities</link:label>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity Period of High Quality Marketable Securities</link:label>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityperiodOfShortTermInvestment</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of Short Term Investment</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity period of short term investment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityperiodOfShortTermInvestment" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred collaboration expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SupplementalNDAForRaAPIVABMember" xlink:label="bcrx_SupplementalNDAForRaAPIVABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SupplementalNDAForRaAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental NDA for RAPIVAB [Member]</link:label>
    <link:label xlink:label="bcrx_SupplementalNDAForRaAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the supplemental NDA for RAPIVAB.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SupplementalNDAForRaAPIVABMember" xlink:to="bcrx_SupplementalNDAForRaAPIVABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:label="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MundipharmaInternationalHoldingsLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mundipharma International Holdings Limited [Member]</link:label>
    <link:label xlink:label="bcrx_MundipharmaInternationalHoldingsLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Mundipharma International Holdings Limited.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:to="bcrx_MundipharmaInternationalHoldingsLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares issued and outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</link:label>
    <link:label xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AveragematurityForPortfolioInvestments</link:label>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity for Portfolio Investments</link:label>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity for portfolio investments during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AveragematurityForPortfolioInvestments" xlink:to="bcrx_AveragematurityForPortfolioInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Department of Health and Human Services [Member]</link:label>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">United States department of health and human services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AECOM and IRL [Member]</link:label>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AECOM and IRL</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AECOMAndIRLMember" xlink:to="bcrx_AECOMAndIRLMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UAB [Member]</link:label>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UAB</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UABMember" xlink:to="bcrx_UABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents proceeds from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Receivable From Awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents expected receivable from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Contract [Member]</link:label>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The base contract of ASPR/BARDA to support BCX4430 drug manufacturing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BaseContractMember" xlink:to="bcrx_BaseContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Development Options [Member]</link:label>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The additional development options that can be exercised by the Government.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdditionalDevelopmentOptionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASPRBARDA Contract [Member]</link:label>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The potential value of the ASPR/BARDA Contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ASPRBARDAContractMember" xlink:to="bcrx_ASPRBARDAContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Green Cross Corporation [Member]</link:label>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Green Cross Corporation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GreenCrossCorporationMember" xlink:to="bcrx_GreenCrossCorporationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMinimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Minimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMinimum" xlink:to="bcrx_MilestonePaymentMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_TransactionCosts</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction Costs</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents transaction costs associated with royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TransactionCosts" xlink:to="bcrx_TransactionCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_Interestreserve</link:label>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Reserve</link:label>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest reserve established as part of the royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Interestreserve" xlink:to="bcrx_Interestreserve-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMaximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Maximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMaximum" xlink:to="bcrx_MilestonePaymentMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RequiredForeignCurrencyHedgePerDollar</link:label>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Required Foreign Currency Hedge Per Dollar</link:label>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Company is required to maintain a foreign currency hedge per dollar under the agreements governing the PhaRMA Notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the royalty monetization transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationMember" xlink:to="bcrx_RoyaltyMonetizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents National Institute of Allergy and Infectious Diseases.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestAndOtherIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementMember" xlink:to="bcrx_CurrencyHedgeAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CertificatesOfDepositMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumAggregateOfferingPrice</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAggregateOfferingPrice" xlink:to="bcrx_MaximumAggregateOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMinimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Minimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent minimum annual license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMinimum" xlink:to="bcrx_AnnualLicenseFeeMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromLicenseFeesReceived</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMaximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Maximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual maximum license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMaximum" xlink:to="bcrx_AnnualLicenseFeeMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NumberOfStockbasedCompensationPlans" xlink:label="bcrx_NumberOfStockbasedCompensationPlans" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_NumberOfStockbasedCompensationPlans</link:label>
    <link:label xlink:label="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Stock-based Compensation Plans</link:label>
    <link:label xlink:label="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of stock based compensation plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NumberOfStockbasedCompensationPlans" xlink:to="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables from collaborations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of performance awards that remain unvested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostsAndExpenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AdvanceNoticePeriodForTerminationOfAgreement</link:label>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advance Notice Period for Termination of Agreement</link:label>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents advance notice period for termination of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Salary to Purchase Common Stock, Maximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of salary to purchase common stock maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesBeginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Beginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares beginning.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesBeginning" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized loss on available for sale investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shar-based Compensation Arrangement by Shar-based Payment Award, Maximum Number of Shares Per Employee, Amount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CollateralAlreadyPostedAggregateFairValue</link:label>
    <link:label xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of Agreement</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PeriodOfAgreement" xlink:to="bcrx_PeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RenewablePeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewable Period of Agreement</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents renewable period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RenewablePeriodOfAgreement" xlink:to="bcrx_RenewablePeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Plan [Member]</link:label>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncentivePlanMember" xlink:to="bcrx_IncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan, (ESPP).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeStockPurchasePlanMember" xlink:to="bcrx_EmployeeStockPurchasePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Text Block]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationTextBlock" xlink:to="bcrx_RoyaltyMonetizationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</link:label>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NonEmployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-employee Directors [Member]</link:label>
    <link:label xlink:label="bcrx_NonEmployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents non-employee directors of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NonEmployeeDirectorsMember" xlink:to="bcrx_NonEmployeeDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards available, stock option awards cancelled (in shares)</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award options forfeitures in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignExchangeContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignExchangeContractMember" xlink:to="us-gaap_ForeignExchangeContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet</link:label>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition Royalty And Milestone Revenue Recognized, Net</link:label>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents revenue recognition royalty and milestone revenue recognized, net.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebt</link:label>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PrivatePlacementOfSeniorSecuredNotes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement of Senior Secured Notes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents private placement of senior secured notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_LongtermInvestmentMaturityMinimum</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Investment Maturity, Minimum</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents long term investment maturity minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LongtermInvestmentMaturityMinimum" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumAmountOfCollateralRequiredToPost</link:label>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Amount of Collateral Required to Post</link:label>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maximum amount of collateral required to post.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JPR Royalty Sub LLC [Member]</link:label>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents JPR Royalty Sub LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JPRRoyaltySubLLCMember" xlink:to="bcrx_JPRRoyaltySubLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LineOfCredit</link:label>
    <link:label xlink:label="us-gaap_LineOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Receivable [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents royalty receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyReceivableMember" xlink:to="bcrx_RoyaltyReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PhaRMA Notes Member]</link:label>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents PhaRMA notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PhaRMANotesMember" xlink:to="bcrx_PhaRMANotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral for Credit [Member]</link:label>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollateralForCreditMember" xlink:to="bcrx_CollateralForCreditMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from common stock issued under stock-based compensation plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RAPIVAB [Member]</link:label>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents RAPIVAB product.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RAPIVABMember" xlink:to="bcrx_RAPIVABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of common stock, net</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrencyAxis" xlink:to="us-gaap_CurrencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of High Quality Marketable Securities</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Interest</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents available for sale securities accrued interest.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeForwardExchangeRate1</link:label>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Forward Exchange Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeForwardExchangeRate1" xlink:to="us-gaap_DerivativeForwardExchangeRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForHedgeFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForHedgeFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_PaymentsForHedgeFinancingActivities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of foreign currency derivative collateral</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForHedgeFinancingActivities" xlink:to="us-gaap_PaymentsForHedgeFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeLossOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Loss on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLossOnDerivative" xlink:to="us-gaap_DerivativeLossOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeGainOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Gain on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentContractReceivable</link:label>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Contract Receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractReceivable" xlink:to="us-gaap_GovernmentContractReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities Fair Value [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of available for sale securities debt maturities fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing after one year through two years</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents available for sale securities debt maturities after one through two years fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Receivables from Collaborations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure representing receivables from collaborations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shionogi and Co. Ltd [Member]</link:label>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shionogi &amp; Co. Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShionogiAndCoLtdMember" xlink:to="bcrx_ShionogiAndCoLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL Limited [Member</link:label>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents CSL Limited which is a company organized under the laws of Australia.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CSLLimitedMember" xlink:to="bcrx_CSLLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from Collaborations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of schedule of revenues from collaborations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyTerm" xlink:label="bcrx_RoyaltyTerm" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyTerm</link:label>
    <link:label xlink:label="bcrx_RoyaltyTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Term</link:label>
    <link:label xlink:label="bcrx_RoyaltyTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of time between the date of the Agreement and its expiration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyTerm" xlink:to="bcrx_RoyaltyTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development revenues</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative and other research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Awards available, stock option awards granted (in shares)</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share based compensation arrangement by share based payment award options grants in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledRevenuesMember" xlink:to="us-gaap_BilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnbilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledRevenuesMember" xlink:to="us-gaap_UnbilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromLinesOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from senior credit facility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Company [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The description of company policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesBillingStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_ReceivablesBillingStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued expenses policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedExpensesPolicyTextBlock" xlink:to="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense and Deferred Financing Costs [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest expense and deferred financing costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents currency hedge agreement policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Market Risk [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents concentration of market risk policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CreditFacilityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MidCapFinancialServicesLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MidCap Financial Services, LLC [Member]</link:label>
    <link:label xlink:label="bcrx_MidCapFinancialServicesLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents MidCap Financial Services, LLC entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MidCapFinancialServicesLLCMember" xlink:to="bcrx_MidCapFinancialServicesLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRentCreditNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DebtInstrumentFinalPaymentFeePercentage" xlink:label="bcrx_DebtInstrumentFinalPaymentFeePercentage" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentFinalPaymentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentFinalPaymentFeePercentage</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentFinalPaymentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Final Payment Fee, Percentage</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentFinalPaymentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage fee of principal amount of debt at which final payment has been made.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentFinalPaymentFeePercentage" xlink:to="bcrx_DebtInstrumentFinalPaymentFeePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SeniorCreditFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Credit Facility [Member]</link:label>
    <link:label xlink:label="bcrx_SeniorCreditFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents senior credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SeniorCreditFacilityMember" xlink:to="bcrx_SeniorCreditFacilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenueNoncurrent</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_AgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a License Agreement (the "Agreement") granting rights to develop, manufacture and commercialize RAPIVAB&#174;.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AgreementMember" xlink:to="bcrx_AgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member]</link:label>
    <link:label xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred revenue from the sale of inventory to be recognized when the inventory transfer is complete.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CSLMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL [Member]</link:label>
    <link:label xlink:label="bcrx_CSLMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents CSL Limited (&#8220;CSL&#8221;) and its affiliates.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CSLMember" xlink:to="bcrx_CSLMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MundipharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mundipharma [Member]</link:label>
    <link:label xlink:label="bcrx_MundipharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Mundipharma.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MundipharmaMember" xlink:to="bcrx_MundipharmaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]</link:label>
    <link:label xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred revenue from upfront payment allocated to the regulatory support for the Canadian and EU marketing approvals, portion to be recognized ratably over the expected period of involvement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PerformanceBasedOptionMember" xlink:label="bcrx_PerformanceBasedOptionMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PerformanceBasedOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance-based Option [Member]</link:label>
    <link:label xlink:label="bcrx_PerformanceBasedOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents performance-based options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PerformanceBasedOptionMember" xlink:to="bcrx_PerformanceBasedOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Carrying Amount in Excess of Fair Value</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of carrying amount in excess of fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossOnSaleOfInvestments" xlink:label="us-gaap_LossOnSaleOfInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossOnSaleOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LossOnSaleOfInvestments</link:label>
    <link:label xlink:label="us-gaap_LossOnSaleOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on Sale of Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossOnSaleOfInvestments" xlink:to="us-gaap_LossOnSaleOfInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NondesignatedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NondesignatedMember" xlink:to="us-gaap_NondesignatedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_HedgingDesignationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest Upon Successful Completion of Specific Development Milestones [Member]</link:label>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vesting upon successful completion of specific development milestones.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2014 [Member]</link:label>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of December 2014.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_December2014Member" xlink:to="bcrx_December2014Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2013 [Member]</link:label>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of August 2013.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_August2013Member" xlink:to="bcrx_August2013Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest 25% Each Year Until Fully Vested [Member]</link:label>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vest 25% each year until fully vested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Dividend Yield</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-Free Interest Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred collaboration revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalLeaseObligationsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease financing obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeContractTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-recourse notes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Awards available, restricted stock unit awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards available, restricted stock unit awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LinesOfCreditCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior credit facility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent upon EU Marketing Approval [Member]</link:label>
    <link:label xlink:label="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information about the contingent proceed which is upon EU marketing approval.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ContingentUponEuMarketingApprovalMember" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, stock option awards cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, stock option awards granted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, stock option awards exercised (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, stock option awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_UpfrontPaymentsReceivableAmount</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payments Receivable Amount</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents upfront payments receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UpfrontPaymentsReceivableAmount" xlink:to="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards available, beginning balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards available, ending balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInRestrictedCash</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards available, plan amendment (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireProductiveAssets</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnDispositionOfAssets1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainLossOnDispositionOfAssets1</link:label>
    <link:label xlink:label="us-gaap_GainLossOnDispositionOfAssets1-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment, Office Equipment and Software [Member]</link:label>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to laboratory equipment, office equipment and software.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentTerm</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BirminghamResearchFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Birmingham Research Facility [Member]</link:label>
    <link:label xlink:label="bcrx_BirminghamResearchFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the Birmingham Research Facility.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BirminghamResearchFacilityMember" xlink:to="bcrx_BirminghamResearchFacilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeCategorizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Five</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year five.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpenseDebt</link:label>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, First Vesting Period After Grant Date</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award first vesting period after grant date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_LeaseFinancingObligationNetOfCurrent</link:label>
    <link:label xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Financing Obligation, Net of Current</link:label>
    <link:label xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Financing obligation as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentGross</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>bcrx-20170930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 04:53PM UTC 2017-11-08--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-document-and-entity-information" xlink:href="bcrx-20170930.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="bcrx-20170930.xsd#statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies" xlink:href="bcrx-20170930.xsd#statement-note-1-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SupplementalNDAForRaAPIVABMember" xlink:label="bcrx_SupplementalNDAForRaAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="bcrx_SupplementalNDAForRaAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation" xlink:href="bcrx-20170930.xsd#statement-note-2-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PerformanceBasedOptionMember" xlink:label="bcrx_PerformanceBasedOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_PerformanceBasedOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20170930.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-4-royalty-monetization" xlink:href="bcrx-20170930.xsd#statement-note-4-royalty-monetization" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-4-royalty-monetization" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_JPY" xlink:label="currency_JPY" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_JPY" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility" xlink:href="bcrx-20170930.xsd#statement-note-5-senior-credit-facility" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-6-stockholders-equity" xlink:href="bcrx-20170930.xsd#statement-note-6-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-6-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20170930.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-tables" xlink:href="bcrx-20170930.xsd#statement-note-1-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-tables" xlink:href="bcrx-20170930.xsd#statement-note-2-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-tables" xlink:href="bcrx-20170930.xsd#statement-note-5-senior-credit-facility-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-5-senior-credit-facility-tables" xlink:label="bcrx_statement-statement-note-5-senior-credit-facility-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-5-senior-credit-facility-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-details-textual" xlink:href="bcrx-20170930.xsd#statement-note-1-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SupplementalNDAForRaAPIVABMember" xlink:label="bcrx_SupplementalNDAForRaAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossOnSaleOfInvestments" xlink:label="us-gaap_LossOnSaleOfInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="bcrx_SupplementalNDAForRaAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCredit-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossOnSaleOfInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueAdditions-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityForPortfolioInvestments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-details-textual" xlink:href="bcrx-20170930.xsd#statement-note-2-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NumberOfStockbasedCompensationPlans" xlink:label="bcrx_NumberOfStockbasedCompensationPlans-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PerformanceBasedOptionMember" xlink:label="bcrx_PerformanceBasedOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_PerformanceBasedOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfStockbasedCompensationPlans-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:href="bcrx-20170930.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MilestonePaymentReceived" xlink:label="bcrx_MilestonePaymentReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyTerm" xlink:label="bcrx_RoyaltyTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentReceived-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyTerm-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_UpfrontPaymentsReceivableAmount-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-4-royalty-monetization-details-textual" xlink:href="bcrx-20170930.xsd#statement-note-4-royalty-monetization-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-4-royalty-monetization-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_JPY" xlink:label="currency_JPY" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_JPY" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_Interestreserve-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-details-textual" xlink:href="bcrx-20170930.xsd#statement-note-5-senior-credit-facility-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DebtInstrumentFinalPaymentFeePercentage" xlink:label="bcrx_DebtInstrumentFinalPaymentFeePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DebtInstrumentMinimumLibor" xlink:label="bcrx_DebtInstrumentMinimumLibor-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCredit-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentMinimumLibor-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentFinalPaymentFeePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-6-stockholders-equity-details-textual" xlink:href="bcrx-20170930.xsd#statement-note-6-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-6-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20170930.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="bcrx_DeferredCollaborationExpenseAssets-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LineOfCredit-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20170930.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-n8" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-1" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForHedgeFinancingActivities-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20170930.xsd#statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details" xlink:href="bcrx-20170930.xsd#statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n8" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:href="bcrx-20170930.xsd#statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:href="bcrx-20170930.xsd#statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:label="bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:href="bcrx-20170930.xsd#statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueNet-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20170930.xsd#statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:href="bcrx-20170930.xsd#statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:label="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:href="bcrx-20170930.xsd#statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20170930.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exh101_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh101_01.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /> OP# 2(  A$! Q$!_\0
M'@   0,% 0$               <("0(#! 4& 0K_Q !O$   !P " 0," P0$
M"08$ "\! @,$!08'"!$ "1(A$S$405$5%B)A%S)QD1@C,T)2<H&AL1F2LL'1
M\"0T4V)TL\+2*#5S@I.TX?$E)B<I0T1C=8.B-X2UP^(*-CE99I3C1U155WF%
MAI:8F:.DU__$ !0! 0                    #_Q  4$0$
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M0Z\Q2" '+V/MZ-T/N_AZ_A'[]]?R^_F?Y863)[#F]H>[KOW?8>_CH>_^_?\
MM\"A14IR& ! !!0"@'N 1, "'\0!^@^(9F)Q5U#D:/M.'X*UT"+*H/?TU 2R
M&ERHF0'OH4Q4F3B80Z$5A5,8/D!%;?$0RTB">C<CC@50JR]\HPJG,J)TCE+A
M^9IH%3()2_25+[5?JD#WE$HH*?4$RADT@6_] ^1$?@  !$1_V!\^9:)3%)_%
M]S"!NNA#KLI?@0'\P$![\L)%$Q^^^O9[1ZZ[[[]P??L.OM^@^9G@'AX>'@'A
MX>'@'AX>'@'AX>'@'AX>'@'AX>'@6TU 4*)@#KHPE$.P$0,4>A >OL(?F @
MA^GESRDI2E[]I0+[C"8W0==F'[F']1'\Q_/RKP#P\/#P#P\/#P.(O"2JT:R(
MBX2;*!;,]5^JNJ1%,44;_65';8#J"!!7?-069-T@_P 8X57!ND G5 !ZM$_M
M-UT(^_V@ AUT A[A$>N_S^/]GG/6T@'9-BC+GA.K!3C@\*LNW!P=&WP3@D.=
M9NHD?VV$4?W>^@<YD7@2HLUD7*2YVZN_3 14+[0[ HAV(==!V!@^?G^7_<>O
M SO#P\/ /#P\L HM]<R8H"5$"D$B_O 04,8#B<GTP[,04Q*3LY^B']X 41,
MAX%_P\/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\PSMW!I!LZ*Z$
MC1)H\179?3./XARLJR,T=?6!8I$P:)(ODC(BW4_$"]34%5(69"JY8B  (C\
M "(C_(/D? ]\/,=F[;/VC9\S5*NT>-T735<@& BS==,JJ*I0,!3>U1,Q3E[
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M1]H@!OR$?M]_]OY>6 1.4_O Y?<(F$?X?O[A['\_[O R?#R@H* /\1BB'0_
M%$![[#H?N/Y=^5^ >'AX> >'AX> >'AX> >'AX> >'AX> >6 5 5#)G !#W
M!?X1$!^!$?=\B'Q\?D'Z_P!ETXB4AQ#[@4PA_: "(>89!$52B/78G['H.O\
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M/P(#]A#]!\/#P/   #H   _0 Z#]?^/GOAX> >'AX> >'AY0H82E[*4QA'X
M"AV(? ]#]A^.P#\OS_V>!7X>4)B82%$W?N$/GL.A[_3K^7E?@'AX>'@'AX>6
MB*"<>A3.3X[[, @'?8? ?'\_]W@7?#P\/ /#P\/ /#P\/ /#P\/ /#P\/ /#
MP\/ /#P\/ YV2_\ A#_XY-?_ *9YM$Q#ZA/D/ZW_ %&\PW0 /T.P >ER&#L
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M K\/+?U _P!%3_F&_P"SSTQC>T1(41-U\ /0?W@)@$/ K\/+';C_ $2?W?\
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M6&,1;N%1_P 5)MUJ_&OQ>- ^F3_%(/'KN+6 #J@5Q'J#[P$XII\2]Y/\;VA
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M53@KO$5&?C>*\TULS[.YV0K4)<OV(F];,)BWUN-:+OG+MR1H'T  LF( (F*
MB "(=_81#[?[/MY450AAZ*8!'KOH/GX^/^T/(JU.0GJXH+)D-Z8G%QRF8H"8
M[/U/Y4QP-V<!(5)[P*CO>)?9]01!0I?HF(8!%7ZB*;?*QZJ'(&PT=UJ#ZA^D
M#4LS9W!'-E='G_7 ;/*)_2>: ?6A[EXVVG< ;5!(Z%%0<1-2<A5'3Y"4".A)
M:59HO(EDJ_\  G:\I.8Q0[*7WCV'P ]??\_L/D5UMY8<XJ#FS;9;UBOI94O(
M'K:KO&>K6SU;MBKF;.FEX?1<92G3:\S'I:LZNNVM\E.0L=5UTI0Z5@?2\6TB
MC.W$@T36MUOEWS<MCB"9U+'/2LM+NU9TYV&LM:_ZN.N3CFQY*RD&$0\U&!1C
M?2U=*2^<M)64C(QS=X\KBM(2$BP9*RA7+MNDH$IH.>_\POS^7O\ G_H>5E7*
M(B!^B====F[[[[_D'VZ_W^0A)>IGOT]4?Z1*Z\]$T<\1L2E'6N?_ "QV@3E9
M_?QS4)V\Q-;+8F7IRQ,.23<4VNSEY_98.5WCRA04Y<&?_NOQ;N21Z^I<W.;E
MWT%#(*E1/2&MVL*5IE;RT*M>J?N,G:GE:>URK7%"<8UUEZ;#V25CEJ?>:/;@
M51!U]"K7:G6)8?V/9X)[(!,F4Y3]^TP#U\#UYZ(] (@'?0"/7Z_R_P!OD:ZU
M\]78'+D[7BKZ;*+8S9@5FBOZ@O)YPN@]3?K'E'#EP3TTFR3ML\BC-V4>T2:,
MUHU^DM).'LJW7)%-DM;V3UY0,B!\8](<X@?_ ,(%'E!S,[,C[_D$4S\2% 24
M OM #G.J43 (^TH&]I0EU!101 !1$H"( (^[OKO\Q#V_]GE0JI@(@)R@("("
M'?SV'P/QY%:2>];$7)2.,M]*]-L,T"*KI+D%RX5<?N_^(2(:0)'&XV()A,_A
M 5<%AC20,?Q!TF8SOTDC/E>1>R?KU22ZQ8NB>D%4VRC)(J'X[6>:.B+MI%%N
M_!RLK]#&<O3D&4B[4C#(MR&C5X5NV?E.ZGU7S<\<$PGE JI@(@)R@(? @(^1
M&UB/]=:05C@NMS])*HH*)2HRPU;/.9.CJM54"I?L0L<$KJV6DD$Y8XK?M4[D
MT:>O$(D+1.S"H<$MBG&^M^W;MU#W/THYEV+M#\8V+FO+^N-RLA)TY%N_-K5K
M54=IGZ,@56.316('TU!0$WU2A+!]9+_3+_?Y<\B26@?7*=GESH:GZ3<$E],B
ML"V6P/F):SBJ4CKZC"7?$Y)TPH)KJ'9^R691XF:$0==PKTSI(6<D68%TY+.J
M,EM#NAO==2K$*GI#[+F=CB\W?70C-$M@>T>+MLG,VB+J[F1!=:'CI^8EI9@S
M.FU>RDBNB9ZN"E^'E)?=[0]P !OSZ^WW_+Y'\O*O /#P\/ /#P\/ /#P\/ T
MCL0*"(F,4H?73+V8P%#W''VD+V80#W&,(%*'W,(]  CYGJ?U4?\ 5/\ \2>:
MN2Z%%O\ G_[DHT/_ /;3^/-LL  *8 '0 !_C_:0? OI_Y-/_ %"_]$/*_*$_
M\FG_ *A?^B'E?@4G-["B;KOH.^N^O[?.7M< PN=8LM0F5IQM#VN!FJW)N*O:
M+/1K.UC9V.=13U>NW>DS%?N5/GD6CM4\3::C/0EGK[\K>6@9B-E6C1ZCU)B@
M8! 0[ ?N'F'[2@I[ $!+[OL =>WLY@$OW'[=??X_L\!@@^F?QP515]]_Y\J$
M< )E4S>J_P"J68KC^ I %0H\QC%5]R:9"@)P'^ I"_U2AYSAO2BXD'*<@RO-
MD2J&]RI#>J+ZG!B*&!4%P,H'^%Z'O4^J!5?<<#"!RE, B8 $(;HUOZ@2^D<H
M.7!\KY&.LP]3C..?V/U[-V;K4OWPP=G@F36YOZ<V@2/&Z7S:MV_CK(:IE^,Z
M::R.XZWVJ1N>S<CLO;RL?0;"ZB:ZI&BPXQ^HE/8Q5*7*Y;Z@<A4N,'$/<<AQ
MB'N49KCNQZVCS^]([U(.4VC--/KR\"V<2&B<=]WM/$?@M6G)GSIC :I3H^FI
MJ,M M,95:^'U@)>E+Q,0*F1&9YMI$1Z^B5+U1/4[3*B!1*)?I%+S!*4G1B$$
M/9[>A*40_JAY:4])WB*X$!7D^:JO^*!N(K>J#ZFZ@@@)V)OHA[N7YA%$#1S!
M04_@GN8,1]O;5$R?SJ->%E^OO"//,IXI478N)NPR//\ ]/VVS&HX_P"F=S/X
M9/*(\B$+7 N]1TO.N1&Y[1*;W$X\Z=*631M"9S>=4!L^:5>3M<F[3*P=&MXY
MD-NM$_&W[U.O31Y+7]"U7+UNYJ]X]CN$\A]I1J>Y:->/3[L=<L6.79!)M-T>
M&UZ.R7D*'&+46-^J\ !)-K YYH#5/\%(@$]LCZ*GIU)R /WN5<@)I_+O^WDN
MXYP<\YQZ=TZ_$HN'$L]?\GG,@=*1&3>/)ITL*S>1<-F[^9.O(,HE1/*5]$?T
MXU%#J?T0ZZV]ZK97V1O,_FW&I)"U_">Q-NW8\C$&S9!4&*(/&S9)%%\*KP[M
M-=20?&<_/&/"CU)I[7&5<TC.>3LI;.0O&[TH_3TYS:.E;K,]AELEU#-J%9>9
M.XQ.CJ35ZHVAZW@9^-M_QS0='BI">%W.<KPLS*RI&<M&#_1<(^,>YY+RSPW0
M>1_!BS3#5YG'HH1%6U/1?2UM'+/2:1=<6X5\;Z;L)J]OD;MU"MO$%]FNHJIM
M[W>+1E&@HPEMJDE8D8U^XS&X1(!]&DCZ'WIM3;)Y&3>-:K,1TA]$73&9YE\V
MI=D?\/(-)5(A6S[D6X11($FR92!DT"))JO&+-RJ4ZS5N=/71WH.>DM$I&01X
M5T5\*CI9XJ[GKCKEHD'#MPF@0[IQ*6/0Y6277("(F;*KNSG:+.)!=J**\G(J
M.H/>$_IZ\IFW)#@?GW*KC[.ZEPREG_JT7N>K^P5&?E6W'R3VF[VZDV["=%JT
ML@ZSPV(;,UK^0[MQVDIY!6[.[/>-I1;/).!_9SY"3?@[P3MF*^D'ROQ# L3K
M/%3ESLD1ZD=2J$M#UV.QR_K669WSEO7N(%EM-Y@V*%J5B:G1I_/%LIMTB_EC
MUFAFAW-4=%BTFI1!SS7T-?2<8BLJ3A)DP@H<JJRSZ2O3\A#-W2+LH%%_<70(
M$*LW!-1-(4TSM57S%4IF3]\W<7VWH>^E S4.5EP[S]LY6%<WO1MFG)NC%$@$
M62*L2]E<@T*58A5&B9P:D Z?^*+V3R#;<^!5FN^,\@*WP9],_4^&U$LWIT5'
M M=QBQU;,ZO';ER*BN4O'NUY#,.,]I.E*5?D+?,%S.N<F'5WW&QJ-']\AM&B
MJZ6WW-I-.HR!F=U?@)7<E]+GDYQ4I60P5[)ID';)"VTC@ME6,\&[1HJ=I<UF
M/LSBKU&"*ZR.8T!A18-")0B;PW=06Q5JJPF3:"24A)F5</0JE/0E]&6%B95Y
M8>"/'>.ABMR?M.8GR3B23=(94LE^(4FY2SBK'JGDE!*H]*\;N%T'2\:HL=B\
M7:J]+#^A3Z0,.U6:L_3OXP*HKG YCRU 1L#C^%)-(HH/9MU(NVY#$3*84VZZ
M9#*"HL8HK*JG/"1QTX7[3:,^XT6K6?3;E]TXA8WS"Y%6=WP\EN.G'_B7;==A
M-:XGYEGV7<O-$]/S5^2B7%&GVC'=6@MGRMU1H9UF3&<B]+2Y.TC#:S<WUMD)
MQVO'/-.2/!R^\4]3<\%>2%^I,-F7JL4.K8+@D=Q[F+SQDS#E7Z@/'/=>)&&6
MM]8>0]8RQ2/H&,YW:&\D>IZ+,5W.0"/S^,6?0L)%R[P'_P GZ)_HZQ+;\7,^
MGUQ%B6JBJ;<',AG==CD!76[!) BZZB"8+*" @DF0P*&$! @#T/FF?>B]Z+4,
M=<LMP4X<Q1TG@,%RRE2KS449!5BB\!B<CN0)]!T,?)-'R;40(J#=VQ>II@4S
M5;R.1KPBOS#48[3M_P#3:GN=>.CM_K3IL>/4K7.)UG;5?0>1?J05;7^/'()Y
M5>5&J9_42L-0Q>NV2LM]*KZLM:*)5OV.!V*5;NTD^9I=J?I5Z+J^?>H9,3GI
MW4",N>G1/I!SG&W+K6^Q;;AR61RO)L#RSDWF64:G:E ]K'*:/07^;6:W E54
M],AH%P^BBS#*:18D"<6,]*_TCTD#/H[T]/3S?-91N[M:;A3B]Q\E6JT4J#<K
MF5CU7M.>-V]>0** I!'BE",A6]S9- SDXJ6X_P!+CTC$DD6#'T]O3M<@BHV;
M)%7XO\=I5Z=S*++BP;*NG=-=/7*[]5)PFP(X6545*@H@U 4T13)&=I/!?EP_
M]093EMGO#_$U</R34,<X;T7(Y+4(6D3M^]+Q_D]HSKDU5HG 8=22XV3U DMI
MY 6GD%5JWIMYS:\S<%QMIU>/0"JR</7K3SN?^F+<LNFH&5R#A-F-!-7/7Z9<
M@$ST"MXCEHPW!^JT>UUNI7]D6$L%'"4H](?69V\K6<M@F[(T=/WSN&SI^L=5
M40E-8^F5Z/LJ[ML?'< ?3A?R=/5*WNC!AQEXUNG52<@T+(E0L+1M33K5E48]
M1-\*3\C YV:A')@,@)3CZ'IO>CRFD@JKP)]-%-LM6V=P07-Q=XN>Q>HOET&L
M?:4UE*0<%JZ^<KHMFLZ4QHYTNNDDD[.JH0#0O9%Z8N[PU7X=TZL^GS$<;M*P
MKA7S&Q'F]R"@-+X\1#;GI9+WQI=8I6J42:R73W.IZZQWW>G\-RM-;.3M8SD^
M6OZ(@H]<Q]\G%$B)9Q?]*3U ,GNO'O*=&QX+]AU>XW>F5F3;4[/H&,26B9;4
M<QYJY?SBY2\<=UD&MX4?:14,NL6=:9D&51645FSTI]0=1H-=+.6.)CK-,UX)
MY$?3S]&E=M&/4>#/IA+M)FW_ -'\2Z1XS\45&\M?"F7*>D1BY*6*3ZW@+5T4
M:VU.K,@9LN'X+M%3VZ>.X,>B%,VO1:'$<//2FD[SD<828U6EQW'SB(^MF71)
MVYW9971*ZUJ*TO3(X[0IG)7UD9QK0S<AEBJ?3 Q_(!>-'HU<R,_G^.\5-\=(
M^!R3)>2N4<[4HN8U^E2=AK/+RR^J#Q&A-;GH1DGIL\W<UG/O3EXJW?38<CE]
M[G)^2UEH<#&V?4&IH6ON1S#TXN2)<QXP<=)'@- 9;I?&^D\Z8'D1S[9:SQ]<
MN^7AM4XO<D./=>/G4M&7.Y<BK?8>5VJ;-G_*#34^353R:L9G8\P*U?+6^9C:
MB5()::=Q1]$*Z5$VF4'C9Z4UOH,/;*Q2AOM-QSB).U"*O5G=UNGTVJ#:X:NN
MX9C;;$]LU.JU:@1D$Y>7=3U9A(EFNO*QC9QQS#!_1[>W#<Z_HN<^F18RUF?+
M9"TJWTGB[)+9A3(^)S+)9Q5Q"V"#]E8J2NFLHN DG#<$X1'1)G]W'RZ%O6<1
M@114GTX.6<U3,+?UW@E$\6)K%.,_IAXCLE70T;C2G-\M=3Q+GAP.WO2M2>-<
M?U&>SF2KG&#+>.6T-:A:-0E874;L;8;#7J763M3DCI;OM4]-/D-I?#CU*J#5
M:].*Z[<>7>L*8WQ_:1G#R$JXYG:/40SCF=1]"B]3+3*YHK"4L&<)1THK5[AR
M2EZ?#1K%K''RR(T2NP\,S"5^$XD>C'&[%(\=J[QK],!EOD/"-[>_P*%QCB4V
MUR(KQDF4HA:'.81U63O+&&407CI%*:=Q ,3).&3M%R!5$%1[>^+^E#DU/E[)
MJR_IYYEGU2UQIF%@G[ZXXV4FEUO>:]&!<6>>3LE/'C(2+UR&BFZ=L;4^170M
ML6Q9M["WC&Z34CTC,\IXX[QAFKVVMI^F;QVV!&O\P^='-.J\PW^EXE%35E6W
MV\:UM>81M0CIVA/-=J?)@CG3:UQFGYNS,V^<PF89PK9H[8UFKZM5"":C@GI:
M\]\(Q_FKGUF=8%KUH]03TZ-=<[)<J*RGJ&ZA?4U6::&9M9K0I?=0N43=WV[J
M<DKC'679J/3LQK#*.X^4-JKE>=LG;)";"6NH2OI)WFL6'0Z)+^G+<Z95L[E=
M+L]ZI[SC!8:S7,NK;J6J<UH$]98<SJ)A\_@I"JS];E;5)OF]:BWM>EX9V_;*
M1#QJU4[,=]]/RSTFMV_'=HX;6;-Y[3H3!JQ:<MT/$)RD26PSK6.&KXU SE2E
M%H)_HTO&NX4(*@,%E+.]8JQ0,XE9-PV.K$)R"]-GE9J^C5.<89AD]QJ5:]-O
MT[LRF*/KNDH,Z'HFY<-?4#S;EG<\!M<;'0>C,T:KIV?TB;HKS275"M, R=3K
M)%=I/PZDJS1X_D5Z7_(/U";?I&M;=Q[JO&F/WGDGZ>TO:\QK'(*)E-LI=4XB
M->3M3OG*$NI9S#$IL1N4I4-OIE<R^+JTQ<'Z5*R:H)VZ:2.[<4&NA]$U<T_&
MK/7M FJGH.8SU0SJQW:BZA+P5KJ,M6J1:<V3-%:'5+Y(QL@ZC:U/4-%C^S;G
M 6%9A(U4D>,?-L8XC,R!$#KO,;T^9_+;GN%3Y1<+Y[%,MFHAEHFO5C<,,E<L
MS>P6I6+K\&UNF@,;6%3J$O8W<K$040A.2S"0F5Y.,CF:;@[UJW/%S4?36YEW
M+TE.;G#3>](R^2Y5<BMOY#Z4EIL*R95[,=4>VG7(K1H"3ML)7*^_)1*WM2%<
M-$7Z%8P,W(U&$MLLFVCY1XS08*\SIO"WF?S"NW(;:YS'G_!)SIS/TFL7@,^I
M^TXS==4(TX7^HFUY*ZMRD:3];B+5BT7*9]E5B?P_'R,M;"_6N<2IAT+30ZLC
M(,,_E0F@B.1'#2XXG/\ (:$VKC3;N.T"WF7MHVZ$TC*[+C48E".S-[(O-:+&
MSDA36QH9X[^G-&>3!1:.WQ4' B[<_3'D8WU$.!<EALGR7BN9/%]S@$+:AHTU
MKZ&WYV.<0^@.6C.7_<24LI9U./8WIU'2+"80J;XR5F=1\JRD48Q1G(-EE4^Y
M)<4]/N7$V(QS.=1F]=U;.]WX_P#(BE6?DM;OV:A?YKCWS"H'*R+S/2+9EF=(
ML(NJ2T;3?Z)8"PL\QGY.M0C>KV*:A[Y8(!R\DFDZ_@_J!:!<L-Y<R_'?B,YU
M3C%S!N&VU;BKG&ZVZ/7U;(K1PBL_&DTKH?(^[X="UBV\GJ[>[<>R4%LZRZF9
MU"9K7:YGSO5RS#)Q;TPE J7+3C+??Z*#4;D%BMV;[S"Z-8L.>U'3Z188W8(+
M(1CTM3ELVDXF?>L;BSSMW)-6=T&"6>K5I85S2Z31!F\502!KZFOIX/KO4LV9
M<WN)[G0[X3-S4NC)[SG1KG:T]AAJ]8\O-7:P$Y^V)DE^K]KK$W5S,FRA9>*G
MHE^V$[5ZW5/"-8O1KY<ZO8LWWY_9J)Q_Y#U'3/4TYK8\;+]3L,Q$\5>67*'1
M>)5]X]4EY+O*&,)NU G6F-:I7>7;)]1(6CVUEK^E1M8A9AP\KMP<OVXQ<$N1
MF2//13=6>1J#:.X)<$]BXZ\C(R-N$FZ4>WV\Y9Q=J]4+4D"0J3"VP,7.XY:B
M/7S]U$_LU)2'<QK60*Y4,T!\^4\V.$VUZD;/L9Y0\;=,V&6A)-7]T,]UG/;1
M=YJNT&7FXV2.C%Q$PK/S,/3YQ>RMG1&"#R/@9%6:4< U76>'/V;CEYQ;9Y3I
M^W+<B\/#(,4LMFI.P::AJU1?4C,;M49!E$6&F7:RI22\=7+C%2DK#QSFJRZC
M6<_'S,.T1CUUY:-3>0#\;/2GY[<6S\<M;B="J^YZ_DT7ZA\57<2V#>KN/&+C
M;K7(*]:].<<.1^*LHC-FDM/()T.SADF[5JUQ<O8(VDZO;)?+6\9*P4A6;9N,
M<]&3E=QIS^UY#0==XR:/0&<QZ:W(G.F[2HZ5QL9S7+KT]]1RE]:YC7*I&.>3
M"#Q7F+F645!'9.0%8LC&6B-%K43< X]6J0>6R=L02=2WJ]>F'7Z93-+7YP<>
M2U#3K/<J96+1'W-B_3G+KF[>F*6VFORQ$5)NHNYUN/T"C/'%5GFT98/V/;*[
M)M&#F-E63D[_ *AW>NZ'3*O?:7)I351N<%%VFM3*;>1;$EH:P,D)>/D2M99E
M&R+8KML\27!NZ8M5D 4^@JW;JI*-THX-/P?FOR2X\7RH[#7>)F5:;.\R^&6W
MTB Q&^:E<*[$Y3QNY)\4]DM(Z9M%KS'.[#H&P3$/CUZ8U=Y XE1J]&1C;/*>
MY>JE9/[424HJ8G.)P+[?J@!C'Z,8!'KL.Q$2F'H!$I1,!1 H%(  4I2E  QA
M$ $53=@/?L,8!#Y*'N^!^P (_P"T0\ROIAV(^Y3Y$1_RA@#Y'OH  0  #[ '
MY!YXFD"?Z";Y_B .A$!'OH?D?S\N^!9.D(E'V'.!OCY$YQ#^?Y_]O_6'OT2^
MX3>]7L0Z_P LI[>OC[%]WM ?C[@ #]_GY'N[X>!:$I"AT90Q?=UU[E! ?@>Q
MZ$1[_/H>OR\I$BIB]%4 "C_5$/=[NOR_C ?GL.NQ^>_GREQ]T_[#_P#$G@@;
M[D$W8@( 4!^X% H?H'P']OQW_,?D./O<:O*P[)BV.J15*YYO*"< 76]S>$T.
MKS3L@E2*<Q"J-(]<ASF $B)B91<Q$"*'*TZ$1?6KE/S4H$/<[;1)^2P;BHJP
MN=1:0RUCII+:XY)0;&S50U_IUQSMS/1+RO24DV93%?ML>DY:-E;'75&+QHE(
M/)F44G969#*NDP"7A%B*,W ME04:22#TJ9S_ $U 4;.!;@U?-Q* .6+ARW^H
MD90%2-/H[)BVY_<G'[=%%-^^XA\%C/S)H$1.X(UU_P!0E!FLX7((F<K F*J!
M3*%]Z3=!!(#"0I2D#HN%"FEL>*?%RI[:CHBFW5SB[QW3V61T89"0L[G4%<OA
M&MY+:K6J=W%6>[EM<7-*7)S$S4VLG,KG=2:R19./</XWY>L<B$$>44%'5?FQ
M-\J)*?Y2R;VW0FF[5$\<YSB[(<J:A>LMSW"E[1M%<Q*F<E;EPYD8G),4MV11
M$);\>UZM:I.:+.4(DD:<OTYQ1]Q2FZZ]Q0'K[]=AWUX&*4W0& ! ![#O]?GY
M_P!_@?-]=<@YO/;7<;)Q1:\PH+CY6LHYT?T.9+;M<ON>S6@M[ODGIWY_5Z@[
M';K.36L\O49H!.8FE<3G]O>4*2I^AT>2,C=*/B^F,%Y%4-DXB<B)VX;+(YQ5
M=,K;W1:5Z1#TKAWMFRW'-B:*ZY]7>T^H&Y5I*>\YL27AH+"X3.)/56D3_1U)
M:#3$G$'&KR:\U(0RL]_TD_\ 0+_=X F0H]E* "'YA\??_C_M\" 3/LM]1>BS
MN7LEJ/+S<7Q(T#5]-L:2FUW^ HNMQ>V\G+8W>5+CUF2TSJBFH0>7\)XF\QF)
MY=R)VRMUO,-(WS.8I@-='*Z_&Y]@S_&37[)Q&Y89G7\9Y'ASA<<+^0T-9]W?
M[M;Z74-FYLH5RZP6.:#E)4KS4,^FI;3;%+SE^IN@Q4%0&V&YH[S?'K<VIY(6
M.S_-OH,\I,0INO<4!Z[Z[_+O[_W]>!#MSWXS:_/2F Q/'S-[E<,?I4.FCJV>
M56^0,>QMD&X]1OTR=MO=8F8'1-!K43=Y*W\>\FY5LTQG5WJ;J$D;G1QF(P^C
MIQ%EL/\ !M\D>+>A4I#+KI_1=-\U,QOU1XFV*[5R4O*?"!C<<:=ZY@T[(2NG
MV.C/ZK<9.(V>[,\*D]%7H2V$6N,XQF@:_5P)F,-,>"9  0 H  B B'7YA]O[
MO^W]1\I,1$G1C%*7Y#Y']?N'S_L[^? ^>G6.,&O6>LV9S1.'VPP:$[Q6'-/3
MYJZVGYU9K%Z>7)>(W#DO*I;I,RMZVUL7&(ZTTS1>,5SJ$=B\CIA\GR? ;=QL
MC82!80N9Y+JJ>Z#PIY,VZ"V*KP7$JY0#B8W;D9?-4L4E9^+TS5>7U)M'K"8K
MRCQV-+G7^$*C%:>YK_$FL:?6X>*Y4HYM'5RHV:4PI548+0K.TCOI7]R'\7\1
M/X^O=\]=]?KU_O\ U_/ST%4@   Y0    #O\@^W@-IXGT\N?813:03(WN()5
MI2=9(T%W3<$SXC0KJ;?2JDFPIG&FXWG)("/E7$BLZ0;0DX9\NH*SZ;;)2KMT
MHLXP#&*("4>NA[_/H?@0^0[#_N'GIQ3$>DREZ*(#[P'[_P (A[?M_,!$>Q_O
M\I\#()VL!O>(_P (]![1$H=" #\@ _/E7T2A\E]P"'V[,;KO\N_G[=_?SQN
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M'\Q_+^?C(>!4::'X_P!IC3+)*"UY?>H<03(E$I%O=Z@7)I7Z@%-\D.(' RA
M]P%4$Y0.<H <0C9>>EGNU7:W);.IK%"PUZL#:GRN.3#:Y,*O:,%XJV3!E>!6
M::QIG[)O%NT2JCGO%1CE^M5Z7KS6#J<;SAY;V:)::"NDT@;STTOPXYTS')=K
MRH31IM??O"\KDUJ;3]TI^6:;#M-R;^G6WJ[*S:GG_#,:EK$1"1_#JYTEJ32*
MK<-+A,_'(D'^R6QU%L8O*YW_ #AX33<YLMXO695V]U&=T7,&E1?Z11HBPQ4C
M;*$SO[24D*.XN, T=+2=;3MT?"2[^N#+MF@S#&/=/& +MDA5\#DN0.3K[S@6
MU8D%MFL^<[)CVDY3^_%65[GZ4MHM)FZA^]5>7$62G[8K2LR$S$+$48J"^8-3
M?4;@)@"*]YP>Y2;%R2QSD!IJF/\ '*,I9^,]=NE+XRZ_H[N7-4, XZ^J#19=
M2CW5QBN7G9P\YI_.G.6-1HD_$L6D-F&>VRT+V.-N4I#T]A-KXE.O,/VKD6I1
MG[1D(?\ :.:WIA^UHE9)O*Q?XRK2K?\ :,8NL@Y10D&7U/Q+)95LX23<I)G4
M05(44S G/)W'K=MN:URE4JY.:-+1>Z\;]'=V1K,/HV43IV2[OG6EW:*BY-&)
MGCFE[)3JK/UYBB\8FCY!Q+ILI%[&LG"TBTBXN?I$6ZTO]P)7-P=Y[6K]#Z3Q
MUK%;9NFUG5E>)>Z8QJL9L4IJV@6;.2Z_9]SG.6?)';^6JL2PTLN7V">JN+4]
MTG!_L9:U0\L_&62=37''CY,2L@ZDW\GAV22;^2DG#AZ_E'K^@0#EV_?/':JK
MIT\=KJG<.7+E15PNNH=58YU#&,9=/_!O_B?^[P(6[OQ)YR;%K,3N&H2N2I&J
MFBYK;J=@-'Y,ZA0X*#-6^+?.WCOH#JO<I,^X>YOO%8A[K(\IZ#9J]07,%;UJ
M%-9[;KI7M/!307-535ZA\4N0T%S59[RG)T//,TFG];N6K0];WO?M@<:<[:<3
MX? OZ.)S(=>J)LKB+S3M"@*W>HCG7F$[EVR:-E%3C,#T[&',?,6*\/I1O_!O
M_B?^[RR82B8/I@!0((]&(/\ 6$?:(#UUU\!V _?[B'@99"%)W[>_D>Q[$1_+
MK\_^_P#N\J'OH>O@>AZ_M_+SCKA<Z[0:U+6^XS:$%7(1%):0DG1550*9RY08
ML6;5HT0</I*4E)%TTBX:'C6KN5F99ZRBHIF\D7C5LKI<KU.H[!64[=3'4\>.
M_&OXF0B[92[MF]QKTS'*(_B8>VY[I5;I^@4V7%JX9RK2,MM8A7[^!DX>PL&S
MF#F8J0> I) .'?O,4WP'70==#\]]_KW\?]@>> D4I_>'?8B81^?C^(>Q^/[?
MT\N>'@'EH42&$3#[NQ'L>C"'_7_W_L\N^'@6?H)_^=_SC?\ ;Y45(I!]Q>^^
MA#Y$1^!$!_/^P/+GAX!X>'AX!X>'AX!X>'AX!X>'AX&GDTRG^F ]@!7D:?\
MAZ#LP/4@#OL!^.A^>NA^ ^0\V"P>XZ)1$0 PG 1#KO\ S?U 0^_\O,*0_P S
M_P!"8[_V>0\VO@>% "E H?8H  =_?H Z^?/?#P\ \LB@7L3>XX"(B;X$OP(C
MW\?P]_?[?/GJQS$+_"41$0'^( [ O0A\F^!^.A'^[_:%CWF4$I3^T2B8O8>W
MK\P_/O\ /[>!D?3*5/V)D(3V /TP*4I0(;VB4!*   %^!$.PZ^!$/L(^88LR
MB("+=N(@(" B1,1 0,!P$!%/OL#E*8!^_N*!ON #XP+/=5VG9[)=Z[E_*CBU
M,.Z4E&RLW7I7A/NT5-,ZE9K#=JY4;4V/9>8M8_>ZCVJ4SV]0-7TNKQ;VA6^7
MH=R3K\JY/#2#%@D-TY$:7G$CKE67YR\&J5(8IHV#T'48V2X%<A91+/[WR^N=
M;K^)M[,:'YW1;0S?3;A?8<I[0W63KD">2?R]QEX*.B)UZQ"5H0^/:8.P(( !
M1'LI13, E]H#\![3$*8O0!T)0$.A /*DT0,('^DB8OR0?<4HC[/>41 /@/L)
M"F .Q#L 'KL \ADGN7FZ5Z_S^5I\X.*U[T>K6Z[T6QTK%_2*YY[I88*SYM6L
M$MF@,Y2/Q7G)H:K1E2H?D]A7[S3BH$@8B6T!G7'LFC8H>R1D/W+?F#:F,+:+
MM(\X^(MGJ%!T/9,CO+&B\".34U;X34L.T^%Q70<_<0$#S)N-I;VR#TZTU2$C
MH1.F/WM]966M3M%)+UNSP$^]"6P4$1$PBBD(F$IC"*9!$QB'!0AC=A\B4X <
MHCV)3@!@Z$._+1V390>S(I?;H0^DB(#\@/S[DS?<0+W_ *I?T#R)L>9UA!W8
MV[CFQQ;J+RL9#L7(6QU30/3]Y342\4W&,+G(N(U"QW.JW3EE5+-7WU$_>.M.
M):"FZY#6J5AIV%MT+5EJS.Q;U;C6W.B_3M)U+4ZUS/X\.LHQ;(E]ST?3B>E5
MSCE\W@\S1P//N4)9UOHS/EPSIDU).<)U2C7B/ID%*REWE$I1S$QU><3\1,P\
M:$RHIIMP Q0#HQO88!*7V^TWR80 I2_/1>OGL.NPZ\NE33,!#E+[0 QE   *
M4#&,/9C&#H>S&'^(3?<1$1$>Q\B*MG-"_5-R$:;EQAML=DTVJ8\,IE7I;<X-
MMK;G1+WE><[92ZZSGL?Y072!6+:<NUK/[C"3B4XO79"/FEVR$H,C#SK2*QY'
MU :U 1?*:7N7-O F\;Q&LE.JVZG@>"_)"!FLPE[_ +'9L6I_XQK8=UN"FB1D
MW>J5;ZBREL[A)2,?2D"YFVTD6%!%%T$OH((@)C"F0QC"81,8A!-_&8IC%[]O
M?M$Q"&$![[$I1'L2AUX*Z0A_$ B'\R"(?/Q^G7Y]>1'W'E\^K<A;TW_*=:._
M9#R>;5S]E<$=)DZ]?'E-UVE\=[A 9?)'N3X-#G(3;;O6*<[;Q,W]1PYLC>=A
MD)*DLGEA;<]9.6]RKT;$.U.8S5C+R<T-;4I<OZ<VOCH45:RZ]QYPU&GS^?K:
M17;97+-):!RKP<\ TEXU!*QTB],-,KIY?. /;2!,J3V&(7VE "@'12]    ?
M   !\   'P ?8.O/13(82B8A!$H^XHB4!$IO](HB'P/\PZ'R(QMR@U-H2PIO
MN4B<U.TV:CH"XYS6?3%Y)6+6Z[)N<AHFY/TGF?5#4+3:UVE<S[4<\=VR5BJU
M*Q<)9+;6,X7>IZ-:ZU6Y2QH'+NV9@SVZ6MO-/('$?QOS>M:[MQZ_Z>7(6X'S
M[.+54YN^M;)*(U+?I9V\) TB%"W7>)AD9*>H-?L%'E+K%03;0:0:?"7H"$*
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M/M$!^_N*:EB00[ /ZP#^OQYN&O 7@HQ*!&/"OB6S(4 *4K3CECS8I2@4" 4
M1II   ( $  #H"@ !\ '@.S,;V]?!A[$ _A 1Z[_ #'K\@_,?/?&;/\ T^.
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MR#]0\O\ @1Y5+T[,OHDC9EJK;[\QA;#SFJG.9G6WCUI*1=3LE3QC/,9CLDJ
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M%7UF-G-KY%2]^WG)N6^);+K-LO3:U6:^9SR]SNM9Q:HTU.?1J./4R3I,1EF
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MW-5PY=.7*B3=N@@DHLLNJ1)),ZARE%U_TB@(CVKV(B/RLL(=C]^BBI[0#]
M  /R /*^@[[^>^NON/7_ #>^N_Y]=_S\!O<CRSXRQB4HLMO.4N@A!6+-I1%V
M@9UW"F1;'=&++L(1[(OXP3(D_P 7^,:H_55.BW3]SERV16Y%]S>XFM00.YW.
ME%_$LHY^V<(+RCM@Y92;5%^Q<-G[6,4:.$W#1RDH I*'%,3BDJ5-4AR%=C[2
MB;W"'9NN@$1$>@^>_:'?11'O^(2@ FZ#L1]H=>"F41[$3]A^BB@!_<!@ ?\
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MTX/VA3>7A?: =_B?3UY\,@$!'Y !><:T $0^/@HB8![]P!T/FMJ_*W+V[VQ
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M!GAS+Y _TDU/'TZUZ8']+%Z@(VVT?+P]4^[#I%QJLS'2LM$6>IT4?3X-9;%
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M@#V(_'_P_%_^S9?,T $1*4 Z$PB "8! !Z^X@/0]_P"SO[^!DM_ZIO\ 7_\
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MD_047E)-W?;-4PL,W4AYNF&T\F?VAI9W\G2M&)DS3)#VM)W.NL[9%J\E&O\
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M&Q;O+5??KKNKB[V*J5./@+/5(-;/]QL.GMG3>&M<GH,!!$LW K@Y)W8C@8V
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MOEINF**"*1A*)DD4TQ$H& HB0A2B)0.=0X%$0^ .<Y@#KW',/8C=\ \/#P\
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M51G<U6L^P!9"%7?2#=PS26^#N]+LTC9H>MV^KV&7I4D2'N47!S\5+2-2EU4
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MC-XDX8BW RJ[U5=D=F[([]X&2(U02?(G;@F8JYG::@F*+<H&S?#P\ \/#P\
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M8%1<>Y!$R:XI"F*XF('N5.0 ("?O'^/V@4@%]W0%Z  \],8ZAB@(A]P  #W
M'?8="(>X>^O[/.5I*YW-*ICA4GTUEZG75EB 8#$*HM#L5#$(("("!3&,7W
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M*@0>@Z,;L $O?70" CWWT/?VZ_V^>IJ H'8? A_6+]_;WW\#\!^@_EY@/BO
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M!^02AF:8&$#',;LWL[$#',/ZF,/R/3B E,)3 (??H>N@, "(=A\C_+X[_/\
M3SA,FD4Y?*LYET$I!NC*9U2))!&5(JC+(I/:U'N4TI-)8I%TI!,J@$>IJD(J
M1P50JA2F P>=V83F #&$H@3HG?8@8>_:/8]]]C^8_(?F/@8J_P#E67_H2?\
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MF*@J);X\[>%9FZCY+E_Q=48I%,=5RGO^2N$4B)B'U1$[6WK]B4ON'VB >XX
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MT>QIT&Q'\<9X9Z(R;0[!!\BVEU8SFTN5FW+ (I>F]S04*4WL,9._>G0<"F
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MXL<*@$IS?U>?NYG*HGT D.<?^3%)T<1$Q132]A2E*4P*',80*^<Q2F#HP (
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M*@=IG'X$OR'?N 0-V @/8?/V'L!_+S+.<I"F,80 "%$QA$0#HH=B(B)A
M 1$1$ Z ?T\Q3%4,83"4?T .@[ H"80[Z$>QZ'\O]_@4E.!#B<$TBF,(>\Q$
M^CF#^$![, ]CT4I?OW\%*'V /*E$Q6*)?II'1/\ (D,4!*?L2B J$,!BF$!*
M'78?S\H* F*!B_Q%-\@8H@8!#]0$O8"'\P\O)F4('M,0Y@  ]O10#K[]@(B(
M /Y?;]/[? ")G]P <I1('S[>P,4#%,!R& H@  )3% 2B =@;H0Z$/+_M+_HE
M^XC]@^XF]XC]ON)P PC]Q,'N^_SYZ ]@ ]"'8 /0_<._R'^8?GY[X%M0IA+_
M  "(& .@ !  'OK[]@/P'7QUU^?F,5%0@F,0B9#&$1,)/:43&$I"B8W1 ]QA
M*FF41'Y$"% 1Z*'60*R(&*05D@.9442D%0@&,L")G HE*(]BJ#<IEQ3 !/\
M1*97KV )O+O@8YFY?XC%$??]P'H@")@]XE$1 @#\"<_0]_'N-UUV/EAJQ0;*
MNUT6[=LJ^<D>/E&R**1W[LK5NQ!T].FF4[IR5DR9,RKK"=4&K1LW _TD$B$S
M?>7\A P]'$"E$!,/L$"G  [^1*80*;_1,( /0CY00QA,;W]%*(@!.Q+V(_Q
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M((A[.A$A1$/I^X2="(=A[!.82=?U?<;KKL>Z2H(%3*D5%(J1/ZB94R F7H!
M/:0 ]I>@$0^ #X$0\3 VZXB5A094VQY66+U:/;2V721M"J(,-)BWJT(W9R5!
M>#+@WN,>[7LU<0;/*ZI(MUUK!"))*'/*L"N-Q<-2S7/I6F05ZT&D4V<T:?2J
MV?PUKMU=K<M>+(L=NFG T^.FY-@[L\T8[MH0L1!(R$D<SIN5-J<RR8&#LE&3
M=42BHF0_L,0Q .FD<$S)G343%,#IF]@IJ(I'()>A*=,ABB!BE$+0L4B']R:"
M'8E( G%-(I_\7[?87W%3 PE(":?L 1Z+[2^W[!URB^G9VVT!CE*]]I"&G2,
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MSTG=Z_H<:EENG#LT/&Z8PNN\<LYM&(<RLNR_AJ']..YY'ZBV<9THCP)U;B/
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MD4\U&$;RF1ZG39;/8K,9BJOK';:VZ9-5KC94JY5T90O/#%*8.C% P )3 !@
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MCY5FZ9I+Q[U!V1)0 =5*.Q;.H5(&RBPOIM9G]1+L?H=PLV\!98 (8?I 9H5
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M]P ? >.*A0 QNE.B@ CTDJ(CW_HE @F./Z@4#"'Y]>!5"G !+[A >_N0Y>A
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M$48])<HK*:)#*T!TUK,<]E<KKTC5,]LMB5>6VY5>!FFL,QG6C"YVM:;M1U[
MTKT.A89%W,.9*>*P0-+O'JA?>*C^'@-X3XH<;T)^@VIKA^9M;+E]3SFC9_-L
MZM&Q\A4*=D+V8D<OJT"LP;-P85[/WMBL+BHQ")2,($T]-%C6[9.4?$7V>?\
M&+COE$FA-9EBF9T&8;Q\!%)RE0I\+7Y 8VJY_4,HK+%9W&-&R[AM7LQH--SZ
M$27.H2+IU>CJZQ!"*3.U.NGAX"7+XME)I!S.-LXI#:Q+:*KL99Q*KP)9,NOG
MH7]&!-0_%JQCGN^$S\"4TMI60<2O[MIDB%%5H\!:FV>6YK5\>SVHYG347J5=
MIT*VAV2\M(O9N=E5DQ.O)6&S6"46=2]EMEEE5WUAMEHFGCV;LUDDY2>F7KR5
MD7CI;OO#P#P\/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\
M/#P#P\/#P#P\/#P#P\/#P+"J7O'W%_K? #V(@ @ #^@#\]B'Y?E^OWN$*)2%
M*/78!T/7V^/[0#_AY7X> >'AX> >'AX> >'AX> >'AX> >'AX>!SM@_\5'_T
M(9?^C_-RL4PE(8 [ I1]WST/0^W[?K]A\T]@ 1:FZ 1Z79"/0"/0 M\C\=_
M?K_, _/S<F4 P"D #[A#V@(]>WOV]_J(]=?R\"I PF)T( 'LZ)\?F %+\_[_
M "]Y0F3Z90#[B/0F'OO^+H 'KOYZ^/CROP#RPY2(L@HBJD1=)4HI+(JIE525
M14 4U4E$SE,4Z:B9C$.4Q1*8IA 0$!\O^,[]0V-E)C@3S4BH"'LD_9)#BIR
M:56'ID--V"XOK:ME5J+5$:C#UIH^L3RU?O#^S3ULD"U5F$YLK%:-]CQ-%0H=
M)&\4,K@Z?IU+K2VD4UEKNFS6Q7&9H&GWG.;6?0YEU752S$-9:#+UJ4@HZ.95
M&M02-4BUV]0EJ]%GA;5 6%C,6!.7Q''#W$W%/K%,_9V@LDJA9M%N4+<H/9=E
MK>M$LNNEM)-/DGFQ5Z^1FF/@N1;E.*O&*]G&,AWR%4DZNR@9+/,\=U:/NR0:
M1N0%-U*@T;76?"Z@<B<3O,[ -\HW9HS@]@'C]S=S70+K2\9D*HWO2V/MK3>.
M#4R^E\KIY\*AK_&W'9UUHRR5;>+ZP;Z3*=,DV>%4^ S*T6N0OE$]9RYX]":4
MYY 9#'UQIIW.C,M:XEDF9>E-*M:LBNL1QWF)A#$86[W##[[38AC-UR#MN<3D
M58AB0F/LO$S);.O36S@F@P=+I-5IU%88_3-2T>FX9*4S/I5O,4VKS^-0-E:Y
MW)0L8JV3B)AB6OMF]\I@$SK1DK?GJ#:K(.3.F90JA3E5 %2G(?Z1UD% *H42
MG%-9$Q%D3@!A$BJ1R*)FZ.0Q3  A!E;JWI5EMLS?<^9\HY&)LEK]#VR6)75\
M3W&-N-AE*SRQC?Z6['!H5^>K<30)2 QLC5;E95V.71=;I0(61754 J\P\:QZ
M"W$FR5QGRDVFO\8=8K.:\PG_ *A^,_N51<WY,6S05IR/SIU3,.V._P#%"O\
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MT _;Y#\@_+S+2  3)T !V4HCT'78B4.Q']1']?,=,HF*J4.NQ*0 [^WR)_T
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MK[;=\UL;60KEJH&-REZNK&PPUB@20"\M6+&SB@F(!8AA H>[L1Z#LHA_U?\
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MU N71OU$U,X%_/\ (?;PB('7Y? !X#N3J%)U[N_GOKH!'[==_;^T/*/KI_\
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M#YCCW8]N@$8"A112:E>,X4I36V-Y([_.S3.<P=@K=%K<Q8M#>7.2L2E,'1@
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M@7^[RYX>!X4I2AT4.@[[Z_+Y_P"'^SSWP\/ /#P\/ /#P\/ /#P\/ /#P\/
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MV'?]_F00@$*!0_EV/V['H $>OG[]>!7X>4F,4H=F$  1Z[']?D?^H?/2F P
M(#V _8? ]\/#P\ \/#P\ \/#P\ \/#P\ \/#P\ \/#P\ \ME J0%* #T8W0?
MG\B CV/?7QT'Y?W>7/,8X_XTG^,_SR_XL0^W\(_(#_/[? ?<?D? :9P#;$;<
M%^&T<#1>/_9?%3CY#*,'*A%73%:&RRLQ;ADY4(=0HN6B[-1NX 3"<JJ9RJ 5
M0#%#EO4L:G6].SGPW(R+)'5X5\K2(QXN#MS/C*X+H2)&17!453(G=?4_#_4
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MB'P*/%E0!#L/N B'70]]" ^ ]/P\887U'>/IP[+GG/'K[?Q^EAZGJ8_\T_$
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M&9R+ML#5VD_1*]<,GX-0=LFSMMU'O$/E54$B%Z$PJ*BG\#\#T(B ?PB)>Q[
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M!$I3K="H'N3*44P$1]W\2A"_'Q[E$P^YB]X3IDU?II%=-T')47C9\@99LV=
M@_8KE5:ND =(KIINVRZ93(KE("Z"A0.B=-4A3E#YN8W:N0-D6(=]*\W;-7;Q
ML>:2>HGM55YL8)'P$+;\EYEZRUH2U9QWCM<-8XZ:1E-GA..V0;95,7V>[8=<
M8B,SFRM']#NNKV^%M;O^+$E=K!RGGX.X,]R2@JQ:XU/-SVO9/4R81$31*YQJ
MQYLYCW57U/+*SB6LLIK9%]4LR=SV+1+'=IIC/1:;A1W-03.M0<R/U>P PN$B
M@8PE+[UP+V;V^_H/R[]G\?0#W[?XNNO+A#H' A?Q)#F5]X% BX#]04Q$J@$
M#![OIC_"H!0'VC\&^? B#ND9L>@26:W&VM>8C<L3RFYY6Z]T6BVO<,M)(\;<
M*C-TRS(J%%-\AL="9.3;!=*GQXV;%EK"H\M-^AI6VA7I-_4;#:V3QIU>L/*Z
MA\<\=T*-L',C7+_![?Q<G>5;FGX?Z@E;T6ST7(,VMFX\C&E&Q3F&^=1#V$V.
MW5-OG2$#@.>4*.EVMU:Y3$,&EI<52"A/HO(#<#%]JB8F$QRE#WD,)C$]Y3E
M!$1$Q.E , ?)>C@/71@\R? AW,TYWEX"\AG+S2M(@.8&N\A]@KE&EXO.#7$V
M!Q=WY*KX!FB.9UMU7&@R&(9U3&L-ID1I,_37BCS*S2NMV%N[?O'5B/RVUZ-N
M<5RU1=959.2\55K=J/&['Y6KVZ&N4% 3UQ9\R\+?7B!R" T^D0N7V3/([A=F
M?*75['H7'Z2O=SF\YL6OOMPM4#*T3C@QBIL?^_\ =]O,59DV7<-'2J22BS Z
MJC0YT&ZAVYUT%&RIT%5$CK-SJ(*G2.9NHD91,QDE!,F8Y#!E=!^GEI4AC  E
M,(&* ] 'QWWU]Q[#KX ?D![^?C]!N^'@8X(FZ*(JJ>[K]0'H1#Y !'L>O+7X
M=$QA3'Y$ ]X@)$_;]@#O^K]^N@[Z[^/,WP\#7BFV+[BBFFJ8OP4#HD$"CW\]
M#T'0#W\_;[=_/QYEID3]A1!,A0$H#T4I0 .P#[  ?[/+;COLGP(_!_L C^9/
MT[\J0()2B(@ >_HP 'W .OL/P'S_ '_GX'IF[<YC'.@B<YB^PQS)$,8Q/] Q
MA*(B7_S1'K^7E0(H@0$P23!,H"!2 0H$* _(@!0#V@ C\B !\^7/#P+'X5J)
MO<+9 3>T2>[Z*?N]@B!A)W[>_:)@ 1+]A$ 'KL/+@IIC]R$'L  >RE'X#OH/
MM]@['H/L'8^5^'@6OH(?^12_]AD_3K]/T^/[/CR@6C41$1;-Q$?D1%%/L1_4
M?X?,CP\"R+=N(="@B(?;H4B"'0_<.O;^?@#=N = @B =B/0)$ .QZ['H"_<>
M@['\^@[^WE[P\#P             Z  #X   /@  /@ #[>>^'AX'@@ B B "
M(?81 .P[^_0_EW_+SWP\/ M @@   (I  &]X "9.@/\ Z8![?@W_ )P?/\_#
MZ"'10^BET4QC%#Z9.BF,/9C%#KH#&'Y,(="(_(B(^7?+0K)A[_<8" 02E$QQ
M*4O9Q]I  1'KLQA H /0B80  $1Z\"DZ!3#V'1 Z$.BE .^_S'_O_M\O^ "
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M\-$OI8J)7SJ,B']@GGD7'K+J-&#N;EW#1%%:2>'6R#Q[;\01P1DS*LD<5$G
M-T <)J'1,W4425^F*A%#-SF0$Q3 84C"GV)#"7P(^\/HT%FG)?D.[KU_VLV/
MXQD.<5.Q/-DY-<@-<I@ZS;%K'J^CJR8<@=*T!C7'>;Y EADTQLM64B(PD7K=
MH832T@I'(M8+0U9^RLF%63;MENVSQ*?+/58O0<[RB@7>[YIH#O/)"%CZUQLP
MZ@M6<W6M"S&R6C.*I6=CV6%K]JH2T-K$]KCN_7"NXQ&6^.8R(6.NP%PKT]4+
M;7(:UU2T0LI6K-6[+$LIN LE<G&"T9-P,_"RC5U&R\+,1KIS'2L7(-G#&08N
M%VCM!9NJHF:W9*S7KE%+05NK4%:()PNQ=.(6QPS"=BG#N,>H2,:Z7CI1JZ9J
M.(^0:M7S%8Z J-7C9!T@9-=%(Y C-N<C(,FW'G,>0G(>:HF4V"K\P[!;=.H6
MX63.AAM!S>?@;'EV.2/(Z(L5=L<^&%8D\W/]Z)VW2T1,:L_XW3.D:3#C^R[5
M +6(C7K<FS])"Y['J<G2]KV,*/ [=G4W<RYPQF)2Y\$N0>@6MC8<=0EH2 ?3
M3G<JI4#1Z4C6Y&2JLW!DA*H:&;O)IJ^DMBZ+28>KP]&C*158RE5Y!BVK]1C:
MU$,JQ!MXI0BD4VB*\U8I1,6A&G(0[!)DT1(S.F0S<$S% 0Z\O\(&/T?HP]@3
MV]"41$?=T4.ODPB)A_,?N/8B/@1-C:(7,/4"L$NAR>@=?LNZ:U5<X:<51Y!Z
M^:[817G'&2K/Y"5J^!!MDKB[R(2DLK+KTX=7CQ5[9'5/3M&TI'6) K1O3;3+
M3Y@"SCS.U'YH]N9^JS+'JO19)B[48%546*Q4<BG]8[,JRJJI6QCBB"JJB@$
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M$(PCS%1@64,H@U60YE.]^H,<XF?<8N&2"0"4 ,ESRW!<"^X>A[*MZ;S0I.C
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MD.*O#8?PZH(F%QSRY D W^(06(9%5;TTU/Q"8I+I@=5$RB1')5VQE#.&[@I
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M<K3I@&G _A<S%Z9/BSA*ZTDI*GD'<CFE6E7[U*:?GDI!@ZD)2.>/EX@[H_\
MX+"J.#1,<V3;L(YDU8M6S9+DDL\]1E,_N'E9PK,43E,<!X#[Z81 "D()2"KZ
MF2I4^RD#X @D]XF4,0QSG$^V"D>H/T'NY/<-A'\Q#@GMH!_L ?47,(?WCX&S
M-P)X4>TI$>*F",DRD2)]*,S"IQ*)@1(":9E$8R,:(JJ%(4I/JJ$,H)2E*)A
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MHQ=,HE$!]P& E*+V4P"/N*;LH_F'FL1HWJ((E$KGE/PM4,81$ID^!.ZI% H
M =&!7U)70B/?Y^\H?8/;W\CU<54N:R;9V29Y!\79%^I^(.V<Q?#O8(=BB08]
M1)F"C-YSGG#.3(R0MWCK\-(,P>,4UH\A&CE<)5 -:GZ?W!1-=DY1X<\8$G$:
MPC(R/<(X7F2;AC'0J$2WAV3)P2L@NS:QB,#"D8H-5$4D/V5'B0H&9MQ3IE?3
M_P""TL/U)CA[QJE@^NLX%.1Q3.Y! 73IJX8.')FKR 5;'<.&+MRR<+G2,HLT
M<+-E3'05.F;.4J7-SZ"9&O(3BNV<)-?8[7=<,M@707>G9)E3<-TB\[6QTVI)
M#ZKD[0SMXJ#11./_ !R:Z1I!72N*=S]!-50O)WAP5(AN_P"/@MM:HD+[OX?>
M)?432]X@ @ F*! $>Q H!\ &P-P$X*.FBC5SPTXL/6ZRK\ZJ<IQ_R>5%49*:
M4L#U(XR=4>&.W6FE#2!&XB**#@$S-DT011 FG<^FSZ=3TYU'G ;A6[44*0AU
M'/%C#%SG(D0B213F5HAS&*FF0B9"B(@0A"$* %* !B.:CZ@7L$S3E'PP0 AC
M )W7 G<7I0]A3"<O:7J/M!]X" &_K")2@("'R!BT?N1ZCQO:4.5G"4/J!_"8
M?3\W< Z$H&_+U- ,'P(?H(=^!K!],#TT1.H*GIX<&S"*AQ[#B/Q[$1[,/W$^
M>>X1[_,1$1'L1$>_+(>EQZ9)/\GZ=/!7Y 2F]W$+CP4/:(?(?XO.RB/8@'P/
M9>ON'G2-Z#ZAZ1O<\Y1<+G1/GWD;<"=R0.81#[E,X]25Z4  WR(>PP]=@ @/
M9O-RWI7.](O_ (;R0XA+"/8 +;A%LC0HF$>RA[5?4">_YH" A[OXAZ$!+U[1
M#AVWI>>FFW6(NR]/#@HS71$#D6;\1^/J"I3_ "!3$4)G7O*8H>X ,4Q1 ##^
MOF^2].?T^F9W0M^"?#) 9",5B'WX?B_AR?XR)7]Y7,:[$E#(9Q'NBJ*$79+"
M=HJ4QP%'^(PCW,?4>8*9&P2VZ<<GQR)QQ70Q_%#28LKE1)@V1ECI%6YERAFI
M7TA^T'K$I553QC=9@Q65E#,'#R3UKFF\SU57@L^0W&UJ50P!'H*<0M*<E9D3
MD8]?_P +4+S3;KOUOV>W?L3'*LR1.X?(O3-S)LS,78<RMZ=O %P5<CK@]P^=
M)N6#:,62<\8<+62/',U?K,V)RC0 ^HS:'!,6S185&R HIG22*H G-;#TY?3V
M,*W_ *@=PQ-^,<+.')C\6\/Z<.'"@J++.!+1 ^LJH;H#JG]RJGM RISG[./1
M*5'FP=%7\'R)XLE.!DP9JK<.-9>-T@(L8BQ'8)<[6YWQ_H%40+[7;847)4W*
MY5Q(9%37C4.?/]5/DKQ$)[?@15X+[3[!^W7TS!ZA*!1#KO\ JF. _'0AT/8<
MF^]+STT7J@'D?3MX*NS" B)U>(O'YT?LQQ-V8SO/%1[,<3&$?=\F$3"'N$1\
MN,_3"]-ELG[6WIZ<%DP 3B($XE8"B;[A[NRM\]2)U\!_F]C\"(C\>= M3?4$
M.  ER=X;$#X[!;@AMBX=]_< +ZC*'7Q\!]^A^>_R\L%HWJ&B/O+RAX8 7^J/
MMX$[B4.N^S?;U) +W_YWM$?[>NO QTO39].Y(I#)<">%3=$G9A2;<6,((!@#
MY]HE&@&ZZ'L?X#D'LQOXO,B0]-WT\9MC^SYG@APPE8_Z(-TF4EQ;PE\U29"J
MX7!D5J[H"K<K8%GCM;Z/TS%^J[=*=^]=0QMM&47G0#HREBY,\6W46+!XD5"I
M\*].KT@1\HHT.T?C(V+G->6HIM2H.$%&0Q  Z2>*C]9%9%NLGG.*#S!7=O'!
M.3&+M$%G;A5HR;<49PR+-H=0PMFHJO.3#MTY402]A57*C@OXA;ZBH(H)G(@D
M&L2]/7@<W9%C6G"?B$@R('1&Z/&K$T4B@,D:7,4K9.B S*0THHH_,!6X"+Y0
M[WL'9Q6\H7]/7@4N4K=YP@X?N4% ,04EN-&*K)"4W0F*8BE&]GM,/M[#KH>@
M[^WFQ)0^:GO_ ,5R:X_"/M$0^OQ!N)P^!+_6_#\N6QA^>NP 2]AW\@/M$M[]
MQ^;_ ,=<E.,X]?KPYT@1'^WKFL4/[@#_ *_ X]SZ8WINN^Q7]/SA&H<?GZBG
M$[ ECAV(F'H5\^5+\B(B/91^1$?N/?B]X[QOX]<>&\ZSP#",:PUE:%8]>RLL
M>R^C9DTL3F*([3C',ZWI,#!IR[B.2?O4F"L@5P9DF\=$:_1*Y< HE1Z1SR$P
M@GR8XG%3['V_4X3:VHMUV/M]ZA>>Z21C>WH#B5N0IC )BD3 0*"P91![O#(S
M7]..EY1HKMP=C^[Q\JQ6W8TSBD$@>?M$LNTMN];LXG7#PRC'\(NS?UY)@1JY
M*JVD#/$SL@5WP\/,%P[70=,FZ<<[=).UQ16>-S-00CB S?NOQ3XKAPW6,V,J
MS0CR P3?.OQDBT%5JDR*Y>(!G>'AX> >'AX> >'AX>!S,W_XA_\ /33_ -'%
M\WR/^46_^1_]$?-#-_\ B'_STT_]'%\WR/\ E%O_ )'_ -$? R/#P\/ /+*_
MRF/^L7_B'E[S'7.3KZ?O+]0?:<$_<'O$@& !,!>_<)0'X$W70#\=^!K#,62A
MCF49MSBHL5RJ)B_Y1RF44TG!N@^%R)F,0% Z,(&[,(B!>HT^;9>1\)K>/26$
M7/D P@GF3<HIFUU+,X* LM*<6O,<I7LN/-YQN]SFV3#65L]_E6L8PC&,W&J7
M1VR95\C212_$1[J3?QH>V\LRY':[Y6(+*+KJ/]"^)Q?(G;UJS-TV&6I^56*<
MT2#K!ZW%V>8C7E]O5B6QW5)&,K#!2'B$H.C30R]LC;%+42O6P&6AR4]1&F[!
MGF3V_.Z+=8Y77\]I]@TZM\4^1]/I^I9];/\ !;DK].P#M'<M2C\"E,1J>JZF
M]=V*ZOM9JFP6JB/:TQ2REGGFO6& XKE+S%YO5OD'L.6Y/2;+7<MH5@P0\7J#
MC@7RROB,6DKR+]/%CH3B/O5+N,UG_(RASV1;9RB5G(JAPN07RN%RJ;9HO#Q]
M!MN@*JE&^LCQBA6MWM.UHW3!LRK<O+0T%=M I6F-"79>+MO*5@N\KD8?+X]M
M-1;?..*UCTN7?5N?LXPREQIF9/$?Z4I9G4W;M*?SNXUWK8:IA%9M5U7T6[AH
MJM1C9;(=9J499(_*IJXURZ3=?L%NIL#"SE883M!M,8VML*]?UB0,G6GK*76B
M]&S-]<@CCJG.SU%3 :=L_%&=D&==_<6U7G.X?B/RAB;-.X%$XE0->U_>,JT*
M;T6;I4OI5VL3F]XWB? 1:##DY5=)EJ<RT95['4V^NU')\5.1G.^^<F97*>2.
M(T[-J)!Y3&RTLZK^5<CF )Z5_11Q?M,F\J>\21+1QQO])DM'TC?*<PI;&SP&
MG5MOF\45^PEU8JR.EU1L'J;\.ZU9;M5I2[Z01[G3;4'=RE X]<A0I$*7'I3>
MJ]=FZNEN,Q1SIT^3LO&#>*[6V;*U.75TE\ZDT:@E-H/H1Q*;'>_4:XS<>9'4
M:E9)FZ674<PSO:-$7R.DT"SS-TMZ.&8FWY 7*NTIR]8Q5.F+&IG,C /HULXM
M<;%_M.TU6)EI>)>V6&3>@TBB<T.==9JM.<[YQ^D7EET+&G=C@ELCXB\L96)J
MVV6?..(MFS;&[W$5ZT[+-P,;"7'5.1=<T34[D[H-1*GG$2C+.L\?U*VEF4I'
ME)ZH<OC5'T6U4UA3G-DM'%@+-7<SX"\EI+1,M:VV"X?;UJT];J@MR!T._7JG
MU&%O^T<?[[EU=RRK7^1E*U.NF&CYW;*J[KDA*9O?-GC1Q@M%=IVVW]_2YRUU
MVR6:&3+2KY96RL'5X:P3DH[.ZJE;G$4U_P!GU2<"/CO>,G(O&C6-9LU7\Q"-
MI%(/^4OXWL-'TO-;-_3%4;+GF)5O?@JMBPC8V6G6C.I32;WD4O-5+"$J&KNL
MLPA= I\;6V\U^X1H2ZR-UJ"6=O+(E(F6\!ER?,[U/YEV9A&\?*G7$74L\AH&
M2L?%#EK+K3V735PD:OG/*Y*)B[FUCH)>9C#05IN7!O0;I0]XS.M.)N3NNE1T
MPRC:[(6[7S.]2MC-\@:_)8Q5J16JOH>LT&EZ3!\0.=6Q3M8B*J')=+*KC_1G
M2XJ)A]^8[M!YSA]EA9;#-:F(G)I6^NZ5?5G-RM%.KJ+_ */]1?C$]?MTT975
M"UM2XR6<2M^D<&VJ'IE.TR$F- AY_/M!>3-&8RV?3=81RV[6.Y2=SAH.H4>G
ML8:UW*S0,'=:*]LJ.RWK \&8]_3'T+K<?;,YO-'OEI::M$&.QI$?/TS6.*V.
M,,W?2UG;UQ@WO%FL'+"@S"4>\DFX5>I-W5NMRL)6)"+DU02;>>5'/S(9[C/#
M9EE!M3KMLP*@S&Q)DXL<E-0TFKZ$]@;4I?[S/VRDVC-L0KM9S9BRB[O,8NC+
MSO)+5Y=J7)LBS-],Z)6+/2TP9\GO43_>:XZ2[R6ZOH5"H8S7*\(\8>4;"C-:
M\AS:Y49CI>^Q'&]O:&&PR%U<<72Y!KU@P.?M%@T1=*'JZ=-)&A843RCT4O5$
MXS2DO3U:FCL%UH]OSAWH$-?:CA>SVIK./5X_C-.5C.J?5:_19.]771[)7>4U
M"G%*I7:V[>UAI":*6U!$O<NT5E6%,Q'U">)7)'4AQ7'M1-9-(-GD?JA*N_J5
MRJ,N%,>5/&+RL[?1-Q@8"8@I.-K'(/)'LI7K''P\\U?V.5KW[./9*%H\14 8
M"YY4<X828U>1B*S?'T?,16,%S60G?3LYISE+G;"K6<?>ZWLLM0&VMKZGC><R
M99J4IL3Q\CG]UU:DSCX;V]I=WE<[Y 0BZ997RQ]2!] Y_=]?S?2Z.^OL<\M&
MM2J7"+E5HC/B_!77.,SN]3S&FX;G,[7[+OB\9?;*SH+^TI4J>UBIEDM!&^NJ
M6SR>YL63[HWU<N LK+4FOM=J>A8=)JU.M5!JKG.-(:W:UHZ7 EMN7UV+SYQ5
MD[Y^_.G4US$6RD4-U6FUMF8>SU!,8AO*V^MQDIT3_P!3OB.VN@Y;_2!)0.LM
MI_,ZL\H&DYSKV<V*%M6JVK)*Y5J?.PLOFSJR1UKFD]IH$I"1JM>_ 2T=,A)C
M-Q]=C++9*\":XWK/J&SU6"T<@\WIM=7NO'7DW<E,NH>8W^#L6/;'DEXHU.R6
MA2%^9;O?D]!>;57+-<;1%(U6#JCAV2HL5:LY!8CY[+:O)^3/,UY4.>B^@94]
M-:^/^?3EEX_1M6XN<D5&%IED8?69&KU*-7UFR9A*<I+NM'U?.5K+5<.FG%=/
M.RKIA'[TE8-)8T+&W/8YSNP/?=/I&4YHMJ+Z>T'#[)R$KDK;,4U;*JY(Y= .
ML.08V&->:K5*:YGFMN1WZHN:VZK+6=C@6A;O SS^$M-1E(,B?9AZAF9[KL>"
MY9C==MMG9[=EDGR&:VV<AK'7&45QR?0$/*9#L[-JSJ=J26K&[RDFK$YV6^2F
M5K#^[5[C9=:/OD!%4:>!CC?EKZLELB:+)4G'<_:1$LG?6LY(V3AIRUCIL2P,
M?ZF%LI-A3JVE:AQVME9+8H?C3PIICRM6K/V3@MWY2J.2O2LYBD0+94V'([U-
M[=O[[+([),RS.F2O(VVYNG=[+A'*31T<LQ^OPF]67.M/G)E*1Q+%=-:;97,_
MRQ<\CF^YV)OBUPU$E&TN.<6Y*,I*2NYMZJ6+Z'2W=F<TS5\S7?P,;-48VKY?
MK$=4)\[[C2ARB=1$YJ= S+0\YKT]$Y\VM;T\)&3=KF)6'K3*P0+"8:76F(SB
MXP7._CS9<(T;D?$3%I#-\RO26<VM24JDC6[''W!Z_ID6QB)>O64T/(4QR5[?
MJNULZ&C%ICK+G"TNRU]OG[RHW!O !%&KS)]4^P2O'[3!XX6.@/ICCHY?[CD,
M[QKY125"X]V_5+'PBF:O+V"8S]_?++RJMS1J?<ZRPI>14>I7OCTVG[LOM<&I
M#YU/R=Q=KA.Y<U+SR#SA+9Z-<*=&,>/-_MU[RZA8)LS/+$;VYSGBI8JL$;R)
MU-_5ZC<YZ7NEBW6$K^;RT-2KA6V3-.N6B'J\WG]HMU\[^!]7?A9:RUU6JV;3
MK+"S[6F.G5PK6(Z?/46K?OQ4./\ H+9*W7>(KCRJPA(>F<K./,_,2HR[B#5#
M3XF)@I2<L41:X> NUOU<N#EM)HB]-T:T7IME</8KE?G.=YE>M-90&9U5S*MY
M;5'K_.H6U,DZ6#&!F9=J!G 6IY&1Z (U@[^:K<?,@QS-N;OJ97"*P65G<1DV
M#6U<H:A3+Y77? KF)5KS8,8MF5<49"TJJ0US5J%%P]6DZAKW)"/=6K4=0:9Y
M5:GD=52B=AY)6C,KFUY!J-H'*+G93=JW:D9E0@<8;79"F%J.@M^&/+.]KTF(
MEZWF3_0+1-RU%B5HW=;Y=];O%MAJG7>*]$Y 5BF5]*PW_:YG)$L@LM5U=T<]
MZI_'"M6C2HJ>A]SCJ[GV2T;7DK0QX];A8'%HI-MD^4J<G;Z]3X+/7EG4H%=K
M?%:W7)/1%V056VPMBIR-3>2$G9*PTL>I+ZF7%S'HF8K^E6"VPKFF-N2,_8GL
M-G-_L4/7X#%[_P M(X6<R^95\52W:VQ/#KD"Y@:W%MY3]K6'.96N13QP]LN;
MI70$W/8N<FH\=M'B]*86VN:[*\O/3:BW\/BE:UC*V55PN^J^G--\O83,+N_7
MJ%]L=$K:EIY9M++I\78FEJJD0VLT,^)!V*IO*[%(T?D9ZG6O9C=XR$J<WF+U
MQPLY-Z"^T)#AINE&OM.Y9T:E<?$ZMQYJE*TB[2JUL:-[GJFQO,YTFEP5PAMC
M84"$BZ%.V%3,;S8=,D-J7.[-K);MEJ,K0-PI#G!L@D]CTIW=LY=0K."8P,Y;
M(R;I:2[:2DT9^YM(BM1]YC2U=S-5^Q4ZX5N4A)MTHNY:H:"=]1?&*\U>-YR!
MTC/[# WRG4;08?3Z/9X,,TD+K=N--5KXVF0J<-H+=ZYM##E?CTO5"50MCADW
M4_(1>EV++$*3J<SG8-^SV_\ /EME',N#N](MEG>5OBWHNC<9Y":JL[ :1+:K
M-;#S>AH''IV;H=TA9&XST1F%"XOOHR5H[/,YTRMS6F(1\Q6LT.TJ757.\\\9
M[!/4%9R$-].QH\1;W<^)CG)LAO>:Z:PUNQ..7=>B,Y;/9S8]+_?;0ZI#9_Q\
MG(B3KK"A.7%HO;B;1AHZ)LU:K-0<EF/.3'M9T^J8Q"0NK5[3[?7+=>&M+O>;
M35/DXG.*=6L=LKW09]>6.@PBX.12Y!8U"1T,=ZK>T[5=%ZU+5&)EJ-I;:E:/
M$N=V5[1)9A#Q]+VRH2FH.CP,4I=<SEF,3"7M2CW36([.K5-QX.V,'9Y7'Z1*
M:G&G>%3KH5&4II)"?9V6^4Z G0CMOW(3U7Z$WU,,UR8ES=TR>YL6B@16I9YK
M-@>ZFC5^3W*F:SBBM5LGR&1JO[ A^+L9QEE./ZTAI^0R.E2E^<T)6QZOH-*M
M=>B7^\>+'S(5U:>@=U7967,7T)NK> MC#&FF7.:M,9;OSC/\X%[*.=6N![E(
M;%E[\VA%7/GM.J[*/K<4\KCJ22G)=NAQ3#U/LDC[/?VVDT#7\NSO/&.BNY[5
M;+4%9FJQA<HT/G93+NZL!Z6$\I"1;.$X$Z3>XU9 TS)&@;?G49:HNFVJS0T)
M.=BMZA68S%3R2Y9G5;QK$?I'(JP<<92%H3>$L5KJUMKF':CMSMR@R@).=K=Q
M:#"Y]&%6/7;<$<UBK02;4FP6@I&$5!I]>3]1BOTK HEW,Z]:H^K<]-;;:3>9
M>-S^1VG4\;?>I/IU"HA=+J;6/H%3JW'2*X;2[#236O(XQ"P/G),G>0].J&;U
M*VU"^S".(V+O--58KK6AE#6^M"V54:/;EG%Q:QD[&@0YF\A'.:OH%%LB+5R(
MD<M7<!;:W)%]Z:L;+,P%%J&9\_,$UF]9K1:FGJ10VV#7G\1N$WD%ZA:/K$;"
MU9E;KR>M3+Z*3<0_]',9,0#.W'OD=3FQIV:+ 5A>RRT%;6E=SJSSGQJZ8I?^
M0E6;7=[D]%BJ7)-[3/5^-SIE>%;U3:;=H=C4%M3L%&;))M&&@U")G;+<G%0H
ML)8Y)_"O[8DXJ]O- !&90*=S_P 4<U64SH_(JTLX:X^JO9+C6MEO]]WEA<ZO
M#^J-@<!Q!IZCC;--D[#7QF^"D7HKC(9:MV)DC'UH;#;'$-8[)+K-9M<:'=/4
MCVK#- C[Q68_'M<8;1PU& >TR#O46K1BDY#Y^ZY54YV?1X7+8_6\^S&@PLP8
M]AH$[H6>;'3)6=C*=L^EEEA9Q*T4?U5.+E\<118T=-;1LM;IC*F=A-0SSL#)
M;U YS>=:?X!47E*E;8KJ&EK4',[Y,PCS(FN@9Q:'< A7:KH$U:+3286RV9_U
M):=4\!D]EL.0ZZA;']WYFTZ@X='5UTOJ=OBN&=NV^/ME[5A)B'K[FMU^P4+'
MB:.T;RK1W,>RZ5*C5F*NEYGZQ#VL&Q3')?U1JI,3E96Q20MUBK-DY$P\7%Q7
M'.?=QNG8EF<!R+',^0S+4([7?Z'ZII^E:!1\)K%?XX2UKC+C/5/0)6ZMZ='1
MUE:GR)S64;5RRNKS?]2FJ!?(O/:7B^G3&%Y YP\M5O&HW=CR5Y:UZCO%H#3[
MI0+2:R/\)QWCU+UN@V"S8Q%21MO<2MRDZR[EXX*'KK%ZLG&&HWFQTJS.YV%)
MFUGM<)KUG/)4.5KV=UVA8CR^VBZZ!+,JW:9RZ'KU=1X6:M5G$2ZJ4+=9)P^I
M]O@:G*Y[98NU.E"E?4=XZ1?'69Y..W-L6SZMZ ;,+0#!K59-"K6M!!"0<'L&
MA1UP<X=%U)"&>,9(VBN-8+GJ[Z2BZ4TM#C1Y2.ICH&?Y%M'JBWZ 7L#VHM63
M;/-@S>*B(J<R*R4EYR#H-HG.(26CNK"[V>B8'=Z3%5&"T7E@WK[R&PRB2,99
M*!GLE*R^D0-&L\;OG:9#M'-1##.0VJV"#T^U7Y';N+;2(A;KQ9T6J%I^=2M6
MXT1/+*2R[C^-WC[WH-:RB5F.0UBIS>G6:SV&TC5(Z+JAN0<VQCY_7%YO?J8\
M8,WDWL1=7URJKQQ<](S[/'EU@8O-ZGL-NQNWW*CZW!YQI&G6&EYD,CG]@SRV
MIR3"[7*E/YZ.C8^9I#6U1-GJ+R=X+9O5*RG/,+LN]Y[0M'TRHM*_K\GG4FM4
M[G4ZSM,WC^ \@]JM%5H=A:TBYO8>6A9'C[9*?:'>D5NDQT8"4I/5Q6ZBQBH6
MR RZG;=ZF;A+'J--5??8UE!Q/%J;UB_*8E86\_,UB,V7CE=-PN,7"RN7WYJ>
M5T#-T.1%4G,P#:Y;7*+#&;4-CQ[+9(ND[+ICDLQU[U.)?C/R0LNF9_7J5NT%
M$9JZSV&84NSV]G7=$FGJBV\T2!38T*NR]_S[-FZS)KG-\IN?;N4[!TXFHBR<
MK9Z)?4ARHT5ZK. H6USE5L,Y/KC"TZWG#^J9G*1]_,IKF4VK4*ZOE<%"65GE
MFP2,Y8&>62DG$7V6Q: P563F:Y6$MB=R=GJ'[Q]K#\_H(V.YUK^@9/HN=.M#
MY+[KQAC\C?-@NFIEO^3[1M&(5N';)YK$VS/',KH5DR1!ZS5D]%@<\AFMD 6V
MIVI)G'KSP,%J'-+U&M!B]?BZ7EKV7UG%%\HS_4:!.Y'*4BOYX%AX;\+=]T?3
M4K_!*:FZN^X1=NY":*O3N/=8H%AFY:E0\3'RN3-[;5&:.PJE6];]2*VH145?
M*M;*Y.R&@XS&1;#/L(LC6JS&"/\ D#Q^B9OD5):O9;30YBEZJTI=@U)S8\$O
M&=0DD,#4'LW?.-=?HJC]&<=+J_J P%(QVJZS3\DT.[A9U]1C9"EKNZS3K74[
M;B>CQV5:-0;&:1<S4 %O87\);/(A.-DY2MV.Z,8^)B+4$78(BRCD9GZE7'+6
M-<JN(0);JPTJQ3USITQ6I=G3%9'/M H>@\C,NL%*N<;7KO/2XO4K?Q3W!D6W
MU&-MF9%9UN'E'=[:1]YHJ]C",S)KSZNV9YYB]1J..VF?M$9GO'9Q*1&\7[4]
M E-&U!3BYQ5E^0E)U?4KK5].8Q:4#8'VSMJKHD1M?'"@N=B8R:BO],5L@Y[)
M])<Y3X[EYI60;HNK>N4<@_>>I!P<G*+,6.C2_&N[3O'"MQ?IYFY%0$)47*<!
M8Z!B2MPB>2[>Z-X5BR=S\ WT)LU>7V*L+BX75S4AZCN&,978H-&K:],36%66
MTQ&CUR#K-;D;K7:M1&U]D;GJLOFR=T#2*WG3",SJ=F*F[N-/K=IVB#DJ1.X#
M5-6B-%H;ZPVZ!S^KMJTF9RM7,+S)7%CH.L5].$S:)LU^<1F=9'R$MG'N<V"U
MRLK2<^J3>LI2L?0YIS6,ZM.LZ*P1NTFT)59",HEDLB()+Q1N_.VW:3E:>[.K
M\PREK 7]_>YB[Y#F636B=V(<ZPYXOF2T7#.[:\+C%"T:>Y#1M#L, SK,E<"Y
MM3P<[;LE&CFF@<CT9+H?K ,%Z;)Q6=%GY*5X^2.B*TJU1F0I0J>Z62!Y3R3_
M  ^VJ0IZPU@(C*Y.!X>P--LR^VT]Q94+]H;V9+IONE7>-KO%^IOC]FK>!7&<
M@K=2E-3TJ9JM,B7-KS0BMW<NRYYGE&7J$(]MD1>KQ$:3>^16/1E8:M*$SLM7
MDY=65T^OT**@EE7O0Q/J?Y22LM[?:,]UN%KK.GX'>M$E6T#$2K3#Z]R3H^93
MF0IZB9Q)5]S*SERNU^DL]:1N(,]I0AWU/EK!<WM.@!.Y; U6W7;U1923N5,I
M=.UJVY>YQ38TJ';=)K>7YKKUVM)J)RL6@5;PVR@V=0M$LT%JL#Q<JN?S%7T+
M*W]DSVWR$R\R*<DY2Y7[#NOXY:=S=U?9\=O5FG-HDN-TCL\X\?/7V79S2V4@
MC,9[SP@INF+QU24"QR/&>E#5.&5KRG4YAK/6BX:9H,JM-79:(<N:%E;SX'G9
M39^DV6P(9%NS*_5S;*OQ[#!Y*N4!OK,WJ%URJ@[K6(>(72TU?*4(]]C&CU[1
MI&=G]1@XFJQ*,]#7%U7KC7IBLM,6B^H+C6BY?N>R0,!HK#.\%:4DEBGKM&4K
M.4K#:KIE5"UY.C0!- OM:-#3M7@-2SJ)M\[I09_G</:+0$6G>'B-;N;ZM U*
MEM>?&A\HLA<::_WJ R#.^4UWM.@1;-KF=#S!W!?T2\[*[1J;6K!F5ABKWL7'
MUO'/>*>@.'&IQL\1[K$]4R3"QK9%W[+N/K?MWR?FM=)#3:[2'G,"F\A9_7N<
M*&E:WG]]N3?%WO"JS9;R*CN)D-BC6R:,AD-;U..+:.*T##&S.A1FX4'?<TV+
M1YULA2K?+WW5I(N-?J)8MRETB2RW/X#0H&QQ%9O4\Z&_-L[KB3]_E>HHXQJ4
M%38Q'2).SZ='9UIBPTNS:YEE>NO'@MG0<5B)V25LJ?[',D ^K_QE6O;K+X6I
MZ_=M'*P2LT;4<]C<MOSV<SN0V:B<>J[H+*4I^LS=;8,['LNFT>D-<[LDY!;G
M7W,Z::O&452LQ,[-18-5;.O5;S.3<T3.3:);(-.J\T;-"675GL#H<W8KC9-1
MYY6;- EI.S9JPBHF0ITLWX553&JL?:\]HZF8WB1BH3&+?6(2;>88_'C#<>5;
MCD[RFSS9TM!LF,4Q//D,;T*UTNL4MHZ78-',9--B.('.Z%%W*9NK9HWT&5G*
M!:M9I;<[US'RL=QWG@2Q%IP[?U=^*TH>)95IAIMKLDO5*Y)ITFKQ%'F;XST*
MTQT_)PV'R5.0T(L^RT!TWK<HDE;#LC8(XDS1$(RVAU,V:M,)C7WKU6,EHJE>
MF9O(M@A,Z8R&K,=WTZUJ956JMQ]>8[$\O6=GK=N3'2).8LUC4T'ASH%'C)6C
M1\]D;A*3B+*;6DHETQ)(A*R'M-[3@ =B " B =@ AWUW]P^_V\LB@(]=JJ#U
M\_(]AWUUWT/?ZCY&@'J442Q.\?;9=DU\T-._[)G64Z1(LK'EZD#A+;1M5U'&
M8:S6^RTR[WZ!N*;Z^9);8J+;9?(7"%$[1 ECME5<R44W?.KY.[M)\><G9Z3#
MY^_U23>;#QNRQK1X2QPU8F90F_<C<IP8\C#RMA2- 'DJXCI@V=A$SKZN0UB<
MQ*-?D[C26<HM;88' "BH F /DH_']<2]A_,   'Y$?N']_W&M--0AP$0Z*(#
MWT81#OH.A$/@!^W7V\:-BW.'$]UO2^8U1*]1&@QY]20G:K:ZDYBW=>=8E*9I
M5-62DY)FYDX!5I4-)TUME0ST3+RE9LU_I&G1]*F[+$T.:FDVR1WK"<;)%*EK
MDH&[(HW;CTUYG-1- 9H]7A>#;]]38]AS%G6$3JTE))90]7NT>+>CQC.5Y(&3
MBK*8^$IF@'Y4PE=\/(^Z7ZDF$:!1=.T&KUS5)"%H4EDT94_97:V=+=%>06D2
M60<??Z(;$C<5J2=YL&E1Z%7BJ[IMJS2VY]^W:O8MNKV65&S0E@>\8'J&33^
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M5)N1>UV"30KT2[._JE24?/K9=:-7K "?7?U0V>23&O5S7LIKM,LG&J%&U;U
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M8+-EDUT3"/L52.51(X (E$2*$$2G*!@,43%$0]Q3!WV ^7O/   #H   #[
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M.ECPD"[=0\:9M&KJ-3!S%V]2RNY=J')[.[ID=^?H\;7FLVV2GJ@YAGC23P+
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MXBIM)]5*1D'IW$HLPXKL9%JHX;O&T4NE7W\$S"/B(\R#9"26EY&4!R?U4O\
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M'N]U;V#1[:7,,]66M[27AG<Q(R+_ %4O],O]_E13E/W[3 ;KKOK\N^^O^ ^
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MTSO3CS-"R63'\_UJ7AIV=RE_<:YJM2Q1RGIDE6Y^?3S4)QE.,VV]%(7U%>:
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M.<PY$G"KZK8MH*C?+<K6K%VIR<M<T(X)?7&+:8=4I"<Q>2+8Y'TU)?20K/$
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MDJ*J"IT_8LF=2+' _2_YHYI<^#EX+<>+%7;<#6U%I%(K$>ZUJTAH$+?--W.
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M-("^;.%T2E>H/VY_PRMQYQNV=TW^@CZ@/+Z+4Z(7\:RI? A5R82J)F$XIO\
MA'(-?<J4AB*=- (4BB@D*F<J:B<&69>D)RBIM8QVKZ10.(7,3)L#I/#NI4[C
MWR<T;3W%8M5<R_C[S"K]QH]]L5AP#9X:89<>MKY9R*O%MXMFECK,AB+"#JMO
MJU7UC+*IIB\D55XL\M:CZ8TQP3J,OCE,U*!XMT#B[F^T1FD:8^@JZG8L[BJ+
MIM[AX%;-T['7S8+&35A4P2LI3<@33'%(IL?9Y?#XJ;=%J8.%<\6]S=%(*'J9
M<X&1#G 4UV= ]-U4JQ?I^XOM,[]/Q\445?>4"* 4OO5 A$U/\84JEC_!/WM$
M>S^J!SM5 3@3K^CCTUCAV(&'[M_3J*($^/E01 @#[0]P"8 &(+1O2.Y8MZKQ
MTJF=M>(MLL/&/8^0S;$+[:$R(950N-^V<@L7Y+56@S/$S9N./*1BRB<CG:?9
M,BSIEA>^9%KU!HV1X$K0N0U89W?0H_,W5<F?3IUW9N?W^$S 9_Q66KSI[Z?+
MJN<A;?:)EMRKX\,^(?)6Y;7M->QBOH<:+*E(P_*?/I]EA]Q:AR.SN'2K+J:<
M6.OW&(7?52>!\B/%C=$"B"GJ5\W'0F R@&6S_P!.?W%*7V ) _"^G\@0!$3
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MVC\7P2$HB]!P?TOJ]F^J!_\ -[^F'QU\]!T8 _SO*S?43#W&6[ /\WV%#W"
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MYPA= '0#[2_D  'Y_/@/%\/&>!QEV@$%DO\ E#.88K*JM#E>#3. HKHIM2R
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M)&K-(9_>M=:1Y%WJ:%P%DW:.G<T0&.B<P"7W ;KH>_: @7[B ?Q?Z0?G_O\
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MAT/P8HF#^'W?(^)9A,<E%953XUL+HK=&/DA1_%RBDRN!7$U(."":04:L3*E
MJX DC^&2!@D!8\HF!K[S!'9F>A\@E^5=3B"3_*JP1%CY5<@H'2J?>^/<S#<?
M*CQ>K^+:#+X[=JOK-@RB#@V4NUTF)QZOU=U3-GL]HT9OJEX6O-"EUX!Z[PI)
M:[+>H/ 1&C;M;[3IQ<KB^5UVK8YNYJ,OI6R2N65WU?4:M"W.IY!$\=*S/T/+
M(/@17;>0KRMSVR6'8<YT&NZ#$?N=)YS&V?19S2@)2@ C[A .A$?N/\Q[$?\
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MB#-G,=0T$822:2DOX''LP"(J%^  04.0/MV/P F[[[ /D?R\NE,@(%$3="
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M8)2F^!#\P$>A$.Q#X 1Z$._L'W_0/T#STQ0-T ]_ @/\)C%^2B!@[$H@(AV
M=E'LI@[*8!*(@(?-TRY4>H[INC7S8JI6M@SWC]8='@XG/:42M4Z]RM!7F?2F
MQG>SY5=,F@^'UXM5J;QO*ZP7O.B;G7^3T4QK?(F._HDLU,L4%5F69WMQ^![7
MR!VKT[=?FZCR3C+?R47JE=I=<UZH2="Y(SN2WV^9KE:C.>ME"B>'W$FN,K=2
MWU[7NMGQJ7SV:.Q5))1,G.).C/ZM4)LP2(!C& ! QQ]QA QP$P]  =B!OD
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MCU\$. !\]!V(]A_,1[^WC,">FOZ=*92D)P%X5%*4I2E O%C"R@!2AT  4M$
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M/]GTNIZG9*71ELFQVPWG3"Z?*-\_:5!Q=&\C!MPE7$ZR1>DT_<)SE H&(<0
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M4)C:,6UK',]C;S8ZZRTB^4B8K6>$M$LBT16"4?V$_P#B_P#[#_\ Q?A["?\
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MAA?J'.F51%5/7:8N@9 B@"950ZB7TCE2_P 8F@=5;L$TSB"W   (B   C]Q
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ME\NH,SFU23IFAL^L8]HV&6^15:N!4*K7SY_JMR91=;]Q8V*D'K>1:D*JR1
M^>"CZMQPY7)\3.05RT^+G;IL7(GB!@>1S.KX'QBV?'IYLMPD]0%MQ[H6C<?\
M(YEZIJV6N9D>06VWB;F]JO5<N\3KEJJ%7)0ZSGT=:_W3>GDL/Q.;,ISU.&,A
M?[59JAS N)'EOI?%^2EVDH>N<=\R]/&Z1-#S^E.[_/5GCK8V.*16QY5LUIMQ
M9G-J5/*IV'2 RRV:-$WMXJ7IAY,ZQ#&N.L[LW(NRYAQRK$;5N/+!:RY95;)B
M[6$XO;;Q%A)BF7S.,@I-W7M<%E&Y33NOVNU6"RS]>OU/H5Y@W\=-14TK87,5
MOB/BM)Q._P#'^J0LO"Y?H;RYO)F%:3[\7$:E=4/PTC'UU^Y,NXAXN,9)MX^O
M1R(G;0[%JU:H$,DB4/ CXD,$S78^6\EEN<[XU8:1Q+O43R-T)P\Q>!D[;26_
M*3DCH^T2%-X^[Q 6ZDWC-K?;DLQ:YIR.@9=?5<MN^//*!!7/*S2]A7<HM/Y&
MUSBYM7)?E93]$MG)7,OW\E^1D!97;2$P^?HFB66N\/< X[-'5?I\%H]QV*6C
M\(0DU=>R^UZ)E=/S^&UV9M#=6=9656@H6::BK<6<^S?99K9LJ?3^>2-Y-%-=
M,IT&M'.L^N<:QNW)O79-7]UY)LJUK%EN&U<HKKJ-XN=:_"V.S3\;%(.UR,W]
ME&8O.>)N-*5'D%4H^/G((W)>QVRWZ5:X.>7978EGMD7"Q:DM6+$*2R\ ,$6N
MPCZO1J**\,SDF'XMU&OC/)$KP(&.9EFRG/E]EP">T?3KC7>.]HYG7^A0%9R'
MCPT<8MH4S6N-7+&]7*WRVW\J<=+R/B<RS'GG!4'(:#DM>J=SE:=;="@KC^_>
MB5FKWUQOM7S+!'FT:'J&S:!JVBZ'#[W1FG(><R?%X>L9=+Z;I_+GT1*30ZDR
MI$AO5AU#"&9(;A?@=-BX_49\9W1ZTOO^[YT^N5<J$9#24N#?TZL%ED])D=/D
M-"VNV['7]1@=9OM]F:Q V>[JZG5.,%'E;,=MD%.RZITZY5>J\.>/K#/[/FM8
MI,I3I*D)V^+6+=Y![95M+<_3DRG2=#F]'TC5MUOLJZJ<_6J>VLLWEZZ^7NY_
M1LJV0L_2+LRR9CJKIO7MCQZHZA3\PON@WC!:I9T4VT)DC2L0-*KU5"//ECA/
M&ZT[JS@/JP*#\FQ8APRCJ'JO%V<Y"Y93%H;CL1C7KE.C0N0.4:6PR^P?X7^#
M8J_O,I<$HZ&TBVU2I66N.(2VJWB#PH;:J97=A?Z/^\&@Z?"<?>0?J*<O[+B>
M9<=*'G.B0^K<6:96.%_(Z1M&@[+RM/5W>:RE>Y>J<A<:KM3@8:Z7//+'47CV
M^/'41)T[1I&;5Z9O&[48NZ);9^]V[7N[U>YPBVPZ:&>KZ?3[+=EJB>2UC+I6
MHYY4:]E.M1+7+,(8U"XY[6*\>G#Q\R&:K3",M,%,V"P= ^].+CM)7FRZ8_3O
MKF^7/CKRAXO6^QFN (KV'+^6NS-MYTD'4<VBT85A8XC00EG-(FH.,B30T189
M*&DFTXS9UTL$#&=CCK'5:2',.G9%R.B=)WCGQBO)[(V+FJ\5KX?"](OO&W"/
M3"I,'J]+4YP9W6--SS=L^DI9%HK0M=C;)1CZF:P6%2CRU#;22^)F56P#6S\<
M\%V6!UB9A YO<W=/A=>LU"S.HX)R<Y:R==YQQ/)G%*17:[L.EZ]E[7)Y;3>0
M\KF+J[-HU24A.+J=AHVT:TQ(QT?09>K9A='M>;4?)Y3]N-ZCG]GP>V5PD?-+
M(219'CEIF>:OGB,@_62<&?LAM&9UI*P)*I_7F(@TJP_$M1D55BI90N'>>Y[I
MC*_15PTZ2KM;NVMZ?G&+S,U65<BRW4-VD[++:KH5.CXVGQ=W>6"RNKWHZ+!"
M[WNXP%)C-)N\+GT)5(:8!@V"#G&<\SVN[(IQX>P.D9J+:-J_I@K:OR-QK"[A
M>*O><]]->=UZLP6<:MBO..299FM)\+5VU[NKUA@ZF4V+4):848(5&?GWM6A7
M)X8C2Y+DOQ>K7#*;GZ!6<$P&G8SH$A+9KQ[L&;6VC::VS;?3G70F^4%/Y#,=
M#N]?RF.BT;E3J!K4*R>V]>8G2S2D$^F8"3&2X3X;/:8&HRK"?DY\_*4.8#^,
MDI-A*UJ6UDG" _I_$0DXB5B'PN*B3"#(.@A0=)NS7YFWLRDL=L+B'<<1F?I]
M4#&M>A-7R_3]/J+.)BJ5"N\S0K/&F7ILU&4&CN,[@62MILG'>;V^LL2U51M'
MN8W/M>ID6/X+W-630)6Q$F@BUR+)L_XT&:8'2->R:KZ)Z=^K\',QQJ]1W!'2
M8R&L]HWG)%.!T ML;U'EH9ORI5D$>0592T:VY/8,"<8SH4;'/-"0LT>HI!/W
M:9UK+&&Y39'.RT9R,W[1D,[OO :2UMK5N--&HNC;5DELE]&V*?=0*FWU*Q5>
M3(SRV>MS:,C<Y2J UET@PA;%.V8IX9%?Y7TR.-SM^2SP1+C1]*4F=#M4KKE2
M=TM#1;3=KWR%H'*N,N=WDYNBSD/>9C+MZRO/KIEC&W04S6*[&5U3.I*O3N6V
M.WTFPJAG/"O,<])CKU6P:#>+=C>R;7O[&_7*8K9+/=]8Y Q6G0FD6B^-J=4:
MA4G9749K-E8P$)6:M58"KQ[.NQ,%&,8>$:QXA%._TKA?K]\C]*H]ET;D38]X
MY)\9?4:J/'K.:[37ELNDER"].NZ<(<UQ%C-R.KTBHUNS0N=\;M*Y)7U[>;I6
MXVE0-"LI9M<\(T+(F2S%+IFN0<FJI>\J96E]G,)$8+7-O;73CY6'=GXSN[9R
MFY@<-:E0I"ZEYX4239SK;?:]L^86%2E\>.5\4V5IQ;2A.S,3-P<RA*\3TU<2
MB(+-D*);]5S6\XOC/&_%\<UNIO,S>:+FD?Q=A-EJ&>W2O_OMF%PHDA=Y>@\@
MMCSR[J6RCV2H3])T"QPJ%/C0DW:RV#7?2YXQP4TI>'S2U6[719T%\SV^VJ41
M_JD#IE'Y#;QRG?;14IIC08R(IMZT/;>1NE6#1*Y4X&%QJ9K#F*RR+RJ"RA@I
M2'80[ZW&Q-EV>.O>6UOEW;;O8%N7W,%IJSK.LNU_/M1J'&KFKPDW1XVI''5G
MSFRK5 ##K5@/%_C+&P451H'3]3KJ;=6IP3MW/6"VL'%$R_)+ZIHG,BQ<@+5K
M2,+M''RE3E]S'$ZRIEO+BT6;16CYOCO'F)+I]V96+']>C=[R;AI++V6PN:S#
MVG+GTI?=#GI. OENC9:L[XI9?F5_R.\UMW;UIK',NY(YI6"RTTU>,W<#R?V'
M&]FTAW-H(QC0'DRG<,;JY8!\W%F1A%NYAF[;R*KINY:693B'F#OCM"\;8B7N
ME4K-2LE9O-$NL0^K4KH=%T*DZQ'[=3+Y O;I5;54GTY6M+B8R>;,+73K)599
MNT-!66NSD ]D(QV'SN#Q)RJUTZB<3QDN0CO5W^$[1Q3=JKYKQ J5^XN:<UXW
M^EOQ2E)^Y1FN<J4JI95YC$LOJ\Q+4; S:^RVOCCRENE;BK@C"6. ?:*Z=_A]
M%SGE!;7(W.Q0U6XG:_MG)3;.126.\=HN\9-#6ODAJ'JJ7O.LSU>+Y&5_EM%Y
M/HU&Y*P/'+DM6W.!;]D^MT!JPCZ;#XO<)/3+2O+SE'"_)LUO#C7)5[8M;V68
MD[M/V;6]1C\[7N%HL%W6RIH,](-*'0*%38F7K%)PK%,RK+NHU2M"E1LKIR$T
M6<L3)U8WMK0>%O'[4F>W,[M5AEB<BKI1K9KJYOV2F_ML)2X3&:P\R>2D@B#2
M#W&=#K&'UFL:CG4@Y>Q-WKD]=X*3,$79%&K8(2K'*\67]=K=8M,ERYGJG+)<
MTN6VJ/* ;/,%T;"ZQZE/)#;Z78L^O$.OR&H^]--6XV7PNBY?9J/DE'UJUKW*
MB.8J3I3F\2%:J;M='6'9'ANVUJDN>0UXU#EDUR'9'.FYWQYRV25I1>/SGC3Q
M]XVLL.J?%RG:D_H7&AW;K-3N-6U9D[?(+A,/LTUIQ&/:OD9[A(49\A?2_P")
MK:3ODK"UN>K"MJ<PTI2V]4D(6OL\$L5?VN9Y+1%FPA&-KB)J5+(<BK+9=D>(
MR"EAAIRQV"1K]@B97.OP=):*_>^&>,732)K:(X;UFNSR["^)IZAE]YG*U8(R
MQWZ@Y?F;Z])0SM69HTQ:HNH8MED8P2M51L%3DD*/7V]MJME8L$F@!%QIV38/
MMF+5WDA \B=ISI/88;@OP%R'0*+E;>=U'%]NQ;D/RVXHW.RHR4 _G\^;*:.'
M+[7< N6@PB8Y?7*LWD=$R[2;S&V;/Y-'@Z!KV&\4.0?)GD564)]CQMA;C*Z-
M*56-X,:W$2%'Q7#^)%1XJV+1,QY DY*0V.(<<\[CN"5CD1=V3!OWNN3A[6Z1
MCD!97VO87-:1+Q6N&U K>+U_"BW71Y.FUS7L]W-HNL;-H*45T6@\EH7EDK('
M1I.:U2NL8BZ:]#'<VNL0=>B:XUK4M)5BD1E,C"11(M'Y3TSL]E&6B1J.]\BX
M^OWZ3D?P%1!? IVF42@V*UZC=K=C<#3[G@5GK-OR^SV76K!)+1^SQ6J6:KG@
MZ,7/;33?W,A/PX,X@XS!3W+2>(CGF32T,7F=JU2[9[QTM^:URMSVK:OJ'J&2
MVPZ_"FUV]Z<9SK3ZD<EJ1L/&O*XG/ZWB TES=TXBYN]CM[?.KLEV-"]-+"MR
M@K=R,RS8-"K%6Y#-8[DEQJ95QSI-*88SJ-XJ/$V<JVD7NN1FK1KC:7M.MO#S
MCK>(O,-),PK4%8H"]5^5BW32TBA!.3JGILU&'M?[9F-?U5]4F&NFU F7QKBI
MLJ=>E*WRQO'.'&D]1G9ZM6[6Y28Q7D9I%CFX"6H&GYFQN]:C:_6M5@+Q%?O$
MUL3KN-6*.,$QZD9F^M;BX/*Y!1B$C(FK];K,0:PK1,4:Y/:W 0# AX.#LUV1
ML=X1A).;M#N&?VR2B&<ZI7F$!%1 1DO/1LBD;^;4JIR"?0-I(QDK8WA9/(:U
M-T5[R'8<XN-O-2D;?9F+>RPFA3( 7B;@W'[5Z6QT^#+I.-9A06U<L^6VBI1D
M^'0(^F=OA=:J&YRW,&%NN@UZT;I*.8[0,TY.6Z@0-5VMWPOE1H6/QSOG\VT7
M/*I6[-PUC;P%6LVK:AGSRYZWH[J+HE:K*L356,RGAX$2[KT]=:K4-S;D<YWR
MOP-QY&XMRDI><(T;)4<,C&NG[Y9+G>JOL>_(9S>3T'4]@RR>L3:L5?;*#E&)
MZ=8:B]M+O:)S8[B^K-FI_MD]-23F-KNN^570,DH5ELLWB<]!P+OC:%Z3AFV*
MW'$[96:?89R;V5.12K$,.!YDVC8+CTIQKJ\E8<\SC0-!@](L]2,]FI9_#P(:
M<R](JJT5G5:M/VG&M#J%/L5+D!G;CQ9@)_=]>JU'K\G(0%#Y*[A:],M;S6*S
M6=FK/'+3Z)%UZHYE#56)XW42AK0\Y].%M=4NV?TI9&5B/3VI4?ME96HG *@<
M4*C54[;AR$W=7\OQ?U3 M!D+71[M5],H4Y1WNXP>"5>C:% 69QIU!8QD7"R4
M927<VS5>NID?/!'H!$?R 1_N\"(;,_3">9+Q:<<?JM>./S68'D#4>0+!N/%2
M>)QV5E:9'5 D/5+GCJ7)8-GUJ#B;C5DM9KDIK7+"Z6N T1"HL$9YSD6=TW)H
MSBI_T@V3R20L]7U'*XJUO8:X5B]_M;BG65*3H]4DM;X8V;-JE8JGG.G91)15
M;Q#%.%6?XIF4?3;9630#E^%XCG#&/B"T"2FC44*H)1+W\ ;OL!#[^WH/]P^7
MD#$$@ 4  0 H&^.NQZ^XC^?SW\^!\^MI]&V5S? JS%9C)9MNFPT>!XP0ZB&A
MY16*E6M$'CQG?!G(6479D4+2::GL@=5KBMJ%DD>.]ET=.H6&3Y&6EJ[N3*5J
M%;L+S:9_Z+<@U@8]:^7C#UIF3PU>E3-'BLRY&IYG0;]H/'%MA6\U+,(BA\PL
M0IK7BQ=I>W\A]"A\E9Y'3[5!73:W=SJNDU.;KL,<D_GAX$7]@]-U&Z9MQPRZ
MXZ529&HXU5Y&'T.H1?'RG1.=;#,63D+QUV6[2HT)>Q2T;4&%PHN4[-A\ZP=N
M[M.358Y*W6QV>V6.Q,)-2XI+LOIH7;0JSQJP)A:LL5PBD97RK8[9.264BSL0
M:]OERR_\)IG&NIU._4R+X_:?7Z5<^67]$6@L9:YP6#.K;$Q\5GMO(X9K0\S7
MA]_OX'S_ +KT>[F[UZL6.QZCG]PAKWLM-T;DM;*QE;;)3:%1J%F/-"B:#5;3
MGKZWZS4[?I',);G+I$!LMGS.%X\4F HQ;)-U"#A[I^PVD_D:)Z2UAK&.%?5Z
M?I'(C9*@AA@)#/X92Z[,[!"YAG>'9G=LZT 'VRTBH6[*]>>,N7>K:QC$W9:;
M2-0G.43JL3L]$J41K<+-/B*!.Q$!,7L>^B^T #^P/;\>8PAT)@^_1C!\_?H#
M" =]=?D'@0ZK^F+.73A5QNX\RR_'#/YVC-M5NVK9B^X_&WCBU$:[R3B-"FM3
M<XODMGT*EQD/#9%H&O7Q#CLRNAKQ1ZIGSH]3D<W?+F@9>H<&^]$>@-;'+7"J
MWRD1MAFI&TSMD=2?'^&?/=#D+I,>H%*7.NZ99XC1JQ=K90=!8\Z&]1T2-"TQ
M=XLU1Q6N(IZ+&V2>"R5R<DJAR!T'M$/=W\E$1Z$?G[&^>N_T\RB*%/W[>_CK
MOL!#[]]??^P? A;I?I7S.4[Q7N3U0>\7'>C4<Z\[0JI6<(VG&:7GMSLM"M66
MW&,S&.J/*JST*CX9,1.H:WJ,UE2V-6NPV7>]&N.L2^FJ6&9;JP\T9$RD[$/D
M?GH?GOVB/8%$1$1'KH ['Y^/+GAX!X>'AX!X>'AX!X>'AX!X>'AX!X>'AX&*
M#Q 7IH\/K_B2-2/#?^"N@;?04640+T]%'\$9?ZB1^VI7 NBI@58R)4CD.;*\
M\]I>_=T'NZZ]W0=]??KO[]=_/7V\]\ \/#P\ \/#P\ \/#P\#'355,NNB= Q
M")%2,FO[O<1;ZGU ,4 ]I1*=(4P]Y>S!TH0>^QZ\R/#P\!$]E2*K!TL! G8;
M'C9@.)0$Y03T:NN!!,_7N)]0R!"'Z$ .G[B&_A,/BV>(QKX=PM-#O^(=?R$2
ME_TO;?H4YP ?R]J93J#^H$$ ^1#Q9_ /#P\/ /#P\/ \[#L [#L0$0#OY$ Z
M 1 /OT B'8_EV'ZAY[XB.G\9N-^W2\?8-HX^XCKL]$QH0T7-Z?E%#OTO&Q .
MEWP14?)6N EGC.-!ZZ<O 8MEDVH.G"[CZ7U5E#F2Y?T]> KI(Z#G@]Q <(*
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M]W7D+/XUF^L6.?DM2R[C?G&:\=M*X7:K"XG8-BM^<[==J3FN'W2Y1-5#[-Y
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MZX\<=5F)'-)W7(UE0=-_:]>TB16F(#Z<@H'UEJ  D, @80$/D"_UA^?L'?\
MWZ\Q#$$1_@(J "40_B_7\NA['K^?R ?;SY$)1M@V;0U/DM$R/B?ES[/-GY&5
M2S4:\\/.""W+VU$SG5^-["A4G4\[CLVS_ ]5M@9]<]-LT_G?"W;:-N-_R'2N
M,5_XY5C<[':9"+EEGL&A8@RB5JM3^-O"?1-2B:9SKHEMR^E\=N.LQ:J/RO=<
M^< XE>G_ %^\TPJ$6>I1TC&WW0SNX^XRE>0NE?I-BM3V8,E4Y.79!]1W1RE
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M/ =UX>-/'@9P>$/;_@<\7"A_YF!96F/_ #B54INOSZ[Z[Z'[@'6&MZ?W!=P
ME6X=\9CE$! 2#B.= 3H>NP]A:\!>A]H?'7Y> [SP\9V'I[\&R@!2<3L%2(4
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M.H=0IA]O0$  ^1+\=CW]S"(!^G^X/O\ =KJ7"_!D2B5-OKX (@(]\F^3)Q^
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M1= KDQD6W'13Z!E5%B_AEB!R+!8'*?TP,H":2B12*I&^J/9P);/RFLY#>W_
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M<8>S&^D3W&'KKLP^WL1Z^.Q$1Z^/*@22*7VE33 ON WM A0+[@/]0#= '7N
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M]0!,XC\?)$S<8O>H7Y#^-,#$^_\ %\#X\,I2E*!"E*4H!T!2@ % !^X
M _V>4"W0$# *"(@<WN, ID$#&^_N,'MZ$W?SV/8^ THW-C("&]HTKEH(] 81
M+P%YXG+T/Z')QK,03?\ F>[W?J >5K<U<A0236-2^6)B*IF4 J7 CG:NJ!2F
M$G1T&_&U9=)01 1!)5--42]'*0Q! PNQ,W;G'W'01.;KKLR1##U^G8E$>O/?
MPZ    @B %_JA],G0?V?P_'^SP&@CS?R'V^\E&Y;"7X[ W 'GT0_\7772?\
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M0QWCAP1LB3ZXG6<*-D4$CJ+?.2#EN9PHS*X1,[211<JM053%PDW<*+I-W"B
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M,4Q@$ABB)3="!1 P]"4Q3%-WT)3 ("'N#XL]=&^GV7W@7W_3 Q??[/=[??[
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M,? O>'F"!U.@_P 8;_=_UAYZ"ARB!A$3@ #_  B/7?\ <7Y_L'\_ S?#SP!
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MG/T ]@"?J@>IJD/?\Q+R]'W%Z$?X1#H1Z'\O*1].W!?N&@<ZP#^?JB^IP/\
MO#EZ ??^7\O$GXD9'S-H^H4^4U:63C\WC<<D:[9*U(:)+V"&?.4:MQ^8XI6*
MMFB%FN]:S>W9.XKFV1>JWV,MUG)I<Q/DF$I*[1LI739,R?\ =[U%<DJE4NN[
MK:I/46/6G:3H)<.K[:_<S[S6I48!6H.:]/T-WMTU0GJ>NDGK\_0;:Z\QJQYB
MWE$F%#P&<N=-XQY\$GS3T_,+:$,FE?.;ZGO/[A%QZFGJ3O3 /0 (%.]Y9.5"
MEZ#^J0Y2 /9O;V(B.6' ;#?:!1N_-D>A[[#U*_4; ?S_ ,[_  J!/U\_83"
MC\]? =-"XQ9-ZATK1ZA+[WJUN?2NP<5^5$7KL;<K5&Q$E4M@LUDP%+AF>"AZ
M?GU%89G-TK)GV]MM:=9_#1CUYH$D1S85;>_@J8:KIMG/#[FY5,XP]-C;K(@X
M=S7#N9UG*=4T#--3B:D?(MO]-"7M\C$*SE<MD4\T2%RK(>9\TI>H:SS%BG]
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M?]8NC@(=_GT(=A\>>(<Y>);CL$=MJO\  DHN85F=C;E^DB43JB!UX-,IE (
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M;W=AW]8ZO70>WVA[@')#BYN   ?\I!S0'^8T;T\.Q^ ^_7 L _G\ 'R(_ET
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M  ^MJFJ;_!74)'T[MS\-T)^,7#0I1#LHDYU[4IW\]=@!O3L2 2B'^< CW\=
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MG#9O=%>C(KG!!<3N=K;D@&V*A.\;+8RQ^A4*I\?%IG*M(B<\UEM*-^++_$M
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M>3RI ^ [Z.KQ9;'Z[[Z'Z8"(  B!1'VA<7TSFD02%;\3\A7_ ,6F*IU.6;]
M@+"415(AUQR5451(;HJ:RJ;914!$3-TN@ SKWKEC'-5WSY1JT9-$57+QXZ5;
MMFK-HW2.NY=NG#A1)%!LV034676.<"I)$,H;HA3"&4FH54H'(/N(;Y*</DIR
MB "4Y#!V!B& 0$I@$0,'R B'@-")I_-4#=K<2LB @??\/RU>+*]?/?L36XZ-
M$Q'[= 9<@#V/9@Z^? UCF.'O$_#ZD>TAS$Z2Y2Q!U50 >@50*IDB"0I&^_\
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M^A$4.OFDZE2ZXD>/SVJ52IKBV"081"9G2BJP.-53*02]=_(&[[$1^WMZ^_\
M:/EUN >TWQ_G]?[/:4>O[Q$?]H_KYZH!5$Q, >X>A]@AWWV(A\A]OS /]@?I
MY4D4"D*'70B "8/_ #N@ >_Y_'SX%SRD2%,8IA[[)W[>AZ#YZ_[/*O#P+!T
M'L2?UA-W\F$ ^1['X !^_P!OMYX1 H=&,'\8&]W91'KX'L/N ?V#\>9'AX!Y
M9%!,1$?XOD1'X,(!\_D !\  ?D'E[P\"T"! $!#W=@("'\0C\@/8? ^7?#P\
M"T*!!$1'W=B(B/\ $(?(CV/P'E(H$Z'KW=]#U_$/W_+]?^ _V>7_  \#$^@I
M^I/^<;_TSP!N(B'O]OM#O^J8>^_R^Y0_X_\ #KS+\/ /#SP0[ 0 >NP$._T_
MG_L\H(0Q>_<H)^^NNPZZZ[_F/???^[P+1T3"81((=&[]P&,/R(CW\=%'X_+K
M[?;X^/FI)(Y#^XWMZ]HA\"(CV(E'\RA^GE_P\ \/*3%,)BB!A*!1'L.NP, ]
M? _/QU\_D/W\J\#DACFZMD:2QDFXN6=>D8Y)7Z8"Z31E9.*7=)F5Z[!NY-!L
MS$3,/1E&B@E ?:;KIT"@! -\B)P 1['^T?C]/OYHTO\ U:.>O_T7&^[_ /#9
MGV?^E_;_ &_EYODO\D3_ %0\"Y_U?;P_[_\ ?^\?#P\    .@#H ^  /L ?I
MYC'0$3")!#HW?N QAZ$3"(CT %'XZ$0$/S_3]<GP\#$^BI_YG_.-_P"F>'T#
MC]_8/_KP_P#IGF7X>!8(D(%,0P] (@(>PPAU\!W^0??K]! ?[?+_ (>'@'EL
MZ1%! 3=CT'0!WT']O]OESP\"S^'3_0W_ #A_(>P_/]?G^WSWZ)/MV?K]/>;]
M>_U_7Y_M\N^'@6?H$[[_ (N_U]YN_P#C_,?[_ $$P$!#W=@(#W[A[^/]O\O+
MWAX%H4$C'!0Z9#G >RF.4IQ((AT/L$P").P .^A#OH/T\N^'AX!X=!^@??O_
M &_K_;X>'@4%(4ONZ#^N83CW^HAT/^[X_L^/*NOO^7?YA]_^_P ]^>^'@6@1
M( @;^(1 >_DPC\_S_O\ ^X>7?#P\ \/#P\#$?L&DFT<,7[=N[9ND5VSELZ;M
MW3=PW<H*-G""[=TDL@LBN@LJBLDJF=-5)0Z2A3)G.0V20A2% I0Z /Y 'V#H
M               #H \J\/ /#P\/ /#P\/ /#P\/ /#P\/ /#P\/ /#P\/ /
M#P\/ /#P\/ /#P\/ /#P\/ Y1]_ZMX7_ -;J?^BS^=7YRC[_ -6\+_ZW4_\
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M=,X![54C@9)9,3I+$.D<Y#!%'8[!I$1Q*YK-:_JNVT;;^)SW1)"YWC^D:I;
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M>>/:G24Q 0 5!'H._8(C\!\B)^Q'^8C_ +_ Q)P###R0$ 1,+)<"@'W$PIB
M '7SWWUU_/S15(Q5*I7%DC =!>&8'*HF;_%K@JW!0'!!+\*IN""58BWR"Q#E
M4 3 ?OS=2YC RD#$^3!'+F)]NA, &$OR/9?D>OO\?K\><=FA8IOFU"1A'$2X
MK[>G5A.$=0Q(E.)<0B,(R;PSA@$$BU@RLUXTC59J6':-(DC=1%*-;(LB($ %
M$2_R1/\ 5#RYY:1$!2((" AUUV @(=@(@(=A\? @(#^@AUY=\ \/,!*,9HR+
MN63(K^.>MFK1P<[ITHB*#,RQT2HM%%CM&IQ,NI]=5J@BJ[ J .SK@U:@CG^
M>'E)C%('N.8I0^ [,(%#L?L'8B ?/Y>>@(& !*(& ?L(" @/]@A\>![X>'AX
M!X>4&43*/1E"%$.^P,<H"'0%$?N(?8#%$?T Q1'[AW2DN@N7W(+)+% 1 3)*
M$4* E.=,P=D$P=E4343$._@Y#E'^(I@ +OAY;^JE[3&^JG[2'^F<WO+[2'[
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MK8*LQ>1=8G5(.,/,UR,D44VTA'0,F9J+V(8OFZ**#QI'KMV[E%)-)9,Y$RE
M(BT^5U]O?)?ART=[GAE>@],Y3\BL[>\<:I(6*O;Q6*OE_&OET=:#V=%UJDU"
M7^0C;CF]1LUP:M<MSUKDUW;P]7@[5>V)PMEE=KQ+U^LW7.MD.PUO/;+8ZEM7
M(I&5LK32)+2HB)CF>JWMS#S4JQG]0N,U3J7'I)N48RBIW*%K%6@HLU>IZ=7@
M&4<QC7G$A(5)Z^DDXB+3D93\-^TI C!H1[(_@FR[)G^.=%2!=W^$9N7+1M^(
M44^@V<+H)>Q)50AM TSG/6#>4:,:'3&32;BS0DTU:5>#;MY>%.19,T1*(HL2
M)R$69-RX3,P=E6:"1=8@I"54X&"&[*=;DJ5Z/LWRKEM[C]*TNY<6(;DG>+!8
M=AV1PRE]('C=7M7L^=5>55Y&SA\7G[-*MI%>*AL1EZ!1J>C-MG=;R,6,>LA*
MO:WODK-5K1\TH]$U#!<PJ%RR#==8>[=M#4+;G#U?)Y/-ZXTI<">!V;)OPSYL
M[T!U<[A//9YXTCZM4'</'Q+MW,25AH[JOZ)<K&&4K@YGGPUY:32FE8']S*Y^
MQE9A%($$992+_9OX$\FD@ (I/S("Z32 $RJ@3X\W*5)IB$)'UE&HUA&N1#MF
M_BJ^E 12<)&/XY\63CWL?%$: P9.V,D0D@S<MFZ2S5\0KM Y%R@H 1HZASGT
M"@3.(%@#Y?I4/*6_A5EN^GI!(F1I->O/,?5,OS>N2E!VRU[1FTC,0 PFAJZ-
M1H:I<?\ 7IVZP<8Q0GGF=$LD8\0<'A&GZM:=UY?5B^WFG!2,WY20F79/6'5&
M-7[*XJTOPKXN[<C#0]D"Y@2Q.V=NOFG34H\>UJ7DWB3:89M#PT+7F[2-<S,9
MAFEAM3.]3^>4:<N\= /:I'W*8J4!)VIA5Y)R#R1K;.PO8]>7:P#]V4KI[#H/
M"1SIR4%UVRBH ;S8KT>E.;2RO#FH5=Q=8UF:.CK@O7XE6TQ\>=)VB=BRL"C0
MTLU9F1?OT3-4'::!DGKM,2"1RL!P8JQY'N<YR/E9=&[VNWFR9KNKJNM73[0;
M.ZSM@G<V^3MXF[6E^\?:'*XYAV?_ -(+>PZJM!EG(//Z35;W>8J&(D16#;Z2
M=Y-;Q'W=?C[$RF!N];:\B:1BZNJ.(J^.,Q:1^A\>=)Y!MBRF7,+RYM45L%4A
MJ<Q%_D<AL(QECI=FSB_-KY4$=)9U^IO?JF)8S1!DS4?(\QIIIN+_ &),FJE!
MJM=&7A?IIH_LB3&(B68OXOZ**27X!W]5I]-),GTO:0H!7!8OCM7AZU7JSD^:
M5V IEH<WBGP<%1*M$0]4NKU"7:O+?6HR/BF[*"M#MM8)YNYL$6@UEET)N715
M=G3DGA5@YGCII\IL&2UV\3C:%;3J[RV5FP_NR\<O:RO9L]NUFSJR/*XH] 7Z
M,)(S53>RD8T?N'KY@R?H1[Q^_<-%'KCGK5:):/Y5Y!3P<+A7;;A?(*55(E-2
MK)!I/5&\<;D43NZ^95S V1T_CK6JC!R2K./E:<FULB#%U*H79^C$KO7:S6ZA
M$-J_4J_"5>!9'=J,X2NQ3"$B&BC]\YDWYVT;&MVS- [V2>O)!V9)$AG+YVY=
MK"===50Z6VOCMQ^N5ZC]0N.$8Q:](BGL'(16BV;,*//7J-D*THDYKCUA;)6#
M=S[)W7W+9NXA'3:027BEVZ*C Z!TR&*#<H?DGK*G*&$SJ:A,PCL4OE\TS,<[
ML\=/K664MUHRJGV2SV8E;M50L=P9&M<1)U.UU?0LKU+,\(#/)&D6Y.OZ?J\F
MUC(.0=GI<E.PN=WN8K#N*866,J%DD8*0G$E5HAE+,XAXZ8NY-) HG49H.$B*
M+D[(!TRB7W (@ XE6QO'ZE;)R^U/)\SJ][L;B>>6*[5NB5:$MM@=VUY%2%J=
MS=CC(IK,2CFROZ_ OK L^>+J3+R%B7,B=RM',SH*<9(@AT!2E']0(7Y#\P$!
M#Y 0^!#P&$,>15F5I6'@WO&(RMPU>3RVD2EL;SBTE4ZE+W/'= U-&:E6D.[0
M.I)6LE4AF5/A9)]7(N?=V>$1CI1=1ZQ9O'*XAH*^FT-O:'+BK/W#::L<$XF*
M-+.IRDSSFOS+Z)<2=6EWI0<NXHZC<6ZHJBJ+24;2,<55P1D5ROND:!2D6<W3
MR5"K)5*3C&QI.II5R#)6I%:1?S*[M=_!D8!%.UG"R2*RYUV:@KJ$*=;WF 1'
MO6C5)!%!%!))JT;H(MVS1NFFDV1;H)_220203*5))%(A2E22(0I$R=$(4H
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M(2O7J5S'.]C80K9[-Q4='V J^<ZM0;$$E7'4M%$2L#=H=\5\@Z;(J2HJ8I1
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MI1MO@-6S:&(K2XV4E)DV9RL=JQ'T;&98DR?OV'8AV'8  B'?R #V "(??H1
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M/)5]F;#2H:=E2Z(6G7:V6F8+FW[OM6M7CXR><RI7%=CV/99:LUA.7_+&P/\
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MTQ_>3VE]X&-[@]I13$2J 8>^@]A@$#]B'M$! W0@/E13%. &*8IBB " E$#
M("'8" AV @(" A^H#WX$+%*NO,>Q.M67H<MRFGIN;S!M9G['7L00P<,?>6C1
M\Q?M:-7HS1ZQ:,LV+DI5</E]4CX"S\=M-'C*UO&<L8S8\^7L=Z@;D_[H)S9Y
M'/Z%#U/8.8"%+NW,+*Z"PF%>,FE5S6ZSDZE .%[K%MFMCQ2V:4PR6:LL0K*2
M_('0J5G4K6)F?D8.O[=&1HTT8R4>MV^O6T]@3@7WXU2K3[FK3Y!:O&IHZP,V
M,=)NHXX/6S?\09%E+1[C\2T_$,E"N2@BY.H14J?1?60%3Z/UDA5'L/I?4)]0
M1 ON$/9W[O@@^X0Z^"CV/Q\^!$H]?:G+YEQ:O]]G^5S%'*N47*NC6^;IV3WY
MUK<YC;1GRTPS%;_?<E@<@G[[8W$[#M,;M3>T1N<Q]?=2ECC-829M:\O'2#'>
M;SLO))/>(-MF]'W2/@HO1.($366,74+K8*'?LHTS8\\B^3F@W-K&<?'%2ICB
MBY=;;K%! W;D*QTRNS>9OKJQRBJU]6&G=-D[G;%!UB'E[!8)>,A8.OQ<C.3T
MO*R+&,C(6%B6:S^4EY5^_<-FD?&1S-NLZ?/G2R39HW347<*)HIJ*%N1TG'3\
M3'34&_82L/+-&TK%2L:\;OXV4BW[<KIA)1[]FHNU>L9!FNB\9NFZJB+ALLFJ
MF<Q3@(@PC'%;#2N6_+2"O$YR/51O>RMM*RJ*7S'0++@\AFCWB=Q9ISQ1KJ<+
ME3Z@UB3@M-R_38^'SI;4(6TC)N9B<<5>2->(N2E>?Q)O8+Q4.4F21<INU37L
M.CS>AXC?[/CU^X\6=]6;;G&2W(\O*6A/(LI:OITFV3=\A;'&6-L&EN81HZ96
M1%\V:)/3R.D50)]/W&_C-\E %$^CB!0.(E+[P]WM*H!^P#L ,!A^#=CD%5;N
M"@4JR9O=\@4BI1-V'R(=%,/R'^<'SU_O\"*:T->1TM4F]_<OM@I,3H>OUDVM
M4"/8;#>+90L2JN9ZS3X1OGE<R_3(_5XEY?-OA,SO5H=T=_6+='U>QRC&SR$G
M!1DL9D_+!%K>KDM75N4[/V::,W=A^W+70)G+K0XBRR+LL0C/4RPSM@GF$LQC
MOH,W+N:?%E)8$4I.03.\=+K*]Y.SL#5"6.Q6>68P5=@JZRE)F;EW:+*,B8YH
MM/+.Y"0>NCIMVK1JB4YUEUCE(1,!$P@4#"&75K;6[C"M9^HS,;9X%X!OP4Y
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M5ID_],7]#-SI3NB2-DI3>I.>/EXT*.WK\=3N),U+TFN6+66M-SJKW&X<O&M
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MYX4 *'0?J(_8 [$PB81$   [$1$1'KY$1$>Q$1\]\ \/#P\ \/#P\ \/#P\
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MJ>BH_LVOVN0S)#CQJ[:[-$XM1[$L]"SF?24AF5O!G(8N?P5^J6][M;(/$;E
MU#3JI5G4<66MN:M:V_U>@R^N)V&V33:%TJVS,0&LP4SF+"(FXRH/Y,L37&J-
MUB*^O"-(\SR 11!4RX))@L<A4SK 0H*G(41$I#* 'O,0HB(E*(B "(B >7/
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MU24FW)TP5*W20X*%L5-I%(M6JSZ["I\8=KP!Q+U.&-4[(ZLFU7/%[](:C!S
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M/#P\ \/#P\ \/#P\ \/#P\ \LK$]Q0,!1$P" !T(_;L._CL '^[_ '!Y>\/
MX^.L,:M<)^K)F7_:L37*G9'WO0,1H6/M,C;H>)*@Y]PE7<"YI4R9VB $%LF+
M,YO>#DHE[#Q(H8A/Z=]'_@+_ /,DQ/\ S0_*Y<@!#\OR$QA#]!,/ZCXKO@'A
MX>'@'AX>'@'AX>'@'AX>8[ETBU*0ZYRIE460;D,<Z:116<K)MVZ0'5.F05%E
MU4T44P,*BRIR))$.H8I1"^)BEZ]P@7L0*'8] )A$  H"/Q[A$0  ^XC]@'SW
MRP=LBHNBY,FF*[<BR:2PI$,LFFN*1EDTU3%%1,BID$15(0P%4%),3@(ID$+_
M (!X>'AX!YA1S9PT8M6SM^ZDW**)$UI!Z#$KMVH4/XEEPC(^*8 H?[F!I',T
M?]! @?'F;X> >'AX> >'AX> >'AX> >'AX> >'AX> >'AX> >'AX> >'AX>
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MFMGN>2;50(:1I+F2Y V +\=I8J&PNTIG45",W\Z\EZU2)R04C4Q>P\7,I2\
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M;$$B,!3*[,6>:"(BW\W*#%P;!>1??L^(C$',A(N_PS=3Z+5J@HJJ?HH  =F
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M@'12B/\ +RH! 0 0[Z$ $.P$H]"'?R4P 8!_4! ! ?@0 ? ]\/#P\ \/#P\
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MY-(M\#]$Q$HJ09<ZVX&T&1O%'ONGZ9IFZ2=-U"W;,\BM:@, DJO<]+L6,0&
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M!NY+;+Z>DJUU/'(ME-14BWOBMSF)B0LA)RJ@DA!&?@F42D*4>NP#H>OM_P
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MO:4>NQZ[]QOGKOH1^ ^_Z>!CB3L1,(K")B%0, +.!3Z/V0 ^D!_I$$1.(?5
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M1Z64* B F#H@E. IB("(=D O8@4P]B4!"!"Q;SZMS%%Y$3&:3]7L]WVR2JM
MC:!7<-T-X@^C,6]02_!6H>7U.8P"F!DII3%^(,L]6FY6QV=Q%:->JC7^2$E<
M[6#3CNZ&SSG.ZC<6I%I4X71;WO$OR]Y4(.I$CO.F,G6,2F]EY&7O G-9F)VM
M;-"H4!W4/Z!<TJ+Q?--2F8*NVR,CM'CL>C8F_:EB82HI_3*)BG%4@@/?1W2Z
MG8F]O?7N4'H ]A>@#X*(F]H )S^[TB31,!*0P@'L(0!^LJ)BD3("9"D,*@F(
M!2]]>P2_Q'4/_744,:$:)Y8>H=FG%;U%^07)+'?W"F,#X:R/(K&W5GB*"A36
M^P5S%-7T^]9,RS6D7V<N<K2\X7ALN:N[9/;79 TQY-69JSF<IL,39,THO4MM
M.]0HE\L3F01U9+CK#V#-:W'Z .'4XNT/<UMERY+C>]B#'8JFV2=F]'J,M1>/
M^;0E&AJZS;M,9TB1Y VG,GMO?ESFE!, VB(..5D7,7&1[!U,O@DIAQ'-TF"\
MM(@V0:A(RRS0B2LD\_"M&K07+TRRQFR"+<5/HIE(%,=%QD.S:1T1',HJ.8,6
M<8QCXYLDR8LHZ/(HFQ9,V;<J;9JU:)JG301023333$"%*!2D L)L]L?K"3N?
M4R4>\4*17M!KM4H%S=LH.:%:'N^GW;B)HF@S4!'1\9S+H9X2$P[DM Q^%VJ@
M:RO9:?JZVA46QUB:CF%<?6YAS)ME]5.AV2QU[-LJFM+AIIUM5XQFS[G5[S^V
MMIEE[YO;]I4+77Z[5FM+XY5ZEYI%<<S9E";+K_$YG>YFT6]O#)S,PI+T++PG
M@5;-US)'6016,@JFLB95(B@I+)")DE4Q.4WL43,/O(<O1B' IRB!BE$*TV;,
M[Q)XHT;G?((.D$'IDR&<I-W:K!1T@FJ)/>1)PI&QRBQ"F]JAV#0YP$R"0EAZ
MJ#?FG9I.%+"WSD>G'6;U'E3(:;H.=1-*>PO%B*]/%R@E+VW%IN(AXQOG$YOE
M?1KR4-%Q%!4/LMECM/>UR*>IS=+>\AQVY&>K'IRF0-=OP*FXC.WT<G#:8V%H
M>B6UC@R4W3T;+..(Y_9$L^I,HG:18343*A5M>Y*O\:LDA 0M[B8.2268OPFU
M!A%)OW<F5JT3DWK9BR>OR)$(]=,XQ1\M'-'#DH LLV8JRDDJT0.<R3=5^\.D
M4IW"PGJ^.QZ^0]QNOGOX]P]?(_?X\AFRW<O5$U"U8W7;CEN<8L:^LKJEH5R:
MXGR$M$?ASYI3<<MIJ7.1=VU3/:5<)AE9Y#0J)"Z_#2%JI-J=))/:3$IQ%1GX
M_2'%J\D-[L_#BIWBKTI_&\JV3SBE2=ZIS'#=(G8S)=!U5EA%IW/\#G,A88NW
M2]9H- UB2E6UAK$SK:5"71+(S,%J+NBV^E/@D424 O\  ;HH?Q& PC]_D/CK
MK^?ZC]O+WU4O],O]_D#V9:7ZD=IS'FEK$U4-7K>SSW!BO:#@>>?T>3C&A5OD
MY(<(\(M#VGYI0=0FH^0/*,.2TAH<*2F6Y7\0E)LI.O6FPL'J+_ZW?U?D9ZG-
MIW6CY\\R3.ZCFMAY+6VE7BZR_&GD:]6SSC]4H?D_;Z!H*<V?7:I5++(\F*/D
MV+@Q<P]AE!XM:!L#.A:]5[C?9B)HL&$T7U4O],O]_E(*F[_QA/IE_(PF 0$?
MT^P?EV/^SSY\6/-/U8?V7?%+'@5(BUOZ+8RR5.7:<+N:*[6LW$\#Z8-RE820
MKU7TK0[OIKD[#F=RASZ%AZS4:4[2O_#JYR=LD(6&K6J0M"=;NG++EQ2$N&SS
M,L TJP/M6JN<WC?*A/<5].LKF":V2V8E7[I0U+CE6_6NK\9=4SVM7+1[\^KV
MAH[M3I\E/>5:'T1TXAU9B?"68I@, " ]@/V'P,8I0[,( 'ZCY 1<>4'JE56,
MSVK6FAL M$SKW'EA(VO&.#7**RQEQIEME^$,]I]/1'^F3:H3 TJ)!:5R:A+K
MM.N2<G592/I)(ZJQ=<NU,MKU5PNQ\IN7\/KFW5O+Z>Q<T.HVR@5//91SPWY=
M:\BG47RW'%72]_?:'F%X@J+L32DS>D:SFK?BYGD77M:=RN<.M ?7L]+JVALH
MP)<C=>TWN_J]#[O[.OG[?/V_3SPGM]H>S^KU\??[?[?GR$MIS.]0II4W5^FN
M-[H*G,63'\[BHMAQ6Y%/M&I3&^XOQ/O-SY+VO.(?4K-H%HI5(MNL[=#/>-D%
M5*SI<>IF*E-G==C;Y6K.UD4VIO)WU%"0^7S+O+]MT(%6EB/8ZLYXXZ;DDIHM
MF7Y/^FPC 6-U+W&J(N<0J2.2[5R6BX3-;;'E>1=0HNBS-]N-R=9)=K5"A.I=
M?;^[4T/Q[P8*=?(]^WYZZ#OH?GO\A'[_ *>9<"4H1,4W('L(A'Q@D^1-_ G'
MLP*3Y^?L;KL3&'X['OOXA9D.7/.RU05KCG^0,HJB0QLZ"PZO(<;>2.'R5GSG
M7)G ZM;):FUK7;"$GDUPXZ1NNZE<;-,VXNDM;*VPMXX/3*.A.2"]14FC<R.4
MRO$]GH5TR.7IVH*;W4\;L5NLG$O:*90,XH]CJM3LBNWGPIYL<_N>D956G<X7
M-EIY6QY19CW$7,AHM#Q=A3+W'0(2]F.4G7N,!>^^N_SZZ[_XAYZ @( (?("
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M+S>R7)BZ:4O]RJM!:=:(67T:(6QT=6"6\JX"/1P @="(#[N_D!#X_JA^O?\
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M7"<;-Z[5:[=;,PSWC/8;9:*;D]HT2>0DU)1"IL[;7X5]8&X2?^8BP)@)A*<
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MM4W!/P"P:7J\ NY:G;IJ*"\;?T465-DX0=?5:$*B[D$W3<$Y$3,E!-& YDZ
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M.@,_P2M.S2V0/*&;UR>GHEE4IQ"XX3?Z?,V6^O+MBN;TIB$L=1@N1E5A8]K
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M_+[_ -WGO@'AX>'@'AX>'@6U$RJ!\_ _'1@ !$  >^NQ#[?]_P!0'"#Y /[
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M@F",8P2!5-4$V[,@*)B;V'!-DDG[R^\I3>P_L]Y!,4!,F8IOS\#/,/O,W$P
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MOF*_5X9U)PZ+E1U89>P0PQ$6UD'$4Z7G1BX]Z#H?II_^3)_S2_\ 9X?33_\
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MTXM*5RG.+5QC'8F6GS-FL+*>L<KH^CTOW-5"U>(AJMC52)J<-:*&$E/X</\
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M\@41#O[]&$.^A\L@042F***8I^Y0H"()@'M6/[E $I0_^"G_ (U.P_C,/N,
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MF*;H?@OL*!@Z#[]]^;(A^EC]=&!0Q0 0'[=%$>_L/?W_ %#Y\US?_P ;D_\
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ME7)79FKP$1;*Y)Z13%""F:HU<Q13.G[35^),7V*!T<@E,T$HD-T'N((>TW0
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MX_/QU\_(?W>>*/&XD,'O*'8? B=(  ?R'OW_ !Y8!9(_92*I'-T(@4BA#&Z
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MBQ$4WWO7.80]H(NP[/T'0%4^AT/1>P$1/_O^/+QIJ/0*98[P/IIK W/[B.C
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ML%>O*V7YW!V"+HUJJ4OJ%[M+P->N;B_G?[UP!.<_)QJZS6:/!S;9]R"O>C3
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MWJ?M/@[(]&$/@?I"D0  .B (B/CN5_>  8HF I0-[O:;V_Z/7?R'?Y_K_O\
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M9TBW<$C6*#N1<'A;)7'#IRXE&[R11237:,FS9^:.,U<F;(/@<6I_E4/[3_\
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MI%KZ@D.A(NT$!33<O4(R,1=+%.NE'M"'! CN!!P)O=[1#H2_P@H %^!#OO\
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M?P@7W'^![[]P@;[=="(="(?G_;YY](H_<3C_ &G,/Y"'QV/Q\"(?'Y#Y<\/
M\* % "A]@#K_ -J/\Q^XC^8^'0  @'QWV/QT'R/R(_VB/SW^OR/GOAX&C4K4
M&M.L[0M%QZUDCXN4@F%@68,5IMC!3CN+?S4(QEU6QY)E#RS^!K[^3C&KI%F^
M>U^%=ND55X]%0-T!2@   !T   =@'?Q\?/E7AX'@  ?8 #\_@.OG]?/?#P\
M\/#P\ \/#P\ \/#P\ \/#P\ \/#P\#$0_P I_P"N&_Z1/,OS$0_RG_KAO^D3
MRDXF!4P@(]@?X[$1#^J'Y=A^O_5]OCP,WP\I((F(01^XE*(_VB "/E7@'AX>
M'@65B"8 $I0$WN^1#V@/7M,'W$0^.Q#X[\L@DH(@ E$H=_(]D'H.A_F/Y]?E
MYF>'@4D*!"@4 #X .Q  #L>@#L>OS'KY\J\/#P#S#6 H*?  '90'XZ#L1,?L
M?YB/Z_?S,\I.0IPZ,'Z?(? _ ]A\A^7_ '^_@8/GI"B<W0=] (>X0$OP ]]?
M?^8?/0?;R_\ AP]X]B/LZ^ ]P^[W?'\OMUW^8_/EXI"D "E#X#X[^.Q^X_/0
M!W]Q\#TH>TI2_?V@ =_V!UY[X>'@'AX>'@'AX>'@'AX>'@'AX>'@6'']4O\
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M=F9V=VP_"NB"U:G*Y;@R<B[.T7!XH1X0J3=9 6AQ< JCYU(?M(1^H@,6+1(
M2_"C^)*]!5P*J@O/QY0^B9(6Q2MPC3"4Y#G_ !8@I]-//\ \/#P\ \/#P\ \
M/#P\ \/#P\ \/#P\ \/#P\ \/#P\"U]$@E O0] 83?<>^Q[_ #_3Y^P?]O=9
M2%(   ?;["(!W^?Y@ ?K]_[_ "KP\ \/#P\ \/#P\ \/#P\ \/#P\ \/#P\
M\/#P\ \/#P\ \/#P\ \/#P\ \/#P\ \/#P\ \/#P\#$7_P I_P"N%_Z1_+J'
M^3_]>-_TA\M+_P"4_P#7"_\ 2/Y=0_R?_KQO^D/@7O#P\/ /#P\/ /#P\/ /
M#P\/ /#P\/ /#P\/ /#P\/ /#P\/ /#P\/ /+#G_ "0_VE_X^7_+#C_)#W^I
M?^/@:]+_ "S_ /\ 0TG\_NU('FS2_P F3^1>A_M#X'_?YKB  *+" @)C.4A4
MZZ[*H"8!T?YZ]QBB _     >;7P#P\/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\
M/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\
M/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\/#P#P\/#P&5:?ZA7%#$;'.4_
M8]"F\YLM>>H,I)A/99KBC0X/A24C'<3/1=$D*[8&#]DX;/B/H"6DVK5!54CY
M5JNR?I->=/ZH/ -JU_'R?*G)HF/5<H-F+V5F7$8WD#N&KQZF+-1\T0!?IO'R
M/U2E#WHC&O55"E0*F<S]@        ^P '0!_8 >>C\A]Q#^8==_[P$/]W@1^
M#ZK7IN%461-S6X\ LW/]-9$=%A062/[0, '2%;Z@=E,4P#[>C%,!@$2B C=-
MZJWIMD.5-3F_QJ2.8AE"$6U:KHF.0I@(8Y"JOB"<I3&*4PE 0 1 !\?]_O\
M^_\ +R@R9#_!RE.7[@4Y2F* _;L.RB/?W_/\Q\!BS?U/_3F=-G+U/G%Q:(S9
MMW3MVZ=;9063=JW9HBX<J.5GDX@FA]- IE0*J8AU" (IE/T/G7H^H+P*72^L
MES:XD&3]I3"8>1V/$$I3G(0@G*>XE,F!CJ)E+[RE]PG( =^\O;EQIE2&7)/C
M6:\,TFO^*3EA@HD9,CGZ8)?7)(BR_'%6^F $^L5P"GL ">_V?P^:*0R3,)3\
M4+_/:.Z,]5=+NSN*?65U'#AZJHX=N%E%XI4ZCAPZ4%VLN<QE57)065.<XG$X
M(4;G_P #RG!,W-CB.501 H$-R0QP#B8WP4H%&Y@81,/P ==C^7F27GGP:./1
M.9W% X_'P7D5D!A^>^O@+@/WZ'K]>A_3Q8'&)8TZ2!%?)LS52+[_ &D5H535
M(7ZG?U.B*Q"A ]_?9^B_Q?YW8=^:LW'C!3E,0^*9(<AP$IR&S.C&*<H_!BF*
M,!T8I@$0$!^X"(>!IV?*KC!(LF\C'<C\&?Q[M#\4T?,M@SQTS=M0$Q1<MG2-
MB.@L@!BG**R:AD_<0P>[L!\SB<EN.:I@(GOF*G,8P% I=5H9S"81Z H%+8!,
M(B/P   B(_ !YS,EPUXCS*I5ICB[QUECD+[0_:>&Y8^'KZ!FO]=S4E5 _P#!
MCBVZ*<I?H?XGKV"8IM:XX.\,GJRBLAQ.XU2(*) F"#_!\H=-D3&7=.7*Z*"M
M1$B;A\L[44?JAV+HQ$A4^4P\!3D=YPUQ[OH;/DZ_MZ]WT=%J"GM]W?M]WLF#
M=>[VFZ[Z[Z'K[#YW3"T5J5;-WD98H*1:.RIF:NF$O'O&SDJQ2G1,W7;N%$EB
MJD,4R8IF,"A3%,41 0'QL2OI^\#5S"=;A/Q'6,)!3$RG&[&CF$HCV(>\:6)^
MNP#X WM^ 'KL._-.X]-[T\W0#]?@GP\,(I_1]Q>-6-I*?2$IBB3ZB5-(I[1*
M<P"'N^>_GOX\!XS609/BJ'8NVKTB*RK=4S1R@X*FX0,!%VZADE# 1=$X@15(
MX@=,P@4X%$?,H#?/0E,4>NP 1)V(=@ B %,/P'8=B/0!V'C&'/IA>G*\5,JO
MP8XI"<P]B"6$YRW3]W^D"+>OI)%,(_(F*0!$?D1$?GS&#TN/3B)]04>#W%]J
M=0HE,LRQJD,7( 8AB"8CEG$(.$C@4Q@*HFJ10@F$2&*(]^ ^[ZA>Q^#] (!V
M"9Q 1$!'^$0+_$  'R8.R=B >[W?'@94I0[]JIOGKHJ2@C]A'OKVA\?'7]HA
MY'TY]*'TYW35!H/$;)6B;9(S=):*C9.%?@T,"@G8GDXB48R2S!150SI1@LZ4
M9J/@3D#H&?))."6 ])[T]" L"7&:JMQ<>X5#-;)H+4_9CE4$4SM[>D=$0.4I
MRBB9,2& !()? D.*;W  ]&#L 'HP"40[[^! ?D!#KY_M#SWL.^OGOKO[#U_S
MNO: _P A'OR.]+THN K<1%MA*S7L1$0::SMS4O8E]HC[6^DIE^2_'V^PB'YC
MWOF/IG\.(MLT9Q-"T.':L#K'8(0W)+DW$),OQ B+A-F6-V)J#9!P)C"X;(^Q
MNN)SBJD<3F[!^?AXPP?36XHB0Y!8\A/:<ADQ'_#8YK@<H&Z_C2.'(3WH+%Z_
M@71,FNGV;Z:A?<;NZ/IN\60 X)I<C6X*',H8K/G!S=9%[,Y=.O:4K3D.B!$B
MK/''TT2 5%)(Y6Z29&Z221 ?=X>,A3]/?CTV*P"/L/+&*/%)*HQ:L9S\YW-#
M1Q%UWKA8&J9.1XMR@HI(O0,"B*A12<&1]OT2ID)CR7I_90]3*1GLW.:$$HJ'
M,K&^H-S3<J**G=&=)J&_;VXS1"@@!C-4VZ1$V9VOM3<MG!B)J$!\WAY'ROZ=
MM+%%?\/R=]0!-R9LZ305-SFY%'(DX6;J)-W(IJ715(QVBIR.4DSHJ-CJI$!T
MV=(>] ]:/IY4Y-9%ZGR?Y_-W2:Q'1"!S?WZ09(K /O\ H@SE;4\9/6A#")00
MD6CE)9, *X2.'\/@2!^'C(B\(VA"D!+E9S=(<@  *FY%S3@PB'R!CINXAPW4
M'OH1 Z!B&Z]IRF()BFN!PL< ("/+SFR;K\AVV- !_D/LHY1'^_L/R$/GL'7V
M^T05+A9&SV9]^S(.*1;*/WWX5Z]^@5R]28H?^"QS9V\5%1TZ02Z1;J>WWBH?
MVID.<O2H@($$!^X'.']QA\CNOO V3GXM1F7F5S;%@Y,U9.HISL]/5CCIO9!N
MBXF1+)Y!.+KS-:;'/.5=HX4/!N[#'1C>?8N8L[SW]DGQ/V1NB5!#U%>;*220
M""?U(O@U(+ 4 'VD.ZE.$+UVOU\?XURNLN80[.H?Y[!\GAXQC_!2WL?E+U)>
M:Q$Q^2$&K^GH<2A^GN7]/UPJ/S_IK*#^7NZZ ,MOQ8WA(I@7]2'F2N4 *)"K
MT;T]W!Q4#Z@&^NH3@@T(JW$?PYDT46[1PDHFL8SU8JY$T >YX>,E><8>0JB/
ML8^HER706Z,4YWV3<''Z(]F*8!*@WXG1IP,!.TQ]S@Y1*81]GN #>8#WC)RA
M(S7_ &1ZAFT!(%0="T-+X?Q <,A=&;E*S!T2.X_QJ_X8CH#*.OH*%6514^FD
M9(Z8'.#Z?#QD#7CQRH9J%,3GE<97Z;E1?\/8>.W'9PR>D $A;-Y0E>IM7=KI
M-%4SN45(Y]$NA<+JF.X%,J*20MC/.(YB"UYJ9DFF & Y77#R-=*&'M7HQ3H[
MHR(3H#(AT*1P'Z9Q^/J@"8/?\/&('QGGN110R7-+"W)!8O4FZ<MP@=._P[U5
M,"MWWOCN4D,90&RH@J=K_ 1R!2IG4( &$^]-0O4(;ID2:<I^'ZB:9C@565X(
M["Z>'3,8QDRJGB_4,@F7:11*F4R,>@4R9"^X@J"90P/2\/&4N:-ZBQ@]K/E+
MPK34!03"+G@1N:Q!1Z'VI@"7J2-S KV)>UNQ(( ;I !$.M4>C^I@5S["<I."
MQVPMCC[S\"=^37([,<I40^F'J1JIJMR%]YU!^JDHH($2*"0"*H ^OP\8R->]
M2INT?-?Z7^#LN_.@<L9+$XY;U66R"ZK--,BCR"/RDMZBZ;)^"SH4D; B,BT^
MDR^I&*@=^:Z[:>I&FJF#.R<('"(I#]0SFD[RT5*L!B_!"I: ](=(2B;^(QR'
M P%#VB B( ^'P\9&P-ZCZ+M TFGPDE&!1-^)*Q6W> =KE_S10.X0LB+02CV
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8>'AX!X>'AX!X>'AX!X>'AX!X>'AX'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exh101_02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh101_02.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /> OP# 2(  A$! Q$!_\0
M'@ !  $$ P$!              D#! 4( @8' 0K_Q !S$   !@$# P$$ P@+
M"0L& 1T! @,$!08'  @1"1(A,1,B05$487$5%C(S<H&1L1<8&2-"4J&RP<+P
M-#5$='62L[31)#8Y4V)S=H*#TO$H*3A#>'FXX24G:9.YXDE88V2$H@HF-T=6
M:+5(58B4E:.DJ=;_Q  4 0$                     _\0 %!$!
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M_G__ $&GT@?B0 #D Y[_ $Y'CG\#X:"JK^+/^2.K='\8'Y)OZ-7 B54IBE,
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MTTT#333T]=!Q.0#E$H_$..?'(>GIR \>@:^E "E H>A0  Y]> #CSKC[1/\
MXPG^<7_;K@9<I1  X. ASR4Q1X\^@^?Z=!BUOQC'_&#?ZFZUD6X@(GX'GP3]
M9]8U0Q3'8B4Q3!]),')1 P<@S=<^0$0\:R:*I0*!#"!1* !R)@ #>OD.>/EY
M^W](<5RB<Y2EX$1(;U'CY?[/[>=<BM4RNU7@'7%59!%L8AEUC-P304643%-J
M)Q;IJB=PK[1PFD5=<HIIKJJ)-VQ$0N #G@HB "(<@)>!X$0Y#SZ#Q\OTZJ^T
M3_XPG^<7_;H.>FN'M$_^,)_G%_VZ^]Y..>\O >!'N#@!'T#GG0<M-</:)_\
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M *<IC>]\1+R(@'(@'H/J'Q'R]HO\A_\ F1__ (F@N]-4RJ%[2]QR@;@.X!,
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M B4"\"/(\>[S\?'GT^?IKB5$PF#O\ 'D.T0$>X! 0YY+Z>N@*K (")#&#SR
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M>)H 2QAV[ALDU?"C.+'47>)/6QHTD@V(V([<-7C0*SGJY8P0$R*NS'JNE7*
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M6X.C@KM6JA$RH&3(IY<?LS"V.X BA0%@DNI( H"B/T3VR2B997 ;-@  !N@
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MHU')6TACA'"U"QUBJ!W(8<N^>8&5VZVF@TR2SE'+;0@J4;3LD*9IR;E>-R9
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M0TZP6:XNG+:R9$S,W@]GCU3'4OCG>Y-MMOD]%;9+]C['-&K^(9#;#D@9"_Y
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M\#QR/ AR/ISQJ\T$(8=;)N)@1'I4=; JXB!>T>G9:13 P^G+DN019 7CU/\
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MNSAZ_((E*9056[F/O3AF^0'M$H*,5W(&.)2DY,8-=5==7EXF=Z#/I@]7R0!
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M #3_ .@U5*)5B )BAP!A\<]P<AR'/H'S'X:Y'$A [C!XY /!>?7^W]AU335
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M';SZ#P/U:"T 0  #D/ !\0UR+VF.0H\" F\ASZ^!]?S\:O\ @/D'Z U\-VE
M3" <%\^G(^/E]>@^@    '@    /J#TU255 @=H" F'QQW=H@ @/O<\#\OY0
MU3!P/=R(![/DW @4>[@!'MY][XAZ^/7Y:N> 'U !_-H,> \B(B;N,/D1\>O
M!\/LU]#D! 0$0$.?(?7ZA\M7ATBGX\B7CG\'@.>>/7D!^6J"J0)D$P&,(@(>
MO;QY'ZBAH/A53E'D1$X<"' B >>0\^"C\A#\^JQ%@,/:8 */CM#D3=W//_)#
MTX_EUP(D0X=Q3*<<B'GM#GCX_@^FJ(^XH( /(D-R'=Y\=OQ .WYZ"_U245*G
MP'@3<AR FXX 0$>1'@?EQQ]8:I N8!#O .W@>1*4>0'CQZF'Q]?'^W5R)0,
M\@'D..> YX_. _/06_T@?X@?YX_]S7--8%!$!X >>  #=W/CD1] X /U^-?/
MHY0_A'_27_N:JE(4H%  #W0  $0#GP''KQZC\=!RTTTT#3330----!9K?C1_
M)+_6US;^I_L)^L^N"WXT?R2_UM<V_J?["?K/H+G33304EC% A@,/J'IW 41
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MSC>6,>!9R8Q4TG'^QI;RMUZI"F/TB=\11[>0%#-G2^7*8WC^&??ZGXYY]XI
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MO(R3J(]_;P8"@4HE .WGP/'_ "@]. U\.B7M]P *(>?!>1$.!]W@!#U'@?M
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M)DRF1SN?<;@""!_2D)U/&-QR[6(FV(.:^PMUOK(;(_MR=Q7(A^Y.[_O0!_\
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M+QT?-Z@*B!!53_9[Z9'LB*^.XA5QWWB<Y0,(E*8R"9CAP(ID$W <T-Y&[5,
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M-TUE&#U2+>R4:H[9*',V<GCI!\P,LD<S1ZZ;BFL>^%),?4A1^T- 3(40$I0
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M%$_!@$/=]H(_7Y(GR4?/@>0'Y#R'B.(>EEM.>BH"S_>$4PJKJ$!#J6]21L!
M.LZ5*JC]'W9)_1CB9\L4I4 2]B@1HU2$C>/8)-^8=*K:JF8@HV+>ZCV%$H<=
M4KJ?B8H>>T"&)O"3["AR;DH%'GD>!+R/(;B1F#\/QSB >-\84Y60J=ZR'DRH
M2LQ7VD]*TZ_98L4Y;<D6FH2<\@^D:K*W*P6:?D9I>ONHXC@\J\; 0C50&X46
MN!L/Q<K4I2#QI3*\YHV0;AEBKEK=;95Z/B\I9%A+56;YDD(F%(QB7M\M->O-
MTB9BW2#)W.NFEPM8+/E%+!(G5U*_<O-L2)1$+?OI*43?P>JGU1"_A#\0#>)P
M)OB)N0Y\^ U<(],[;*@F\2)<M\YB2#4C%R*O5,ZGCA3Z,5ZU?B5!1?=^JJT.
M*[1(169G07,B*[4ZIVCMT@L$AHJ&]_\ >S>Z( 7P;W_L]WD./'GR'//GP.J9
MA.I[AB"0!\]W!C  E$!X$.TOK]NH\T^F3MH0.)FMXWXH!W<F$G56ZI*9C^ X
M'DF\=,0$/(<B!OJU<H=,?;44?:EO6_1-0PF,!T^JUU2"F$%#&4$1,&\;N[C&
M.83CW>^<3''@3"&@\UW/E+^ZD=*7VA#]PT/J(%2$" )2+&QIA WO"90@E$R)
M5P(4A55#<&X("95%4Y2.P_Q(;]'/ZA'7YX,\[%<!Q74_Z<F-E;SO0<P%VP#U
M$+8)YCJ5]1J7M,?<,>_M/&%?D:7>)?=2^NM),-8R!?XJP1U/L5?C+?%RA4K:
MVFR0D$2/]>L.W/%<?N/;8-A@W:*Q_P!\%?A"_?OUW^J)CG-UYB7\+2[';<E8
M,PE+[@'\/E[%.-(FYJ(72RM\NUJ>;V*CY!K4;4)"3B($EG"<E$!*4W< A[_Q
M >?P2ASQQSQS\?M^6N!CJF ."&)YY$0Y$>.!\<"0 ]1#]&H=:_@SI\6.;?P3
M?/?4+B31\5>9L+-;^I3UDZ'C.;B,9O%&=_E:7ER];F:WC&_1=7!%S*/Y"EVN
M<;&K35W:T#JUMHYE$L*_Q3T]HBH9-ODWE;JJUZIX?Q<&:+Y+V3>CUWZX5GC$
MJ<FNYM5?9SF;F#^\H1K6'D'TU'45K9)B"CTDI"9CF+)VT77":'E;YJ?YH?\
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M9"3N%/SA,341 0;O&60XV_EO,32PJ*T9/V%ZT=8_/2;D</T$JF$54@+R8HG
M#@ @ $$@B8#" @(CW" %\<<>O(AXUTV@JB:!0+SWK(OYA%<OD#)%&7=?1NX>
MWM$ 9@W[0*(CV=O<(#SJ'!/;OM!C:?"2R^['J^R36_S5L-4&CC=#U2U+^>#J
M3J(9V"RL*5$F1OC?#< XFJ^0<T3M97Q\N2VUA8^0I!&T5I1]T^2P]LS;W5_"
MSN__ *G<18"U>DW.Q*5#>MOHM&*Z/C^^2<R;&&4+OD.,&?Q=C"BWR'KLO&0]
MZN-KK=$L852Y.2/E[-6;A*,PGU]J;VG9V>.[M[N1^7//';\OK]=<S*$*/!C
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M82\E !X$?3N Q>..!]? ^O'C04_F'D!#P(" @(?F'SK[R00#VI3&$H 4!+P
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M;$N6G,FO8JS7U[G'L8YJXR):7CN3,B(D,!A, \ (<=O'KQ\>X?E\M#HB<PF
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M:^O38##W['&$Y;<Q3<?I8ZI>>$*95+:\>U)O9ZS&U.K9<JR4I9%;-"4''[J
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MD0X\FYYXX\"(>/(_TCZZ"([<\H!^L1TG>W@>_;GU2TR\@/H+'9&<3"//@0,
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M]GLKGC;=>*W7L-7#)\=(;=*U7*?:XC,+T48)E/V<RUEJ4%7\;H2UH824X_\
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M/: "  //'//(#Z<<^.-5=-!: @<1 #^"B \B4P"/U>I?S>-70 !0X*  'R
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M7@0'R AW_$-728B*9!$>1$A1$1]1'@/(Z#K%?HU,J<,XKM8J58KE?=K2+AW
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M2Q4IF>7:R&-L_P"X+$T^JZW#7X,I9E0D[-B_*-0L4U$WG(8!;G\%,2C^$83
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M17>M #S^U[XH_#<=CN&W XQL-1R_?767%6^*\:R\7D^1>5+$^1TZ(K=Z#]V
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M01VK;.T?:% 1'E)3V?M$C\\*)&(<  #<!*\Z 1]J  (B*(@ % 1,;DIP[2@
M"(B/H   \B/'&H<^FY>*=4[WU6G=QNE4KC><ZPV7ZO"N;#.15?:R5B<;9-I"
M,?6(Q>4?((R-@7(Q<%2BVJBD@\6:O#(L^6ZY$@F6.L4@@' F$0Y]WM'QSQYY
M,&A5BG'C@Q? CR;M / @'P,/GSJS  '\'@>?3MX$!^0@)>0$!^ ASSSJ@Y=-
M6;9=Z^629LVB"SET\>F!JU:-FZ1EUW+IPX]FBW;HI%,=598Y$DP*;O, E$ #
M+\A\P_2&ONL:40'@Q?' CP(!P("'(" @(<E,4>0,4P 8I@$! # (!>HG$Y1
M0\EX*(\\]P\!R/H''/Y]!5TTTT#3330---- TTTT#3330---- TTTT#3330-
M---!9K?C1_)+_6US;^I_L)^L^N"WXT?R2_UM<V_J?["?K/H+G3330---- TT
MTT#3330----!&KF4P'ZL'3_,'/ [)^IQQSZ^,K=,T/Z-+OL2F[EN+LN=T;9@
MQK(3.=<(Y:@K=([8UIK<ECNH8LJ^*J_8<2T#<2;/,8I7JSD-WC"5<3!$<:*5
M].M94R)59BGVTMCE))?YE\HCU6]@(@ B!-D?4X.80#D"@.6NF67N,/\ !#N.
M!>1X#DP!ZB #Z2YW16J$W>*X-D("@OL2/Y3'N.V-_C+/+(W2O9MN^*<N9C#'
MUKKCJ)6@!2:T;%4;,D?(6".D5QS#C)BRA7YW$BZ*%G,[7,Q7Z:W1M<H9HQQ(
M8\W,87E<-*P^.L%6NCY#I$6K$W6NUR7;WVT[CLH5:8DX2$R!8ADD6^+8)E-S
M01\H@$.W0>14EC[;M6S=>K^QR5:LTXX=69L3%T"NWK&&+;2ZVI4*O5\WP-X.
M1DKGZX23RX2LIG&1LF/IB>?2\9CC[U6<&QB)):V7*SRGJU"WAX@R/=LF4FNC
M9U#XG-DY&XV(\.W=U^(>X=MK>E7^)GB0LE+6*BS;68<?3*="9+K])ELN51I+
M7O#C/(%(@YNPQ_6Z[O1HF1\(93S/C2MY#E82@4-"^Q4D-,;SD'<JU-UIU9JW
M9Z-.0]K;TB^M1B&YYBPTN'R%'9"JS4C:,NL#3IF=KK:2#3VN=+JUTFNTUY#Y
MRD9O(-)A8*K,UHFR;BMNM8F:T;:_LHV^VX));;SN*KEQ;S[JS;-(')-8=2-C
MM\%"0%OLF,7$%(2;M/*[?T6Y=/RXK8(R)M[QM?\ #]>JV9<#8ZP[?)V^X;N^
M6W=9?8SQY7<6P<ACN/MN>/OM7J#>M1"DW4*OD3+-TG,;9"-(Y 2N%ZG[7816
MVXR+N;Q]B*D8QM%R7EY5_EB5"LT2%KL ZC96Z6=I1;5DF68P,9<G->*Q,C1Z
M)<K5'1D])LY:980GW(KR5@L\C#1,K3B-RL).Y8J6,V%#RH1*X83J>:X^?DL?
M6V!)$1ERLZM=85N]UNPP$59<>VI@5(9"7@;>SA9J&(E*,9F(9/XAZBD&/C<=
MYOC]U%MRW])Q*IBVW4#'V-W,6 7(,CLHC'3S*5HCY5!V(?>LL\D[3E%ZR>1J
MC5-)O!Q+5XA*'?.5F2?C%*VNYBI&'66$XFVX7C4<4[?I+ >",OQF/YY',3:-
M?L:<Q<2EFFBSS=M3OOA8TB('(;>AB[4NEP1@\@1ZM/7JD96E]G7>?Z-&9?A,
M*S+6RP5HM)S1]2E9J%-'U:VV9*GR^0G-2K,LJX]O-S#:CUVS611ZP8+5A5"J
M6V*:6%S8ZK886-\[I.\+#F5*=.W/'!<DRJ3'&<UEF!B+EA;,^'9>]T^&9^T<
M2M#89?Q]2GUN:)O%XB/?.*\QE@B'%DJR\F@BUM%>4E0U4)LJSC';<=\>%HVX
M8Q>2N\C[Y#-Y&VW+</D%>@$OFVJJ;<+(WL%^RM>LE7W)BT(PH%;M-<>$-0XY
MTWD9&GFK<"$.UM<Y)?5/OS4KS-:^M*PRM0J21I-M3Y"5DZ\D@$D\^Y7T)]-Q
ML3)+K&AP8&D!7CVQ"20NTVQ3M2HJ'ZQAK*#'+N,Z3DAC7;75VUTJ52MB4';X
M)[ 34<2U5:&LI&#EJ^(E[1Q'$E2QS]1N*K=*2:O&I53B@)A\DW.[CIC K:F_
M<2 Q>X/:GLD5];L\YH5V]88J[6+6A6J,+,94;XTRR5#(]R=SR!<;4AY5V+6X
MM8*YKC:8=>O(-)4/",V[3\VY0O.XS(D'DVN5N>L@[03;>XQ!X];U5H3:7DQ[
MGRK-<UQZ]+F9IT@\S=8K;(6%7'-B@UKQC:0A*')C!NX +-(X^*V=Y%@LR8EG
M8V,V^KT/$&\C/^[=M?Y%G8%\UV]?<S3]Q5=N-0,R0JR,/2)6C&SC$0D9>4[K
M=C9&Q]CZ!J,G5Z #=J_;[%+;PL75N3I]1R1'9$I>0IUEC1"X0$;BO)^4*7B.
MZY1+#I0N/<IYVQ-2[G@>DV-I(ST2V=C9,BQ+,(F6KUO%8E1M%=FY/--=T>)I
M7)B6+XXV1).3>7>6Q@PN$3AW*LOB9YD6MPEJL-LIH9>BJ>]QRRD*<TJ,U$6:
M6E;''U>.O39?%I9Y?*4=,TR-#4:I;$L@8Y@-P["DW>@/ONE2+5B#:-4Y2K(L
MJSA+!5ZOUARY>L<O$K-%9:J3&1M$Y=0Q&UF&V,+9C^N8GP=MU4E<-W]2JV:J
MV/HN/-B672Q<S$9;IVW*8@YW??A#=L-8E[<[RXPB83'6#<88LF&;1R^VR8AA
M76082VXJBLB4>Q)TF*^D/)YPW>2%>E:\VL,WNQ";U=NL^ZR,@QN5E0;8=C;7
M(99G)K$&9*W4L:O*2^;M+#3[O=K!08ZG5K)B;-]#V>*Q3+3K3)=DH%EJ&2JS
M4YC'UQJUFE\78M\>$8''$ADPC'+\A'0^6L&8:G*DI@O+=2RO!6;<'E2A8EH,
MI*8?R13Z3DM*J*S>0HJ77GT:LX:RD%&3Y*B%FL,9]P%@UAA]G.8:(3'-DBJ#
MMDS#(X^N?4 1:8CR-<;53,<-Z#O+W80.XJI6.&N#;!>5EXVV8>J=6;8Q4I">
M)@B+&A9Y61B\A5*-A2U^S]!G-C%^OMSK=O@&F+W5$G*G@Z@VN";W)/'$C@T=
MM5PL#V%4P)/,]M60+W-5!I*O6EOQ[6H7(.VFRXVR!&3=TBK\\G+PW=T*1/)N
MYS%&'J;$9#OC/,C*JR[.2DS2D#MJW(WE6MQT2D=S*2]_AJ+BFQS6,XA@V(J]
M=2>1(^KL$F*"[P[D&B"RQ.D3&Z3!V"EZ+0<B7"6;WO(\3?[W0:?5<=9.R-:+
MY6:W:HXMTDJ57L>4RTS%I^\@ENK;Z[M()D_>T^#EFEFL+:-K2@2P!KHGL[R'
M$[A<5Y+C\7[6)I/&>[K,6XQ?.;V<GJ[GJUUC.5(S)CN5J+^';X3LP-)S'5.S
M8UJ\3+.<SS<3?:O@?']>-#8S86Y$N)]M=W&+;3G;:AN5PC4&=0<VW-6 \LXG
MAFEYFY6#I19/)=$G*<!K)-PM5M\PVA&HS:BSU5A5)9TNW2,DFP[E@%/*K[G<
M,A./:N6Q6!2=C\^1NV&0B6V.,EO)!GFF7Q_&978UMTT:4]=PU@CXRF(J^*Y(
M<))8P0JDBVFEKFFR]HJE[$_E6D7$NYMXC*J,F$8ZEG#:-A)J9FCMF;)5^JBS
MKT-'OY^3DA11.FVAHV-=RSYX*4>Q9.7ZZ#90(IK9L&RRO7;] TVS0?W,N63L
M [B_H>1\Q7?+EKE\C8Y;-XVV[=KQEO,V(\KV:[;?H%Y"PV3,'7>YP%LLE%R6
MN\03Q8THL37JTRSDELDOIL+8PQHABS#$^:M9=S;EB4B+%G>;9QM+MN1(7($1
M'7*D#%;05<-W!&RM,@71E></W;:Y'8VCW.19:WQRMCM]10D;MZS@+?;%94Q=
M9,[WC'MGQ)AQ9U4S8F7G:7N--EC)45?C+NJ65/$5MVQXXDY:WV6+=5Q2)J6"
M9_<&5U*S+J!3F3OHLBLE[U);L\!0N-X;+D[>E:_C^=MS?'K29L-2N\"^99#=
MV):G,L>V.L2U:9VNGWV1NR:5$B:7;H2#L\O?9&%H\7%.[7.PT0^",C)_3+S+
M:D,$QS>ZTV:8T#:EMSV]S!*LPVW8,9X[N&"E[(]?93P4PE-@.X\<8OIF8L,)
M9J0PPDOM]3Q=/8LH)JR5)"/KJM']TOVU3<M8MZ-#STQ;82DZ!2<\0606DFO<
M*_1[NECQ?!UHPI9*P:"A-F-DO\Y.1S:]V*R('L&[%Y!79VR:02[+'U5D&D)5
M))J7<86_UF*MM>+-IQ$PBJLU1LE6M-)L#86[MPP=-9FHW:&KULKLDT>M'+5W
M%3\)&R355$Q'#1(WC6K.1]V\CC/,DGCR8PW:9"D0LWMDKTKDZ%L]0= TD=UN
M47^&<<N"4E\^C9QS$QN1&*<5<7*#M23BHM^VG8>#L+=-T@B'@==V97Y2R[Y)
M57%.W'"EXW*?LR*XRW6XLN\Y>-P%*D;WCV#QI5)!S"RVWW%:E23C21S[)DQ'
M5?,DVT3O,C+%0+,R%AF+BMU>[[)9S(&,+11";--F.+V-OR'L1/=*G2<D3<W5
M,DXVVU;JZGF2Z05VCE-ME'@9"$B*<QM;*E0LA6YIQD$UC=UZ[*U:'!%N&^S#
M=)M]E+O>,<1N5ZB_N>+6<T^RQ$,Y#Z0GB)"!9,Y9X3+DL1,83%KYW7GR-LK\
M1?I&NS%KIJ;VX5AA+UJ-D91I9J;L]NC2IO;O+96KE:KL?8J]472]Q"2I<F6S
M71V=CCZ#1K=K80]E=R&4'@M&^)$6D0O^RTI+P(8U&U!8(47X6VV;&%GQ%6\B
M5&7@*C5JPXSCF&U8QKE*E%7\/#8XM]M6LD&FJP-7:RSJTG)R<G/SDA5(=":B
M8=:3$B$^[55511TOZ@NU/<5N(M<;.8EB,;.AI&/DE\32TS-X?IEJK&82SUDD
M)J9E<@WW9]N:R73XG[GM,<NL>R^WVTXFNT?9F=N6F+/ .5:E;ZYOHON+Q"C1
M&F1D[.\D*V]G75610AJE=9ZVIVB.!Z::K#S'D)7)'(,=9:TE&2KFVU^1J[28
MJ3*(EWUE913.+?KH4[UN8P!C)C4)*_9?Q]56>0XJ2F\=*2UGBT5<C1<.P9RT
MF[QVV*X.YO8,X609SBJ%32EW8PCA&73;GCU4W)@THF=IV1/V?LG9VC,5XN>Y
M!F-\F#;YC3*CBSL(V^TO:NPP7MXQYG.(82Y**_F&*EFG*%EE-[BMM)$B+JG;
MV,W)V5@\!-.-Q6 MG.5L7YGVYVF4QC@1H7"U$RM2LN[B(?(=J4S;N:M%O@*@
MC'Y:M5);XFB822F[U9F-CNE_)D#)4_8Z#:9J=B*+8;;!RLM8+5OHSW&8.D<@
MM<71V3:I(79Y]ST6\9'R 2#(TK,59M>X2L'L+(CBM(7:=H+M+(,%17$PE<YO
M'W=?(F!>T]-2;)YI)[UMO['(\)CUAD:AV+Z55<VV^VV&!R/CM[%8TBL"KL&5
MZ7NZ 6K[ILV,7*C8(.;FF;-S$4ZQ5J1KUS<P4J=LBJ';MU%-O%^PI8*YCF%8
MV&X%L6,K)%0LE84ZJSE2TC*U'NDG&'GU6$HG&+/H: D4FCE6/<M_I?L47 )I
MJBH30?.6TW-F;K,]S-D6DL7\$_GFGW;VITZ3P[DI*Q1E;J45"XWR'8F^?JA'
M87R!DFFSTEDINM1[))UZE-J=<*_;X:[.<HXHI[62W_K^Z[;-;<?V'+%2W 89
MMV+JL6&&=R%4,F4RUT^/4L8,AK;=6>KLS)QYG5E"4ARUIJFN=Q8EYF+9PJ3Y
MX\10-E4]QN#3T>*R0;*%/;4N;FUJQ&33^8;1WTBU,V\B[E:DI&/C-YEE;Z^U
MAIUU9JG(1S2PUEM7[ XGXV-0@Y51H$>>0=BF2[5C; $3%E92MQ?[?IW9GN-L
M&3\AQD_=H7;KE!W3IVT7* N$5B(C').:<2A2GE1Q>D_A:A N39)M-KL4_-R4
M0T&7O&FSO(5?W<I9"0A+*\9*9<B+C4<S4MY@"K-*#@*OU.CPT=MF?KR5*/F>
MLT.-<UF6KZ>%\;1D]B?($#+N\E6"\X_R]89AVQWTL>Z/;34*U4KG:MP>$*W3
MK_5FUXH=MGLLT"'K-WI+IU66:-QJ,[(V%M&62J'<76G)!8X=R\AC*6NMID>F
M4FXTCGW;GQR/CR(>>/GP ^HAP/J'QX$.0 ?&@C5L./=U%OKG4(I=/IIL)VC<
M;7LDJ8+S>ZRK IGIE^-MHQ[@K'%B>,Z(QEKA6G"=OJ1[RVFH]6:E(.)0;"5!
M*:1;Q)M,LH8U=X.QUF.]1N+I#95@:]9 Z:V/ZYMOCLV4;"Z<C9Z'N\L4_NLO
M\7,8 R2_H,.3<'@R^5['UD<3EYK[[)E?Q,\'.:--IR;J=3F#4W-;<#.\H1XY
M\PJ9UA&$L%GS.V)EB@?2L25VHJ/TK9/Y-:A8?I%"A*NM%22-BE;6G$L896/?
M$D%VYV;CV5&H[E=O%\QY.Y;HF?,*7/%=8,9*RY+J>6:#8L?P"Q$6[DR4Y=(:
MPO:U$J V?1SH2R,FV,#>29+& I7!.0BWLFV+</9IBORL1CC+M=Q$Q2RK;L:8
M*8;EQK[[#OM[3L#>4^A6!Q3,^MZRG:UT\.[L7^/34&WW.AXC@,JKT: N%7AK
M++QRG#*>U?<_(0=*CFD1ER=BXO&4WA>BPE"R7CH]DP-:JQE'+AJWG>)O.4<O
M0#R"2N./9;$I:WD^I%R'G7'$+0&$,]Q>_/:+C6&TIN&\]T/.Z^50H"SF088F
MR:7%\I/DD*I,UVT22^-,;9786*ES=1LUG82U7D*KE.ME0<OU8F90EF\Q'2,&
MR.Q(HYZ'FO=I1,#3UFC+E4LB2,!C_#J^?,GWNJL*C,5O&V*8^??PLY:;'$+W
M2/R+))0+*'GK.^8TRB6N1>5^OS P+28FVI(14-3;9A#*$)N</EFNTG(B4I8.
MH!BJQHVEE<L?23>Q[=V6QIIC*]DCJQ+YBJ;.K4X,DQ=BF<@0#" 3MM@EF<'>
MH_'U\>0E=-"^G[2\!L,"Y/RU MMKKRDO['DO/60OVQT0^Q*%"NU:RUG2>RC
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MN,22RYAV*F*78,H!NN2*TS-<XRQY)V]XYQ3F1";O%0M%HON1[G,TAD&3#$B
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M,9KMEG:3M0TZV4:MUT4GBK<.YZ:^ (&#DH@(<B'(" AR41*8/'Q*8!*(>H"
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MJY.;P55#M>.=J%VKN'L*XMMF;F<G-[:7E"=X*R)0,4QU(EX!.C8VF<2.$+G
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MQ)=&^<[1[3*$.RJY6DS4EH?<O3</1S1A8*+4[K7D<@;?\IRM3MB$J\K<W&L
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M+))H(IAVP;H:G7G=(BX/!V:*0CN%W(Y/JJ]_SOG/"&;X"&SC96N2HJQUS/\
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M3C<V'H29EF<?-2$7B8:4U=VN/C;.JD:R,6DFE[XY% K=<7*A4FP(JBX5.K[
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MOFC/",?[H\1/>H'N0P>OG;;A-W9CA[ ):ECRGW!!SGI*4@+!NKE\AXZL]/\
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ML)2E=Q+-XGE(?*+P^3F^782*BJ[DUQN,2CW4[*W6HL7BSIQAN5:S48Q/3X&
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M#DOGCX\<\?K'0:0]24PEZ=F_E0I>X4ME6ZHX<^"]Q<#W[@!$PE+Y$0 >3 '
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M;I)H())I$*4,MIH&FFF@::::!JBO^+_ZQ?YP:K:HK_B_^L7^<&@QYO[I8?\
MV_\ Z,NLDE^*)^2&L:;^Z6'_ -O_ .C+K))?BB?DAH*+@1 Q1 1 0(;R B ^
MH?$-76K98HG.4H<<B0WKR >>/D _(=7.@::::"-7K)G G2=ZCYA\ .RG<@3X
MCY4Q99$RAP'S$P>?0/4?'.I*M1F=9XW9TENH\/SV:;@2_P"?CB>)]7\;_P ?
M34F>@::::!IIIH(@7)2CU](<_P#")T@;(4/ >2J;SZH(\CZ^!2#M#T\FY^'$
MO2OXH_Y(ZB45(8>O Q4X'M+TD)4@CP/'<?>/#& .[C@!$$Q'CGD0#GC@-2V*
M%$Q#%#CD0$ Y]//V /ZM!HCU.EQ;=-+J(.  !!'8YNU6/SSX*EM^R"IX ! 1
MY,0H" #SP(\>?.O8MGA%$]I&UXJJ;=)8NW3"(*$;*"L@"A<858IP37%9P*Z1
M3%$B2HN' J)%(;VZHCWCX_U. ;_N:G4/(\%4&X[']VI%_HX%,N*0;?\ ((+_
M $<BATBJ+>Q!04B&.F43 '<<A0$P>E[(G*KO9?M)>.%HU55WMBP$Z.K#B\^X
MZAU\25!112)^Z0?=/[F'5,<['[I'5?\ T8R8NE/:]Q"!M"0PF(4P\ (ASX]/
M/IZ_5KGJFE^*)^2&JF@::::!IIIH&FFF@H.N0;.! 1 ?8+<"'J ^S-P(<^.0
M'SYU%'TI6+9DXZF MB"G]-ZL>[E\N'<)@,Y6B\5D5.4!$>T%/9%.)0X#O$Q@
M#WAU*ZX_N=?_ )E7^8;44'2D$PK=2XI@]U+JR;OBI"(" B15CBYP?R/X7[\J
MIP;X  %#P&@EETTTT#3330---- TTTT#3330---- TTTT#3330---- TTTT#
M33306:WXT?R2_P!;7-OZG^PGZSZX+?C1_)+_ %M<V_J?["?K/H+G3330----
M TTTT#3330-6JY#F,(E*(AV '(<>O)OK^L/3G7-?O  ,41 I0-W<&$OJ)>/0
M0YX\^/Z1U43$13((CR(D*(B/J(\!Y'01[9-*O^ZI;+C)B0J9=A?4O.X[DP.)
MD/V>NE,4H)G$0]@<'(H"*G:<13*=(2\*B8L@@G,8R AR4#]PB #R AP' #X\
M_H\?#YZC]R@L*75.V7D]D*@.=@O4P1,<ITRBB4N?NE.X]K[,Y@47$3-RH@DW
M*JL'M05$GL$ECDW_ /BV\\_A^0^P-!=Z:::!IIIH&FFF@::::!KB!"@/< <#
MY'GS_"\C^D=<M- U\ I0$1   3<<C\^/3]>ONJ8JE#O]?WOCN\?/Y?/CX_R<
MZ"P>=R1%Q*;WA3.8!   0]H)N0\\@/IZ^/7TU@:/_O=B///+(#=_(_OG(D_?
M?/X/?_% 1 !#YB.NP+*$,"ZB@%]F1NL(@)1-[A ,;N$G CSQYX !$>/ ?#74
MJ$<XU*)/W";VB<@9(3&-R5NO)NUV8%YY$I2,U&X)I^ 2(!4@ O9V@'?M6:_@
MXC\DP_6?7,5.$2AR83G)X$!'GGQY$>>0]?GZ?HU14$1 HB/(B@01$?41][R.
M@O$R=A>WGGR(\\<>H\^G(_KUSUQ,8"]O//O& H<?,?3\WC7+0---- TTTT#3
M330---- TTTT#3330---- U\,4I@X, "'KP/U:^Z:# +IN#NHH4G (D*H]46
M3%$#BN0J >S2!0#D.B4%^Q502]WMDR&;G+V*"(9M+\43\D-8XY#$<QY3!Y K
MT1X\\ *9/C^</TZR*7XHGY(:"IIIIH&FN)C 4HF'G@/(\>NK0RACFY 1*4.0
M  $Q1$.1X$0Y#@>/[>@:"-;K1\_N2G4=X'C_ ,C?/GZ/V/9OD/SAR'Y]2:@/
M(<_6(?H$0_HU%QUIU#$Z2/4;'O.'.S[.!.>XX_C*3)IB'KZ& PE-\!*)@'P(
MZDZ%3O,<2&.!0.H7P8Q0[DSF3/P'(?PRF#D/ ^OGG070JI@(@)R@("(" CZ"
M'@=/:I?QR_IU9<@'J/KR/D?(B/D1Y'U\Z<A\P_2&@O?:I?QR_IT]LE_'+^G5
MIVG[/:<!V\<_A!SQSQZ<<<_5S]7KH4AE.[M H@'@>3<>H?4 _K^&@BB44.'7
M<9H@ ^S-TDI)01Y#@3DWBQ)2AQQSR!3F'GNX\^GQ"6S41Y#&'KME3.!>YOTD
MC&*;R8X_2]XX H F'SV@#-(0  #D1'N$>"\2U'6*7N  $3 /'':/'/CX^/'G
MUY^OSXY#2KJ2N3M>G=OZ6:ID5<([*]U+A,AEVC8#N$<&7PZ:9G$@FJP1[SE
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M,;8X.HMIAXC7Y&89HP;O;94Q143X'\ 1[N!, A[Q!\]H@/H \AY WDI@$HB
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M[?2Z!)$7KL'?F<#(L6-6B:XS>QJR=5CXNMC%1$>&V0B!0$QA "@ B(B(
M<B(B/@  /(B/@ U]U&OF3:?DF\96R)98F!Q!/2.1IO%LM4-R%LD7K#.>U)C2
M(" KKB#PC!-L7V1M-MX>7973+%$2E,EP%?/D',&0XS(->G*.=U$6[ME4VZ/&
MV]/*&<;I@#&EDCI>Q5Z9Q)F65R$YM-NQF,9A6!H-AD:?BR=I Q&+[==I$;#5
M[A<,?6A&PWJC-:RUO$M(1D!!UV'#?L1  Y$0 .0#D1  Y,(%*'GXB80  ]1$
M0 /(Z^Z\3W&5J^W/"M]J&-6U4>VFT1S*OF8W1"-<03^K2\Q',<@,"I3U.R)6
M!GWU 7LS2H'N5!NM&3MRT&I=ZI8:F68B7<8>(]B66J]5(O&&4\9XRR!B!UOE
MC,RN,>3MMQJ^KU?V_2>T%/%<S#$IN.MM&#,3Q4RAGAB[N=JQ50,;0],N\/;[
M'(V"[6V4MU\:3 34:^ ("(@ @(EX[@ 0$0Y#D.0]0Y#R'/J'G4)EVQS>\2TO
M;W4&(UVF[G[=FG=UM_Q55X9G(Y!KM1V>[J,_72<8DCD$Z1(8[K49MBPU"X(R
MU 5^XUV'IAUL%EVCUFVP<5E]*8D)@\>TBKXUH=*Q[2(0:U3J+4JW3:I71=.'
MPP-:J\.SA8*&%X[>R3ET,9&,FS,SIQ(/G#DZ)EW#UVLH=PH'<=--- TTTT#3
M330---- TTTT#33306:WXT?R2_UM<V_J?["?K/K@M^-'\DO];7-OZG^PGZSZ
M"YTTTT#3330---- TTTT#5FX_#'_ )L/UGU>:H+)=X<@( ;@"\B80+QR/R >
M1'GCS\]!'QE4C4W5-V6F<(>T52V$=3 S%8&_M3LG1\^=*E$[I)P9,Z4>H+)5
MXU*[6.@F?Z2++VICO"(K>"6]*PIY%>.U3YW<[Q/V^6+8>O*Q!<I)4U7:DKG"
MC3TR6N-&;B,PVIM^CMD[JV-,E2]D!U7U=Q;*Z-&;B1W*)T2&6V&R.<#=4G9N
M8.0 W3_ZEH!SQR'.XOI.AR/ \>/7U]-;Z@80 !*;W0/P  ;P)P'D2< /D1$!
M[B^HASS\=!$=LXS=G_,".$W3[+F;LBNLNXYML_FYK>=NE5PS5]OS(M;(3'E_
MPY:38EB8RUO+#;"Q#.MUZY367HK,5?LTSFBGGIE&H#NA2^/VV7J;/TSJPRW!
M[@\[CF FT3;W#9T4R;0ZU;[CB7+]EPA7:[=\?RJSS!+LU\N,A?XFSM<GQ>0V
MV2;LRL$V_3G%X+[KUY%.4?%^-<?85H\%C7&-884JA5E%1G6:I$*."PD$R5<F
M6&/AFKQVN$='ING!_H\:S,DQ:F5[&K=$#B4>[/IB+BD?I,L_9138%F3?Z3)/
M&K%#Z1)/F\7'-_:N%DR>WD))VUCV*0CWNWSA!H@"CA9-,P1P/=R=BFJ-M.G9
M#(KK!^+<F8DO+_*N:VM$CF4C5\[UR/QK$4W$1HK(M0FJW1U+I,3^6Y)N-DII
MEI>?Q=!8_K;E&8ND6RF/-F^Y/=.M;8RVVQR\Q[7X#$G3RN-EQ \Q-]#*^L>Y
M[<WE3#.<5K&^EC3-UJS>FXK@:;D=GC-E/HVS#5MDV(Y.MUMJRRE>DI=%'#=$
M2E6712,82@4%%2$$PG432(!0,8!$3*JI)E /)E%4R!R8Y0'F50APY(<AP\#R
M4P&#@?0>0$?7X?/X:"-2O;C;S*[TUL5H97J-EHK[)%FH;;%%:AUSY'IT#5<,
MS%GE+EDRGV2KT6]T>JH99H\O7X'<3 W_ #%AW(9[E3<7,,;5^P6)&_P&W^Y&
M_7S%^$<@7[&=3+=+G6HMF\CH91HZE$6C%69C6=AM3B CY&'E;8VHE;<R]W<T
MF$F(F?N[>O*5* E(Z9FF+Q'VOVJ0B<OM$Q,0 $Y>\O) 'NX$X<\E >P_'/'/
M8;^*/!-9)9,JR2J:J1R@8BJ9RG3.4?0Q3E$2F*/P$!$!^ Z"(BP;P<JU;$2M
MCI67]ON;YY[GS'&.,!"YFJ0I.[LGEFK3F;E]NS"=QIE%AB'&68+ =*3>4/+_
M -U)FK0E5/%/+WADB\4YGI[K[7?;>;3BG;7<XS-F'(6I94Q7D>XO]R)JG5L?
MXJM>=,>6Q.%F]OQZ1F_.T!*45*I(-KF[NL$KD5]DJR1U#M+VES-=1I%U>,9D
ME%^ $"@("!@+W& O;^%V_P ;GR/@/'GD #R(:X"=4W'KQSR E*8.? ^.0'@?
MGQY]/JT$8=YW.YG_ &QVW/ </F/:5A^Q9;VP6;,N0Z/>HRQ9@O5/R;7<F[>:
MM7JE4$XO-N"G-DI&2PRQDNLUN>EZE7I125Q667C6<L1U/1%>[11MT%KNF?6^
M.G^=-I^-IIIG3,%#=[3KA'R[S=%+XTQT-QA:S:8:2-GJ!.69R>SJ+'</6Y!Y
M@!Y7V^$[K%UULXEG<:GDNRR&_2D^WO\ I*8$X*/>*Q0* ' !((F$W: ' 0$O
MGWN0XYUS*X X ":Q5.XO>7L.4XF+P \E,41$Q?>+Y 1#R'S#01$8OWVU*=H7
M48DZKNHV67"T8/OMHG,2WM/)$DKAQK2[EMSP5<<47O,"#3.V5Y^+QK#Y;O4I
MC:\77'TO2*;+#4YU]7*E3IU67]GA6>_S*<QA)U;JC8\*6B7D=W1MNJ^7HRI4
MEYA3#L ?;R;-4%(6Q2/WZ25 R>_LU[+7\"0T\QW2X?2-DC,%(AW]*9SU<=5>
MZ2^Q5BA)S[I_<.?B)H(29>5V9&(E6<F$188[V/W0@I3Z&NM]SYEB+A 'D6\!
M%\V]LE[9 GM"<Y?O4.4QP,!B@7SR("4P<F*( ':)1X$H@//Q\#\=!$5-;Q<C
MS&-Z$%MS!M/VU*V;'.3Y)7)63YP+C0<\+TC(]HQPE^P=+X8W;PKVB2LS2H2#
MRS8(B/RKFVXXL3R]1J>VD+C<J+:99QO[MAGV]MVZ85LC&>:VC[L8MJ$@O/-)
MAO/IR\PI L/NTZ<3#=TY1?OEIW[HFE%OI!5 D1=)KIMU2'13]U6.<&;PY3F!
M0J"XI@0?> Q4!$HD  Y P&'W>W@>?'RUT_'X@6GPI1,<YSL53F[S@8_>Z6.Z
M4$W<(&[0574 H>>T@%*'@ T&CG[<R5BLRX<PY8K%@IK:<@;J-S6$+327$Y'5
MG(==QICG%.7\R8NRG'5FPY++8)<J$#2<:P%\:1E=ED[$&7H/(41]X=49"R>:
MVQ/44R3%86Q;DJTVS;_>)7/F -L>X^F,\;PC^ILL147,V<\$X:OMXRLG+9MR
MT\N6$<6)9V0O]]R;!_L80M8IF,;Q[1^NN\^Z=6F01C(:*?S%C291$?)33=B,
M]-$:,&CU^VA$5TH\)>3!!%R[1C$'+DC,'SE9)BFJN#<$066]IA)AM&7.NP#J
M)FT%(A:3IMKAI:"79/XZ88Q,K&6B'*T<-E#-9&&E@9LU$U&3HI%V2A7#1QP)
M#&"(UUO)R74[%F6&HV3,.;A;\[R[@W%\I=\=V5&9P]BQS8-ON3,D-)R4PU<M
MS$#$XK=Y*G,<1&#:?4)G=!4Z]<<NY$HMP>7T9.9E:4G[VOO!RVAMSPED1RMM
M_JN4+MN:A]OL]!WRY5$U6M[9SF&SX=FY:D/L29SS3#UJ\0[.,+E5SC(<A96D
MHHU5M.%K/+U^=6?Y'I,CKV-AY2.D(B5B(^1BY5BO%2<8]8,W<=)13E-=%>-?
MLG)%&SQBNBY<)+LW"2C=5-PNFHD8JJ@&MTX6$;Q3*!:PT:W@XYNDS81*,9&I
M1L>R;)@@T9L(XB ,6K5HW &S=!)N1-)N4J92\!SH+6BGM"E0KRESFZM9;,I%
M-%9>Q4F$?5NISCI1/O\ NK 0$E:KP^AHU^D*;IO&N+C:#,R+?1RS\L1,KY?5
MBL99NB.['-M&N68,4Q>/X%+!#2C8QEX!I$9#,^R15[< GC[0KE-(DJ%IME=>
MD@T%\>+*O!JUDA(-=\Z;/'3+<-$$VJ*#5HDFV:MD$FZ"":2222*2) 332121
M[$DDDTRD(FFF4J9"E I"E* !K$O("MR,W!V24@85[9J\65;5F?=QD8XFX,DT
MU(E,(0,DZ2._C@E6;,A)-%BLF#YNW*1T55)$I2A'WM#S_DUW'81Q/E!_#VM_
M>\.[E+[4<BK6<+#8U:UMDSUCW$4<\R5)IQ]=C;)9+I3,N8ZMM@DH9I&(UZRL
M+C7'[NUB2.N$SVNDYSR+&;7)6UU.LL\B95C-Q.6,&0E;MN5(B.-8WE:WGW[
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M06:WXT?R2_UM<V_J?["?K/K@M^-'\DO];7-OZG^PGZSZ"YTTTT#3330----
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M1#M*!? =OJ <!P >]\>/S^1U6]/75!4@J"7M$@]H&Y 1_C<<#X WR'Y:"P?
M8&[_ +N>19/!#D>?=%-3MX\CP'KX\<?+6%H_^]N$_P FD_G!K-OP$K5V4?4L
M8X >/3D$5 UA*/\ [VX3_)I/YP:#N&L8]3*95N'X(?2&QQ[0 .3 J8W(_/D0
M !'UUD]8U\<"*MS&YX]NV#QP(\F5, >HAXY'SY]/GZ:#F0ONI'Y'D52E$/''
M@PCSZ<_ /CJ_U3!(@%*4.>"F X>?B'/K]7GT#C530---- TTTT#3330----
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M*/D!\"'(A^K@=     #P    'U!X#7W301"3J!AZ[N.%.QV/T'I&9J3(HFF
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M" -Q#GGCCU#CUYUA*/\ [VX3_)I/YP:#MQS=I3&XY[0YXYXY_/P/ZM89\83
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M0G8<Y@ZI&\)'E80$?:J 5(A2JCP8$BIH@7M2 QI#-1^=-=,3[=<B\& O&_\
MZL?J7GGGJF[R/K#CT^O0;\(%$3B;QP7DH^1YY$ 'P'''\NKO7 A 3#@/4>.X
M>1\B <<\"(\<_(-<] TTTT#3330---- TTTT#335J5XV.Y59E4[G"*2*RI (
MH)2$74622Y4[?9"<QVZH"D!Q4(!0.<A2'3,8+K3330---- TTTT#3330----
M!9*& R@B7R'!0YX$/(<\^H!JHW]3_83]9]6*ZAD_9]O'O*%*/("/NCZ\<"'
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MX%_ 7_(+_7T%H[_N1[XY_P!PN_'S_>3>-=>H@+%J,(5PH194(HP"LF3V9%B
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M1[_B+S_0FUAJF(#5ZX(>0^X4<(B "/  @ "(\<\  ^!Y]-!VLA0,B4H\@ D
M!X]?Y0']6JI0 I0*'H4  .?7@ X\ZI$,!42F'D0 @"/'K_*(?KU5*(&*!@]#
M  ASZ\"'/G0?=--- TTTT#3330---- TTTT#3330---- TTTT#33308 WF38
M@/D/N9(?_K&*UG@  #@   #T  X /S!K B C),A / 1K\!'X (R$4( (_ 1
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MD,FY/D=- TTTT#3330---- TTTT#3330---- TTTT&$* B_1  Y'Z$J/ >O
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M::!IIIH&FFF@::::!IIIH&FFF@PSC\)N ^@N$@'[!, #_(.LBB %46 /0!(
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M5--J)%%!,<J4IF@BZZQS8CS8R]9JB8J;K=STU6RAB\=Q2+]2?:4D<2]P"7N
MIA$.X!#GU 0\:E%U&3U>  =EJ(#R(#O(Z9(" #P(A^Z7[1N>!^ \>@_ =2;:
M!IIIH&FFF@:MW % "FX ![^!-P'/':;P(^O'IJXU\'R @'Q =!8?(0$?'D!
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M5D4@&6, ^G<H(\>!'@WCD?7CSZ:#0;9N8";D>K*(\\#O[QB7P'/D>EKTV_\
M;J00IP,8Q0YY)P ^./7GT_1_LU'CLT<MG>XKJRK-%T7*)>H-CIJ99NJ19('3
M'I?=-]F];"HF8Q <,GB"[5VB(@HW<I*(+%(JF<A9"DP$%%A$! !$O B @ \
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M)C"N4O/NA[P!QYY$AP]?Y=:"=)S_ (+;IJ_^[]V9_P#P=\>Z"0+3330----
MTTTT#3330---- TTTT#3330---- TTTT#3330----!A7/DS8@>3'7*!0^)A
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MR;D XY^KZ_3ZM8H/[O1_Q-3_ %EIK.:!IIIH&FFF@C\WEI@IN)Z3Q1,<H!U
M\A*<IJ'3-RETM>I0J4HF3,4PD,8@%53$>Q5,3I*%,F<Q1D 2\ID'Y@&M MY(
M .XKI.^H?^< R*/@1*(B7I9]2L0Y$H@(AX ! ?!B^Z8!*(@._P 0O84"\\\!
MQSQQ]F@Y::::!JF*8>1)P0XCR)NWD1Y'D0]0]=5-4#' X]A!$#@;SZ@'!3<&
M\AZA]7.@CCV+N3/\\=6E8&P-Q3ZD,"U]D5($>X(_IM].MC]($GTQZ BZ!O\
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MTTT#3330---- TTTT#3330---- TTTT#3330----!UERH4DM% (&'O,J0O:
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M  ;_ +/^C5-8 %4>0 ?=+Z_GU4_P;_L_Z-!B9C^]4C_D=Q_HS:L*E_O8@?\
MH\R_T!-7\Q_>J1_R.X_T9M6%2_WL0/\ T>9?Z F@[+_@W_9_T:^H&Y+VB(<E
M'M*'H/ %*/I\?CR.OG^#?]G_ $:IH@'M0\?P3?T:"\TTTT#3330---- TTTT
M#3330---- TTTT#3330----!@P_N]'_$U/\ 66FLYK!A_=Z/^)J?ZRTUG- T
MTTT#3330: ;R/_2*Z3O_ +?^1_\ YUEU+-;_ .M -Y'_ *172=_]O_(__P Z
MRZEFM_BF P (#R ^@Z#[IIIH&K5,!]J<X\ 4IU"\CR'/<;D./''R#U^.KK5)
M8HF)P <CW%'Q]OK_ &_5H(L.FR<ILP=7< $!$>J;;P W " "GL>V()G*)PY
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MSX$3<#QP'R+\^?\ XOJ/P4C%+W&'@>\H  <"' B <^G//D?&KW7$Q0,  /H
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M@ F @  _'COU64)[0HEYXY$!YXY]/JY#5H40*<AAYX W(\ (_ ?@&KPRA2D
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M JY5 H*K' H!W**]A14./)CF]XPB(B.KG330---- TTTT#337P1 OD1 .1
MY^8^ #01S['%/:[@>K,<>>XO43KJ0<@ #VI=-+IPI>@"/(<)EX'U$.!'@1XU
M(SJ-C86I[7._5K5,8# 3J1L$A-\@2Z<G3O2[?^H"/8/CGDOQ^,DI3E/SVF W
M''/'PYYX_4.@Y::::!IIIH&FFF@::::!IIIH+4_XU7_%S:Y?X-_V?]&N:A2@
M50_'O"F8!'SZ=OI\O@&N'^#?]G_1H,3,?WJD?\CN/]&;5A4O][$#_P!'F7^@
M)J_F/[U2/^1W'^C-JPJ7^]B!_P"CS+_0$T'9?\&_[/\ HU31 /:AX_@F_HU4
M_P &_P"S_HU\0*4>XW'O 80 ?CQV%\?RZ"YTTTT#3330----!UA*V,%;F]HP
M1MG))L:Q%VPTNK4[&G3'+"4E9>')&LKT:,^]%U9V3B'.ZE*FE,C8V$5(1$PO
M&!&23=T;L^FF@::::!IIIH&FFF@::::!IIIH,&']WH_XFI_K+367.<Q5$BAQ
MP83<\A\@#C[/7_QUB _N]'_$U/\ 66FLV)2B("( (EYX$?ASZ_JT'W35)14$
M^W@ ,(F( ASQP0QN#']!Y @<B(>.>/4.>=5=!;./4GV'_635#GX?$?0  1']
M >=7BB8*!P/@0_!-Z]O/'D/(?(/CK@1$2& PF > $..WCUX^/</R^6@B$WQ'
M W4EZ*20>O[-6^-SS\.Q+8-F- P?/N$[Q,0#CCM*<1$! H&ERY$!*(>H#R'@
M1\\#\ \^G(_FU$=O61.[ZFO1603 _P"\9*WXR"QBD[TTR$V37B+#VQNXIDQ%
M280$A@(<@^4S&*<R?=+F3D%" (" @?@0'C^*(_ 1^>@O""(D*(^HE*(_:( (
MZY:::!JW7-P %X'D1 P#XX "F#GGSS_(.KC5 X)JCV@8H' >.>!,(=HB(AQR
M''GU'GS]>@B@Z1JBHXOWGJG.)U%NK%U0"F.H)CF%-MO%R8R;DY,/($1;-D4$
MRE]TB229"\ 7@)8U!$I#& >! /'CGSSZ<?7Z:BBZ23<$\3[P%!$" XZK75*7
M$P@/ F+O9RXW* <FX\@V'R  'NB''/)AE5.J8QN"#V@7D.2B ]W/ @/ AP''
MY_(CH(ANJ@ JY+Z0:8&*!AZN^%E5 [R)B8J6UC>BX IRBH4W;WH<IE. >T4*
M)4@44#M"8/D!'@! 1]>.0YX^?'YPU&COO9H/<[=)9)R[5:)EZDSYV54BKI,3
MN(_IS]1&0;-A%JLB?M?ND$62Q!'Z.NDN*+U)RT,JW/)!R8#]P&-R(@7GQY*)
M@\<<>GCGC]/.@O\ 3330---- U9K?C1_)+_6U>:MERE#M-Q[PF !'X\=AO'\
MF@H:^B<PIBF/G@2@40   "AQZ^]SSX^7Y_E\TT&BG5&<N&O32ZA;U-4J"B6Q
MS=V<KCDQ ;^PV[9*7(L8P"7V94U44S]_> AQP!BB(#KV[:/'M([:GMDB6L8R
MA&45MXPHP90T:D#:/B6S;&U:;HQC! J3<$63!))-HU1!N@"2")" BF =@>!=
M5OC]RXZDI3"/;^T%WDCR(\ 3G;GDGDP\!Y#@1#R(>OKR  .R^W8O&WO H"7_
M /(MBT $0#SVT>" ?K#CGT'0>Y%  * !Z   'Q\ 'CS]FONK1$3=Y2B8PE H
M\!XX\  !Z '/'/QU=Z!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::
M!IIIH,*0 ,_[C>>PA2@ ^0$I^T!*///N]P@IV^@G*4P^0#5V<  YP    -X
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M- TTTT#3330----!04./*J8@' (F, ^>?3C@?A\]?/\ !O\ L_Z-4U@ 51Y
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M(:#Z)>3E/SZ%$../7GX\\_5\M<]--!P55313,JJ<")D#DQC>@!R !]?(B(
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M,)TEB%02[54S]I0.10H@<IB]Q1 P"4Y@'G0=E_P;_L_Z-?$"@/*GGD!$ ]0
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M(H8/=X]X!#XCX'CR'CY:"Z-W 4>T $WP ?3U_-\-6H'Y[B&$1,*X<AY$O;W
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MK&T,H  &#IV]1TPB  !N#[D>EIV\F .1#DIA !$0*(F$  3#S(D0XF.H40
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MFX$1$H> X\<@'V_:/.M"LB\EZH^SCD! 0Z?W4OY >.?_ $BND^/V>FM]?(&
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M/(^]Z /D T&@W2D_X+7II?\ N_MFW_P=L=:W[)^,3_*_JFUH#THC=W2VZ:H
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MY;%*00<.&YU$2GS!" 0. YXY$?(\^N@Y::::!IIIH&FFF@::::#X8I3%$I@
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M]Y[@Y$ 'C@H%$ [AD(U'OTF^[]RZZ:_<("'[G_LW[./@7]KGC/D!^OO[A\?
M0^/.I"- TTTT#3330---- TTTT#3330-4U?Q1_R1U4U35_%'_)'0=5LX@-:L
M/ \\0<B'J(\ #<W !R(\ 'G@-7T)_>F/_P DI?S=6EJ_WM3O_1Y]_JY]7<)_
M>F/_ ,DI?S=!G$OQ1/R0U:* ("<!#CD3&#T\@8QN!\"/R]!X'5VE^*)^2&N!
MTN]0!$?<[>! !$!YY-Q\/3S\]!7TTTT#3330---- TTTT#3330---- TTTT#
M3330-4EBF,3@H<CW%'CD \ /(^H@&JNF@Z^EYE'@_.-BO]=G=9Q+\43\D-8)
M'^^;O_)D5_KL[K.I?BB?DAH*FFG(#Z#S\/S_ "U\-SP/'@>!X'Z^-!:*G,8P
ME]"E$0X P^]R!1\@' #QY_3^<:>JB105,<Q^>1 @^Z(E#R @/H/U!KB8@D-V
M^!YY,' B8P%$W!>0XY^KGR'@?.@B5V?J%-U3>L20/*J).G>17N >0']KG:E2
ME%00'O#WA'W1, &,;XB;4NQ#"8A3"  )@YX#X<^G\GKJ('9PS%/JG=9>0!<B
MR;F0Z><=V%$!417C]KTHY4(JF B9,RB,HV6*42E$2*E$ $!Y&7Q+\63ZB\#]
MH>!_ET%3333062@&*H8?>+WB(@(&XY H 'GM-SXY\<A\=: ]5\YS=+;J3\_#
MI_[R2B("(B8/VN62>1,/R$P%'S\>!]>-2!./4GV'_634?W5<#GI:]2SZNG]O
M*'[!_:[9%#]0CH-NL2LP8XOQHP,JH8K*@4EL"I^TRJQFU8B$ 56]B0B(K' @
M]QDD4D_  1,I> 'T\0 0X$ $!]0$.0'\PZZ1243MJC56RA1*=O7*V@8! P>\
ME"QQ#< 8"F\&*8ODH" @(" " AKNIE"E,4OJ)N>... XXYY\AQZ_7H(J:5[$
MW6SW%*K%%-5/I9[.T4TS)B("W#=]OT(<_/LR\%,*+8Y \ 8IP, JE*"@2KF
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MF9@XE7!WK)$C8BQ'L@,F5*157=."+(QT81NDU%!<SO*"'("'S 0U;E.)E_(
M %!0H<<\CP8 Y'] :N=!222]GS[W=R!0]...WGZQYYY^K5NK'MEG[.24!?Z6
MQ0>-FXD=NTD 1?F:F<@NS27(S=G$S)N**KMNNJU[5/HIT?;N/:W*B@)E_P"4
M(#VAP(\\<<^@>/7X\:H L/M ,?W2@4? "80Y^8@ ?H\?G]-!$ULACT ZB_6K
MG3%="\7W!;,*TH0S.138$:P?3]V_S34&DHNX68.5P<V^0^EQK!%HK')_0W;Y
M$YYA!PM+:H(E(80'@0 1 ? ^GV\AJ*W90U9$WX=9]^FX3-(K[LMK+9VT!)<J
MJ+)ETW=H:S!P=<R8-CING#^122225.NB=HJ9PFDFNV,M*4H83%3$>0 Y3B(
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M_+*B)1 "@4Q'B0$$#")A*<#  %*)I%#"!CF-P/O#X#CD>. ^7/R'4?>SD/\
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M@^&LKK&1_I]GM0'ZA!0.0'ZP^(:R>@:LUOQH_DE_K:O-6:O(JB !R(@0OH/
M"(CZB #QZ@.@N$OQ1/R0U4UP(42D*4>.0#@>/3Q]H!^K7/0---- TU:*F5Y$
M@C[O(&#L PCQW#P B'' ^/K^?KYU2Y.'/'?Y*)1Y*<W@>/3GT'QZZ#(:CYZK
MZAR]+KJ5"(B02[ -Y I\&$.1+MVR28IO='P;@O//@0XY#@>-;\)B/M">3?A<
M" B;^*(^@C_8-:"]6(3_ +EQU*0,!1#]H%O*$! /(%';EDL  1X\"'U?/U'D
M=![YM/(9':]ML1#N*FC@;"S<H ;@H 3&M6]WL 0  X$? !QZ_, UL9KPG;&
M&VZX"4(F@BB.$L3^S;MRB5!$HX_K9B)HIB)P(DF'N)% P]J8%#D1Y$?=M TT
MTT#3330---- TTTT#33306!B=AA)SR  40'C@?//C^37(OX"_P"07^OJHN0
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M9J0I=Q/5B "E /W0#'1A "@ "8_2SZ:ACFX#XF,8QC#ZB81$1$1$=2 @  '
M  !\@\!H&FFF@:C.ZSASDZ2_4>,0QB&'9EN#((E,)1$BF-I]-0HB AR4Z9C$
M.7T,0QBB @(@,F.HS>L[XZ2W4>_]C/<%Z_7C>?#_ ,/KT$F6FFF@B:VYG,?J
M[=4P5%%#B7;;TOV:('.)B)))COD>]B11*/LP%5VZ4/P8"F,H8P%*<3BI*^DJ
M"G(> ,'(B <B' #QSR( 'Q#X_7]01+;<#*!U>^JF4X![,VWWIA>R$ 'GVGW+
MWM&5 3"  ( 4A1*!>1 3<FX VI;N #T  _-H/NFFF@::::!IIIH&K=9(1]Y,
M/>].  H<\CR(F$>.?U\_;JXTT$;&](O9NTZ01.1[/V[6<Q,<! #%']S%W^"'
M'U\&,/( ( )0].0 9)]1D;UA$N\KI ' >.S>AN!$ $?=_P"#%WQF 1#Y (>O
MPY'YCJ3?0---- TTTT#3330---/3UT#37P! 0 0$! ?00'D!^P0U]T#3330-
M--- TTTT#3330-4!:MC.2/#-T!>)(*M4W0I)BY3;+J(JKMR+B7VI$%E6[=15
M(I@34401.<HF3():^F@::::#$1GX3C_&7G^G#67UB(S\)Q_C+S_3AK+Z!KX8
M>TIC>O: CQ]@<Z^Z^&#N*8OIW (<_:'&@MBKF QA$IA*/':'N@)?7D!X'S\.
M/(^FJH+)B ")R@(@ B CY#GX#]FJ I* (@!1,'/@>2!R' ?6'QY^&N  81[0
M*(F][D.2^.T>!\B/'K\AT%R1=,Q>1$"CY\"(<_V_1_3KE[5+^.7].K00, ]H
ME$#>. Y+Y[AX#R \>OS'7+V:G\0?\XG_ 'M!=E,4P<E$! !XY#Y^!_I#7+5$
M@ BGR<1#D0$WCG@PE ./= ?'(>NJV@MCF2*?D"B8_(B/!A\"''J FX\@/'YA
M#C6@W5AY/TL>I.8 \?M =Y!A^H!VXY)#\_DP:WX42-W"8O)NX1$0Y*' ^Z >
MHAS\?Y/M'03JNE.3I8]2LH\B'[G]O''D1 >TW[77(P"0 Y]  .0X\>OG0;4X
M(KLC2L*X?ILVFU1F:OBW'=<EB,7A9!B64@J;!1#Y-D_3*5-^U*Z:*E;O$@!-
MRB4JQ0 #\!ZYJR%/E10"^Z(]R@%+P'O@)0 >0XX[Q_?!'P/<81$>>1U<)$,4
M.3F,(FXY P\]HASX >1]>0^/P_, 5=--- TU3%5,!$!$>0'@?=,/G\Q>-?/;
M)_QA_P P_P#W=!5TU3!9,1  ,/(B ![I@\B/ >1+QZZJ:!IK@90A!X,(@/'/
M':8? \A\ 'Y#KZ!RB43@/NASR/ AZ>O@0Y\?9H.6FL.D[E#23])9BP3B$F\>
M:,?)R2ZT@]=*F??=1%[%FC$4(YNR(G&BR<I2L@K(G=/2K-(TK%$\A?"X/P/N
M%_2/^S055BB8H<?P1[A#QR( 4P<!R)2@(\^!,(%#XB :Q;!9R\CVCURP<12[
MAFV<KQCU1HL[8K+)%469.%HYR\8J+M3B9%4[1TY;G.43(K*)B4XY,RR?:;@>
MX>!X 2'X$>/0>2\<#Z#KAW@9 X   ($'DH ( 7GG@ Y /D/I\=!A)H>(B7+Y
M[ABGPA[IN!X1'GWN.WQXY 1Y#D/'D.:D'[,8^._XL&J0(>3<=@=OLNT1'DP<
M"/ F$>?/(CQK'V5! (B6?^Q3^F-H6113=@0/I"+1<6ZSM$BH<*E26%J@=5,@
M\*&03$2B)0UD8<H!!Q \>\#1N'(>#!PD(\<^!#@0Y^W09A<AC !B^1* ^.!$
M1Y$O@./L_MZA:F 0 0, E'MYX'CT'GY"/R'5V10I4TQ.8>3%YYX,81XXYYX
M1^(>NK90PJ&,/@ X$I?7R ";@1 0Y#D!_MZ:"_TU; N/GDH![HB7CN-R8..
M'@/ #Y\_RAKF18I@* CP<WP IN.?ER(<>GKYXT%;37$QBD#N,/ >G/ CZ_8
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M>4K[U/J&KCI+#]A<3:_5RWI-Z3:(;+UXD*)1UW-@N/4+*PI=?GI^NY"^D/\
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MA*B#84T0=//:J'7'Z00A$A5"381Y,(^>3&,(!Y$>.1$ X#GT ?/'C7SZA[P
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MY]X>SI. 7D>!$>  .1#@  2AH-\_(>H&_P TW^S3@3%,8/)2@'/(F#N\CP
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M]D#M3,'O<"4![A#D> -X$WCGCG^*'(CP4!'06[@Q$E4"^P<*BY5]GW(]HD1
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M!R/ \!\QX\!^<=  "@!0]   #[ #C7W068 (',=7D@&$![ ]\IP .! P% ?
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M1Y[@*'/KYY'CGS\?.N7LT_\ BR?YI?\ 9KGIH+8R) [C=PE+ZB %#@/0/
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M0PD$Q2B)1$HB7DI1$/@&@R)S D)0(0@=P#SX[?P>./0//X0ZX@= 0 3%+W"
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MK]O'&OGE;O*(@ $4\!VE, B0P&(<0, \"4Q0,40XX, " @(!Q7X#Y!^@-?0
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M0@*;-BW;4U-%HU3X 4VZ!"(D$ $I X#6WY2 3G@1'D>?(B/PX^/]OY-#% X
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M19%TK90;2SC:7DI"--'.4F+*#%6&E0F4';J5?A GCTH>4D^X#Y!^@-?0  ]
MX^S01\!D+JFD(4H[.NGZ"HE .XO4KW'$(8P#Z@G^Y2";@ 'P7VAA 1Y[OAJV
M=Y.ZJ;-(AT]E>PR26/P046'4OSXFH42I**'6,$MTL&B((F,F5 A2*KK$562[
MBBA[=PWD0X#D!X#D/0?B'/KQ]NN)2 41'R(B(F\CSP(\^GR#R/I\]!$)/U7J
M1W'<!B7<O(;0-E\==L+XLSYAVN5XG4WS(G 3-<W 63 MEM\G-(-^DO*2"DG'
M/]O5/)4G4?8X0K=A)SY9R,>.';$D3ZF\S_U-*^O-MK'TY,,6Q)BE#*03W!_4
M'C[6VGQ?%DAF$'!<U[6]N+V)7@Q;1A/WUF\;20R:@M7)"L%!7DC/V)F$X<]X
MAV<%[?'CD!$/'\7X\_+TUIGO,M>6:Q7<+N,?3V5:A2Y'-J$=N"N^"L0(YQS#
M3L/DQ#EZ4BI"C8[_ &.,SOY%:=SO&X3H]GDH?#^0Y*$HULM,FFQJ;9!SDFD!
MXS';H^HB\Y%?I82L.!O>(5]O:V\J'$ ?.&8E4+$MI,A5C(()2J12*K)&C7;<
MJBZ,L1U$MK"L[TM\Z\D\1O71PW6Q$2F4"L)&D[H>G1=GCMP K^T,M&67=QC1
M)FR,F+06C@LB[>+*'?$<QK(C1HK)ZV8LC^J+?1O=QN^9LY8^QM!(UM5$AJ!M
MM@,L6BD0VR+&5G;RN/<&3&R;(+N.S;D7<;-R[C*,+9,I7:D4*2;Y'P]0:NNY
M@ZNM%8-;+N_.KPK2"O.1=TL+!JXEGKJCF2L;&&&<,J*9OC,";8[Q4<4VK'^(
M-O"T*_QA8[AE7.T;:649BZAW-:2P?"8\ALW4>T'G$I\-WGN]/<?'H^W6Z2W4
M%.@FFHHN#+(G3'D7)$TO>'Z.SC>HN[<.U3$'][;II)JJ'#L2!41'MP\EOPSO
M',7D@KTE^I&+=BP/)+$:O.G/,/U&Z15S*)-(V+ZB:\C)2)Q('L(F/:.958W8
MFBR6.Y0 =74=X'4);'FZ*[V_R2^0L@Q^\QGA%:DXC=3-9J\_2]U>(L!X:BKI
M8;9>,;TFQS.':P^S5FZ;;3]EPU4,_P""H*BS./[J2<5NSR&[[2][.=Y+;KOV
MMDU2(BJ;G<08OM.3\$8$E:)8&\LP?T[8AM_O5KJTPW9"[')32N[S9S,6.',]
M3;%.,9A&*0KM?L,NK% ^5#(RW56R- RX0DAT@NK^HY,*0"XA,*;7+%$D%9%%
MR!S3M;WDS,+VE26*54"O#&2< JT4 KM!9 EY7^JX]EVC]_/=,KJVX^19(MW*
M!++L_B[$^E45Y6PPYS1['%V7K^_(LS=5MVJY8R3:/D#1;^OSK5HXA+)!OWW7
MG&['=%B6^XPP_D+(&(4KO))[8Y-6CY=Q(V@L[;A6^>=U%VQ;DB)Q"SP?G^U8
MIA9'!.):[%6V4D8%3,48P7L4/;,V*X5QW_\ A/+:^XNZJ&ZAI3\-Y8SMC2K$
MQQ9HK;;>LA5FKX.M$3FV5Q;N"P7EJ>BKSA:G5#<KGQK/U63W!O-OM!J4Q?OO
M&MC>&AMQK"^8QJCRLUBW+!LQ^[ T+VIDE-B?5T]H0XI<#TP-U!R"?O$@@5R2
MK*M#)\@ @L5;Z.)1!0%C$'N#U0G5*VZ-H)M.6/%G4&IR2K=DL^1LO2JZD[<8
M1=^*":3"5>1NUV4AA=).W*4<H,=,/VKA\'8Q=N4U4%5/&FO4(RC7L,=/#)&4
M;/M7JMKW$T*&F-P5%=R$_67;::L-'(0M^Q3'V?(Z&0H+!M$RDI$Q>1;,ACK<
M%9JG7;769B]0F.\<1^0LV4+K&T'JC7;.>X^D[<[K&8SEW$RVRI CDC&:<2WK
M.1YBB9,W',8#*6-Z_$9ZS'/M,.V3%N!HY1U/F-=<<0&6;E)8RFL],,BU>OXW
MR.&QK/JJ[3W0=Q(/>RX*<I#(G9]+?J:K$-R8A#AWM]IK\AS)JJ)MU4^4SH.1
M^CJ![;DA<=<NKELNQRU;R.0B[R*$P<K)-FS^X],KJ859JY<.! J+9NYG-HS%
M%998QB DDF<ZBG( 0@\ZZ!MTZJL)G[-6(L9IT(T! Y/VI!N>//,0O=DF&!,A
M9 VK!A6AQU>94E)S8'*6%]W.([9F._UW[MXIIU_LDA28.\6!IC/*<S6?$,,=
M9*]9D>U>MQ&WC';&UVR)I,O'@^W!2BE=?/L_8.J>5]N%4@'U<PK9+)/2\I9+
MC#T++SY*I@TQ/5'5<SC9$VE.N4=!18;5P76(Z=MD1%S%9VLHBG8'5478RNWO
M<U!SC2T1R+EX\KKVOSN&XV;8S"+%FY?_ '.>,4'9V*)GR:)FG"XUX[K1=*F0
ME4X5;?IMQK,DHS*_!KD"]-L;',V,!A'L4R C641<(@0PNV8J?2V9>#.D$0$.
M=^L4Y&KF8\88[RY3_NN2HY0HE/R+5PFXY]"3'WN7BMQEIA/NK$2":3R+D0C)
M9L5_'.2%<,'8+LW)2.$%DR=[.  01*<XB ")?WPP\C]G/GZO701UI]73I3N5
MRHAU)=BJ1U ,)#J;J<(MD#D$3AW&=.;HBV >4S%'E;\+@.>3E =@\(;OMINY
MM[/Q>V_=+MUW"RE2:,9"U1F$,X8TRT_K3"367:QS^?94.T6!Q#,Y!RW<MV+F
M13;(NEFZZ2!SG24*78DPF,4Q3 8Q3%,4Q3D$Y3%, @(&*8!*8! 1 0$! 0]=
M4!;-OI:D@+1L5^HU29*OBM$RO%&:"RSA%JHZ[!7,V17<+K)("I[%-5990I .
MJ<Q@K>GGGCCR @(AQ\/4./GJ]3$13((CR(D*(B/J(\!Y'5F3@3DY\AW /IR'
MD!X^KU]-7_IZ:!IIIH&FFF@::::#'_(0'@0$! ?D(#R'KR'J&KU,1,0HB/(B
M "(^ ]?LX#5EJ\2_%$_)#05---- TTTT#3330---- TTTT#3330-?!$  1'P
M  (B/U!ZZ^Z^&#N*8OIW (<_:'&@%,!@ 0'D!]!U]UQ(7L*!>>> XYXX^S7+
M0---- TTTT#3330-4U0$4S@ "(B'   <CS\-5--!CU ]LF+<Y#&3,G[,Z?IW
M=O('Y,40,4/ !X,4?EZZ^) 0B:"*9!*1-0G:'(B $ >"AR8QC#P AY$1'5)_
M]U46YUHAHP>O_IC,A6TG(KQ306*L@U))N/IC2+F5@=-8PSQTP:"Q]E(/T&T>
MX=QC=TK)M+X4?WWD  I  H^ * "8I@'C@//ISYX#TT%QIIIH&FFF@::::!II
MIH&FFF@::::!IIIH&FFF@::::!KX8Q2AR80 /3D?KU]U\$ ,'!@ 0^0@ A^@
M=!UY$0^ZCPO(<EBX@1#D.0 SR>[1$/4.>!X^P=9Y+\43\D-8)$ ^ZCP> Y&,
MB $>  1 KR> H"/'(@'(\ (^.1X]1UG4OQ1/R0T%33330---8:&GHZ>"4&."
M1 (>9?P+T9&%F88#2,:9,KL6 S+!A]UHX#*%*WFHKZ;#/C%5!B_<"BL! S.F
MFF@::::!IIIH&FFF@::::!IIIH&N($*43& .!,/)AY'R(<_,?'J/IQKEIH&F
MFF@::::"V42,8QC@)?0. X$1'@!^7S]/'/C6AW4!W-W7:UB>CVNB/\60\[=L
MJHT!:6RL\JRC"(B$,7Y1R7+259J=VSEMCJ.0;&T9XY.J\JTUN(Q,=G22W&YP
M,E<[14H/%.0-^M:;;L=Q,EAB3P90JYAQ#,EES[D:4I43&2ALA)56MN*I4)G(
M););G&,<)9]L\;$(.Z\Q8H3R]"+78.6?1TA.V*";IIN3!H8RZW6'A3GG<AB^
M=/'UU[>B/1K^2<:*3R<-B.8W*U7(TDZHEYD\?W^(EY6S[5,F#@VBS5;87G-=
M5<0L\P@:Q+1F1*M0.[.^L9B>N5&%R#?L+9@I5$EF^5IU:U.YS"\I%QE/QYMD
MQ)NKJLL]<QF2E6Z<SF7'N:*G'XWKYUTTU;6TE:K8IB"LLA1(6[^3J=2/:IC>
MM9)/A#;E7;;7J?N>W:2UB>M+/0482>MN++!8<I9"SG$SE:99%3;266L_VS(-
M-Q1)70].CY;);.Q,).W4UTO%,)#;#.V[#:5B6\0:&2L-'?Y"QYC?'N0JB@OC
MO&RMXJSO<7^R;CVMTBE#:9N'=QMPF,>;<<X3&30B)&/K5+P_A*RR-^LT=7&4
M6FY#SBU]8G!]21LB2^$]SMDLU*R,SQ#=,<8TH])S-DJKY-]EN=G;%47U<PK?
M\BL7SNG8]VH9"R'9'L%.2T<QAY^CPIG7WVO+9 T[T5]U%$AKN3[S7\ Y"M-1
MJF4=JF*L6I,KOAUA;-P#_<[F>*QC'VK'D4MD0U>@JS%UVTUC($,VRG:\?7*6
MC/N\PN%4QPO#G74Z$PS_ +(G^-LWQRFT:-C*GM[SKC'"]:QV\Q#MT=QN6\D6
M_/,O@K;I*87B8B\OZ6QB<@YULTE#8RLV3YC$Z5:<7!U;+>K0H-[8IIIXWE?=
MKL/QO#[A<=96Z?C>OQ36HR.\_=+C*[4;I]PBLC:FEIO\LSOV3<;6S<G$RF3+
M[,Y)Q(#R(SRQ@+IBQY8)2HW97-3. ;3MOK ;-U[JAX(R-0;W<,75C)UGE*:K
MMSA$:I*13>KO9"Z;N\_6K;GMTJTB]^Z,RG47=ULT-5,E3?WS-F4C2L Y8Q5E
MZ:A3Q5P91I<?%;^+B;)6+,;V'!\+%JRV0$L=9EM,3F+($[4<7V^:O<A0Z15V
MTX[V^P+.+M<TT=T&V!5=UJVSJ0R'&Y+JT1MB#<YD$XU4V!P)GG8Y<\5[J)I+
M%CNIXZN%1NVX_<74LLP=;OU5R'5J/'3FVBYOX%>N7?+N%\HT:GX[VOU"HJPV
M&K+:,<0-&<XSA'1&4_-/XD.I8NKG2VS'(X/Q+ [2\*P:F4<,WRR8N;/L.8@D
M:W/UFF3SR$R54&=YQU/6NKVJST:6GSV"]M86S65.C6FQLUK+8H/)<N2+7#<_
M9CO%Q'O=Q&]S)A]R1>M-KW8JD)$K37;*Y.V9MXVST.??/*G-S<?'*Y$Q!;,;
MY3:UB2>HVNIQ-ZC*M=XF%MD++1#';(HF#CD3> 'P)S\!W"41 />\  D#MX'W
M0Y O &, Z8M]U.T6H/+/>&LW)P4Q>8W.-JM2D=A/,C>SV_\ :;WN)VZY46=U
MQ"@K3\U9ZG=G5<QM2X5M$+6_+!5*PSQ.ROL(2'/K93&F2:;EZD0>1*#(R,E5
M[ $DFT--UJS4NPQTC!S$A7;%7[12[K#5VYTRV5>Q1,K6[73[A7X.TU6QQ4I
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M]JM+^97L5PL$A)3-IDYB0D7SAQL2LL9)1JF5%54'"YDCG(41(W*5NNO[980
M0*F8Z)$ $1#E5=, ^.J^@URB]K^#(28M-C@Z6\@K#<J[E>K2T]!W:_PTVQAL
MYY"E,L983J,O&6EK(4&1NN2IAY=I*<HKBN3B%B)'2,=(LEH:'%CU:M;+]OM2
ML&/K) PF1T9G&!YIU2%9+/\ G^P1T3/6NQVVU76[.H.PY+EH";R5D"7O=T+D
M/*,[%R61[Y%V>8@K9:9>$<BP+M>9 O =GNB _$3"'' ^.!'Y\?HUS33!,O\
MRA .X>1'GCGCU'QZ_#C0:JV39GA.Q5V1KP,+?!_2R[@7,?.0N0[>6Q5J?W+Y
MCA]P&2+77).5D)4&$\VR_7X:WT<%D'</0PCV];K$1'U HU\?7,2XEK&%J##8
MZIA9$\/%.K%,/).>E'$U8[-:[K9YF\7RZVB773(>4M5ZO-DL5QM$B5%LB]GY
MR1<MVC1NHDU2]2TT%))/V8>1Y,(!W#SR'("/''@. \^G'^T:NFF@::::!III
MH&FFF@::::!IIIH&FFF@TJE-]F,*[]+1M>*=XE?>QIWZ<H@WV0;K[PP:#&@Z
M.Y70M.,,2WBES#$Z+11RUD("R2[%TW.BHBY.*I2ZZ[(]2#;M$MY-S+5O=Q$-
MXEDM(R#N3Z?.^]LW8LFY$E%W*P'V\$.JFBBJ194$!,=) %'"A2H)*G)OL!2@
M(B!0 1'N$0  $3=H%Y'YCV@!>1\]H 'H !K[H(UE.KKL$:HF6D,O7:.12 _M
M',GMIW2Q#4WLA("RB2TEAA!(Z)/:HF,HFLJ0B;EJ<RG8Y;G5/.KUT]8XQ22&
M=Y6/.8#"4C[!^X5F<2DC F3G CG%"1O9DB1^Z1E..PK(#.!,"1#&"2G301M0
MO5\Z<,^ "QW05E AG!&J:DW4,FUI)9=1J5Z0C=:QTB*2<@9L8% .@=1/D#I]
MWM2'(7*J]6;IPH>T]ON]Q&W]D9$BOTB2DT!3,X*<S<# M%D$/;E34,B(^%2D
M.*8F H\2(::#0)IU5>FT\=_02;X=LS=V+4CP$)++52B5#(G225[2!*2+,#N4
MP63279$$SQNY$6BZ";HAT2]J+U(^GH80+^WGVAD./'[TKN-Q$BL41#N JB*U
MN(JF;CR)%"%,7X@&MNFL#'-HB.A5$ON@UBV#:.;JR9$7SDR35LFU(JNHLB)%
M7!TTBF65%,/:J<F.4>1#7GZV!\*N#]ZN)<8J&X H"?'E+4$$RB(D2 RL$<WL
MR<F[2]W(=QA >1YT'C;3J"["WQ2&9[V-I3DJJJZ*8H[C,0' ZK5L#UR0O%P\
MBW:"#A?CPDD('.)0UD5-]VQ])3V2F\G:H17A(WLC[A\0D4[5TTUD3=AK@4W"
MR*J2J0\<*)J)G)R4Y1'/RVT+:S.B[/-;<L"RJ\@<#R#F3PKBR07?]JS)R4'I
MWM0<%<@5Q%Q*Y16*<X+1,:J!O:,TC%\Y-L>V:*WALB7:;MH)&,:M.D6B28)Q
M<E&.GTY-5EZYD'4<G5@8O7@?<1J"3QT@9TT$SHK90A7KKV@=\C]Z6SJ6*\/%
M[L=M$D6/9N)%^9AG?%KPK&/:)F6=/W@MK4J#9DV2(=5PZ7$B"*9#'4.4I1'7
MH*.=\'N" HAF7%*Z8^AT<AU%4@^ -X,28,4?=$!]?00'T'7CRVP38RY4,JOL
MVVL**&(=/V@;?,2)*E3.JW7]F55"H)*\$5;)'(83BH40'WQ PAK!N.F[T]W8
MG,ZV/;3')U"$3.HOM\Q4LJ8A$RI%**JE6,IP"9"E\&#GCD>1$1$-IHN^T:;1
M.XAKE5)=!-4B!UXRQPS]$JZJ0KI(F5:/5B%550 5DTS& QT@%0H"0!'6<2EX
MI<Q2(R<>LH80 J:3ULH<PCR  4I%3"81X'@  1'CQK15WTK>FZ^5;K.-D&V@
M56QD3)J(XGJC4QR('(HFW<BUCT?IC,#D*8S%Y[=FH(F]H@<#G V%-TD.FH=L
MHU-LQP>*:HE,HI][)_I:ABJ'4*<[\'?TXQP.<X]XN!/P82]W9[N@D0%8H" "
M"@C\>U)0_;R #P;L*;M'@0'@>! ! 1#7P5RAQP18>1X\(*^/=,;D1$@  >[Q
MSZ=PE+ZF#4=*?2+Z;J10(EM,QPD0IW9RE3<VQ,I1>F=F6 H$L8 4B8/%$V20
M<)QR"+%O'D:H1L<FUMH[I$=/&'< [AMORD*[*+;M=PV7,Z1#LB;1($DFY',=
MDULN1F;M36<,BJ T=O$6[YVBN\;H+IA)+IJ/EUTM]E3Q,4U:!DQ,!3!/O9[H
MMU<>N4A3=Q0(X89K;+D$!\ 8BA3 013Y[!$HW,7TR=H\$)!@HO<!!^Q2D46X
M0V]?>M%E:)RZ7LI,K(C'<(@1F#\!$[OZ*5+Z0N)G*O<X,940W]TUH>MTY\ *
M")D;QO(9*]JQ 6:=03?."A"KK/EA OM]PJY ]G]/421'L$4DD6Q2CREW&R:F
MP;%"A5@#+V]U,5C=XF3Z@.],#)C[05#>Q <YF*F4PB)>P"]A4^$TRD*4H%#=
MW36D"NPO'!1]M&9QWOP[TH*^P>);Z=U<V#<54E$^[[EV_*MD@'8IBH55(LE$
M/2$523-V"7VA5+4FQKV!>&V\'?2B;D.5%-P0R!A+R B3MEJE()% >..XB150
M#W2J% 1Y#>G36C(;*)EJJ1W%;U=\<?(I)K)MWJF7:/.I-O;E(!U1@[;B:QU>
M05[""BE]UX)^1J5=5RU*D\(BL2S;;0LR-FR:!>HOO?3.4.%3F)LID#G.'!1.
M"TILF=J@!P+[04R]A$S'.0@=I2FT&^6FM%2[1\T<F_\ .0;X _>U2_WIV(G_
M !B1T@,'=L9]TR8J>U2,4>2JIIF$#% 2CF"[8,XD16*GU%MXPJ+$2*FHK2>G
MT;Z*8G!#JI@38@F*QEC'.X6*X%0#K% J1FY%#B4-Q9*18P\<_EI-RFSC8QFZ
MD)!XMR"+1DR04=.W*QB@82I(-TE%5#<#P4H\ (\ -1F\;2#1L^9J@NT>().6
MRY2G*59NL0%$52 <I3=BJ9BG(82AW$,4P<@(".C;S:CN&DV2\?(]1?<O*1L@
MT!A*Q4IB;9"9A),'*16TPR<*0^U2#E$DI%H=TBFJRDF;AF=<BR:I_8^R4[B7
M 6X%K&MV33>WE,56C1LU(\?8@VTN%%SMVZ:!G;I!CB2+;&7=*D%TY(S28MO:
MJJ$:MVJ'LDD@V\TUI1(8'W8&5<%B]]$XD!S HR2F]N6$9=%'AX[53*\^YL?7
M%7A"-!9(?[G4CU!=-5GI52D=$9M,<ECO>I$6FO0Y]WV.99L\B;5)N_NIM08%
M%8S"1@2,&W_QFS5"G2(W3F5D0525*91NT;D737=*K/\ 0;T::U 5QWO@]DX!
M'=1@ JYB<M%%]GEM611."B9S"Y12W;M3NDQ("B12).&9P*<#"J8Y.XV*0H?4
M*2,4/VU6T%TF#<4S_3=B&8#+&<_3%%2N 48]0N/2*3Z&J5F=#Z.;N.@@Z*JF
M;Z0DY#=336F)Z7U"R,7 $W,[,G$E]%4!HH?8UF]FQ!Z503$,X1#J'/EQ:G1#
MV9B)+@LFH'MP.H4WT<E@%/ZCY7A%/VQVR-S&IN4SJM?VE.=V3YPS*L!ED$WW
M[?R009N56W*2;LT<^207$'!F3E,HMC!N[IK4-Y&[\TC-@C;SM%D2G55!V+[%
M.984S=$&RQD#M@0S-/@\54=@@FJFJ+ J+<55B*.%0(@.%CG/470D&YY6(V52
MT00%R.D(^Q9SKTBZ$#*%;.4'3FKV=LP 2^R578J,Y+M$5&Z<@8 *Y$-UM-:@
M??!OS+W?_(OVBJB5\@D0O[.V96_M&*A!,LL8W[71S[%VD<2IIMP(NBN4!6,Y
M;B((!@'E^Z@K"5*W+M_V;R<6!DSJN3;NLV0S\$3')[5)-F&R6=;F433!8R:Q
MGI2JG%,AD$2E,H8-WM-:6DR9OM$A!/MHVD@<2%$X%WM9B$H'$H=P%$=@ ")0
M-R!1$ $0X$0 ? =8LF>=Z]5!-:7VR[7#,U$%CJ*1N]/+#ITF=/M!,J;9UL+8
MI*%.)@[SG=I^S !$$E?00WYTU'P3=MG(J!#+X$Q2"@$+[4";B[<J4#^ .!#C
MMF;^T*!N0*<441,  84R"/:%N;>;E)@NV-.X,H+2,.LF1XZB,[6&5D&Z!Q$#
MJM8][@*%;.UB ')$%I-FF<> ,N0/.@D/TUH _P!]D?7VRIYS'$A](;-'SQRG
M&VAJ_3*1@Q+(+IH+N*_#"L(HF B(J-F_<IR"AB%X/KH)^J#C@@"8V-+N  !A
M'M?P)A'@.>.!<E]?@//CU$!]-!)[IJ*6<ZOVVNNKLT'M*SHN>0*]50%O6<?G
M(F5C)N8I4IQ/DML8.YPU442X!411,0QS$.(IEI3W6&VT5YXU8O*/G119Y,/8
M-([6KT!1,KMBT@'BJJ@K9/0,#<R=C8@F8I#*&42=@9(A2(F7"5_347M9ZLFW
M:T*^R8TW-29AA8R= 7=:HJ)0:2H.!;IB*&2'(BY(#<_MB<>R)R3V:RG)NWMW
M[II@?_\ -++G_P#0:;__ -[H) 0(7DI@* &,!2B< #N[1$/'/'/'U#X\!K(D
M+V% O// < /U?#^36F5+WJXIO$4_EXF"R$W;1:(.5R2,16T5SI@9V4"I$;6Y
MXF8_='KC[ZI X43][\(">HM-QM(>MD7245:BIKI$5("C&( X%.'< & LX<H&
M /4 ,(<^@CH/?M->6U7+E;M\PE"1K*<0=K)+K%4?-F"3<"H)F5.!CMY)RH!A
M*00* )" FX 1 /(>I:!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::
M!IIIH&FFF@:I>V3'CWA\\<>Z?X^G\'576/*'X(?(2_R"&@R&FFF@::::!III
<H&FFF@::::!IIIH&FFF@::::!IIIH&FFF@__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823780832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOCRYST PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">bcrx<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,404,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824358464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 117,776<span></span>
</td>
<td class="nump">$ 22,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">3,122<span></span>
</td>
<td class="nump">1,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">43,848<span></span>
</td>
<td class="nump">32,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables from collaborations</a></td>
<td class="nump">8,985<span></span>
</td>
<td class="nump">8,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,421<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred collaboration expense</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">175,370<span></span>
</td>
<td class="nump">66,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Investments</a></td>
<td class="nump">4,539<span></span>
</td>
<td class="nump">8,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,613<span></span>
</td>
<td class="nump">9,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredCollaborationExpenseAssets', window );">Deferred collaboration expense</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,955<span></span>
</td>
<td class="nump">3,813<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">191,492<span></span>
</td>
<td class="nump">89,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,603<span></span>
</td>
<td class="nump">4,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">11,871<span></span>
</td>
<td class="nump">10,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">10,705<span></span>
</td>
<td class="nump">8,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred collaboration revenue</a></td>
<td class="nump">8,686<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Lease financing obligation</a></td>
<td class="nump">73<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Senior credit facility</a></td>
<td class="nump">4,727<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Non-recourse notes payable</a></td>
<td class="nump">28,572<span></span>
</td>
<td class="nump">28,243<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">69,237<span></span>
</td>
<td class="nump">54,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred collaboration revenue</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">8,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease Financing Obligation, Net of Current</a></td>
<td class="nump">2,770<span></span>
</td>
<td class="nump">2,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="nump">18,379<span></span>
</td>
<td class="nump">22,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value: shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 98,389 in 2017 and 73,782 in 2016</a></td>
<td class="nump">984<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">711,965<span></span>
</td>
<td class="nump">566,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(612,300)<span></span>
</td>
<td class="num">(566,061)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">100,632<span></span>
</td>
<td class="nump">1,578<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 191,492<span></span>
</td>
<td class="nump">$ 89,847<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredCollaborationExpenseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents deferred collaboration expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredCollaborationExpenseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LeaseFinancingObligationNetOfCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Financing obligation as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LeaseFinancingObligationNetOfCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824405632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">98,389<span></span>
</td>
<td class="nump">73,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">98,389<span></span>
</td>
<td class="nump">73,782<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823981136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales</a></td>
<td class="nump">$ 1,501<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,501<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">3,501<span></span>
</td>
<td class="nump">7,252<span></span>
</td>
<td class="nump">6,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopment', window );">Collaborative and other research and development</a></td>
<td class="nump">6,817<span></span>
</td>
<td class="nump">4,262<span></span>
</td>
<td class="nump">12,543<span></span>
</td>
<td class="nump">11,350<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenues</a></td>
<td class="nump">8,760<span></span>
</td>
<td class="nump">7,763<span></span>
</td>
<td class="nump">21,296<span></span>
</td>
<td class="nump">17,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of products sold</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,142<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,509<span></span>
</td>
<td class="nump">14,105<span></span>
</td>
<td class="nump">50,038<span></span>
</td>
<td class="nump">48,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,343<span></span>
</td>
<td class="nump">2,756<span></span>
</td>
<td class="nump">9,235<span></span>
</td>
<td class="nump">8,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">22,109<span></span>
</td>
<td class="nump">17,004<span></span>
</td>
<td class="nump">60,846<span></span>
</td>
<td class="nump">57,789<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(13,349)<span></span>
</td>
<td class="num">(9,241)<span></span>
</td>
<td class="num">(39,550)<span></span>
</td>
<td class="num">(40,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,140)<span></span>
</td>
<td class="num">(1,465)<span></span>
</td>
<td class="num">(6,334)<span></span>
</td>
<td class="num">(4,356)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (loss) on foreign currency derivative</a></td>
<td class="nump">130<span></span>
</td>
<td class="num">(931)<span></span>
</td>
<td class="num">(892)<span></span>
</td>
<td class="num">(6,561)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,134)<span></span>
</td>
<td class="num">$ (11,528)<span></span>
</td>
<td class="num">$ (46,239)<span></span>
</td>
<td class="num">$ (50,641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding (in shares)</a></td>
<td class="nump">83,570<span></span>
</td>
<td class="nump">73,734<span></span>
</td>
<td class="nump">79,749<span></span>
</td>
<td class="nump">73,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available for sale investments</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (24)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (15,136)<span></span>
</td>
<td class="num">$ (11,552)<span></span>
</td>
<td class="num">$ (46,244)<span></span>
</td>
<td class="num">$ (50,413)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAndOtherResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and other research and development during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAndOtherResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824257408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (46,239)<span></span>
</td>
<td class="num">$ (50,641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">522<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">10,307<span></span>
</td>
<td class="nump">6,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">658<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AmortizationOfDiscountAndPremiumOnInvestments', window );">Amortization of premium/discount on investments</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeAssets', window );">Change in fair value of foreign currency derivative</a></td>
<td class="nump">1,858<span></span>
</td>
<td class="nump">7,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(217)<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">500<span></span>
</td>
<td class="num">(620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities', window );">Deferred collaboration expense</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,303<span></span>
</td>
<td class="num">(12,066)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Interest payable</a></td>
<td class="nump">1,715<span></span>
</td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,224)<span></span>
</td>
<td class="num">(1,075)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(30,624)<span></span>
</td>
<td class="num">(47,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisitions of property and equipment</a></td>
<td class="num">(213)<span></span>
</td>
<td class="num">(5,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash</a></td>
<td class="num">(1,576)<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(39,572)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">32,527<span></span>
</td>
<td class="nump">38,272<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(8,834)<span></span>
</td>
<td class="nump">33,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock, net</a></td>
<td class="nump">133,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from common stock issued under stock-based compensation plans</a></td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from senior credit facility</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">22,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForHedgeFinancingActivities', window );">Payment of foreign currency derivative collateral</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_IncreaseDecreaseInFinancingLeaseObligations', window );">Increase in lease financing obligation</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">135,130<span></span>
</td>
<td class="nump">20,972<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase in cash and cash equivalents</a></td>
<td class="nump">95,672<span></span>
</td>
<td class="nump">6,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">22,104<span></span>
</td>
<td class="nump">28,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 117,776<span></span>
</td>
<td class="nump">$ 35,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AmortizationOfDiscountAndPremiumOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to the discount and premium on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AmortizationOfDiscountAndPremiumOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents deferred collaboration expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_IncreaseDecreaseInFinancingLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period for financing lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_IncreaseDecreaseInFinancingLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3581-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806379280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> &#x2014; Significant Accounting Policies</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on oral treatments for rare diseases in which significant unmet medical needs exist and that align with its capabilities and expertise. The Company was incorporated in Delaware in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1986</div> and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">With the funds available at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>the Company believes these resources will be sufficient to fund its operations at least through the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019.</div> The Company has sustained operating losses for the majority of its corporate history and expects that its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> expenses will exceed its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regards to the progression of its product candidates in the future. The Company also <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>consider other plans to fund operations beyond the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> including: (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>)&nbsp;securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>)&nbsp;out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>)&nbsp;raising additional capital through equity or debt financings or from other sources; (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>)&nbsp;obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div>)&nbsp;reducing spending on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more research and development programs, including by discontinuing development; and/or (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div>)&nbsp;restructuring operations to change its overhead structure. The Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings in the future. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.&nbsp;&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, JPR Royalty Sub LLC (&#x201c;Royalty Sub&#x201d;) and MDCP, LLC (&#x201c;MDCP&#x201d;). Both subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30,000</div>&nbsp;financing transaction the Company completed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011.</div> See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,</div> Royalty Monetization, for a further description of this transaction. MDCP was formed in connection with a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$23,000</div> Senior Credit Facility that the Company closed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 23, 2016. </div>See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,</div> Senior Credit Facility, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-Q and do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> adjustments other than normal recurring adjustments.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These financial statements should be read in conjunction with the financial statements for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and the notes thereto included in the Company&#x2019;s <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K. Interim operating results are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> necessarily indicative of operating results for the full year. The balance sheet as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Cash</div></div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Restricted cash as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> reflects <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,713</div> in royalty revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>) and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,409</div> the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its Birmingham research facilities.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Investments</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> years and requires an average portfolio maturity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> months. Some of the securities the Company invests in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>have market risk. This means that a change in prevailing interest rates <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> collateralized. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> realized any significant losses from its investments.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months and which mature at or less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months from the balance sheet date are classified as current. Investments with a maturity beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months from the balance sheet date are classified as long-term. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>the Company believes that the cost of its investments is recoverable in all material respects.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair values of the Company&#x2019;s fixed income investments are classified as Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> active. These fair values are obtained from independent pricing services which utilize Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> inputs.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">September&nbsp;30, 2017</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated<br /> Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,897</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,986</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,230</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,261</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,108</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,140</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,235</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">169</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(21</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,387</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated<br /> Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,266</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,298</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,179</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,199</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,962</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,975</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,407</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">77</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(23</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,472</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company&#x2019;s investments at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43,848</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,546</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Maturing after one year through two years</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,539</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,926</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,387</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,472</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Collaborations</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&#x201c;Green Cross&#x201d;), Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;) and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company had the following receivables.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">September&nbsp;30, 2017</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,906</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,969</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">653</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">653</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Mundipharma International Holdings Limited</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">46</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">46</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,794</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">475</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,269</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,604</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,381</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,985</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,495</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,495</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,451</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,451</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">686</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">686</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">957</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">179</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,136</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,094</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,674</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,768</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Product Sales</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB<div style="display: inline; font-weight: bold;"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">&reg;</div></div>. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Inventory</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s inventory consisted primarily of peramivir work in process and is being manufactured for the Company&#x2019;s partners. Inventory is stated at the lower of cost and net realizable value, determined under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-in, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-out (&#x201c;FIFO&#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> years. Laboratory equipment, office equipment, and software are depreciated over a life of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years. Furniture and fixtures are depreciated over a life of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div> years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Property consists of a leased building which did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patents and Licenses</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accrued Expenses</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally enters into contractual agreements with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with its service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; min-width: 700px;">  <tr> <td style="width: 5%">&nbsp;</td> <td style="vertical-align: top; width: 2%"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top; width: 1%">&nbsp;</td> <td style="vertical-align: top; width: 92%"><div style="display: inline; font-size: 10pt">fees paid to Contract Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;</div></td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</div></td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance and drug products;&nbsp;and</div></td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">professional fees.</div></td> </tr>  </table> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016, </div>the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accumulated Other Comprehensive Loss</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> reclassifications out of accumulated other comprehensive loss were recorded during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017. </div>Realized gains of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11</div> were reclassified out of accumulated other comprehensive loss during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2016.</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research and development arrangements and royalties when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#x2019;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Collaborative and Other Research and Development Arrangements and Royalties</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &#x201c;stand-alone value&#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party evidence of selling price (&#x201c;TPE&#x201d;) and (iii) best estimate of selling price (&#x201c;BESP&#x201d;). The BESP reflects the Company&#x2019;s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2015, </div>the Company entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&#x201c;EU&#x201d;) marketing approvals. The Company received an upfront payment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$33,740</div> from SUL, of which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,000</div> was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$21,777</div> of the upfront payment was allocated to the license rights and recognized as revenue in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div> Approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,740</div> of the upfront payment was allocated to the pending sale of inventory and was recognized in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> when the inventory transfer was completed. Approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,223</div> of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Company received a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,000</div> milestone payment related to the approval of RAPIVAB by Health Canada and a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,000</div> milestone payment associated with the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of a supplemental new drug application (&#x201c;sNDA&#x201d;) for RAPIVAB extending its availability for the treatment of acute uncomplicated influenza to pediatric patients <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> years and older. The Company evaluated each event based payment under the provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,</div> <div style="display: inline; font-style: italic;">Milestone Method of Revenue Recognition</div>, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. Under the terms of the SUL Agreement, the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>receive an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,000</div> payment related to the successful marketing approval by the European Medicines Agency (&#x201c;EMA&#x201d;) for an adult indication in the EU. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> event-based payments were achieved during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div>&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016:</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three Months</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Nine Months</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left">Product sales</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,501</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,501</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">442</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,501</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,252</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,020</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,490</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,813</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,305</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,846</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">296</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">296</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">888</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">888</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; text-indent: 20pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,031</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">153</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,350</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">616</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,817</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,262</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,543</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,350</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,760</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,763</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,296</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,370</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development Expenses</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#x2019;s academic partners for modification to existing license agreements. These deferred expenses would <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-Based Compensation</div></div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Interest Expense and Deferred Financing Costs</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,140</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,465,</div> respectively, and for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6,334</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,356,</div> respectively, and primarily relates to the issuance of the PhaRMA Notes (defined in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>) and the Senior Credit Facility (defined in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div>). Costs directly associated with the issuance of the PhaRMA Notes and the Senior Credit Facility have been capitalized and are netted against the PhaRMA Notes and Senior Credit Facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Senior Credit Facility using the effective interest rate method. Amortization of deferred financing costs and original issue discount included in interest expense was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$219</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$116</div> for each of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$658</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$335</div> for each of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Lease Financing Obligation</div></div></div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 12pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on the terms of the lease agreement for the research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,589</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2015, </div>representing the Company&#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, which ended in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.5</div> years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> impact on cash flows associated with the underlying lease or construction in process. Interest expense for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> includes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$82</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$86,</div> respectively, and for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> includes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$217</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$300,</div> respectively, related to the lease financing obligation.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At each of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016, </div>the lease financing obligation balance was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,704</div></div> and was recorded as a long term liability on the consolidated balance sheets. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>the remaining future minimum payments under the lease financing obligation are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,444.</div></div> <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0 0pt 12pt">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Currency Hedge Agreement</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> resulted in losses of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,858</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,372,</div> respectively. Mark to market adjustments are determined by a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party pricing model that uses quoted prices in markets that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> actively traded and for which significant inputs are observable directly or indirectly, representing Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized currency exchange gains of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$966</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$811</div> during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement. The Company is also required to post collateral in connection with the mark to market adjustments based on thresholds defined in the Currency Hedge Agreement. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div></div> hedge collateral was posted under the agreement.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net Loss Per Share</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,996</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,291,</div> respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,519</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,190,</div> respectively, of such potential common shares, as their impact would be anti-dilutive.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Significant Customers and Other Risks</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Significant Customers</div></div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">All peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) are made by the Company&#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Other than royalty revenues, the Company&#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of galidesivir (formerly <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">BCX4430</div>) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion (as with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2014 </div>BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Credit Risk</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assumed credit risk.&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recent Accounting Pronouncements</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2016, </div>the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18:</div> <div style="display: inline; font-style: italic;">Statement of Cash Flows (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">230</div>): Restricted Cash</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18&#x201d;</div>). The new standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for annual periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> and interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2016, </div>the FASB issued Accounting Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15:</div> <div style="display: inline; font-style: italic;">Statement of Cash Flows (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">230</div>): Classification of Certain Cash Receipts and Cash Payments</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15&#x201d;</div>). The amendments in this update clarify how entities should classify certain cash receipts and cash payments on the Consolidated Statements of Cash Flows. The new guidance also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> class of cash flows. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div> will be effective for annual periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017, </div>including interim periods within those annual reporting periods, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2016, </div>the FASB issued Accounting Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09:</div> <div style="display: inline; font-style: italic;">Compensation - Stock Compensation (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div>): Improvements to Employee Share-Based Payment Accounting</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09&#x201d;</div>). The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> eliminates the requirement that excess tax benefits be realized as a reduction in current taxes payable before the associated tax benefit can be recognized as an increase in paid in capital. Under ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> these previously unrecognized deferred tax assets were recognized on a modified retrospective basis as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2017, </div>the start of the year in which the Company adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09.</div> The U.S. federal and state net operating losses and credits recognized as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2017 </div>have been offset by a full valuation allowance. As a result, there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> cumulative-effect adjustment to retained earnings as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017. </div>The Company elected <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to change its policy on accounting for forfeitures and continues to estimate the total number of awards for which the requisite service period will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be rendered. The Company adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2017. </div>Adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on the Company&#x2019;s consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued Accounting Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02:</div> <div style="display: inline; font-style: italic;">Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>)</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02&#x201d;</div>). The amendments in this update require lessees, among other things, to recognize lease assets and lease liabilities on the balance sheet for all leases with terms greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months. This update also introduces new disclosure requirements for leasing arrangements. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> will be effective for the Company in fiscal year <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019,</div> but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2016, </div>the FASB issued Accounting Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01:</div> <div style="display: inline; font-style: italic;">Financial Instruments - Overall (Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">825</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>): Recognition and Measurement of Financial Assets and Financial Liabilities</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01&#x201d;</div>). The amendments in this update address certain aspects of recognition, measurement, presentation and disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01</div> will be effective for the Company in fiscal year <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> but early adoption is permitted. The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect this standard to have a material impact on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2015, </div>the FASB issued Accounting Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11:</div> <div style="display: inline; font-style: italic;">Inventory (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">330</div>): Simplifying the Measurement of Inventory</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11&#x201d;</div>), which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> apply to inventory that is measured using last-in, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-out or the retail inventory method. The update applies to all other inventory, which includes inventory that is measured using <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-in, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-out or average cost methods. The amendments in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> are effective for the Company for fiscal years, and the interim periods within those years, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2016. </div>The Company adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2017. </div>Adoption did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014, </div>the FASB issued Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09:</div> <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>)</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09&#x201d;</div>), which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2015, </div>the FASB finalized a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year delay in the effective date of this standard, which will now be effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018; </div>however, early adoption is permitted any time after the original effective date, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2017. </div>Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company will adopt the standard effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018 </div>and expects to utilize the modified retrospective methodology. The Company is continuing to evaluate the effect that the standard will have on its consolidated financial statements and related disclosures.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814883952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> &#x2014; Stock-Based Compensation</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Company had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> stock-based employee compensation plans, the Stock Incentive Plan (&#x201c;Incentive Plan&#x201d;) and the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The Incentive Plan was amended and restated in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2017 </div>and approved by the Company&#x2019;s stockholders in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2017. </div>The ESPP was amended and restated in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2014 </div>and approved by the Company&#x2019;s stockholders in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014. </div>Stock-based compensation expense of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10,307</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10,107</div> of expense related to the Incentive Plan and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$200</div> of expense related to the ESPP) was recognized during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> while <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6,478</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6,331</div> of expense related to the Incentive Plan and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$147</div> of expense related to the ESPP) was recognized during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16,282</div> of total unrecognized compensation cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> That cost is expected to be recognized as follows: <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,264</div> during the remainder of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6,745</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,527</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,395</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$351</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2021.</div> In addition, the Company has outstanding performance-based stock options for which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> compensation expense is recognized until &#x201c;performance&#x201d; has occurred and the award vests. At the time of vesting, compensation expense will be recognized. During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Company achieved a performance metric under a performance-based option award resulting in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">404</div> options vesting and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,193</div> compensation expense recorded as a result of this achievement.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock Incentive Plan</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#x2019;s stock at the date of grant. Stock option awards granted to employees generally vest <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25%</div> each year until fully vested after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> years. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2013 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2014, </div>the Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,032</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,250</div> performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75%</div> of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2013 </div>grants have vested based upon achievement of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> milestones: (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) successful completion of the OPuS-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> clinical trial, for which vesting occurred in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>) FDA approval of RAPIVAB, for which vesting occurred in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> and (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>) initiation of a Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">BCX7353</div> in healthy volunteers, for which vesting occurred in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div> As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30%</div> of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2014 </div>grants have vested based upon achievement of successful completion of an HAE patient trial with a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">nd</div> generation compound, for which vesting occurred in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2017. </div>Thus, as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25%</div> of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2013 </div>performance-based grants and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70%</div> of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2014 </div>performance-based grants remain unvested and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year. All stock option awards have contractual terms of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>&nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Related activity under the Incentive Plan is as follows:</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Awards<br /> Available</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Options<br /> Outstanding</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Weighted<br /> Average<br /> Exercise<br /> Price</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; font-size: 10pt">Balance December&nbsp;31, 2016</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,273</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,095</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.55</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Plan amendment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock unit awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock unit awards cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,591</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,591</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.49</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(422</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.49</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">912</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(912</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.22</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Balance September&nbsp;30, 2017</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,581</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,352</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.19</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For stock option awards granted under the Incentive Plan during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.74</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.17,</div> respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. The following table summarizes the key assumptions used by the Company to value the stock option awards granted during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#x2019;s publicly traded common stock. The Company has assumed <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> expected dividend yield, as dividends have never been paid to stock or option holders and will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">zero</div>-coupon government issues with a remaining term equal to the expected term.</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Weighted Average Assumptions for Stock Option Awards Granted to</div></div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Employees and Directors under the Incentive Plan</div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 65%; font-size: 10pt; text-align: left">Expected Life in Years</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.5</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.5</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected Volatility</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82.0</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82.0</div></td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Expected Dividend Yield</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.0</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.0</div></td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Risk-Free Interest Rate</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.9</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.4</div></td> <td style="font-size: 10pt; text-align: left">%</td> </tr>  </table> </div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has reserved a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,475</div>&nbsp;shares of common stock to be purchased under the ESPP, of which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">330</div>&nbsp;shares remain available for purchase at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> Eligible employees <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>authorize up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15%</div> of their salary to purchase common stock at the lower of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">85%</div> of the beginning or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">85%</div> of the ending price during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month purchase intervals. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> shares <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be purchased by any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> employee at the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month purchase dates and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> employee <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>purchase stock having a fair market value at the commencement date of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$25</div> or more in any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> calendar year. The Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">91</div> shares during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#x201c;look-back&#x201d; option were determined using a Black-Scholes option pricing model.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808469824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Collaborative and Other Research and Development Contracts<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> &#x2014; Collaborative and Other Research and Development Contracts</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">U.S.&nbsp;Department of Health and Human Services (&#x201c;BARDA/HHS&#x201d;).</div> On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2015, </div>the Company announced that BARDA/HHS had awarded the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&nbsp;This BARDA/HHS contract includes a base contract of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16,265</div> to support galidesivir drug manufacturing, as well as <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$22,855</div> in additional development options that can be exercised by the government, bringing the potential value of the contract to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$39,120.</div> As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$20,574</div> has been awarded under exercised options within this contract.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;).</div> In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 2013, </div>NIAID/HHS contracted with the Company for the development of galidesivir as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,000</div> to the Company. The goals of this contract, including the amendments thereto, are to file IND applications for intravenous (&#x201c;i.v.&#x201d;) and intramuscular (&#x201c;i.m.&#x201d;) galidesivir for the treatment of Marburg virus disease and other hemorrhagic fever virus diseases, including Ebola virus disease, and to conduct an initial Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> human clinical trial. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>the total NIAID/HHS contract amount to advance the program through the completion of the Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> clinical program is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$39,477.</div> As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>all options have been exercised under this contract.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Seqirus UK Limited (&#x201c;SUL&#x201d;).</div> On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 16, 2015, </div>the Company and Seqirus UK Limited (&#x201c;SUL&#x201d;), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &#x201c;Territory&#x201d;). Peramivir is an intravenous treatment for acute uncomplicated influenza and is currently approved for use in the United States, Canada, Japan, Taiwan and Korea. Peramivir is the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> and only intravenous influenza treatment in the world and was approved by the FDA in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2014 </div>for the treatment of acute uncomplicated influenza in patients <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> years and older who have been symptomatic for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> days. The Company retains all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Pursuant to the SUL Agreement, RAPIVAB is commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL manufactures, commercializes and exercises decision-making authority with respect to the commercialization of RAPIVAB within the Territory and is responsible for all related costs, including sales and promotion.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in the EU, the Company is also responsible for regulatory filings and interactions with the European Medicines Agency (&quot;EMA&quot;) until marketing approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company received an upfront payment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$33,740,</div> has received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,000</div> of milestone payments and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>receive an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,000</div> milestone payment related to the successful marketing approval by the EMA for an adult indication in the EU. The Company is also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 1 - </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30) </div>and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years from the date of the SUL Agreement. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;).</div> In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2007, </div>the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 2008, </div>the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Green Cross Corporation (&#x201c;Green Cross&#x201d;).</div> In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2006, </div>the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross is responsible for all development, regulatory, and commercialization costs in Korea. The Company received a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-time license fee of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$250.</div> The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;).</div> In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2006, </div>the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&#x201c;PNP&#x201d;) inhibitor, for use in oncology. Under the terms of the license agreement, as amended, Mundipharma obtained rights to forodesine in markets across Europe, Asia, and Australasia in exchange for a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10,000</div> up-front payment. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2017, </div>Mundipharma obtained regulatory approval of Mundesine<div style="display: inline; font-weight: bold;"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">&reg;</div></div> (forodesine hydrochloride) for the treatment of relapsed/refractory PTCL (Peripheral T-Cell Lymphoma) by the Ministry of Health, Labor and Welfare in Japan and is responsible for all commercialization costs in Japan.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&#x201c;AECOM&#x201d; and &#x201c;IRL&#x201d; respectively).</div> In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2000, </div>the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &#x201c;Licensors&#x201d;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,400</div> to almost <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,000</div>&nbsp;per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> quarter of future payments received from other <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$150</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$500,</div> that are creditable against actual royalties and other payments due to the Licensors. This agreement <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be terminated by the Company at any time by giving <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div>&nbsp;days advance notice or in the event of material uncured breach by the Licensors.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2010, </div>the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-half in the percentage of future payments received from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> apply to (i)&nbsp;any milestone payments the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>receive in the future under its license agreement dated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2006</div> with Mundipharma and (ii)&nbsp;royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2012,</div> the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of galidesivir to BioCryst for any antiviral use.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">The University of Alabama at Birmingham (&#x201c;UAB&#x201d;).</div> The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party partners. The Company has completed the research under the UAB agreements. These <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> agreements have initial <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25</div>-year terms, are automatically renewable for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div>-year terms throughout the life of the last patent and are terminable by the Company upon <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months&#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808516528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Royalty Monetization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationTextBlock', window );">Royalty Monetization [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div> &#x2014; Royalty Monetization</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Overview</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011,</div> the Company completed a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30,000</div>&nbsp;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$22,691</div>&nbsp;from the transaction after transaction costs of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,309</div>&nbsp;and the establishment of a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,000</div>&nbsp;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 2012 </div>interest payment.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As part of the transaction, the Company entered into a purchase and sale agreement dated as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i)&nbsp;its rights to receive all non-governmental royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&nbsp;the right to receive payments under a Japanese yen/US dollar foreign currency hedge agreement (as further described below, the &#x201c;Currency Hedge Agreement&#x201d;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&#x2019;s collaboration with Shionogi was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> impacted as a result of this transaction.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Non-Recourse Notes Payable</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011,</div> Royalty Sub completed a private placement to institutional investors of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30,000</div> in aggregate principal amount of its PhaRMA Senior Secured <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.0%</div> Notes due <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020</div> (the &#x201c;PhaRMA Notes&#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> (the &#x201c;Indenture&#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14%</div>&nbsp;per annum, payable annually in arrears on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1st</div> of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes. &nbsp;&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub&#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may, </div>but is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> obligated to, make capital contributions to a capital account that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be used to redeem, or on up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> occasion pay any interest shortfall on, the PhaRMA Notes.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 1, 2014, </div>Royalty Sub was unable to pay the full amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>pursue acceleration of the PhaRMA Notes, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>incur costs associated with liquidating the related Currency Hedge Agreement, which would <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the default of the PhaRMA Notes is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expected to have a significant impact on the Company&#x2019;s future results of operations or cash flows. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>the PhaRMA Notes remain in default.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Indenture does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>the aggregate fair value of the PhaRMA Notes was estimated to be approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> of its carrying value of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30,000.</div> The estimated fair value of the PhaRMA Notes is classified as Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> in the fair value hierarchy as defined in U.S. GAAP.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Currency Hedge Agreement</div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div> yen per dollar for which the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be required to pay a premium in each year from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020,</div> provided the Currency Hedge Agreement remains in effect. A payment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,950</div>&nbsp;will be required if, on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> of the relevant year, the U.S. dollar is worth <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div> yen or less as determined in accordance with the Currency Hedge Agreement.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Currency Hedge Agreement does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> qualify for hedge accounting treatment; therefore, mark to market adjustments are recognized in the Company&#x2019;s Consolidated Statement of Comprehensive Loss. Cumulative mark to market adjustments for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> resulted in losses of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,858</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,372,</div> respectively. The Company is also required to post collateral in connection with the mark to market adjustments based on defined thresholds. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div></div> collateral was posted under the Currency Hedge Agreement. The Company will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be required to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>the maximum amount of hedge collateral the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be required to post is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,850.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMonetizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyMonetizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806044768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Senior Credit Facility<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div> &#x2014; Senior Credit Facility</div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 23, 2016, </div>the Company closed a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$23,000</div> Senior Credit Facility with an affiliate of MidCap Financial Services, LLC (&#x201c;MidCap&#x201d;), as administrative agent (the &#x201c;Senior Credit Facility&#x201d;). The Senior Credit Facility was fully funded at closing and bears a variable interest rate of LIBOR (which shall <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.5%</div>) plus <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8%.</div> The Senior Credit Facility includes an interest-only payment period through fiscal <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and scheduled monthly principal and interest payments for the subsequent <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div> months. The Company has the option to repay the Senior Credit Facility at any time prior to the scheduled principal repayment date subject to prepayment fees. Final payment of the Senior Credit Facility is subject to a final payment fee equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5%</div> of the principal funded under the Senior Credit Facility.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>the Company had borrowings of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$23,000</div> under the Senior Credit Facility bearing an interest rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.2%.</div> The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date. Scheduled principal repayments of the Senior Credit Facility are as follows:</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: bottom"> <td nowrap="nowrap" colspan="5" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Principal Payments</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt">2017</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 82%; font-size: 10pt; text-align: justify; text-indent: 3.2pt">2018</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 20%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,900</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt">2019</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,900</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt">2020</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,900</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.1pt; text-indent: 3.2pt">2021</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,300</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; text-indent: 3.2pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,000</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The debt agreement contains <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> provisions that if deemed probable would create the recognition of an embedded feature; however, we do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe either provision is probable.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808507552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div> &#x2014; Stockholders&#x2019; Equity</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 3, 2015, </div>the Company filed a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$150,000</div> shelf registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). This shelf registration statement became effective upon filing and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 26, 2016, </div>the Company filed a post-effective amendment to this registration statement, which allowed for its use by the Company when declared effective by the SEC&#x2019;s staff on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 18, 2016.</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2017, </div>the Company completed a public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,061</div> shares of its common stock at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.50</div> per share, which included the underwriters&#x2019; overallotment option to purchase additional shares. Net proceeds were approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$47,750</div> after deducting underwriting discounts and offering expenses.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 2017, </div>the Company completed a public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,864</div> shares of its common stock at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.15</div> per share, which included the underwriters&#x2019; overallotment option to purchase additional shares. Net proceeds were approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$85,750</div> after deducting underwriting discounts and offering expenses.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824210096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DescriptionOfCompanyPolicyTextBlock', window );">Description of Company [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on oral treatments for rare diseases in which significant unmet medical needs exist and that align with its capabilities and expertise. The Company was incorporated in Delaware in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1986</div> and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">With the funds available at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>the Company believes these resources will be sufficient to fund its operations at least through the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019.</div> The Company has sustained operating losses for the majority of its corporate history and expects that its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> expenses will exceed its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regards to the progression of its product candidates in the future. The Company also <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>consider other plans to fund operations beyond the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> including: (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>)&nbsp;securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>)&nbsp;out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>)&nbsp;raising additional capital through equity or debt financings or from other sources; (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>)&nbsp;obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div>)&nbsp;reducing spending on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more research and development programs, including by discontinuing development; and/or (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div>)&nbsp;restructuring operations to change its overhead structure. The Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings in the future. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.&nbsp;&nbsp;</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, JPR Royalty Sub LLC (&#x201c;Royalty Sub&#x201d;) and MDCP, LLC (&#x201c;MDCP&#x201d;). Both subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30,000</div>&nbsp;financing transaction the Company completed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011.</div> See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,</div> Royalty Monetization, for a further description of this transaction. MDCP was formed in connection with a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$23,000</div> Senior Credit Facility that the Company closed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 23, 2016. </div>See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,</div> Senior Credit Facility, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-Q and do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> adjustments other than normal recurring adjustments.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These financial statements should be read in conjunction with the financial statements for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and the notes thereto included in the Company&#x2019;s <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K. Interim operating results are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> necessarily indicative of operating results for the full year. The balance sheet as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Cash</div></div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Restricted cash as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> reflects <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,713</div> in royalty revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>) and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,409</div> the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its Birmingham research facilities.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Investments</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> years and requires an average portfolio maturity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> months. Some of the securities the Company invests in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>have market risk. This means that a change in prevailing interest rates <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> collateralized. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> realized any significant losses from its investments.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months and which mature at or less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months from the balance sheet date are classified as current. Investments with a maturity beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months from the balance sheet date are classified as long-term. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>the Company believes that the cost of its investments is recoverable in all material respects.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair values of the Company&#x2019;s fixed income investments are classified as Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> active. These fair values are obtained from independent pricing services which utilize Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> inputs.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">September&nbsp;30, 2017</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated<br /> Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,897</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,986</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,230</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,261</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,108</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,140</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,235</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">169</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(21</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,387</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated<br /> Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,266</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,298</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,179</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,199</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,962</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,975</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,407</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">77</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(23</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,472</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></div> <!-- Field: Page; Sequence: 7; Value: 3 --> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company&#x2019;s investments at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43,848</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,546</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Maturing after one year through two years</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,539</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,926</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,387</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,472</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Collaborations</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&#x201c;Green Cross&#x201d;), Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;) and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company had the following receivables.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">September&nbsp;30, 2017</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,906</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,969</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">653</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">653</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Mundipharma International Holdings Limited</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">46</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">46</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,794</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">475</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,269</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,604</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,381</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,985</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,495</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,495</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,451</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,451</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">686</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">686</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">957</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">179</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,136</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,094</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,674</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,768</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Product Sales</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB<div style="display: inline; font-weight: bold;"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">&reg;</div></div>. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Inventory</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s inventory consisted primarily of peramivir work in process and is being manufactured for the Company&#x2019;s partners. Inventory is stated at the lower of cost and net realizable value, determined under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-in, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-out (&#x201c;FIFO&#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&nbsp;</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> years. Laboratory equipment, office equipment, and software are depreciated over a life of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years. Furniture and fixtures are depreciated over a life of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div> years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Property consists of a leased building which did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <!-- Field: Page; Sequence: 8; Value: 3 --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patents and Licenses</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accrued Expenses</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally enters into contractual agreements with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with its service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; min-width: 700px;"> <tr> <td style="width: 5%">&nbsp;</td> <td style="vertical-align: top; width: 2%"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top; width: 1%">&nbsp;</td> <td style="vertical-align: top; width: 92%"><div style="display: inline; font-size: 10pt">fees paid to Contract Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;</div></td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</div></td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance and drug products;&nbsp;and</div></td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">professional fees.</div></td> </tr> </table> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016, </div>the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accumulated Other Comprehensive Loss</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> reclassifications out of accumulated other comprehensive loss were recorded during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017. </div>Realized gains of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11</div> were reclassified out of accumulated other comprehensive loss during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2016.</div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research and development arrangements and royalties when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#x2019;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div> <!-- Field: Page; Sequence: 9; Value: 3 --> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Collaborative and Other Research and Development Arrangements and Royalties</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &#x201c;stand-alone value&#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party evidence of selling price (&#x201c;TPE&#x201d;) and (iii) best estimate of selling price (&#x201c;BESP&#x201d;). The BESP reflects the Company&#x2019;s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2015, </div>the Company entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&#x201c;EU&#x201d;) marketing approvals. The Company received an upfront payment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$33,740</div> from SUL, of which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,000</div> was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$21,777</div> of the upfront payment was allocated to the license rights and recognized as revenue in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div> Approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,740</div> of the upfront payment was allocated to the pending sale of inventory and was recognized in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> when the inventory transfer was completed. Approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,223</div> of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Company received a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,000</div> milestone payment related to the approval of RAPIVAB by Health Canada and a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,000</div> milestone payment associated with the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of a supplemental new drug application (&#x201c;sNDA&#x201d;) for RAPIVAB extending its availability for the treatment of acute uncomplicated influenza to pediatric patients <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> years and older. The Company evaluated each event based payment under the provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,</div> <div style="display: inline; font-style: italic;">Milestone Method of Revenue Recognition</div>, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. Under the terms of the SUL Agreement, the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>receive an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,000</div> payment related to the successful marketing approval by the European Medicines Agency (&#x201c;EMA&#x201d;) for an adult indication in the EU. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> event-based payments were achieved during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div>&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"></div> <!-- Field: Page; Sequence: 10; Value: 3 --> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016:</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three Months</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Nine Months</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left">Product sales</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,501</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,501</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">442</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,501</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,252</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,020</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,490</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,813</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,305</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,846</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">296</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">296</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">888</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">888</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; text-indent: 20pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,031</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">153</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,350</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">616</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,817</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,262</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,543</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,350</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,760</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,763</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,296</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,370</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development Expenses</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#x2019;s academic partners for modification to existing license agreements. These deferred expenses would <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-Based Compensation</div></div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock', window );">Interest Expense and Deferred Financing Costs [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Interest Expense and Deferred Financing Costs</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,140</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,465,</div> respectively, and for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6,334</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,356,</div> respectively, and primarily relates to the issuance of the PhaRMA Notes (defined in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>) and the Senior Credit Facility (defined in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div>). Costs directly associated with the issuance of the PhaRMA Notes and the Senior Credit Facility have been capitalized and are netted against the PhaRMA Notes and Senior Credit Facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Senior Credit Facility using the effective interest rate method. Amortization of deferred financing costs and original issue discount included in interest expense was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$219</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$116</div> for each of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$658</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$335</div> for each of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Lease Financing Obligation</div></div></div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 12pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on the terms of the lease agreement for the research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,589</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2015, </div>representing the Company&#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, which ended in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.5</div> years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> impact on cash flows associated with the underlying lease or construction in process. Interest expense for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> includes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$82</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$86,</div> respectively, and for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> includes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$217</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$300,</div> respectively, related to the lease financing obligation.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <!-- Field: Page; Sequence: 11; Value: 3 --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At each of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016, </div>the lease financing obligation balance was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,704</div> and was recorded as a long term liability on the consolidated balance sheets. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>the remaining future minimum payments under the lease financing obligation are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,444.</div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock', window );">Currency Hedge Agreement [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Currency Hedge Agreement</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> qualify for hedge accounting treatment; therefore mark to market adjustments are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> resulted in losses of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,858</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,372,</div> respectively. Mark to market adjustments are determined by a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party pricing model that uses quoted prices in markets that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> actively traded and for which significant inputs are observable directly or indirectly, representing Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized currency exchange gains of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$966</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$811</div> during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement. The Company is also required to post collateral in connection with the mark to market adjustments based on thresholds defined in the Currency Hedge Agreement. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> hedge collateral was posted under the agreement.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net Loss Per Share</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,996</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,291,</div> respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,519</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,190,</div> respectively, of such potential common shares, as their impact would be anti-dilutive.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock', window );">Concentration of Market Risk [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Significant Customers and Other Risks</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Significant Customers</div></div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">All peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) are made by the Company&#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Other than royalty revenues, the Company&#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of galidesivir (formerly <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">BCX4430</div>) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion (as with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2014 </div>BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></div> <!-- Field: Page; Sequence: 12; Value: 3 --> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Credit Risk</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assumed credit risk.&nbsp;</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recent Accounting Pronouncements</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2016, </div>the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18:</div> <div style="display: inline; font-style: italic;">Statement of Cash Flows (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">230</div>): Restricted Cash</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18&#x201d;</div>). The new standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for annual periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> and interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2016, </div>the FASB issued Accounting Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15:</div> <div style="display: inline; font-style: italic;">Statement of Cash Flows (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">230</div>): Classification of Certain Cash Receipts and Cash Payments</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15&#x201d;</div>). The amendments in this update clarify how entities should classify certain cash receipts and cash payments on the Consolidated Statements of Cash Flows. The new guidance also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> class of cash flows. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div> will be effective for annual periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017, </div>including interim periods within those annual reporting periods, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2016, </div>the FASB issued Accounting Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09:</div> <div style="display: inline; font-style: italic;">Compensation - Stock Compensation (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div>): Improvements to Employee Share-Based Payment Accounting</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09&#x201d;</div>). The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> eliminates the requirement that excess tax benefits be realized as a reduction in current taxes payable before the associated tax benefit can be recognized as an increase in paid in capital. Under ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> these previously unrecognized deferred tax assets were recognized on a modified retrospective basis as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2017, </div>the start of the year in which the Company adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09.</div> The U.S. federal and state net operating losses and credits recognized as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2017 </div>have been offset by a full valuation allowance. As a result, there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> cumulative-effect adjustment to retained earnings as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017. </div>The Company elected <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to change its policy on accounting for forfeitures and continues to estimate the total number of awards for which the requisite service period will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be rendered. The Company adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2017. </div>Adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on the Company&#x2019;s consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued Accounting Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02:</div> <div style="display: inline; font-style: italic;">Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>)</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02&#x201d;</div>). The amendments in this update require lessees, among other things, to recognize lease assets and lease liabilities on the balance sheet for all leases with terms greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months. This update also introduces new disclosure requirements for leasing arrangements. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> will be effective for the Company in fiscal year <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019,</div> but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2016, </div>the FASB issued Accounting Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01:</div> <div style="display: inline; font-style: italic;">Financial Instruments - Overall (Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">825</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>): Recognition and Measurement of Financial Assets and Financial Liabilities</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01&#x201d;</div>). The amendments in this update address certain aspects of recognition, measurement, presentation and disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01</div> will be effective for the Company in fiscal year <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> but early adoption is permitted. The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect this standard to have a material impact on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2015, </div>the FASB issued Accounting Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11:</div> <div style="display: inline; font-style: italic;">Inventory (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">330</div>): Simplifying the Measurement of Inventory</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11&#x201d;</div>), which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> apply to inventory that is measured using last-in, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-out or the retail inventory method. The update applies to all other inventory, which includes inventory that is measured using <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-in, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-out or average cost methods. The amendments in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> are effective for the Company for fiscal years, and the interim periods within those years, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2016. </div>The Company adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2017. </div>Adoption did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <!-- Field: Page; Sequence: 13; Value: 3 --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014, </div>the FASB issued Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09:</div> <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>)</div> (&#x201c;ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09&#x201d;</div>), which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2015, </div>the FASB finalized a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year delay in the effective date of this standard, which will now be effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018; </div>however, early adoption is permitted any time after the original effective date, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2017. </div>Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company will adopt the standard effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018 </div>and expects to utilize the modified retrospective methodology. The Company is continuing to evaluate the effect that the standard will have on its consolidated financial statements and related disclosures.</div></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued expenses policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents concentration of market risk policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ConcentrationOfMarketRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents currency hedge agreement policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CurrencyHedgeAgreementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DescriptionOfCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of company policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DescriptionOfCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest expense and deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75025870&amp;loc=d3e40691-111596<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e4975-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813165168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-for-sale Securities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">September&nbsp;30, 2017</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated<br /> Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,897</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,986</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,230</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,261</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,108</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,140</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,235</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">169</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(21</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,387</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated<br /> Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,266</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 7%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,298</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,179</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,199</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1.1pt; text-indent: -10pt; padding-left: 10pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,962</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,975</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-indent: -10pt; padding-left: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,407</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">77</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(23</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,472</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock', window );">Available For Sale Securities Debt Maturities Fair Value [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43,848</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,546</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Maturing after one year through two years</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,539</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,926</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,387</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,472</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock', window );">Schedule of Receivables from Collaborations [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">September&nbsp;30, 2017</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,906</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,969</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">653</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">653</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Mundipharma International Holdings Limited</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">46</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">46</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,794</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">475</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,269</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,604</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,381</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,985</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,495</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,495</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,451</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,451</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">686</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">686</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">957</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">179</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,136</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,094</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,674</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,768</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock', window );">Schedule of Revenues from Collaborations [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Three Months</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Nine Months</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left">Product sales</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,501</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,501</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 9%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">442</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,501</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,252</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,020</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,490</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,813</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,305</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,846</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">296</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">296</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">888</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">888</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; text-indent: 20pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,031</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">153</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,350</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">616</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,817</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,262</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,543</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,350</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,760</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,763</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,296</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,370</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available for sale securities debt maturities fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure representing receivables from collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of schedule of revenues from collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814883952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Share-based Compensation, Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Awards<br /> Available</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Options<br /> Outstanding</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Weighted<br /> Average<br /> Exercise<br /> Price</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; font-size: 10pt">Balance December&nbsp;31, 2016</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,273</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,095</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 11%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.55</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Plan amendment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock unit awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock unit awards cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,591</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,591</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.49</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(422</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.49</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">912</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(912</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.22</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Balance September&nbsp;30, 2017</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,581</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,352</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.19</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2017</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td nowrap="nowrap" colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 65%; font-size: 10pt; text-align: left">Expected Life in Years</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.5</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 14%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.5</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected Volatility</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82.0</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82.0</div></td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Expected Dividend Yield</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.0</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.0</div></td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Risk-Free Interest Rate</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.9</div></td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.4</div></td> <td style="font-size: 10pt; text-align: left">%</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for share-based compensation plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814952416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Senior Credit Facility (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" colspan="5" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Principal Payments</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt">2017</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 82%; font-size: 10pt; text-align: justify; text-indent: 3.2pt">2018</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 20%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,900</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt">2019</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,900</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt">2020</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,900</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.1pt; text-indent: 3.2pt">2021</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,300</div></td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; text-indent: 3.2pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; text-indent: 3.2pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,000</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828735776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies (Details Textual) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 23, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 09, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnSaleOfInvestments', window );">Loss on Sale of Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,760<span></span>
</td>
<td class="nump">$ 7,763<span></span>
</td>
<td class="nump">21,296<span></span>
</td>
<td class="nump">17,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
<td class="nump">1,465<span></span>
</td>
<td class="nump">6,334<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
<td class="nump">$ 1,465<span></span>
</td>
<td class="nump">6,334<span></span>
</td>
<td class="nump">$ 4,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease Financing Obligation, Net of Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,996<span></span>
</td>
<td class="nump">1,291<span></span>
</td>
<td class="nump">2,519<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,858<span></span>
</td>
<td class="nump">$ 7,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">966<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember', window );">Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember', window );">Birmingham Research Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease Financing Obligation, Net of Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Capital Leases, Future Minimum Payments Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember', window );">RAPIVAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue Recognition, Milestone Method, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=bcrx_SupplementalNDAForRaAPIVABMember', window );">Supplemental NDA for RAPIVAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue Recognition, Milestone Method, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="nump">$ 33,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">21,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVAB [Member] | Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="nump">3,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVAB [Member] | Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="nump">1,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVAB [Member] | Contingent upon EU Marketing Approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember', window );">Laboratory Equipment, Office Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Birmingham Research Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years 182 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities', window );">Maturity Period of High Quality Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities', window );">Average Maturity Period of High Quality Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityperiodOfShortTermInvestment', window );">Maturity Period of Short Term Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AveragematurityForPortfolioInvestments', window );">Average Maturity for Portfolio Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LongtermInvestmentMaturityMinimum', window );">Long-term Investment Maturity, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember', window );">Royalty Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember', window );">Collateral for Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember', window );">Senior Credit Facility [Member] | MidCap Financial Services, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AveragematurityForPortfolioInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity for portfolio investments during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AveragematurityForPortfolioInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LeaseFinancingObligationNetOfCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Financing obligation as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LeaseFinancingObligationNetOfCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LongtermInvestmentMaturityMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents long term investment maturity minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LongtermInvestmentMaturityMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityperiodOfShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity period of short term investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityperiodOfShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition royalty and milestone revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of an investment.  A loss would be recognized when the sale price of the investment is less than the carrying value of the investment. This element refers to the Loss included in earnings and not to the cash proceeds of the sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=bcrx_SupplementalNDAForRaAPIVABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=bcrx_SupplementalNDAForRaAPIVABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_CSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_CSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=bcrx_ContingentUponEuMarketingApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=bcrx_ContingentUponEuMarketingApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816820048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies - Fair Value of the Company's Investments by Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 48,235<span></span>
</td>
<td class="nump">$ 41,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">48,387<span></span>
</td>
<td class="nump">41,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">27,897<span></span>
</td>
<td class="nump">20,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">27,986<span></span>
</td>
<td class="nump">20,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">8,230<span></span>
</td>
<td class="nump">6,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">8,261<span></span>
</td>
<td class="nump">6,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">12,108<span></span>
</td>
<td class="nump">14,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 12,140<span></span>
</td>
<td class="nump">$ 14,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents available for sale securities accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808499872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies - Scheduled Maturity for the Company's Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 43,848<span></span>
</td>
<td class="nump">$ 32,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue', window );">Maturing after one year through two years</a></td>
<td class="nump">4,539<span></span>
</td>
<td class="nump">8,926<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total investments</a></td>
<td class="nump">$ 48,387<span></span>
</td>
<td class="nump">$ 41,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents available for sale securities debt maturities after one through two years fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825247456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies - Summary of Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 8,985<span></span>
</td>
<td class="nump">$ 8,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">6,604<span></span>
</td>
<td class="nump">5,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">2,381<span></span>
</td>
<td class="nump">3,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1,969<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">63<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1,906<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_MundipharmaInternationalHoldingsLimitedMember', window );">Mundipharma International Holdings Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_MundipharmaInternationalHoldingsLimitedMember', window );">Mundipharma International Holdings Limited [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_MundipharmaInternationalHoldingsLimitedMember', window );">Mundipharma International Holdings Limited [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">6,269<span></span>
</td>
<td class="nump">1,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">5,794<span></span>
</td>
<td class="nump">957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 475<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_MundipharmaInternationalHoldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_MundipharmaInternationalHoldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824064592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies - Summary of Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales</a></td>
<td class="nump">$ 1,501<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,501<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">3,501<span></span>
</td>
<td class="nump">7,252<span></span>
</td>
<td class="nump">6,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">6,817<span></span>
</td>
<td class="nump">4,262<span></span>
</td>
<td class="nump">12,543<span></span>
</td>
<td class="nump">11,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">8,760<span></span>
</td>
<td class="nump">7,763<span></span>
</td>
<td class="nump">21,296<span></span>
</td>
<td class="nump">17,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">1,490<span></span>
</td>
<td class="nump">3,813<span></span>
</td>
<td class="nump">4,305<span></span>
</td>
<td class="nump">9,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">296<span></span>
</td>
<td class="nump">888<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">$ 5,031<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">$ 7,350<span></span>
</td>
<td class="nump">$ 616<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative and other research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_SeqirusUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_SeqirusUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826377936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-based Compensation (Details Textual)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2013 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NumberOfStockbasedCompensationPlans', window );">Number of Stock-based Compensation Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,307<span></span>
</td>
<td class="nump">$ 6,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,282<span></span>
</td>
<td class="nump">16,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear', window );">Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,264<span></span>
</td>
<td class="nump">2,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,745<span></span>
</td>
<td class="nump">6,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,527<span></span>
</td>
<td class="nump">4,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,395<span></span>
</td>
<td class="nump">2,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bcrx_PerformanceBasedOptionMember', window );">Performance-based Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,107<span></span>
</td>
<td class="nump">$ 6,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.74<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">1,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Non-employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate', window );">Share-based Compensation Arrangement by Share-based Payment Award, First Vesting Period After Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Vest 25% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | August 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage', window );">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | December 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage', window );">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum', window );">Percentage of Salary to Purchase Common Stock, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesBeginning', window );">Percentage of Common Stock Shares, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount', window );">Shar-based Compensation Arrangement by Shar-based Payment Award, Maximum Number of Shares Per Employee, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfStockbasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of stock based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NumberOfStockbasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares beginning.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of salary to purchase common stock maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award first vesting period after grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of performance awards that remain unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bcrx_PerformanceBasedOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bcrx_PerformanceBasedOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_August2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_August2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_December2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_December2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813899984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-based Compensation - Stock Incentive Plan Activities (Details) - Incentive Plan [Member]<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, beginning balance (in shares)</a></td>
<td class="nump">2,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">12,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Awards available, plan amendment (in shares)</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable', window );">Awards available, stock option awards granted (in shares)</a></td>
<td class="num">(2,591)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options outstanding, stock option awards granted (in shares)</a></td>
<td class="nump">2,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options outstanding, stock option awards exercised (in shares)</a></td>
<td class="num">(422)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable', window );">Awards available, stock option awards cancelled (in shares)</a></td>
<td class="nump">912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options outstanding, stock option awards cancelled (in shares)</a></td>
<td class="num">(912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, ending balance (in shares)</a></td>
<td class="nump">1,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">13,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards available, restricted stock unit awards granted (in shares)</a></td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards available, restricted stock unit awards cancelled (in shares)</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share based compensation arrangement by share based payment award options grants in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options forfeitures in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813223776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Incentive Plan (Details) - Incentive Plan [Member]<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life (Year)</a></td>
<td class="text">5 years 182 days<span></span>
</td>
<td class="text">5 years 182 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-Free Interest Rate</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813292720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Collaborative and Other Research and Development Contracts (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
<th class="th" colspan="1">49 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 16, 2015</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>Jun. 30, 2006</div></th>
<th class="th"><div>Feb. 28, 2006</div></th>
<th class="th"><div>Jun. 30, 2000</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember', window );">CSL Limited [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="nump">$ 33,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentReceived', window );">Milestone Payment Received</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyTerm', window );">Royalty Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">National Institute of Allergy and Infectious Diseases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts', window );">Expected Receivable From Awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember', window );">UAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PeriodOfAgreement', window );">Period of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RenewablePeriodOfAgreement', window );">Renewable Period of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember', window );">Base Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember', window );">Additional Development Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember', window );">ASPRBARDA Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember', window );">Mundipharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_UpfrontPaymentsReceivableAmount', window );">Upfront Payments Receivable Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember', window );">AECOM and IRL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMinimum', window );">Milestone Payment Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMinimum', window );">Annual License Fee Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMaximum', window );">Annual License Fee Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement', window );">Advance Notice Period for Termination of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents advance notice period for termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AdvanceNoticePeriodForTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual maximum license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent minimum annual license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents expected receivable from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents proceeds from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RenewablePeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents renewable period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RenewablePeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between the date of the Agreement and its expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_UpfrontPaymentsReceivableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents upfront payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_UpfrontPaymentsReceivableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables that are derived from government contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68054760&amp;loc=d3e55295-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813999840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Royalty Monetization (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 18, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 09, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 18, 2016 </div>
<div>JPY (&#165;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember', window );">Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,858<span></span>
</td>
<td class="nump">$ 7,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Payments for (Proceeds from) Hedge, Investing Activities</a></td>
<td class="nump">$ 1,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RequiredForeignCurrencyHedgePerDollar', window );">Required Foreign Currency Hedge Per Dollar | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | Japan, Yen | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeForwardExchangeRate1', window );">Derivative, Forward Exchange Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PrivatePlacementOfSeniorSecuredNotes', window );">Private Placement of Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1', window );">Percentage of Carrying Amount in Excess of Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member] | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAmountOfCollateralRequiredToPost', window );">Maximum Amount of Collateral Required to Post</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | Royalty Monetization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet', window );">Revenue Recognition Royalty And Milestone Revenue Recognized, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_TransactionCosts', window );">Transaction Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Interestreserve', window );">Interest Reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_Interestreserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest reserve established as part of the royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_Interestreserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAmountOfCollateralRequiredToPost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum amount of collateral required to post.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAmountOfCollateralRequiredToPost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of carrying amount in excess of fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PrivatePlacementOfSeniorSecuredNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents private placement of senior secured notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PrivatePlacementOfSeniorSecuredNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RequiredForeignCurrencyHedgePerDollar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Company is required to maintain a foreign currency hedge per dollar under the agreements governing the PhaRMA Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RequiredForeignCurrencyHedgePerDollar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents revenue recognition royalty and milestone revenue recognized, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition royalty and milestone revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents transaction costs associated with royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeForwardExchangeRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual rate at which a foreign currency can be purchased or sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeForwardExchangeRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3581-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814024128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Senior Credit Facility (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 23, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,379<span></span>
</td>
<td class="nump">$ 22,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentMinimumLibor', window );">Debt Instrument, Minimum LIBOR</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term</a></td>
<td class="text">3 years 120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentFinalPaymentFeePercentage', window );">Debt Instrument, Final Payment Fee, Percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Line of Credit Facility, Interest Rate at Period End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentFinalPaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage fee of principal amount of debt at which final payment has been made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentFinalPaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentMinimumLibor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum LIBOR interest that will be added to the basis spread.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentMinimumLibor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808661984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2017</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2018</a></td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2019</a></td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2020</a></td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2021</a></td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 23.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813766720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stockholders' Equity (Details Textual) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 03, 2015</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAggregateOfferingPrice', window );">Maximum Aggregate Offering Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">17,864<span></span>
</td>
<td class="nump">6,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 5.15<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="nump">$ 5.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 85,750<span></span>
</td>
<td class="nump">$ 47,750<span></span>
</td>
<td class="nump">$ 133,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>43
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " #B>6A+1#/_X>\    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+/:@,A$(=?I7C?G37I/V3CI2&G%@H-M/0F.DFDJRLZ93=O7]<F
M&TK[  4OSOS\YANPU4'H/N)S[ -&LIBN1M?Y)'18L0-1$ !)']"I5.>$S\U=
M'YVB?(U["$I_J#W"HFENP2$IHTC!!*S"3&2R-5KHB(KZ>,(;/>/#9^P*S&C
M#AUZ2L!K#DQ.$\-Q[%JX "88873INX!F)I;JG]C2 79*CLG.J6$8ZF%9<GD'
M#F]/CR]EW<KZ1,IKS*^2%70,N&+GR:_+A_5VP^2BX7<5YU5SO^4W@E_G\SZY
M_O"["+O>V)W]Q\9G0=G"KW\AOP!02P,$%     @ XGEH2YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
MLR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(
MR-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J
M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1
MCVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.
MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.
M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07
M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!
M_]':-\*K^(+ .7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7
M<LW(QU2ODRG8.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD
M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W
M<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-M
MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(
M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R
M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>
M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X
MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5
MYYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(C
ME1P&%A<RY%#NDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>
MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+
MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y
M,M\Y<-LZW@->YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,
M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:
M,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_
M 5!+ P04    " #B>6A+L3)(C(D"  !&"0  &    'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;'U6?Z^;(!3]*L8/\!3\_6*;M%V6+=F2YBW;_J:6MN:I.*#U
M[=L/T.<<7/>/ IYS#Q?O <J!\5=QHU1Z;VW3B8U_D[)_#@)1W6A+Q!/K::>^
M7!AOB51=?@U$SRDY&U+;!#@,TZ E=>=O2S-VY-N2W653=_3(/7%O6\)_[VG#
MAHV/_/>!E_IZDWH@V)8]N=)O5'[OCUSU@CG*N6YI)VK6>9Q>-OX./1]0I@D&
M\:.F@UBT/9W*B;%7W?E\WOBAGA%M:"5U"*)>#WJ@3:,CJ7G\FH+ZLZ8F+MOO
MT3^:Y%4R)R+H@34_Z[.\;?S<]\[T0NZ-?&'#)SHEE/C>E/T7^J"-@NN9*(V*
M-<(\O>HN)&NG*&HJ+7D;WW5GWL/X)<$3#2;@B8!G B[^2X@F0C034&R2'V=F
M4OU )-F6G T>'_]63W11H.=(+6:E!\W:F6\J6Z%&']NP#!XZS(38CPB\0* 9
M$:C8LP"&!/;8H>-_!0XN(H(%(C"#R-"C!3V&Z3%(CPT]7M 3:P%<1 H+)*!
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M+.>LZ_.=(6C3/V%H>$?S?U!+ P04    " #B>6A+_:]9+6($  !6%   &
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;(V8W6[C-A"%7T70?58<BJ0HPS$0
M6RY:H 6"7;2]5FPF-E:R7$F)MV]?ZB=>>6:4)A>Q1'\SY*$HGC&7EZK^WAR<
M:X,?97%J[L-#VYX74=3L#J[,FR_5V9W\-\]57>:MOZU?HN9<NWS?!Y5%)(4P
M49D?3^%JV;<]UJME]=H6QY-[K(/FM2SS^M^U*ZK+?0CA>\/7X\NA[1JBU?*<
MO[AOKOWS_%C[N^B:97\LW:DY5J>@=L_WX0,LME)V 3WQU]%=FLEUT$EYJJKO
MW<UO^_M0="-RA=NU78K<?[RYC2N*+I,?QS]CTO#:9Q<XO7[/_DLOWHMYRANW
MJ8J_C_OV<!_:,-B[Y_RU:+]6EU_=*$B'P:C^=_?F"H]W(_%][*JBZ?\'N]>F
MK<HQBQ]*F?\8/H^G_O,RYG\/XP/D&""O ;[OCP+B,2#^&: ^#%!C@/IL#WH,
MT*B':-#>3V:6M_EJ65>7H![6PSGOEATLM']<NZZQ?SK]=WX^&]_ZMDKB9?36
MY1F1]8#(*:)ND8PB<"4BW_]U$)(;Q%J2<'G;P882B49C^-\DVP^3W PS9N<J
M[N/C:;SAXQ4;K_IX-8U/T%P/2-(CIV$BM0 T&31/C/)DG\FS_3#/C1[-ZM%4
MCT5Z!D1/QJ$4?K:4B<E8,PHE4N,'3"$CI. E&5:2H9)2),G03BR@^=]02$F#
MAIM1"*16Z/7;,A3X">)5):RJA*BR JE*2"\V,0C:4"A)#!IO1B$),C5(%:4@
MB9,959959<GK:&=VG92-3^FLH">T3IFY)^N7YB&OXV?R;#_,<Z,'!+^7"ZJ(
M;.:"F7@MT"+?<)@"@?=<!M-"Q&@7V#*8LG9N#<.,4P%5I[ ZH'M)C-^H#4/)
M1!NLC5*IC#661BEK4CFCC+6_!Y!4F<;*)+.$-!;&0%A]QD JQM; 0%+-K4;>
M+2&FJ@Q6%=-N)-#52#%(A"!5",6,L IO/0RFD\2F,^IX+P=JGA:;^<A,.[H#
MOQZ)/(9+I<(6R&%QJK7 ^AA."05S GES!^KN%KL[4,.5DBQ*"I$GG#&0QKOH
MEH%,.E/! >_O0 W>8H,'ZKAW$A0V0PX#9<@6R6#&+P*LC<%4K&?J2^!]'JC1
MI]CH@7'>F&BCT%V*-XF,HVR*;8VCC#8S5@V\UX.ER@ KLZ3HO0,->*HW+ =:
M6BR/X921<8H%,IP61LTIY*L1H/:/IW(],NFT)_$%+!;(8\3@6$P3\V8Q8].;
MOYF?>WRA(FFADN)"1=*:P<8ZP2N5P7P=B9]YQF%I@G?B+9O-)#/&)_E"1=)"
M)<6%RLC<K!GRFY=CB# &PC4*P\C):K_5Q)<HDI8H*2Y11H:\?P;KXCC0^-=<
MQG'^_5-XZ^0X[?TN1@JCR9E(Z>J7_H"J"7;5ZZGM?D=,6J^'8 _]&1AJ7\-B
M TQ[!HOM<,3U,_UPXO9'7K\<3TWP5+5M5?;G+<]5U3H_?/_&A<'!Y?OK3>&>
MV^XR\=?U<-(UW+35>3S%BZY'B:O_ %!+ P04    " #B>6A+S]38UV8$  #]
M%   &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;'V86V_C-A"%_XKA=Z_$
M&=T<. 8B+Q8MT +!%FV?%9N)C94L5U+B[;\O=5FO/'/8%^OB,^094OQXV5SK
MYEM[M+9;?*_*<_NX/';=Y2$(VOW15D7[J;[8L_OGM6ZJHG./S5O07AI;'(:@
MJ@PH#).@*D[GY78SO'MNMIOZO2M/9_O<+-KWJBJ:?W-;UM?'I5G^>/'U]';L
M^A?!=G,IWNP?MOOS\MRXI^!6RN%4V7-[JL^+QKX^+I_,PXZ3/F!0_'6RUW9V
MO^A3>:GK;_W#KX?'9=@[LJ7==WT1A;M\V)TMR[XDY^.?J=#EK<X^<'[_H_0O
M0_(NF9>BM;NZ_/MTZ(Z/RVRY.-C7XKWLOM;77^R44+Q<3-G_9C]LZ>2]$U?'
MOB[;X7>Q?V^[NII*<5:JXOMX/9V'ZW7\)TVF,!Q 4P#= ES=_Q? 4P#_#(B&
MY$=G0ZJ?BZ[8;IKZNFC&WKH4_4=A'M@UYKY_.;3=\)_+MG5O/[;K9!-\].5,
MDGR4T$QB;HK %7ZK@5 -.:EPNJ]@IQ5IC&M@F ,/\3S/(<7Q$8R/AOAH'F]$
M&XR2=)"<!\DJ2HC7(A,@B\,D\K17#-W$.IL,QR<P/M'9")OY*(EG-F.2G:(U
M;#QYI-!'JGR8,!1&M(93X2-5/LAC(X,V,F!#]FZFZC AA]*)5B51ZNF:-?2R
M!EY$N^=K74N<"2=:P^P9,2;$PSX$5E@._%"W"\7""Q!%LP_NWHR'00:8B:09
MH\UDJF6 *N64/'8@L)X,J1%H0E_S8B(9!ADIKK+RNB(COSJ@(A\>#>:;T8!C
M92;23)##=0=$JX1"CQF,-Q.#IDFEFUAWMFH8K4D2#_<-1J71K)1(SPV I9%6
MM"9BCQ,,2X-HF4DKFH6&Y:C= =7*4)@D'D,8FT9S,U*]!+B9&@4(K<J,KY\P
M-PT"I^HH3467-T72#I*%OA%%&)\$\&GDY$::C"L.$^4(Z:(TSB*/)0Q1,II:
MO@F;,/B(0%9R?II$@EKR(T2JF'RS)6&*$J"HK"DG0%$3IXDTI&5S(M_;P1@E
MC5%CY#1% )&\CE.UY@5,]@P*PB E %(Y^'+2D&1R'2'= %E&OGF3,$U)T]08
M.<^01N4JRUB-";#\Y/GZ\=X0ABJE8$CX&AECD,#RT4@N$^"@6Y"IZ1,4YNUS
M#$("(#02A*0)9R*YH]D!%84>Y#"F( ,*DJ0@$*DU/FL"$LV7O?=N,  9K"))
MKO2!2+O1:TA'N+7GVV/,4@8LE7NLG#4EC=I3 A'[!@)[-L@ I"1!RH"0'+L%
MAO0#%J3AVL<*QBQEP%(Y,>:L6;J.$X52($NBS/?Q8)@R@*G<ZN2L*4FD=BH[
M),LRWYZ(,4P9P)0D3"?1_+S! 2Y5DQ_0<<R99$\P.S2J;/,VG*^UBWW]?N[Z
M\YG9V]L9WA/UAT[B?6X>=N-)W,]BQH/!WXOF[71N%R]UU]75</#T6M>==2[#
M3Z[%CK8XW!Y*^]KUMZF[;\8#N?&AJR_386-P._'<_@=02P,$%     @ XGEH
M2_+:^>BW 0  T@,  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6QM4V%O
MW" ,_2N('U!R7+K>3DFD7J=IDS;IU&G=9RYQ$E0(&9!+]^]G2)JE7;X -G[/
MS\9DH['/K@7PY$6KSN6T];X_,N;*%K1P-Z:'#F]J8[7P:-J&N=Z"J")(*\:3
MY /30G:TR*+O;(O,#%[)#LZ6N$%K8?^<0)DQISOZZGB43>N#@Q59+QKX ?YG
M?[9HL86EDAHZ)TU'+-0YO=\=3VF(CP%/$D:W.I-0R<68YV!\K7*:!$&@H/2!
M0>!VA0=0*A"AC-\S)UU2!N#Z_,K^.=:.M5R$@P>C?LG*MSD]4%)!+0;E'\WX
M!>9Z;BF9B_\&5U 8'I1@CM(H%U=2#LX;/;.@%"U>IEUV<1^GF_1VAFT#^ S@
M"^ 0\[ I453^27A19-:,Q$Z][T5XXMV18V_*X(RMB'<HWJ'W6NSX7<:N@6B.
M.4TQ?!VS1#!D7U+PK10G_A^<;\/WFPKW$;Y_H_"P39!N$J21('U#\/%=B1LQ
M^^1=$K;JJ0;;Q&ERI#1#%R=YY5T&]I['-_D7/DW[=V$;V3ER,1Y?-O:_-L8#
M2DEN<(1:_&"+H:#VX7B'9SN-V61XT\\_B"W?N/@+4$L#!!0    ( .)Y:$OY
MT]-NM@$  -(#   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL;5/;;MP@
M$/T5Q >$-=XDJY5M*9LJ:J566J5J^\S:8QL%/"[@=?KW!>PX;NH78(9SSEP8
MLA'-BVT!''G5JK,Y;9WKCXS9L@4M[ WVT/F;&HT6SINF8;8W(*I(THKQW>Z.
M:2$[6F31=S9%AH-3LH.S(7;06I@_)U XYC2A;XYGV;0N.%B1]:*![^!^]&?C
M+;:H5%)#9R5VQ$"=TX?D>-H'? 3\E##:U9F$2BZ(+\'X4N5T%Q("!:4+"L)O
M5W@$I8*03^/WK$F7D(&X/K^I/\7:?2T78>$1U2]9N3:G!THJJ,6@W#..GV&N
MYY:2N?BO< 7EX2$3'Z-$9>-*RL$ZU+.*3T6+UVF77=S'Z>;^;J9M$_A,X OA
M$..P*5#,_)-PHL@,CL1,O>]%>.+DR'UORN",K8AW/GGKO=<B29.,78/0C#E-
M&+[&+ CFU9<0?"O$B?]'Y]OT=#/#--+3=71^V!;8;PKLH\#^GQ+YAQ*W,.F'
M(&S54PVFB=-D28E#%R=YY5T&]H''-WF'3]/^39A&=I9<T/F7C?VO$1WX5'8W
M?H1:_\$60T'MPO'>G\TT9I/AL)]_$%N^<?$74$L#!!0    ( .)Y:$M9>B1Y
MM@$  -(#   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL;5/;;MP@$/T5
MQ >$7=;9KE:VI6RJJI%::96JS3-KCR\*, [@=?KW!>PX3NH78(9SSEP8T@'-
MLVT ''E54MN,-LYU1\9LT8 2]@8[T/ZF0J.$\Z:IF>T,B#*2E&1\L]DS)5I-
M\S3ZSB9/L7>RU7 VQ/9*"?/W!!*'C&[IF^.QK1L7'"Q/.U'#+W"_N[/Q%IM5
MRE:!MBUJ8J#*Z-WV>$H"/@+^M##8Q9F$2BZ(S\%X*#.Z"0F!A,(%!>&W*]R#
ME$'(I_$R:=(Y9" NSV_JWV+MOI:+L'"/\JDM79/1 R4E5**7[A&'[S#5<TO)
M5/P/N(+T\)")CU&@M'$E16\=JDG%IZ+$Z[BW.N[#>+,_3+1U I\(?"8<8APV
M!HJ9?Q5.Y*G!@9BQ]YT(3[P]<M^;(CAC*^*=3]YZ[S7?[I*478/0A#F-&+[$
MS CFU><0?"W$B?]'Y^OTW6J&NTC?+:/SP[I LBJ01('D0XFWGTI<P^P_!6&+
MGBHP=9PF2PKL=9SDA7<>V#L>W^0=/D[[3V'J5EMR0>=?-O:_0G3@4]G<^!%J
M_ >;#0F5"\<O_FS&,1L-A]WT@]C\C?-_4$L#!!0    ( .)Y:$NR"T\;MP$
M -(#   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL;5/;;MP@$/T5Q >$
M7>PTVY5M*9NH:J566J5J^LS:8QL%/"[@=?KW!>RX;NH78(9SSEP8LA'-BVT!
M''G5JK,Y;9WKCXS9L@4M[ WVT/F;&HT6SINF8;8W(*I(THKQW>X#TT)VM,BB
M[VR*# >G9 =G0^R@M3"_3Z!PS.F>OCF>9-.ZX&!%UHL&OH/[T9^-M]BB4DD-
MG978$0-U3N_WQU,:\!'P+&&TJS,)E5P07X+QI<KI+B0$"DH7%(3?KO  2@4A
MG\:O69,N(0-Q?7Y3_Q1K][5<A(4'5#]EY=J<'BBIH!:#<D\X?H:YGEM*YN*_
MPA64AX=,?(P2E8TK*0?K4,\J/A4M7J===G$?IYLDG6G;!#X3^$(XQ#AL"A0S
M?Q1.%)G!D9BI][T(3[P_<M^;,CAC*^*=3]YZ[[78)W<9NP:A&7.:,'R-61#,
MJR\A^%:($_^/SK?IR6:&2:0GZ^C\L"V0;@JD42#]I\3#NQ*W,!_?!6&KGFHP
M39PF2TH<NCC)*^\RL/<\OLE?^#3MWX1I9&?)!9U_V=C_&M&!3V5WXT>H]1]L
M,134+ASO_-E,8S89#OOY!['E&Q=_ %!+ P04    " #B>6A+CEV%*;4!  #2
M P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6QM4V&/G" 0_2N$'W H
M:]O-1DUNKVG:I$TVU[3]S.JHY$ LX'K]]QW0\^S5+\ ,\]Z\&89\,O;)=0">
M/&O5NX)VW@\GQES5@1;NS@S0XTUCK!8>3=LR-U@0=01IQ7B2O&=:R)Z6>?1=
M;)F;T2O9P\42-VHM[)\S*#,5-*4OCD?9=CXX6)D/HH7OX'\,%XL66UEJJ:%W
MTO3$0E/0^_1TSD)\#/@I87*;,PF57(UY"L:7NJ!)$ 0**A\8!&XW> "E A'*
M^+UPTC5E &[/+^R?8NU8RU4X>##JEZQ]5] C)34T8E3^T4R?8:GG'25+\5_A
M!@K#@Q+,41GEXDJJT7FC%Q:4HL7SO,L^[M-\<^ +;!_ %P!? <>8A\V)HO*/
MPHLRMV8B=N[](,(3IR>.O:F",[8BWJ%XA]Y;F69)SFZ!:(DYSS%\&[-&,&1?
M4_"]%&?^'YSOPP^["@\1?MAFY\=]@FR7((L$V3\EIF]*W(MYJY)M>JK!MG&:
M'*G,V,=)WGC7@;V/C\A>P^=I_R9L*WM'KL;CR\;^-\9X0"G)'8Y0AQ]L-10T
M/AP_X-G.8S8;W@S+#V+K-R[_ E!+ P04    " #B>6A+)LR7L;4!  #2 P
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M3WBVXYB-AC?=](/8_(WS/U!+ P04    " #B>6A+T Q][,4"  !,#   &0
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M93??=@LMVGYV3X8_$.M_4$L#!!0    ( .)Y:$MI[O+HX0$   $%   9
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M--9O/[B]GM_R'%@U+&-*UO^*\@]02P,$%     @ XGEH2_90U[^W 0  T@,
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M<N%X[\]F'+/1<-A-/XC-WSC_ U!+ P04    " #B>6A+U5=+1;\%   M(
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M$!"S!1*S@L0L>N<$)&8%B7&R$@AHV:*W6X+"+-DRW%GA@< E0(<6Z- *.G1
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M@+V_J/)M=S@_.OR'P.1_4$L#!!0    ( .)Y:$LZ;D $0P,  +D.   9
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MX\_JF=T3P9Z8Q2QLTJV=>V>Z529[S<.8I/AJ"TV:YU$3+C4?%8=[!?%G"38
M,T6X21$Z/_U 05<4HR9VFLYI*$EHLB*Y5Y$PHKMM&+()0S9@HA7,J(F6,!%Y
M7+'<BY+'\!\H=!.%;J#L5BCT?ET2DL0KE@U50.-P!8,7V\8>XV],GIM.>2>A
MS0YT^Z020H.IZ#^8QFIS<\P!ATK;:6SF<CP_8Z!%/UT->+Z?\K]02P,$%
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MCS <0$, G0+H<@ / ?P9$%T,T$. /@7PY8!@" @^ ]3%@' ("+_:AV@(B$2
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M-RUJ?M#];6'NY3#H# LMNG&(2Z9)<O,/4$L#!!0    ( .)Y:$M1E[I@^P$
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M4;*=4*^I?&^'$_C0$+S1MXM@O.*L_@)02P,$%     @ XGEH2\RJS]DE @
M\@8  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULA55MKYHP%/XKA!]P
MRTL1-4@R-<N6;(FYR^X^5ST*N86RMLK=OU];D"&>W?M%VO*\G6-ILU;(5U4
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MQ@WG"K1=N---M?J>6A8,&F6FF9X+][>ZA>+C?!'AY38L_P-02P,$%     @
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MP7V8Y:D/+3_ZRZ#ZUH?S3\?7/]_<BJL?IM>7T^/3S[?GQ].+&W'^\;BAQV.
M(O4C &0>?!'_%3Q7W[M-_7D8WXN;Y^5=$E6?WLW2+]7OCHLTQ;F=A=D,>OXY
M\%/$GSCQ\QK$1T>=[E&OTP#<61@%J3B&=O=)6H-L.IL%\!R>SOG-IBE*>*Z#
M59+F-)?<SXO:8O]<7W_9PT])!"3EIQ*BVFL?DX:&?PFBZ.B7.'F*Q4W@9TD,
MH)YG6=$,:[)< BG<Y,GL%T_<$%&*3T6>Y7Y,RW 8QI)6WS02U>WSJH;H3OOH
MSXT-KH(T3.:-BZ3H_/_\QW^L)69[P<_@RQJ>JF_*<9WO_KE76V]H.N?FD7]?
M?;KPHZP&^7$29TD4SHE&/OB1'\\"P"HPCDP<*KJ04'R._6(>PHMO@!U\OCD1
MAP=OQ($ ?-\^)$4&^*_/)YCI/3ZL@9ME,$P-(C][$-"7F.&'X.]%^.A' $7M
MQ>L -GHX0\#QU>KC\_@17EBZ6\X"Z/4N M)9I,E2S)(H\N^2E-A,[77L*<[K
M^POY\;MLY<^"/WT###<+TL?@F^]$M?E5&JS\<"Z"+\"H,Q@2)Y?D#[!Q9Q+!
MOA,3)\$B@.?S,GBJGQH;2G(@F/4]7J4@+%+810@"HG:%^/%$'.0U[DP NKOA
MH=S/+D+_+HS"/)03I8WZD$1SX K_^7_'W<[HO3B%D7,7MT*YE(F5_XQKXWB>
M%H'!8WV9\@!6(6]JWX#.-(#5+6IO7P W"L0BC&%'(%M)[J+PGEK4-W\<)K"6
MT'68BX4_P^G79O<QB8_2 &:80K=QD@>-\RPO9&3PV3@A?-$-_YF&_Y.&WQ,?
M@UPD"\7V:RV3^/X(4+D4)&[Q19I:;=Z.E0UH9=\YMH $-6.^?=!NM=L=P$ J
M8'<7P7O)LH5?Y ])&OX*KU*?W?=BX+7;[?> ,_5.B/)ASMO(,/XZ9R-!80UH
MC?=NS7B@+O&(:X?3KT_&7F\\02Z(K)]>&_6\T;@KOZJSO3D@$]8!%AGYPA&\
M-O-7(2RZ@^*+91$1;Y8,(UD"IWD ^@\? Q$E68TH[#;S8!'.Z@O'!)8U+I_[
M_:BRL;=O_T(9<WCEXY.'( ]!%&8H= [$6[4J:G'6")\:U>GE)R5ACFP@A6T(
M>*7>:OI"K8,ZT:S1-II:2WIZ0<MD.S6G3/F[3KK<>J<9.YMNGJZSV=9SM6@+
MM=: )#YQK=)>N8"](@Z=*HR#E+P->DUO:[.GMOVO6=ZX9/.\F.4B VVGKK$D
MSWX$<KM!6!T;B093-?H%*B5^.F-]:@YMHX0DOGN'IPV0G38(W.,D(SFR8LAA
M3P(W<&AI6X'P?1 ':&;A:_Y\&<9DQN%\&G#AG@/J-SZ9,$UJ A$":7WR7:?&
M)U4)@\HP!MY;@T6_V*"4?0]6MSA$/OU& (F#*1N$][$4[K-G0$@*BJAKEBBC
M7?S]@Y^%,T9F&!5(];%\D_;T3.XE).DM-_Q? *0'[,A_!'S<!SONP,]Q&O@1
ML0:" D;W'_TP0M4&)TP$#>AKU,:/-\JT=9L<C82S*'EJVMSK]_$G32[^#%;!
MJ69-YW\K).@B3P0J<:!2P9PTXN%;_$P&2Y$!C#!DXNBYIA>=!##S6<B**%'^
M$@WP7YUZYH7$[CS,5DF&M$Y;SZ'0.S6UHSL_(^5WB92ZUI286E#@*//@+B<^
M3I)[!MN^CJ1*$YC7,BR6;P%8TNH1\'4T\.#']T@EH#^'2EY!-SML&.XBJ^">
M;!3"CJ6_U-;!,@AWL-[<!E#5C.%UW6"[6*J\D\%_W(:\W!;P!N*> =%DI(]F
MVQ.46:YTO1%^50#K]Q%MT/>:];]!H4=C+OV\2%G+7-]$H^10XN0- O\8@CP6
M=\^RY?K)&^NH^1V$#"&9E904A\&,\   LR"8:Z^"::+4H +TA92_<FW(%2C'
M+LW ZC7;RMR\\I_)$;1^#[$IG*/@K1,/C( F)"QRM+4MK!?%7HK%%FBVAYMM
MZP%J=!4)/Q=WP7T8QP3N J4?6!<[M0]PGS>U_ @&O.B F+D!S(9@9:'#6>Y\
M'/(*Q-7,,<V/9/B#O)"D!US<R+,:Z:WO6_SU-OB2BP\1T%+5'>YV34FH;Q\"
M4H[]^%E\")/C]!D4F"N0[DMXOV!KRQ.P(BUQ"(R.+-UN^[UL0G]UWK\!BA:^
MN NAS]E#G$3)_3/1,O::/P "YT$&$X">DE4>+D%!R&P=, .#'CZ(;.E'D5@F
M43 K8*?-T^(^X_9W.#'Q2_ ,2_$K4#.R]L<D>F0&B("M?+!*[D%QS$+B%B!L
MD(:R5FF*"W2>!B0Z$]0P<R T*<Y1/4E14U(ML>>GAQ#4U<Q"?A$O@:Z7L.'0
M)QO37@R^A%(_)&!! X(M]A3F#R*$CL&@+UO+R/A!0&9!&;8G/R/-,ETE[*:'
M\4^"R']"H.!S9S(>BK]@KSC?!7"/S-*N8%PP-8!Z[H"GJ#"+!Z^&Z1P_3UKL
MDZ ?2__9>@)DT!4]T1<#P$L@AO08=4M"Y!623)PS3T)X9[8&MM"TFQE=#&81
M%?. X/25"(2N<FNVB C$SM,#L)WGH^0)O?U9<9>%\]!/ 56>^/'J6BACYZ:X
M$Q<7Q^)0$J#UO29"[/+RY/C**[V)WZA76N(#B.O2,.()E'9<?%A2W(R2B<)<
M+%Z%0:0,&19*1B04:R:M$HRXB+(SY%Y)' ?4C,G!%P<]<BB)2[*#)K1,G9;H
M@Y'9[=$3LXKP!5F-+3'P;$J1'I9LBY5X #T>N%\0HQ(&UC^#A6N2SDF!8[ ,
M0UFEL'CA"B7P/5MAT3,^1Z#T7OL<AUK[SC2B/[=N6N+[Z51CFS 5HE44+BWP
M4AU9XAV#Q V*0R'1BPP1$"@Z;72-HJL/IFY$3GE^&2CS$0B60&"04Z+\;T5L
MX9PVBZNM6L=GC, $:+O#=IO)#23#%/Q#@E)_"@^TW* /IY;<L/>VP26N68A^
MLKJ@@9G#1) %TJ.'()(S6BZ#E*"?/02S7UAX\J[RQ Q9"?*FG+6D.6 7=#@/
MV&@,['+II[\ OS*[,+7U*.R>%7I: ?Z.L%96O?*'- B$%62AR5:"+J #X[MU
M+B0..MZH@PP&/O3;$V&%8TI88L@(J@>P0Y5>\_?"1[6F"GB5BD/Z6KTB5B@:
MGSW)PH&7L0SB78X^!11#+#K F J)0S_C!-",8\Z<W/T-=^]C4&%>>@/6AL-Q
MH'O0X8J4.\_\12!5:"E\M5W$K7'K%N1F\I$911A,$1BAS^$?KG44 HW,$;BL
M6* 3%X?#.01*P5J S0L; %Y+F;;+@@44R1F*LQPE%7R2I$=(<^'9[!8DBS O
M:&-Z)4*DKHE+X\SN07RG,>'!!U(GC00-DQ057  U F3G+ Z6; $N6#3RP" 0
M$T18"RC#N:QJ+6T!@BH'"C[HGA&)(S*YT_=$UQEH$I*,232SX$-B!K[2&=/?
M^(\Y#?^S43>+P+"#[862.XH4V#8A^I80/@*6<H0NCI:P/"'WL([2[ 3*8N6C
MU$,:D",!=(Q?E=BH>D$\T#LB7#D_AD]E)TN8::;"Q U,A(U2F#(P[&")"D4*
MZ-,*S0RU:T2FJR]0_NZY(^,4JQ 4Z<&H $7DA@R#IZR&&&2O+C!@8691&#.%
M6!;^78!4C X%<4>Z!V+L"9  .B+PY\= LJ^9L>UG83HKENB8(OJ.Y\0&>:5Q
M=C,_39^)76JJ TC(5->KSM30Z>+_+@4*Y[T %25Y(D6  \59L01*4_RC[*98
MSR<R-(+RYY74_= L7;+XUIU4527=RR+\0O2!SL<:!6E*G2-)7J!B#5J=HFG7
MW(3TTT +%4[]/D4BX)^G&C03+M2@L:RW=KW4YO3N/Q#=D3>> .\7DR'\4!&R
M W$X$F_X,>JSQTK=K>W7L=?MM45OHIL>CJ$A?#OLB&.WT(,U]#KML>CU0=8<
M#N%U_*+?%NP/ME%V(/HXP  ^=(83_!-!ZW8(MCZ&\48.>?\;8ZP-DT-D]1"8
M+@+49US!@\EX#:Z&7F<T$5U05QA+\/=DTHREOC<9 L&/Q$@<=G#*^,UHX$83
MBFQ<QA'^@+<133U&$SP:=5T[Q&R0C(4@*"YS,.FT2^>YJD4[MXK3IJDOB[%L
MAJ!78_\ !XJ?6"IW,!0Q3P"YYXW[8T1QUQOTK=?]!:BII@5PA:0 R9@_)?1%
M!AKZ &AQ[$T RPWDA#2CL5++*SDNY974GY?S3K142%$O160Q#P,UIB"99XO"
M-. 8+WFDP^5=D6:T"DTA'W;;\K":-D_0/LB5H^@'$ LY-_RA6/J8D94^AC,4
M^*F./U5F</, D"?WH0?[ 4V.8]H5BFI1Z5&F@O5<&0N>N 0M*%R1ZT%0+"7V
M96C\AR3"R .P-=0C,("H;#O3I&0%W@1_#],B$Y__J];DYO.%&9*U,BO6ABB$
M-UK2YK"GB L2((-6J)X'F!B!:1$ARI5G(7TK2&X^;@?288R% L0"/879 [)H
M4'I\6!AC"Z$1UQ+3[2C><[WU(8QPAWV.[_@#4^DN:PO4.^SA+O<F[2'_!MZH
MEE7\I[]<O8?U;(F+?-X2PT%/\V;\W+3HL-_4:_!QAU6&_:D;#EUK.O!&$V#U
MP+F&P#DG0H4NS:+!A+QAF]@I;$]D7K"#QP,':W\5[!DIU_/ZDX'^W81">#KH
MZ%;\5Q,:AV.##OSLP,=D,!(H"#I>IS=T8F/@M2=] FLXZA,V1L,QQZ\C,K 2
MF@G2>E;<0:^2UG?E$B]D264U$W7 *$-K"HR02!IN$E35::! 0>T/YJIX&_O3
M,:6+I!](YI5,A)$^#'*^1Z0=@O:<ISYF(#N=+'XTPZ9*F+.>:PTFAY X0XL1
M :7P(RE[=>'?JG-_%?'GX$?M<9E)O5 V<&.8PO7TZORGZ0<@I\ZH_U[HG$;G
M_$/]E*P,,EA7:8CB/7J67G%_&3Z"^OJ4I+\@?BGTD;$&#XMX%R"6@3R*!6"Y
M2"70+NF/Q!4':=:R@ HS]MH0U\1&P%I15B\8^S@(1ES9D"$B(S7:,PQ:A5K8
M%91"(_Y92H$\50$NX<Z,+&/=Y[6G#6'"MF2*+5<4BB\R4H=0^P'JPK#Z$9H]
M8+;G#PF0YJ,$R)@ 118L"DRN>C0V ,<56X2H E44 P^Y-.3@@>S0A]:+P+AL
M%FA 9F@\D1G@,*^UUZYL73>:>.Z@(+OZH&F8TI]HM[V:S985R"\X>FL;ZU?0
M,)81W0O@.A22M1E(%@2_($WEY*!),3K!OI>8K/F0Q0_.4'(B(FVB7>FJ5^DL
M()FC2/6DMA1S&M(+.)1+N^R^,7G%Q(T)/6#(%13G]3.B*\RX,%XHFC0U #Y2
M</(4D#&Z^_PP;FD#1"7D-+@; YPCXAD@4WRN0.CN@3PL?Q]' Q"KI!T-WXM%
M0&FI(4WJ6#85.H7G4WKOQS+(;WS Q]>?,A,4JCO D5QA%U#LA+R_R9=PQO&B
M+ >.*=&NW\G3$$3 >S=0,JQ[S\@%RT926&7,[3I3R+'Y5.KLCUR&3!?2D>?B
M9*G_A,9.0&-Z%,NBN ,1/DL__$H1V'OZ2D$&WRZ "%DO0C#+@O&.PU/DSY.K
M;['YRGS)W82O2CZC64MF9#5*&YG6&BQ@*ZN>D=.M0,H6/KL<%9*4D[B(<HP5
M&*EN.PS9*PX$P9L;VI((X\!^C,E%#DA=J+P+'OQHP2@PODGD[6HNH*I;!%V1
MQ'%PG^2A3'=^1 ^4M+?D@MN+S\ ];ZF$G[,KYM;_(O>?RBMY5EP>]VQFE([J
MS*S "\=*J+\<^T,7(LLLZ(-[0XDF4T/@E89\%IJ])?FT(C0/%] X(+9[%^1/
MJ&4V!F6@^SN5JM$T#O*W%.69GY%,-P(OB'V*"F W4CG"QOZ3) 7%,F>Y=E@"
M@H#R<,6(-V(O-L#5%I@:DV( U4YQYC(%1ZKG-KG32G:G(>%K8;M&71[<NM.W
M[+I@U0=3GJ -,WD?MAPH."CN<*0DEJIK<_9T"SU.I-DAW]0./J)??YM)E766
MC$6>*YG1[+T=<FA;XB-L+U1JZONE)0XZG8:'0U2 *;<)-5UT?.O@LE%;I4,\
MTZFH-3?)5NFM@((4E0^S+.R_")48UJN,\7^C0Q(O]%/80@;8,-O\-G<J@P5Y
MR34V2T.2!W+;Y._$8?@&-2W@KX33 --D4#Q(1[6!G%,,0$H<AM!D'J"."(SL
M 4-N,ZE&8'JE8NDF[ILB%X?'U!3:,N<'$S<U2G<*;93=<%<\(U$H;S-TJI@)
M3I3%U&'X^(86 O:C8GB,FRS!UYZ19R!/:(EZ-C+OTE(J\(FU7-/J<EWKY5++
M0'00L<)'TM'XI%:<Z@3?D/)I_4TKWT0CI E4XC"^ICS#DG")R46A+!S)-")
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MU1X4Z2IA]VKT_&;#D.3Z!3,!7JG*#&,BJF1/&!F6>C">U+SX ^7+IRS)=FN
M)+B!=L9=^#?<1#5=3'SOM>'+J4SV<2?'.^(*0)VC=M^92=_W^OU^2Q[7,GL&
M8V!^'XBIIH%S=[Q*%^R"R+7+5>227#WXUY=3015I95Q2_)!8,N8T-(\+3Q_H
M*^7H8K(!]"<R/LVQ.!,(QE%*2;,_^C BBJEG<EM&K)[8R2=<ORZ-Q29(YDG
M_I#UR]/QQK@UT8SHJC(ISI0]F& 2YKC3J;I1FE.O'&L(9(0%D"2*KN )G4XF
M/MKU^5R8'Y9\>#C7IVH1?EQ0YU;E:;TJW]HM:H.<R$,!Z@.:JA,*O] Q G$=
MM 5GLLD.,R$5*>@2%)@ UO NF/E@+"BPK&XEA*00%7'P!16A.N-G5Z$]I6I8
MR*Z4=>D$P7(5)<]!(#M>R1IC*I[ETBYTJAW1^0A 3DP[5DH/EPHRGHQWMX2!
MS=($Z:;C3< P1?.TLX$S$)5Y@P[E:4W@T>>,]L"I#M#>4H298T42QH8Z.]SL
M*%J5$\FD<ZAZD*RTG3&#RO\EL(+!%,8#+"_EDG" CD-QIF CDP%"HYRY $*>
M3-D%,&P187T'J9<<R%/IIL#AS?"M4M'L<0&KN$0%UPH4$!]QOS5EVI391^RU
M.0Q;0<M3*4[\87I\.V75^^KT>GIY?G;Q^0T'84"Q5CE:3:E(==DFK61R@_-I
M!AR"UBUT%@AJ3KJ:'4]!D 4[E(R5A]FBE$7;DE,FEV35 ^^Y@:1$+# ;$R!\
MJ6>R)XK6$:TGJA@QN6ZZ7BC#VM<E%2R1SE#)I[L'<QTKIA"SAV2O00_BP_'_
MZ_=[;7:V2[+N2^[))X/1@G%]6*F(FAP?Y9*%<IV1+C\C17"58*I-2#DL.I9?
M)F0\>B.(<[-'4.0H>1%\D:DZ4A5PA3?+QT^5?9 R5]Y1,;7T_X;>$&>-E+-
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M )C&T?9Z6 $$OSOXN]MN.P*,0Z\_&K.MW(%W^Z-ZB/ 6M48R#?W5*DV^D H
M"W$ A-X=NTK46F@*=8=],\BH/Y#D"Z;0H#N2^P9>ZTWP21>,^MX 2;S;:;$M
M)X\Y@/9]K 3H@=+5DUSFG"0(FAE7J"^64BC9I?42?Q;E)N9&-\7T/_+X)\H#
MB/8L*$@T@M%MR]#8D<?R$\\-52K]1LK6\M$)RGJW]!X%6.&K)*2L#"_YE:KJ
M!8\C,W/)'86: 0XBO4X5&-3XZ(Y4D[>24:E*MSOX%M3J(K7$3\^P"-[T':_=
MZZ(R/6@[*7@$?=C-91$G_)?AB5QSV4V7!LH?Y)\]> X*S*@WZ%GO#5K.(7KM
M;\M0837EW!IUY&[7K8 VJO4#1(E,AQBTVNLR>/+<2 U4#)'):&CV3DP9X9^D
MUJ[/;5,ZC>,D Z\[ZF&\K4V%*</68, ]^_JDZ Y%]U5L4\<XUY&Z6O'##I9;
M[M1TAH!2K4VOUG =<1V"\33!JD7^/6CU)\[WC=&I*TC[W2ZTZS6U,!!-0#(?
MXH\WL$HM:*5UQ;I1AXXE(+V>UQMT";%@V6%FBVN3JCDT+O.\,8E#*@2N;X&I
MM;"<I]M""G2]H?0:^O5KD":&8J;2R3"UC$ T>QE!3&"*W+XW^_M4[V_RSRK^
MUCPS ^VILO$OL%8!5.:?J<)RT!K0/_WXIP1M=')@CKNMMOA6_=)OG(24,3<7
M/X=X6$:;GO)/-$..SI M:!?Q-3*P3FL"3SNM/O:CG <\5W5 &<.K4A].;Z[,
MB2:VA'CP,U7R!QL8<)+S.7Q8_SD@;<DET,@$ !XQEO^R\ OFT_3H ?(%_").
M.-VFRR?R3&JN**?,[X'^L7.^G=:BUI\C:J7E"4MWV:B']';+8%!(K^6Q*.7$
MN&U):QBB+[[KC8&7'?0F7J?;=G-E4%J\ 6R15\Z"L0=#;N^I#*F.$XH. =D?
M-8B.6_9TVTJMQ@/!IL?G% 70#X]649$=4:KFT2*PFJ.VA;ET6>W0#+N:3F9I
M5:Q_Y?;CG 1=IN(X<B6W(.9CWC++B90&&Q(:;!\#3@1V$6>=PE0\C.UC'40(
MND83&L@50PXM5:]$#O\LTX%!Z.$^5;5H"MP0E'F[=D-/H1J'J[E;3""+\9J'
MRX .L^ !U DJ5&Q/.0KDV+'#OA@P3U+I;;#.32%N@BQ9L5#E2-? S2*?SBY#
M7')"+M5-!5EEV4M?T"J8_%WE[+(/;,FI>!EG0BM_EW*P(J4E3@IT6168:K]=
M476+?4/283%0XJBL K$/!.V0*ZNZ! &#GHPO7[OQ9)ZM#*=3(!.S(FXN_I"9
MP[R>/6RM#ORA[$MZE[PR8;R(BB#^U4?'*AJV%#575?Z8$XWI%%QYQ9FJ,HD!
M?E#L_1%H'[DO^O:BY,Z/I *-+DR V:H:*IV4HX^Z4]H(QL5FM$V.@' I<:*4
M!H@B924K5U2H5W6EB5:AQ<H;O U2Z /-=5EZ@/U@BH$Z>A=W="FYHY+'8BK>
ME@F.8]L?I;!C98DJ[*4Z[**(%K!+::+HKD6FQ9CCU)@E4)+MS:Z%KLY.IG^0
M%N.CK[/J/YY(CRY%3>0@7'J(/($.;$.G,T4>LX=PQ3GU\U+)BX2450SEZH>>
M]2D -G5JCZ3:INC$Q>.:-(WR0IQ^KI]3A%7,5<28)"" *:*X SM)\0A.>1::
M1L)I@667("DO,;N43L^9WE/XZ_";T\OI-V\$>A$531*R%<)P+&L;)7?(561>
M%E:4J".Q:,*. M$-2T['+<!CF=+CB[\E(<9_\B!(S0KGR-"IZ$56U_BQM$9-
M;$LGZI#&(6-'Q(M0=\ 8;T*I"1GVQ26ITIBF,+#DAJ4Z,\W]K;R)QLWDW$@T
M17-)@R7 7K(_K$H[(%R8H"E1H!@U9ZQ[*F7=2KDFCQ4>,BH][V]@S-B1V.EQ
M9J=FS/(%PYTM?V4;=(Y/((V8+;?'+SJWHZ42[]M#=J:!T@I*V.L<YE$&%R/C
M'3X^T;BO/%7%/HU@'KDX17\\QB91?PWN2;]3FP8__QP -WCTT46/M!3F2NV;
M%QF5(6I5N8+*Z>GQITOE2-3%FNWWY]=*]BG6#1U'SQ9BVAX??-=&GQ5";^H7
M#CH#S,K'5W"QAVW+^=GV'(4.&A^D![>'XI.L?.CP69)=5B.MV9%^2_D>*.I-
M&H@YMW'ZP>";1Z,"@0%7CZOCTISJ?1\H4N437 *T3>>5N][9;#STR;--&_U3
M7#XRT],G::+^/P0+"?-SVA/T[U5.T02DH#,4F8C:HM9YGFO3'70XF1(NL<;/
M9-MP#(G//"R!1FN%5_Q<JRM^^*3?*WD&>/-4.OU6^UMV8I9[[/2_M6;405NV
M?/XI::>)=>H4"BP@%WF<IU1F=/6?5&_MM ]2%.T>LB0*6"&R$T94U:?2#?4U
M1H@O0" KN9PQ:RL8%I(]BJFM\DJHKBG!.:+\#GGP!I=%ZHF0TF"#AU<3@"*7
MF*6VYU@.\<%V\O2^PIWV*;:1[$FOH3HB4)T\P+\Y9[+!B,/K 6/*EM;)*,W>
M^ $LN22 EN#3M&KK B0)5*?.^:6,JI467_;J6+H\?J:&2Y.A6'$!EW+T-*7<
M25>7 X'R* \&!W-!R6B3)Q&0-A93(JLF-%O#MF!A5[*#",O]_][SG*S2HP9X
MZLG2A&E44(D%*/ZE;OX@/H9**X[-%"*]^AVI;U!X"UD0":W)H$WB"+[#%UX_
M\6KK9*JF_29UI#$H'4X9,L"@'!^3+Q,4SAJ.R3_!0_5V\6T-RAQ#'==LCG)&
MF-LM=/1]*\^HZ[<%Q@<:F8%J.6EUH<F5WI,Z\,=9@-;]9+ R0V_2IM#L1'\$
M":(_=O#LJ[8JKCD0<HC;!WF.H!%IZ#6@4G>4_P"\<]9#%>64%>M_:+C"S_4.
M[;R=<#PTXK)G/'\#EI<]2ST<*N2S:H@10G9\VZD'@.&AUQZ"LC!NH>+5'WFC
M >E<)7T!774C;SSL V6U.@-X>X#O[7HF_Z'Z5+LGQWF"__0N(Y]-#1$G039+
M0\WPU6[_ZQ4?.;SKR?^V#-P?^;\_\E\?^>^Z7HH0:\C5$Y+H-A/?=_L;!/8W
M".QO$. ?:VX0:+R(IGJAP"Y[[_=S*\$.Z*O>7_"U2'ZM^Q":;ZO> 1JWK-_?
MM+"_:6%_T\+^IH7]30O[FQ;V-RWL;UKXWWC3PIH+7'?3YO87-NPO;-A?V+"_
ML&%_8</^PH9_Y0L;7/Z"F$^3VE[<_5XO?7!<J$WW&7B4]<\]ZZL@=D'H_C*)
M?^?+).K; SJ]IV3-*;WL8?4M,.VC"TS@VXDP?L?75#@"G^5;*U[JV-Q??[&_
M_F)__<4_]_J+.L]4UV'LIHCL+]'XYUZB4:_\LYWBO#Z[K.C^3HY_RSLYZ@ZQ
MVB'P7QV/W%_[L;_V8W_MQ_[:C_VU'_MK/_;7?NRO_:CRH?VU'_MK/[:X]L.1
MB;?V&I =L_KV5XKLKQ397RFROU)D?Z7(UUPI4BN7L@ZRM ^\]-0A8ZR-V(>&
M93OP[?T%)OL+3/X5+C!Q1!)WN,]D*X?Y[^^"E"H.+C#V&7CJA.4ML+:_865_
MP\H.-ZS48B)-5>_;%&/]K@\QN'WU,P-^B\M:JFMVJER^^NZ676S(_<TO^YM?
MMKCYI4HVU8M@=B&YW_,E,O4 =N5FD$NN-Z6K2;8Q)?9WTNSOI/G=W4E3%V)/
MS??3O$(FP/X"G/T%./L+</XW78"#YY-N/!3IEN1*[4@D/O^-']82RNIY73>F
M)/.OU&AG!K2OT]W7Z?Y&=;J-]$NI+S<5^J5SYR[-R29GZ';]B8SMEY+VOT&5
M[HTL5.:\D_6EMZ^XP_<UE_N:RY?57*XG8#M7]96H=Y_#\KO*8=EXA6"CZM0<
M6)VJ:\5>2H/[:\;^I:\96\>3'/=&\G)ZI:N]P)+_B<Y(H%"YY</[>MWC7^6>
MKQW/!6[>9Q9V+TLGT5TD\?T11@Y9F7LIZG[3\WY?;K&=!#GHKQG-I_"C-]#F
M\\V).#QXHWSW(59Q)$7FT^EJ!Z6_J^-VE!@[Q?JZZM,?B[BE:'Y06X!@U=)G
M6M9/R9VU=,RQ^O 2(U%M>5CFIG/\W.<"<@RKEM5"81[8.J35 RE8)^XY3IB1
M]4(S*[=G4[64JK^2XV-(*<0RMKM@@9GQM_Z730D"'E%ES2AARTU[*HERSU7H
MD9('-G5<ZQ(H1\5;; OG] MEPLV5>H35YWI<5Z2-*ZRJW8/Q%. QN] =129-
M6>Y?+XE9_K?X'PR+PE3P_$%U/P/&')&@C<M(OU^GH31\)*W $VIAS7?KWOZ>
MJCS6O=T<06X AE2OG(JTIQ$>3OH,>Q)/8@#\W$/K>V1SQEBL';]K;OK0N8J:
MQ36.R5F5TG'GB3/.T+S$0QR+I6%+)_7QU!D535T[R\FJ50A>M0;AUSJ+N,$L
M14(= (JW-=DW'#6-7D<WT,KQS87]YZ8^KK#Z!P]_)C*6I?SB+-#G?]1A-?-3
M(OC2_X*H? WX\"O;'VBS('9<<BC5H%+\167 6L=_J*NRSC/:FE34U+Q!9)J1
M'-C3>99UI]U+9Z2OQ;J1-WGH2:*L]F-_'OJ<+'CZ64;V<'M/Y857%)I(Y4W:
M>N*@$U 1$GJ*C5YQI;/!SKGZ:.V&?.&,CNG&P7ML1X%^)]1KN( \J\,<*;*&
M/M<=9?*93P1!9:S:LL=.G9IL8R,)U\+JYQ,>C1I8\- !7LDBIU/+FX ;N(<X
M*X#[ZZ*GL_ +'R+1U,NH 5!D5UBM*\Z7B$\90K(6X47<$+0J=G9UQETQ]Y]K
MXV[ .#E!ZZH(,8#&02_5N7V&.'_ HV/_+,^,O30'KQH16_<X<O[(JW3681]@
M9]QV(L$QQLT#[MM;5(B-/N3N=B/DN.NO=$G"&O5*":DFQ!HEW72BA_&4C&NZ
MN<KX*+<1V MC5C2]W6!\6#1[&<Y!'EM!+W.D'QY/W]2QZ]#['82R;DN'X6OY
MM5DN;VU0'-DN[G(AP!\R>X4Q#>+V>15H$\0V/=9;&28N@9ILTS$T2J&M/N?H
MA76R,*IWM3%J;UW0202U5#(=!&E6UC[?V)&0J8J D$YNA[H:*4_%0;9N48F$
MG,A(2-/[.RSNC3Z"]++A"-+**N^^NNNB&HWO;@II5!O6HAI?@Q,ZI?6Y&NS8
M?>;2 Z\=SDWKI5WTF]^\V=I)^XI=D$C^S0"$WK='@'8QD]W/#N:7O;S#I#;U
MLSWX3:&0E[Z_PR2VZ&K[>>P0\WK%+G:8[<MZWX$.ZR&,%[RZ"PVN[65[P%_*
M!V6WNS/!%P>E7A!SJ3D_#\1;R^V)676@C[W$#]I=ZPB=%O?:G=GC[IWN4!4?
MD)C;_DTSC\UMAK4VZ[RO_<VO#-VO?-3I[HT+0F6!-61QA2JF-S;$PII<EJ<J
MBUS*D,8.,!%+W2(RE55_I0%0SR3OXS-F&C=JR5L/6!O/,=QI.6?>\G=@HLEU
M@)>;S!FA9V&&5;,_.TRN5\9!,U XN+A]JA=;_&,!<%T;](\%X2PI_LFK<.;P
M4%_5JAQE86ZS$M- NM9I3FC#K0E%FB!DP*YMBP4P3_V?!HY3KA3^A\#X/5<)
M U=701@=$%=N"WI%G)1=\S"'9L[Y"@!:(UD17,\1/\70:!6 =JO=KL5(7P&J
MVDJ:-#BT!QE3.ZXNO&_VB17%;ES^E_9#[I?U_J37I*Q33B) Y#B(BADYU_2:
M,VS1O?::T]W@E^RTW6;R5PR)EZ3K,JX3.L$D2=?93%^_4R@O&WD-*:;LL)R2
M8\#LW%><(8XDNH-OQ2F6IQ+G_0Q=1>*LP"H29GJ_Y83IEY[P-1(6!DB VC!^
M=E^;:W?P&W&#,B",^>HP_5TIS))8BLGLS@C6=*)6\#/&;6Z*&9;=8 Q%QLED
M!/N&3WR;E4X+NC2'O_US1!-[)W?GK_\P=$!OI@"GUQSR^6J*7$.0Z+Y]E)I'
M\Z;XUT"6SK6C(HXF=/6<XGSD_+;"OJY4">UOK5#5-0,^$@^UTR:"-:M#[?"0
M)(IO:Z"/N9J8IN(UA=D[3F(J]VUW) 'TQ(?@/HQ1!%?;CG\KAJGD<0U9F">C
M5ZX)71;=OVQ[;#5\4Z8.X^Z<2[CE 96*+RF,KB.^9KZUV6.C"N@JFW9JSA*S
M'4Y-6]OAT%GK5-GD39'<1I]0C?E;DJ+$G4SZ/ Q5,7PM]5 EX%IU_SOV\)?J
MT0(J;Y4/YFGJC4]QL KCWZPU9NK37)5S?]= 6&_K.M-(I^?NB*P7]K41;9OZ
MW1&!6\-NTHY?&_IRSU]- *XA3 ;T:RSC5KV]"!7EGK\:%0$?V/'2_;Y]\XV3
M=72UX^RLI%GFM^0)%X?7-Y^!L3:F4-5PLO98L2TVZ(X];D4KVPB9FI%NY\ZC
M?Z-D$DHHOY?S ;U%B3\^AL 8O^;<X8IHVD)JU?2[4@+^(9J?M;D.-J0X.;+T
M:RI0UZE<NI/W:W3DSM^O*6ZM27V(3JM?_Y(6KP=(VOD,>E-/O2[E?7U4A_+7
MY6$%[OQUJ3'TG"WY8;N6W'X6W+5$=^Q^:+=LU],?TN:T>$Q>K(3^:NUK&:Q-
MN:XJ;\CEEWK9,=3;)>+*G4U9P!N7MI%*K?RN,TK+_YI>/Z_+(M99<CJ?M.Z$
M<3M"KH,X>"(0M^CD QM%E0SY6@C?9!U9EUPI5-28K3Y4M80'):T:N?[-U34=
M4;X9'CO(WI@0LH)UQTH(E8UNK9W;'IF>'G^Z9#*[OF@>NYZL[<X)G,8Q.F"M
M#/!=WFQ( )>'*@/[PN"/7& DOUN^AD-Y#!H7?.A.SR1^V <&IO;G)<Q0%WZX
MXMOK,Z_PM)A24-C)<52M3<,[KH#T-@'HM3'E1G@,R#]>_8R'VW>&@_>U]^QS
M]825OKUKW<:5?2SV88E7O>%./)G^1@G@VBZM[W8Z>XMBN53W4H$$#?$34MH
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M+0IKG>!4=;$M2N=U40"GH_<"SV7 S5-&187/X V_4J*?QC7%>=+JUCM^M<6
M-RZ2> [D1B#=^?$O6,)#!\42;(>T"LTV>PUK'^B0[9L5UB1BS>-/?AJ2\N5B
M_F,7UC;1L)U$;HJBKP-]XX2J&FB@?4GIL#DC5VD:978[81HJHU]>_?<'*N?9
MN*M>)R/0-M5&;JVJUU3>+)FYK@NE%>93]8!H7N*?Q^/_Z UWQDHFFWL\@JG>
M76^LZ0+C2J#%M'J;9?EW_Q]02P,$%     @ XGEH2\$94%UB @  60P   T
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M^Q?)IW.+?7W2_;J:?@-02P$"% ,4    " #B>6A+'R// \     3 @  "P
M            @ $     7W)E;',O+G)E;'-02P$"% ,4    " #B>6A+9O,+
M8((   "Q    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+
M 0(4 Q0    ( .)Y:$M$,__A[P   "L"   1              "  9D!  !D
M;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .)Y:$N97)PC$ 8  )PG   3
M              "  ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ XGEH2[$R2(R) @  1@D  !@              ( !^ @  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .)Y:$N;$!Q37@0  '45   8
M              "  ;<+  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " #B>6A+Z)DO&S$"  !3!P  &               @ %+$   >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ XGEH2_VO62UB!
M5A0  !@              ( !LA(  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( .)Y:$O/U-C79@0  /T4   8              "  4H7
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #B>6A+\MKY
MZ+<!  #2 P  &               @ 'F&P  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ XGEH2_G3TVZV 0  T@,  !@
M ( !TQT  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( .)Y
M:$M9>B1YM@$  -(#   8              "  ;\?  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " #B>6A+L@M/&[<!  #2 P  &
M        @ &K(0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ XGEH2XY=A2FU 0  T@,  !D              ( !F",  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #B>6A+)LR7L;4!  #2 P
M&0              @ &$)0  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( .)Y:$O0#'WLQ0(  $P,   9              "  7 G  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ XGEH2VGN\NCA
M 0   04  !D              ( !;"H  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " #B>6A+UF_YY<$!   W!   &0
M@ &$+   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( .)Y
M:$OV4->_MP$  -(#   9              "  7PN  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ XGEH2]572T6_!0  +2   !D
M         ( !:C   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " #B>6A+.FY !$,#  "Y#@  &0              @ %@-@  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( .)Y:$NJ(:PCV0$  *L$
M   9              "  =HY  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ XGEH2[]VW !< P  X1   !D              ( !ZCL
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #B>6A+YSAS
M<><"   5"P  &0              @ %]/P  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( .)Y:$NEGW^9J00  +P8   9
M  "  9M"  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
MXGEH2RRZ6S;! @  50H  !D              ( !>T<  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " #B>6A+49>Z8/L!  "\!0  &0
M            @ %S2@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( .)Y:$NL-AE]5@,  (8/   9              "  :5,  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ XGEH2T0[5O,  P
M[@P  !D              ( !,E   'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " #B>6A+S*K/V24"  #R!@  &0              @ %I
M4P  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( .)Y:$OF
M?OF=W@$  !D%   9              "  <55  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ XGEH2X=Q(GU; @  2P<  !D
M     ( !VE<  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M" #B>6A+G@F"%VTR  #C# $ %               @ %L6@  >&PO<VAA<F5D
M4W1R:6YG<RYX;6Q02P$"% ,4    " #B>6A+P1E076("  !9#   #0
M        @ $+C0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .)Y:$L-+_HY
ME (  !(3   /              "  9B/  !X;"]W;W)K8F]O:RYX;6Q02P$"
M% ,4    " #B>6A+=P+D<6$!  #Y$0  &@              @ %9D@  >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #B>6A+&*.>G8(!
M  #"$@  $P              @ 'RDP  6T-O;G1E;G1?5'EP97-=+GAM;%!+
4!08     )0 E /4)  "EE0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>134</ContextCount>
  <ElementCount>241</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-consolidated-balance-sheets-current-period-unaudited</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-comprehensive-loss-unaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-consolidated-statements-of-cash-flows-unaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Disclosure - Note 1 - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies</Role>
      <ShortName>Note 1 - Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 2 - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation</Role>
      <ShortName>Note 2 - Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-3-collaborative-and-other-research-and-development-contracts</Role>
      <ShortName>Note 3 - Collaborative and Other Research and Development Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 4 - Royalty Monetization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-4-royalty-monetization</Role>
      <ShortName>Note 4 - Royalty Monetization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 5 - Senior Credit Facility</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility</Role>
      <ShortName>Note 5 - Senior Credit Facility</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 6 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-6-stockholders-equity</Role>
      <ShortName>Note 6 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies</ParentRole>
      <Position>12</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 1 - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-tables</Role>
      <ShortName>Note 1 - Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 2 - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-tables</Role>
      <ShortName>Note 2 - Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 5 - Senior Credit Facility (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-tables</Role>
      <ShortName>Note 5 - Senior Credit Facility (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 1 - Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 1 - Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-tables</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 1 - Significant Accounting Policies - Fair Value of the Company's Investments by Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies - Fair Value of the Company's Investments by Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 1 - Significant Accounting Policies - Scheduled Maturity for the Company's Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-scheduled-maturity-for-the-companys-investments-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies - Scheduled Maturity for the Company's Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 1 - Significant Accounting Policies - Summary of Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies - Summary of Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 1 - Significant Accounting Policies - Summary of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies - Summary of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 2 - Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-details-textual</Role>
      <ShortName>Note 2 - Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-tables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 2 - Stock-based Compensation - Stock Incentive Plan Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-stock-incentive-plan-activities-details</Role>
      <ShortName>Note 2 - Stock-based Compensation - Stock Incentive Plan Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 2 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details</Role>
      <ShortName>Note 2 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual</Role>
      <ShortName>Note 3 - Collaborative and Other Research and Development Contracts (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20170930/role/statement-note-3-collaborative-and-other-research-and-development-contracts</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 4 - Royalty Monetization (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-4-royalty-monetization-details-textual</Role>
      <ShortName>Note 4 - Royalty Monetization (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20170930/role/statement-note-4-royalty-monetization</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 5 - Senior Credit Facility (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-details-textual</Role>
      <ShortName>Note 5 - Senior Credit Facility (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-tables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 5 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details</Role>
      <ShortName>Note 5 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bcrx-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 6 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20170930/role/statement-note-6-stockholders-equity-details-textual</Role>
      <ShortName>Note 6 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20170930/role/statement-note-6-stockholders-equity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bcrx-20170930.xml</File>
    <File>bcrx-20170930.xsd</File>
    <File>bcrx-20170930_cal.xml</File>
    <File>bcrx-20170930_def.xml</File>
    <File>bcrx-20170930_lab.xml</File>
    <File>bcrx-20170930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>49
<FILENAME>0001171843-17-006746-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-17-006746-xbrl.zip
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M3>%7;CRXT20/PRHXUK?+]2? KR/]23\(IY8G=B.:N*&377=]9H71'+06WPD
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M 9UA!+/HL*&^ZOJVJG)/*_O(/.L!@8+/%5Q[#_J+'A-<PH19SI^Q%8J>]]R
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M?#O;Y=ED$;G&C-G[E$'F*WB8,_[H3].9%\P9DS=)MT@!'_!&'=\$$4D'X&M
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ML,?C(,N]#XU.KYU=^/HK>7)$9,)+6X<=7EI*3YT<.6V%U1OFLP<\.@?(: ;
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M.JB4[ 2]3R_#"YGV*\LJ#6H=5@6@R;35)!+DNU")MN>"VUBR]YE@92[7$'A
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M0MM#@YEN9_%&D-)_Y&6@MO?:%T+FB\>Q%^:"M8;WF91UA/>9N/U#D,GV!+<
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M^18#R#,0QB2O*[ &M 85E-\AA';@(8-YF 09%9C/I[,HP(1$F^AM]^#E,NG
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M@E[GC;%.?SP@S9>@/1%EM6REE<R>U#*;@B&=#NP';DI-R%VP#?XC=6GE:79
MQ:+;[FP9%ZJTXX9V/.41*0[P-UD)  G0F)TXAY!T1<T;2O0)*.P)TP+G9 :
MYJ?BGA,QD^9L"^E-PXL58$9_H123%L/,Q3H]&%=K4$)1.*\/YW7Y$3WY>/U!
M1U=X#F7 [BOW-7U! R1:@L?&P*+8=U#Y\48B0K>,<*JI 7'25Z[[N@IKG/D%
MCHK$1"Y%C,XUI3(#Q)=Z' 7C1"^N\)+2F-] .R*_$BK;P0/R\:%Z(!%_@L5/
M"=\8ID$YXR5R\@UJQ G!)\)<"H DT@/G1K7TN6E:&]\>/%%P_SX">SZS81BC
MO[[9:!0$":@]U9WQ?G*@6$)Q5G**R?Q0"\PXT@M\YUF7N7#K%CO,=>>$LO%
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M[^^^:E7NH0%*0V^ LN"15G%(*4H*[O#I4./>Z<>K)"I?W23E[2HN?,\IJP^
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MM"(.I=\O5U+RWM1K,B7N>NF61'^XDAH95W)2LP>E+R R1QAE#FWR4&?+_8-
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MHNWU>J"8+V%[=[=?7MU\>7-3GF3]HCWUIWJO>^">WCM@W+&OQO>J ?!NMPF
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MI4%#^>ND?$/X*R7\RY*1CV.AK[S]V!#\9!I^4#(F<7H4UAP%*V>;/B\'\YQ
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MXUAW/GP!G6WFB;=_!4C\9"R5IP*H%GAPL!/QRXMV/Q%.'4_[O1> 9*Z>$>X
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M/1>&<\^2Y<2J:%G]W:?+4>KYEEP%7_, 3BSUXG$LS5CBD1/:/7/ %+3M-=@
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M_97\(SJQ)*.H*6$\N *^&3AXEX/B<B#Y U("B6MQ<M1)=#$."1 (EM+<4J0
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MJY5W&1XL^CEW.$-F\L+&A ;;$(+/ 5.(P'? %S>F&2RE$/L,1/>0Z!Y;,$<
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MX%[N1; 6 @:VK8N&"!PHMA0M7$BXCL-L2:J6^C+:P.!.&!YMV4&+V6%SCE\
MP1', 2&!)QUI>LJ$$XL6?@O O4=[Q_76<C:/[W[G&*R_7\<[B*!'/_GUE\^T
M*ICO'-00/22"U<KF.,<(?T/_><$,B^QX4WGDH"($%V2L W<\ *1N  ];X +
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M>TZ,:,S/(VS2@$B 1V[&$%$*"Z1)P<RE&*3$9=ZID\_$YS-]YF9@/L(7E10
M<8UDHXFZ^)3O,4-F<HP5O@E$J<] 98*F-H$R"7J@.L&W&T*X)D\"<+2PZ,XP
MP$;< $2_"9"\-@0^AO]Y"V+XP;"1+C?^:\/S,+OS'\,.TL$/G@@<_+YKH8+E
M<;;P%SE5,P[I[AHNK ^W1-?T?C:&LL\&+P\[-!D6S'C#?N=ZK^$L<7\W?HJC
MJX/-X./Y\5,<+YL,"Z>C]_5>[X*VLFOV-&RE>-SY<) ==UYI*SZ8!LQZ:W@.
M=A]/A,M!L8*MF#,Y>W>LM5<X.;L]TGMXZ-(;V 5#=9AW8GS:*\RXM(>C47>4
M337L"S.)[B^QP?:1@R'INPY(,%!W5OH+?Y,]LS,$^[O*V'[V5 V E)$R^;CK
MY/=ZA5/F>]WP?\D=[[N#\V'@#J,79/$8]J<W-R ,OQAED5(XBWY8"U(JSH;7
MN\,F$']-@7AIDB88Z&I"[[$%+F+7.SLC7H4@I;=5'%WV/,.Y5[$"<K[)S,18
M'06*P6BWI2?NJ9^IKHK";*  9!!84H*+W=^6BV+T7L72XFG5)CA/&(8EYV3)
M !,O^0\Q1C%8'!B8NM;8 SB.Z,^[6&V1W()T ,7/\&CR6177E@$LUU3.5C),
M'_MB86R>UD@N(@.1MJWZC\69 @]#D\IAF@5KC&\#-?AW^8JP-L2@ND#$Q$O^
MD%@6*<9,WYAAH'BMD"A<_/X:/:# JQA,['>ZPU,&)[:LGUWU_[3;VCO.;.LG
M[=:X9SA)_J\ *?F3-OU9(QOM)ZVOM=LGAJ.\9*-_ZWI<67N@M'J]<2ZI)$,K
M3"?>9,_EE_!<5I1LVX38QFZ/(\\Z_0+"A)*#1%<8LL$(94N)H74B6H7?]1._
MRTAA@5BCV.AF#BR,8T0Y,*:,6(Q]F!C=Y!0T 1/*9U'D-AG^KB-,E$+V//#"
M>)G/G0 EI4HR4$C3G8&F"@M%O0UPP[W(C10]2,6I] V452*4S5'PK*.]D[%F
M##U0)!B_+PE&V:DXW$RAGTQT6&4XDV_?&?,%N1ZF<2P5X(W+["A3! L92NI'
MU;?%6XB(J7*Y42)#*C N"!%Q*!N1"5^=@T>52"?!_Y'G EL&/Q=X1$68A(KA
M#==0<&?X$);%!!9* GM]K/!SX1D[]?K?B!=,YJ%7N#6CN1F336>7%'N)C;.?
MS-7QF'(@"A/K@T7KQU6HIBOSV"&UTX'*I/FDWA694;(D@7+]R,.<]'!(6I5H
M"G/LC@R][U;?3X/&^8N_PR+6I#:B(XZU^_8#4S45RKP"Q"]=#S\$Y)U>4H*K
MF=HODXYO2Q;4*M*WHNPQD.M'M$MQ=3SI@: 0,_-)ZA<4] ([J)(%[:\ @)SS
M4 X(O)J /($^,YFB4:P;N0V6C$P_"JGSQ"V!<-4$]LA0)@V32 $*'X &9P1V
MJB%\+)D0#&U.$YP4=\D\R>/IO(JD58$YBG_PE3V.M0VJ-@>1MV5S:6D;%EJ3
M:4S*B<QA>(+626Q.@A<+R9T/: D4XO$G59/V&18<O@KZ?RWK, !!@MP&#0ZS
MY7IM52A@@K;[0TK<E/,P-[@G'VN1QW#&@HDD6&G,I'+"7V_?IG+"RJ% V&>
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M9,1*5/0 ML:F*R)]:E@OI(@B 6+X]$C\1[_?&@^ZZ9@#QF. L"VIW+%LJP9
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M;W^I[C9T.8>B"^I6RG\,.Y +"Q$LY6<5;H7I33.CYI)8B?L_>QHMSVKC&W>
M:KRY-!J6KMK'1I]4<O2!SQF<7NV_S/"VC'"X]"LQ@TNZ;3'L7,!]F$OM[]20
MZGP)W_31_X]K@W%@@[WQ'$(')V>52:]SU'LP_VRP?@E8OX@48OI@O@$GP&*.
MI?V7,[NIMRC#)MWF;#X_I)]947[AXL_V.X\Q[3WZ $SXVA?#+]_FXII90^\<
M-?S2G,=R2!_4=AX/"74='J;*A,"8#2B[_XTYS#/L&\>ZL9;<X<*7P^2/-/2D
M>"I$/S-BI!P\Q]G#?E-2"J=(],;#T=GVL%?[^5'A;(=IKS\\)QW*]ZH?%<[S
MF8RFO>I[R TF5QN&U.T5CK/1N_UN>GI,/@"' ;G/H*1NKW".PV@PGAP)QL2D
MKU?K?&E&__H/6 A NEL0TJZEET'_[_0<SA.C$6)OERO;73.6D(WA5#+;<*)A
M9>\=#$H",^"GZ@OJW?1W_+DW!##P:V\-<X&QO6_PA/TNL.TU_IE9X92RQ-2I
M<?_%K[>#_^Y"V6'H.!*BW_X5<'_]WH'S$%!#_\\^*,6O"\-1NN2=Z\T9F'W6
M>T>^^0 ZQ#<RB1+?@,'$E[MO)6E1S*[ DPEV_3[S;-X6N$T!2J4$LYX$/W41
MYC>\="4NDBJ#0JKHHYK(DL;.D6CRSN >VE8L85>%088PQH >3:VB*DF(]Y_>
MI2BA;U)B%7CLQ:_'H$%9;%PB\O=!:IJY4^;3U:)TTZBH@M)-*?XL41KG!^K@
MT\*CWYGT3HS7]$8O +/'9=?A%6 68W48J@LC=75P[*00KUU]>B+$YNWS[&@]
M+KM.MZ!U\/30^M'XSI?!\E. VU;1, %F7FA![<^E*=OK-O#,!;RSE*7;VS0&
MCNQ_[-KMD9 :KG]C630>W+#EFVX"?^%Z_&]6SL&HXC3HQ4Y#M]L]#C9W;_/(
M^-R*17X"CM2+/6)],!X>%XWU("]LAPZ>-GEUI\?AIB**3G7_R)Q8L,=S87+4
MUGOMOE[E(/>+L=?KC8\D%B\4?4>0@\--=1T=X.%$?TKH^QS:KM3H E\0-K)7
MO>O#=O74H?XXV,Q&0$8% >WVBGGM-'JQQ/T(N-UOU\=%M0I&!DA4QP*G@7NT
MPGYAPBK<6ZQ^IGKO.,Q;=J\UH[8T;Q\#[5DV'Q:,1\]A<[KF6R,9ZN/^ R+B
M55B]V&#M#:='$M2GC&;GKOV;YPJQB;I^NSM1J*,?P41(QZ_AZ3E63@ *I5(Y
M--'V;>4Z=X%I,B'F@8U;LAG""<IJ!:28<_,->V"VN\)]?.0V/.(ZX>N*R34<
M;TE*=/O'%4TY*#T#S08QNP^46??4:+89:8MHUAL>R1(_#\TR4I'^^,;P611,
M.;G*Z!;44.2HC'YG?(Q T6&(N# J5(S-;5"AO.+N=?3Q,Z%"8J"7=$5.XXEN
M<:5ZW>F1@B%%6ZH=8T>P:4;=8HSU^\/C:LGZ,+:?VWD(YV6/]:"@V"O7[1P.
M3X+4(QK>HIRSRR[$&2JHTLS5;(-]?/ZCXN'(--@JT&LF0*\T 8;')4!Y))3!
MOEP4W-K4_L6M:W-SO<=-?\**KI]L".S5K[AYA71I>/?<^4F#7[1N>2!2]]8/
MO640-Z5L$TMI29[:N%"0\[.V<WMTOR <H-T;%^PX?=?BN(O?V+9&A[@]HSVN
MY&$4+<",:0>H@&1?>*&Y<TWDM.@$+:5Y6V9UM#18';YANO<.Y<ZXH_D+1M@T
MG'7<$7CZLX /'6H;8.!2=S[\AZ#!=^/W/;8  L !UCZ@KRQ!=FD][FESL'*U
M!S1S14?["J^(/R@"G@L-G> EO2\0N%N$C=H8M._,A0M.;OC("G:(7UBZ%K/S
M7K -"_BF)+@2J9I%A0.V2V]>D52'A?#OIKM<PE=IH8XFV5 N8*;KQ(6/:R?P
M:V!3:EF>CQO5L$8>CT,;.1V!@*^[($KI-1[[*^"" Q2">0_X_I4,NRDP"/J.
M]AX64LG6EO;(M(4!-'!C(P6?"H,0"LPDN@5PIZ<]+KBYR/+M">[[.&[JH*3P
M%6(FC;( J\"UF!7-GQ/[B3^V?L;G+ 9,:6F^J[!@FH'G,:M31B04_;Q+=VY5
M83DZ<+;;])QMJT[_@J@6JE8>=.X3J=HOM&6&XUYA^4PO:[<?&WD711\,!Q!B
M;X+[ %#;U?L*ZY<>5=P@:6$);V=\G20-)W!CJ/B)$G6Z&;H(B=I_&C3=5O?Y
ME7G+<C>@=OMMR7A/[\6OM\/_ZI/>FR/@:.<&SH>H@Z*V243UGR*B=I8B?&%+
M@SO TF ^@[%G^H%AEV>UHZGM+[@1^NM'@&89+',NTTU'1($C8/]PK%PO6605
M:AY9QD 6O?N<Z"(MPW2)5)F[[\4JDZSR).ZWY3R+0_"#[F S '_DC>:@4KP'
M*04+H),)FZ+/<K,/_79?WZ*BQ]/RM5B3SC"[T3PPJD";O0F] 6U!OX+<(*:>
MM1M+0,O!AP1[![SY&]-TT9-T[LDOXTP<T$]4C*;][J!70XSQA-&V3Z[/:G#T
M]71 +#%;2DN018OIHH6$J1BR4RU!_@ 'BL_7F5!;MS/DSC$#>6</@GY-A.N.
M%_>L%XFEHJ&ON/O:6PM?NX6#OC1,%E!+)='20+%VM)<8$4M&B39BF-;//V"(
MR-!F'(Z N7!<V[U?4P@*OJ?Y"\,'625@X[ FQL:6 **,H5K288)3[,(/F@ N
MM[6E:S,SL)EF><&]D,_/2*#\R=8:<_Y>X[GGSH-K/\2AU97A+]Q[!@X7I] I
M$)J!\E!1404TH,@,!(8W'<WU#%OS/6;X,MR*T3H/)6[X)*XLPW<B<; "9\E\
M;<DL1!)('T;S\#C@#S=$P!*1M4?N+X"C<)[3RICAQ3>N=HWQ.,^'MZ1A>S3P
ME:;KK0 T7^[L#;,Q&DEM66N0+> NI#@,H<4M+)AA_148GL\\BNH"-2(( V]A
M+%O:)]>#_;XV/) VCI'>&0<]<(][$D0J@-SD*P2:* 5L@PS3TDQD0^  %[Z[
M6L 'A&58S=;,!5MBXY,U@82L%0 L,BQ- 6R75J40;X*QLARU2K,X0..YP?U"
M,I#GHFNO_>FXCPX&E/&"OHG5H>W[@%NP6^1'Q<D=+3HV"TDVBH<"8H105';8
M/;5I ?J+A3:WW4?@,=!4< 28JC,%QL)Y#_@O,FLZ)SWHIUW\^$O^+QX@I,P\
M<##G$I;Z:W#$3G\6M&@*AQ8.WVAIR5TF\CG:#+@0.([86V""0;B!!]P$0@#8
M;\8T$<SGJ(1!@ "KXH;H7"58 39E@]CQ4SQY^FWZ"^Y9*>*I<XXG\_2OQQ18
M*HF0DAMXM 2H2G"=,(DDD06G79TRE-B(I:7QAPMO62/()'!#$:HM0&:X2F@P
MBE(H?8)?JV5WX]3F5"9&\07[;C)FG0L6#QC6";(*,L*22^8[AV_@SR3@-BE0
M).=D;BE\ _Q@@!8U@,%)RZ?.@@A60"P?-/*]BRO'1R(%6#IE:O._0"0CR:4"
M#H^9#4*$V6L0TL#!2^*:V9IX1,C +;)(XM"!_O( ?,Q5 BA*"]S#\168-U/L
M!!]9H AP+J-%65H1VASS -5#&H&@5MPZQ-/26*?$$5!+@)8"(F$[&6V%J;)(
MUB2V/&-KEPR5*Y$NJ;='^?V?M)<UNVH_Q.I7@#'B$:]["!&<#DJ%?^O<=;3?
MT(1QT"(ERM&W(C8$NVB9JE)P9[X,*Y'U KQ(#YHJQB1^KF.7O8)=N@%FWTVL
M70#XJ/>E%"M@^P+0F=,E$!F;)ZVEK0)/!(:4%=(:3RK>1S>PL13#9)$$6D:9
MEUJVWR_8OF=PVK@1W==&1P#?$6EX1IV@<.,6FP&]P=)UL-J"<"%-13K+RIBH
M93N#(FI&G);8T :]4)H&MB%U[@K^_$".I*2;I-4]=3.DKY)V:"4()HW[4(W4
MLM]A$?D8[ RW*T!CR[-6AP<&6$@)+!=]'"HE I_40R4:.S=TUO.D J@\<H9(
M?>,'B0?(I_L1EJT!MZ-"W(:N55KADW188 18&L<@"='QC!VQM*8]@Y+E&!G5
MI/Q&=SZ)]63Q$H@MC\T9N83J XNM7 %@P,F0L=>6JA9:J?O]L=B& V-XLOX,
MR8V17/@LE!HKCS_@^8'-FE+>PU..@ <)AQC%8/=@]S)\^2J8P;Y!U@(P)%F*
M+9>TA26_D#6T6@20C&:LD5P@#-!:@C5=V('Z#EECH2D&5ME6:ZS PL+W8+@G
MR>NRZBX2,"@_%(IP$0R'B]"J2^PQX?9>F -\91'55X8*S=VB-'/\8]>47F!L
M]2L5-2;*.Y6.!]TIXD)/*4.8K#V4<7L1UB)&;H7B\L>%:]OKMON(ITD$,[#Y
MN>&1*/J?VR_:%W=MV' T[X*9]N'#:Y#RB<AMXH_IZ"TN_O'-Z]O6YC/X<>K+
M'>T56"6I5VN/(&O0&U<E@G/#1 &!0BJR:=)"*O3<U>XZ*;@Q#JH6X]04V&'T
MF(RH&C7(_7_TNZUN-SW0(&*3W"VE:&7*TB!9]UJ#EOJ(ED$^'Y_^[=/6MG-S
M&J=.3X>,[AC3:LJ^#=*[#=GV(]AM/O_;D+7"R-T&J!^/K'>+"=/CLIR:#C4(
MP03G=.CD70+3]_I9I@?,.APV\QI,">YK[^2Y5BF=%,?;KJB-W>/ +$",@=E1
M)V6DU<@.PU8)=.W-$'@_ 5,F7I1"2\I.%-8S.2E:R&KL&6..QFP.)A8JF<[S
MT9VYINENA1IC!<SPE>')0X6JU;-HPK8\5'&*'&QJ!U-2@%'IGX*.Q;\CIT49
M1NPR'=[0$&DM*4,W-S=I54ET)T+R90)0 ,GUZ+6&"L1Q1[HXH1/T#EBLCG1?
MZK"W_S_I7-81O71</R<N!]8/<+XR?+A#)4CRX@K -7=='QZC:#+X))YT)B+$
M$ZY#Q9O+%1TP+L"!SF48<-9LD+?T?L/"4R _E^E<CZ&?!RSJ&+(X*<V/[HH[
M)/=!9(-3@QX>T' EC5RZ+F.O:0%*11K(#L0%@B+MK>*+006,3GXDO1#6"&P_
M$]1NI:,H,HP.]AD9:;5?1$EB4T:S *>.>@(#=X'GR:A2]+WG([]$/B=J8D&A
ML!G&=8Q0X?\1. F-3PYLWK.AZ;QFAJ<Q!_/2->C<L,K^7%9F7S^#F;E9"X&(
MET((69G)Q!A*KNTW_,X [8WC!, X7YA*KIU)I_R[(P>F\64B>1B*+:,F@936
M-:&4YC86IF 9#V4O8QF:@# \;/, 1#>>.!DQ4^87G&/&?"P5J26;U1S"GZDB
M@ P["Q[$ZB]*DU#@)+#(/"L=;ME^9)=XQQ3S2EA+>2EGZ0B*\1G%$U^CB8-2
MF7[ L2H/AHT4?OXQQ=#OCIV5,/TOI.7'8FR@,3J3IC7]:<%L97(LEWA=05;7
MF7^2%::BCRW*TE+)HR^+]%3ZH@4'PV%K!.M/%'U1M!(=G0<66GK<D2E-'D^Y
MD68-F+\J=5*/S/07'DMGU !^?T$ VYB!4($,K"5'B,)DC)3SIN%Y:\1+=-W=
M#'EN \N4[OQ.M^I%\HZ\)0MH*.NQ /G1QER(YAB47I&^#E[-!N%TD.%[6-'?
M.5(>9Y<7\= HDAA'E!+;!(+\=Z<'?SF];$AL47)J7:9)%),[FVW2/8-MDBVH
MHR!"'>;^/_366$]5GE IFXI&J\H*;65P"I+<+<"M=.]Y)A.*_X FZ;2T#[[5
M20>T4H]$\2Q9^RPMJS"TA:.05?[C=F%\^7A#L5>AO;38G%*^ %A=P?E4O0&)
MZ5I(,>BFJ\R2D7&>B%>!&L!;@%3]9&!XQ[8Q&@0*6 :(;>:KTCA31I -(5Q0
MT(CO*"B 1<),8]^9&42QL5G ;:OM!GZ84'_%,=]^OS"6<>6(RLJ!ZKW\ ,O9
M=<7[V)BY'FM26G!DO2T D2$7_@7.#V9],@9>-IS.Z>/P*]J*VK2$M5_40@:%
MASH&>%<:0)4EMZX07)64 /]B:;$TO]S9'Y@$>V"99'C:4]MX)[X,WL$<@286
M&5[&G/DRATYA6>_!"+,O\FD4:'C)H(7G\I%A%%A$9Y7JG:,ZF'3U\A(# %&L
M-3SJ*MZ<Q"U5ZPA"$I9]"V6G$^;RD!U[KFA#<S]0L=VDU4Y+4^H?=W8?5XX:
MX!?@C3\D$] (@ZZNAODA:>P:2S3:HVIY^6+V'>A -4'O\VD;$C0CW>A&!@7"
M$)$R3HZ^ 7U.3D!<+B7CZ6>HVR+O2-"6LU6V>:A;ITJ\TAX/?'T9X/5M=8LC
M/A3PS< !UEC!W^0MI? :@@P9DJ1VB<L25%P9*W5G":0]O$!6_/GW $A[9IA_
M8IE' AB@'=;,8?AQ6X'\YJ%0K(DL2.F)L.H,F:\=<EV"= FJJ13T4MZDIZ#9
M [<0!<J=6Y_+F<.07-B-36W/ .Z5=^XU#-?,8?=NS7!F4B!4P$E9CQI"1I,<
M9[>CW;G+2(BFCF.N\#_# :6,K3IB'A=_(FN#<%DRNL5 6;BH-)2RNG@9# 5S
M9(/*ZX7GD"U&()0BDUED//Z1A)6IS.@P8G64C<6L "WL,:4)T52$K:<EK# 7
MS ILI3J2*C@;3R$LF2Z"8"FQS51CEH2&4B6:_B+ &W4NM\+V?_@'! ^T 6-+
M/$9)&>)A70-*>5_$A\FB3=R0KH!E[(QRL-Q:")*-[ZN[>"CG,%ILQ"G74,5)
M=97@&\*[9GBR8I]"RAEL@\H(0VU;$K9)\IPGN1'[%-CCK[-QFZY^B#PF8=&(
MFQ,7J<-+?'G8KBT0=@(KVK1!D<,F41?)<H;LR342EUG;X/JUA6'#0?KF1+BZ
M![-3ZC6%)=?98*YT=U$SU2D4GVII@2-#G [\%"V-?T*[+0P8RU,_8\GLO,^6
M:+EXLFQ!6O"FH:1<WEH++/:FA0JN[ZD.FWCKVJ8 !6>/FR(-W> \,+"V6UX7
M!W 2L54XZB#2J!VH;/&)&'L$)#"\!Z[JP[$NA#0'/6URSPR6V,*3S'&9_V-Q
M15L4\HU%.%H49)J=0;F<0WP29Z$)-;,S-RZ2UYR39F"&):A&)ZQ_R2$B:).E
MS+_*/&LL=%-"65&MHWTI/!;R'%#831Z#: 7\DF0E;*FP9'&R;Y]FNV26>ZD;
M#''#7*&Z_FDXB%LE2]"K7#)_X881FV3E'N+5LV2=I %VF._;\@('79TB#D;O
M*Z/B78_?4P^$A*XWU#.)C$5XL?.,.15Y^E!8+&5ZP_"C/$M=]F\O#[ H29Q.
MW!,*J<=2*+*ID3"U<G#\'%(8L>U3&[:/L2,;?$;*.X&U=LF]$T(9[ H_3V^J
M_L5*-!56U#WA+AK47QM,./>1A QN$SL@+%%<JFA9NOUV*5,4+UVM5TJ6QZV_
M$ZW#MRXUY]])N"HQFK9"THSV@2[XUY![R:8^,IA9<. 1D(MK!"J1B(C*10D7
M(#3QZV$##H_%W<K=&44)*8;%/2H-I6"/^H4[JP #/K$F^RMP$:?4SERVC0>W
MSC:\EC8+ZCAR&Q6UI)/ W&JEDO 4MZ60JG2VR3Q*PTZ9G?!I_+/:27:=<(&P
M1O8,FY1;"6F9Y&>$1UY9#FN$\.CA55[ESLJ[O;+]NU!:*_ YVAEGXV+DJ2JN
MSX$9A.AG&?@SF6VO\)*W<__+B^X+^EVL##/\7<$RH\!RFQS.E0" PI]^QIA&
M^Y%;_N(G;=SMKKXKI2#?X84+/&"%";!8F!69N;[O+E_$T%B K$?/6/WR0OXW
M>G4&"WE;]*WD.OG/Y26--+7SMH0&OMC1R[PA"RD@ W#F_/)"GQ:!G?OZ9)H(
M:\^8!Q:YQ'0($<UID'!I9,K*F1V;"?A0]6;!_='W8M"OC!S]>JAQ@R%\=%D0
MGIFG_4C O0:[YCK189I>D$'&>^6I725":$9G"AUQ\"?U\6_H\38HVH:B#Q0*
MN$H<O0UM^11"L$5[##8U:Z^B @ 6>/>]YP:.A>K>]7[2O/O9RUYWT.KU)ZW>
M</C#BQR\*PM@V/WGSP5VBWJ-S>992Z8MOQ62!;^14"Z?9_"@LMJ5XY*7U47W
M,<R$%[.' E/?A+*T(BM>8G.CLF9HYUKC76M1/Z5#2USVM5/'K<DT5>MV1%Q4
M0W!#H_ :_JBASR73)]FHNZ'4)5/JY:DDW0\-6:HIH4QWZEJ.3E5+Z7\7W&=Y
MYM%Q3:+74:U9IN2NM%U\N-M^L#"Z&-X"([;?+<=:)]O]->._/VV0_X0LDX8,
MIS [)L=$_A9;H\%Y4NZ/]'IXOHZ(RP:,N6&M_>R*_&O >^#IP-!:.LM4& 8[
MIF]4\5UU,J[>:^G=D@*C3A0VU*_%7!HTE+].RC>$OU+"ORP9^3@6^LK;CPW!
M3Z;A!R5C$J='8<U1L'*VZ?-R,,\)U/DA:-#2H*5!RQ-&RUGB&YLIDZPMTNL,
M]]0J7UV?FBZD^W\<9@G1VZM9)[2$9KG!S&9E]?B6S%[5=]3J[&!:)C6?J0;<
M'<7E:>A>R?0=E4P'-41_/D2O$MEH2/XD2?ZR5S+W<C3$58EJ-+2NJ,O[DY*%
M536<\=!:5;_@O:?X;U6ZU!VOWUU-*\7X;RY_/=G+7YN-X?NZG(Q4Q4U[;M1H
M[GXU=[\N "'-W:_F[E=S]ZNY^U6XUF65W7=;O5%SM^BB:52V'JBASYG.4$.>
M2R;/RU,=G^;"5U7-,RU9X]I<^&HN?.W#6Z.6/F[N')WQ;)>T*!ODG\\<:7#?
MW/)Z%C@'83^M2=@WM[R:&O C%L(,6M-126G=7/EX=M2ODBYO*/^$*=\0_DH)
M_U*O4A'57/-Z>A1'%3^N4N/<7/-Z6MY.<T.E04N#E@8M3Q0MS36OHK=7LTZN
MN30<!ZA?3FEX0_>ZO-R&YE='\TK^;4/S)TGSE[U^S41OKGF=4Y>/JV0L+O&:
M5\JJW'/&UK$6/QS@/48-QI,&Y837</:X%8^]Q.%PY<9?USMGLA3V3U%ZVVUM
MH\U)RN+2B2$J=Z\!U9MWS&K&M'X&3(\Z&[*LSFFBL=0L=3F3!.,O+^0UDN:N
MYD5>V\D;R'<M&Z]T&[7B5:31H'1M\$=2=J 4N:.Y#M/6S/#".=;%I%/OZ5U6
M1;>^<]NUFH?]UF10?TEW0Z2]%&VO-1Q<UZ"58I$:R0)C#J(N%@?^ EY^O]#\
M1Y<^J!(^;A+IQQ MK6'9*2)-W<QS(_ZD-2U[H^#RBR@.2)$UN<PFQ7LQ*=YC
M*N(X&MOD:R]%V%Y8*Z^&[DULOV)L7[WTCT#X?+ZN%O#?_<K\Z/Y.VJ7",(>2
MG)[[PDS&'Q!A0IM[[E)[C0'!&=XFQK8J11'/BT=LJ8#KQN;-U.8UPV.:QTSD
M7XNR'<82E)LO-"M@FN\FDQ_P/1L;\.#''N/+6> )BM-Z3(!+:"XH-&^Q!V:[
M*^I,8[K"5Z^-&M>\82O#(Y6&-Z_^Q0S;EP_^*U@:CG;'O =N,M'2/'<-?\.W
M9G9PMP#(W7O>TG[S&'.TU]@]20LOB,/?M)=QGL;\.?&E^&/KYQ]:VD?0XGRU
M,.#,RQ9=#CT.>O=?P'0@287V@2\Y;CFU8N*YU(JTC3OV%_<"H7W[=_[#=]\^
M9,# IU:>:P4FV.0&;A,0#%_K:%\7@-D4 I!<[,&P@Y 0%@.XE\#_&I]KDD@"
M4,@P@&=@MLMP3*:)A1O8EC:#AP6*#BX6\+CA:\P LGELA2W<P.NW8-F.=E-O
M+DOK=ZEYWS@ERYHTSPG3/.EW)L_XPK#H]SA5FF"_3@4!=:#XBY5MDQ(Z>?M.
MO9[42$X6.Q0!59RSYT:.FA)5K[AMRZYZ5[?U;\[L>C=/$89S!//"9HF3TEF4
M?0S'0Y(W9TV&[5RLUMX1)6L7KZAWVV412&]-NTU[RHNG4=F1+L\BH2R-.N65
M)P#$G_ ?<"XZV@??ZCR'C,3I1?"PI R^QGS0R;$?QV8&F]' A@S/[A!<Q 5/
M>J@@F-FP2ZD<77-6&Y%YW62HZPR<V<XLG[1IN*8,US2=:1O)>>5DJ.L,7(2M
MN2U>O9F[W@,93:7O"5ASV!I/JXR*;<J\GS#Q!Y?3*:\A?=T]O'N5IH)?5(5_
M68O_&=HN35E_@Y:+0LN%VJ#9BP^)HK,*JJ@I@*^F@T;=*K9G<^_A29*]U^I/
MFK9E5T?V26LZJ>)N7.QMEZ8 ^3C63XJ=GG8!\F;1?U^G^N-*'5N>&S6:^N-3
M;[VI/SZ'>]+4'Z?6NJC2R?TS8DV5Z[GZ)K4&TY(&8T.CJZ)14XG\//+BP#W#
MDI& :XS67J R;,CPM(_!143GZ:&F&KE"X'S2%-4U4O/*R5#;(;BD_FU-*=WE
MEM1,A\V<X2LEO3Z^F%JJAO1UW\76^TVKW&=ENC3%8PU:+@HMEV2!-H5TEU=:
M,VQU*UWB:"JJGB39^ZW1N"'[U9%]TAJ/2E[%?EJ%=.JEE]3=^",\M;#7V"??
MQ>(+ZH\K@MF2^ZH_[KY]AP]L<DR]>J,FJAP L86KP9^Y;\O%E@K4<%$6@@)[
MY*"EPV[),T/  ZZC>0"& /SP52 AX@[M!@P'YMEK;,UJPIJ>8?JIM\?Q3YQ1
M"0:(B<]3LV=\FR_2;U3O48C[ S\&:(W XKXV6\?X^\T%@\9!H*MT@3UL+F#Q
MXI?77/Q6=7*^,T*3ZWIZBZ>[6!_86EP^#*SZY>;V_7]N7IV(H$KH=OI]MDR)
MV0E.2UNY@N.9^4E"QA_@B0V#'DXJK15CVF/WA70^5SOOYK3&I_6]\P ;<[WU
M\SZ8A=J A_M'U2&X0*Y;>1R'((-J@C.W8IZQY _<TQY=[T]4.7"F02T*4GN@
MUV8,&0LT9C 'Q1-XZF@7SDA&I>LP#Q1DA'M<!MC6ERR+3P)?X["YN51(^":'
M@6("'<W_)N6+1X2UXM-A22U(#Y_>HIMS3_A),@$!6F=YKQOXZ6D"[]Z_^QS_
MCC,(ELQ?N%8+!0:0]4^6-@XT]GW%' &B1UH;";F+N%0"'&<HD&4B*<914HEB
M"RA:4UDHP$3<17O%##R/:.5S&ZP+>-3G2Q!MON0DF\,BV&X>V& >(#-IH"X<
M=\E-^*O#YO*+N+RI@)Q)E7+OP)& 33XN."QZ#]_U0#H29\&.N % !2NTH5#6
MKLC, M&,=A#RG[&"?0)+=;1O\DL;?VFEE-,CMVTPI%9$Q;_)3A+LKR"><%$6
MBYU*I[Y>07-V60V&%#"2OR9V>_M7P(G9CBBXMZ&._JWK18[P<<5U:J<LW&G:
M?C(DKY$? Q]R.>B$XSE>K@)DOD#08'N<8P]. 5*AC0A6 D%#\YW^"B8#"'SY
M!)L'MF:#=4,&%_[5$(*A._-:+NLEX(&76>'+F5K0@*?G#!\^O3CT%QYC*?33
M)-*.]D'.L\$#'$$+ G ^!X<N^0FB5[AS_Q$QB_^<=3MS0'O>;MX%GL-)&"*\
M<_X=?Q;GAU> L'9RT<_ $%[ >=?X$L4G>;828+#XP1+]F\7L!Y9%$0,J]@RE
MO8W+:JCPE9QGN 0P(<ZE[FC1H5&6#'&P(9\"TSC@U Q.:0B+US%,QG%3X@E.
M'I/V#;HT;8(,@_^:":O 2D9H4R4/.?KG<P.PI$P>W&Q,=SCS4IU'^XM,LAS>
M4'H83H!AA[HI5J: V/#0A_J+0*S/83C2VL<'][VC&2;2A+RM1^XO5 SDYN8V
M;1I(%*-72*&=!\X>!=%PE2_3T5:&4P($IE\?%\S1\%SYQ/_FPG#NI1UE<L\,
MEF F.R:3$1L32"1M)03 -#R/8D#2J49*DH$EY7<-S YH6VM;J%G#^5+&(# [
M.@FH&J5[8(2F5_17;G.?K,,HNF8XD1S";V)326$B)M&AD;:H:8B%-@??A$S?
MP":7.AIF!K(KI3/E80;4$SGQQ"$&5!@!O1]Y_/"/DHI$KL0[4%[6C\.,<2T"
MU)J<@'1#_!4Q7&POM!(_TT8>/8S .IKE/CI*]*0D?RSBDJ(\?58D1!*+2+2Y
MLH@PNI'G.V8!]!)OD7*4W$L,,3';WE/,;5J'W4X/[,8G;F,#,4A7 ^(_@+6$
M7MS5A$: #=B?&*% '*# ]IERVAR,M0'RJ+LL2G;E[5*TA,(A3"3']@$/W\ #
M:J50FTK?D$)\TD&F0Z:<57K<L$!:<337,<(8^]&D%B+WV1!9018*>WK XM)
M!.D6@++P?(,[3= OP>0WIND%@,>W"KW7P^!Q8(0N9J,= 1P89HU01QGWX%-)
M>YW,G#J\..Y9J: 6A@C7&BA&R_60]UT\5@_<*LZYM1(!2)#XTK-S01MXF@CS
M>"H6!48<& 04\,2D&QZ=&7K*Y$/<N<M0B<.?0KQL),.6'+2'[SJL+<T'F6TD
M58,>9?A&? J]<9O%-CA8&=]!**!QKZQQ?!U?LG143GH X-IP><0QXA9%.!.@
M(<G@%4ON*YJ1H/#CP"B*)<V= 5M*(VAAH'^0D"8M#'<9GD7Z4.EP@ <WHWY3
MN50$D(LH_(N?V@^4'T4CE[X/QRF)-)2' 5 +W39*;(-9@, &#MJNY(PABQFK
M%; -A7435K1P'8>1E\*1O^$TQ8@E<VEA@(2DK<"WP8Q>2CL.+:X96QCV7%H/
MTL(((R$V\@R)2[E6XEG\MC):7.4VD7D0B=TPK!T^2KA.C\JLP\[.&FQK,#45
M18E.%AHZQ/N/'! /7^=SKLRED&&$"@(OC3]<+U0@(4;D6?-$N&!JCV'6&DX3
MF%?H[Q->(M)$^$SS\]+X$_X8FGO2-5=2.%)R!GU,&:N98:N\%GK,F+7"%Y(K
M#(?7 ?+8,F,@N3XRXFE0:<1\*9<I#4_*30.6G8/_)23Y32"W8:[#W'@,,S$K
M?K2)*7R;W*)AH>R78/&YYC \+"!N.J!M#!0%<I.1W;N!!6 W.[#83Y5U:K%.
MB1L7)1L591L9J7=%S3OR>A5MPK&U>5%.Q4O8>^.?I<N+LEE7WUW]K*EE>O_<
MPS#(*5;%I$FO5_*6V#9 ]./L9UIA0W.&Q]'@9&2^5E)9^Q)JT,_>O>'POU4A
M2"J']/K+Y_1D;(H_H#R6YC =! PNP<L1<BDZW>\<RU?O04[[@<6501Q]Q_?@
MT(JMJ$V7S29050&55<APPF=/M]5SL7YU9%7E<<RK@5R]E[Z3X+X*G&48M^'(
MAB-KXLC0%DZ61WBY3+F9)2XLH/",1PUM!^+>EO;_M_=EO8T;6:/O%[C_06CD
MH0/(;LORVC,30-XFSKC;AM7.W'EJT%))9D*1"A>[E5]_SSFU4Z0LV1*U%?!]
M$[<D%JO.5F<_W3CK4P":U!QN&.%'TA-A0 "^<\3NB'U^.P<:ZX%ZRZ<M(>7O
M3D-?19G',[@YFKM[A_-U2,WL1D%[@T=UE-IN9'SD+AAIE%K&CV%')B(!4)B@
MK ?VDUR9W 19G&0>=W]KXYJDQ@!C$$,S%]D/X2UIQI4Z7 YU.6XOP[.4B\EM
ME=#KLZ*=EHH=;E-S*TH;8>AE2+3'Q/ >Y5PF(>N#(4K:9KWVC/X7"IPH"6E*
M2]SA$N)5/*:#TCD+,2P#8GS$8W08CMFMW?%_2D=,4N(KZC)$',(2)3YZL$0<
MCB,]ZZ!%B%%N%L9@2,FL[R' 1KG>*;["/4?B.K!1I3U0E$?'K4CT<4C3%)G1
M#DQJ\A,>'I6618XI'A97)$D93H]%[A'E0>&$JND4X$:V.U\5MB7B0=SG8+N4
MQ+)T8VG7@PKYY]\!].++E&(S8Z4@*XO;W]*2C\FE29%;>'L 5G@KJ28YHM9F
MPY1ZRM::>]1*]M@BMHIH7#:VK<E^MG5K%U8<C\?%"CTSF 7W0Y./;T72=/8V
M?)0\ <)V*)<@86D:,%<@,)9RW$')\<W[,=?(P\HDK^$%(=W6(YELAK&H1)>L
M%-XPR*>8&8I!=<R*X'!*$4Z[M0?A_(:%9$)KE_48.6;A)RK4#&QE^LQYDI1*
M$E:.PJ[?@X<9Y5(\LO0%_:?Z5M,)\R3U8'E^XR-OE+P'@W<QYM9Y">5 Z^0[
M%GH\G@[+B-(:?-A[$?>RC <:07<4I;"_3JI]S.:&\T_$F CUMCR=+4LA;74Z
MV4!43]U2> @I,68 Y02=!C=1LN'10!,"/$#6L2 08'\WD44:^R+-(@MYZCW\
MJ^_Y0K/$7S+2&;UGSP]0G=\!OMW!W#;ABQDHA0931?VD$U#B!JA"'MP.0P_9
M@=X$BHQ(64JCSI^8.@@$;4H'R@))\?X6)4/H?01>Y*$-4@R\:4YFI] F/*3/
M1(T!?TK(':4+A]3K@Y9MZY #['6<='8KN-*_1A95:#AT9$U?EHI+_'5PO# 3
M'ET*GE940Q'".M9)*+($=@\IDTM1T'8MW>C>)OE*M,:?&E9?284?3>JS8'?+
M\7DT[HUP*JBHTP3S%K3V>UXYH_IX;NRMET^MH'(A2EU ."32%Q$$O'  .4A?
M"*5E3F X87JNON7B:.0%I ^2WJ8NS2@V:]?(R^/%(<;()28HZ?N57_-%,1%-
M6-&]" M J>Y;)9"3#@J0^.C_K"&*Z1291X*!8<1:F-U>:!X!5$K,FO\'/&H^
MVV68C1_S[(:H(W(AS)"_3L2(D=GA:UK#7(2[NX) 3%C1Q8 QY1?P3/3';,3S
M^7O^#_X*J;E[U/D (?'1?S:618R!%FRD\P+@D@A_/T)-'37Q=]F>L_H:Y[?\
MVP7*F+'W1B%Q/L8.7&.^-]GAPF"'5IX=[B4[K)]IN]LL08QD6)(8 <^0%=XV
MSOTCZ3:$3WARM_XWR8@R:4*1(ZF?\GI&GNG)7Z@L010&P/-&)E:BLLR4EZ[J
ME"0+V+TL%BH)6O/DE[0<?BH;33G\S.WJC+DQ3Z'QH"[W-5W0V@&]6[MBIFN=
M_YXCC Q[[:E65KCAPQ<9_^;;N2M!N!PX)A6>5&Z?RNL1OE73]S 2;G?"MI6R
M5'P$A4P9RI/TQN\-/R% "/L?202 B1$9/S6<O61K"<\VNI%U08E=^B?7$/O.
MT2$LFZ"_ 4 9C-Y7M#H%CRUZ?>Y+$IG1$V.MDL$UM=@N9T%>R1CO"_Q2S;&O
M,<=LHQ:+VE5W"TKH9F8*>9G6(MZEM!>9]-GQ0E[MC->?*F;AT0=A-E-*SE2W
MYGK@N'CQ*VR.8=Y&Q.(B8Y6[TZ16 X ?1#'548452,HH9R0Q[B"OB] )1WU=
MA7$ 79]0'<35D=.QQDAX(+$.OKA1") #=V2D-2ST0[LQR?E<,E#ZA1DI7*XB
MN[=K54R9]5%R50-ZI)_2#6,DCV$>0A=L #@ICP^8F612U>N ;1 -6,QIG HV
M@27Y2SFN2K1 _"(5:G#4D6<GX$TXG"UM90,7TDCI<B(M5.:>&H?CV]-"\M4'
M:@8(+2>P5M6??/@IW/]$>KS@B;1UD>^^@W(6O3EPV_W!):ZELYNEH*BH+S%!
MW]R6#1DKF_#;W:6=3,CU>-S[(WK>S*J["<N<7;;OK'4X<O!CP&@/)5HR*7J=
M>].+K)NT7_DB^^CXO3%*?R%M#%M#Q" H$ZQO%OVPI)!&7VC-9 "@.Y]': >8
M2MZA*((5E24W?B)Y&V"%%$^'ZHD./R)5/L<D40FQVC\;YY("YA %QUKE-"N
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MQ!/SNFH&'/9SII;!"76AI>F!?(B29S3F%J$PV"MVQ/:-SI>TZ=W:%QQ$-XD
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M&V1^4H)1:383WD2V)!H*.++<GH+&O6EPK08>XD>_2OS,(B>L881W]'H(WPH
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M/60=3)V^8,\LB(8(ZR\^T%<*&%OWN\B$Y8=?Y,<E0)TG0YCX$8Q0@*5YOM%
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MIZZ\#HYJ'JTW)9<=6(C1UX[MR*B0C&;JG;VFE%.0Y_3*21VQO$XL10VM-X=
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M-!4!.*XM;&&\=LZ.X]D]I(LLKBR8 TD5WA=2.K6R?I:D6.8OY)<KII^?=+1
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MI#[ <6]/S(XOF?Q^>7[[!<3:]?W->C/?Q+GH^4-6Q6I^"-B'YS4:%!#$-_-
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M"/UM264*+5;Q45\VCY' !IPBXHAB$JI)4CA<ID 9I9%?3,,->3]<!+@/0#9
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M85-L^T!,/Z##!'/I .']B Z>5K4%(OL+4F008PP(\:]((2HU:B"VOR'%!E+
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M$ ] :"9"%T5*'LC7_(*_Y//X,2OG6X9#/\(]#&Z7$;I(KK^&2[&0=R*CU+)
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M@LF$+HW$ '(3^\JU>^6[JA?>HPA3C,*C.$4SMPKT<<[<*68,N6S[-YB!J,S
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M:A'\$7W  ,#T0WH/!-.7^87S,TT._];"D0WP">(VR?*T$.(ONN8I]SG]$)]
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M)\>OW?Z.+[T%W@$;G?B"DLR/?;/P[M(H!=AF$GX[,<:7WP)I6(U.@+55:D<
MM4WZ4(IL^XJ]WNC3L+W(\&+QMB*[_25GB7S-KRO=\^>W&5F('XSG(8ACS?J<
MO"@0K_,+U90VH_N@:DC6[F!%%_>$?<J)M,4R.JL%!JA5WQ\@9DMY77:$M]75
M[$# EO)Q[  >/Y$TX-H\!/>L'6Y+47M[JQ72\1F(S5(0UZX0K[<?<[9D:?Y
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M#4VS_#=^9G#AK\*8XWE.TE_XP/R*6T8M9J7YRVQ-R(OM2/_EJH/ST_88/:Q
MZ3QT\ X+\,4D?_?C]M'70;@4A_PG?I[%-T4<;WXKWRQ?T V&6V):E&_.BC D
M638OXFT)6^D(FE55CN$5>2(QJ]K7[()CBK/3VD-- -JY[64<EV\C4?V".PE+
MG%S_8C;8 SBQ",2B5UQA4TOCD57EG5(2JIZPZ__BJY*AT_*?.J;KZ[A<LMK$
M%GM@>1"?&F0?6?X'R;77W77^/H]3*#18A7X)IG</H;9QX0G;BN:&3EFMZ^)W
MRJJ\TY_3J[\/MD2E-BN9UE![8)\;O*>]<4YYKB'QQZCZLOA:HEXPZ_] &VY[
M?Z6WO0\7JJ*Z4+6IMZ+\SS-OQ7L9^@Y>T:.)VB>HC+.L6)6Z6;8+-5S1)QJ1
M1+06D5ZNZNJ]/9I2G0/1]E1"W]>C*7R.95SD2Y8J;*S.WM/?*7L*:"P*[VY8
MY:+M>.9DK^O1!%:&:5:RG]TFU9;^+"/:UMSIW]3W:?N=T,52N#.J/+E]D.!%
M.F2G4PKF N%T9TJUHW2C)1'(M.KR5</$&;X*B4JM#WR1^LC75M^]%PLKDT;8
MG+RK1U,WW>FW' 3-Q#EYLC55"89EE5'5ZZ0(8E%UK31:_'#2OVFO(I[/%9:.
MYE7U*@\3)TUD/X4MSWCWQW1=#UT9W_*^R%Y8?]:.1\9S3<\>M\RR\/,M-[ZY
MO5VD>Q]&);/2C#[YEVCU-/?P'VA>->^(A+.!;W(*,5/2(F#]=YHO[TE<[E79
MDJX?V'7-5;XZ4+"GO!*X_O6TK?:C$,L:"F]L*N>^EJ8'K)H(@?\;U]LWGY?5
MJ^'!"+V_#S^2^O0H5D/0EV]3G]_#7#HB,$Z+6GE@E@YDC,CKSB<&.A4PHJG-
M_& O_^X?C\U;D:3I+HX_$:"7?OW\,VA)$+31B7694UZ$9"1T/>GLJ_E21M5D
M;L%97%F*;%AT2ZO3@YL9UR&A7*E>M)^>+/BNY6?W'F">,;3C"+H]0VKPH]LQ
MZG4[UK9"">7*-U%S6RU8A[VK'"U84 8XNNU,+]P6:]: Z/'='Z*H_T*W7<E\
M+?MV3\H&/BAW)5/_4D]4"=V7TG4Z @*RU&;.YBWQ^A@4NF75U*/%#%MGH%R
M7?G]6BU42_T$+<JUI) &G2S7!1>.8"@*\%!*)S20TI-C0?=UY)6<0"B6ND^B
MO!/\5=V1/5SL9=]:U/=+-6XTA<\DAO7';="XPZV%9PVJH[X&;A5V.]+NNQ>I
M6V40^YS5MDAT>^SW8HI>-MH$3A*6"SR\=&P%SA&6*T"\-/X%SA&V*T2Z+P:
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M$=I ,N>+C+(BNZ)9>7N[XEZ\-@^R *0ZZ#1'HY3(!@,I"PGANT_+G:W-<RS
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M /V!O]W:9W_VL#Z _\*L03\\"C7P>R)T@$@D?-_0+ QBP7S[25 ^ML>1MC.
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M'KJD(-.U* _-HLOZ,8&FC76@R^PQ00>)[@$!NNMCW@1@FS7GK@6Y";).P]'
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M_Q$JJJ!_\9CJB@2325D?9-$LS+1X#GUA+JG',_L5VE,9#5WP287I_1(VSLG
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M[)!5$\<9S[2XZ=( ?).5X-A)4II?<(6]9OEQO>N)40BSKV<VU^(C01(!D]1
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M9LATTUBE-Q<W[Z AS]WU\"8;'(2*0#J>S+E5  !EZZ6[:_RNL( W,KBFBW^
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MH"U^84)1,)+(;+#:U"G.]E%:[M^QC);)[\)6'HI?5!Z/<HR/S.N\J*:$3;K
M-6(1G5.#=+Q55&TZ2(3P'JL(#-/FVTP2OAXX&I<,2G4-'%$:7]I.^&HAN-Y
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M3!L=1A-A= 4*H/,2+152<&9VT*K?R;J(V; I//' FB61U]H"=&=^S)_X .D
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MWY/R"4I24TCK'BK)8'=2ZT6%5(![*\(@RI-7%1A83E):S*WNG-9:*14DTE\
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M9667+9,MQV 3C>2H# U"):4<3^8\"Z4%:)!R8HXUSH*XRJ UC7PAWM*\Y (
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M'YR$%D1&!MC&U'CA.SVXI 4W\R!*:MQ:&AF)3@\^F=%]>G!V#C7==CDWCS*
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MSA)F-=%CG/O<F2B=)MKC;8C(C%K,@V_7/EVRJ<S_QZ?SQH^X5E;^6]GLJOW
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M:Z\CG!S*<]NI*0+14BI4"3O7=T@X74Q%PEV94&;,+'AIJBL;DT'<@,TOG&N
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M1D"C4\<N>/T-"O)'\O[@8@;$5 98N&5?DFP1*JXYVQ6;<;M'S ]PB 'F[N.
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ML*\'^WJPKXU;C%4TPB[6L(0H]7%$O92QG/F1II58^?F=JFJ1\EBOO&5?<?F
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MLD-B?:)HGD5C/!?99X"1-K_7E%L DK5S\7=++$H/O1(*"VRB(/(IS8LUN/N
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MQ !S]W' SGVVP\@9DI 98()]JKW$-SAAGX4DY=?G *F-L*1SL<)+]K2N9##
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G+3(P,3<P.3,P7W!R92YX;6Q02P4&      8 !@"* 0  S@\"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
